<SEC-DOCUMENT>0001819790-23-000030.txt : 20230509
<SEC-HEADER>0001819790-23-000030.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509161545
ACCESSION NUMBER:		0001819790-23-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tarsus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001819790
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				814717861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39614
		FILM NUMBER:		23902218

	BUSINESS ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 409-9820

	MAIL ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tars-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf,d:2779edde9dc94c55bb7cd8d1f6f5224d--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:tars="http://tarsusrx.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tars-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV8yLTEtMS0xLTY2OTUx_48310a2b-0ab4-4b1d-bff6-85e2346a15a8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV8zLTEtMS0xLTY2OTUx_ce2873bc-38a4-4a94-b6a5-7f95821965b9">0001819790</ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV80LTEtMS0xLTY2OTUx_ab5c0290-fabb-452b-9534-8a8e0576117a">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV81LTEtMS0xLTY2OTUx_28b3ec0a-ad5e-4d82-8b03-315e61003273">2023</ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV82LTEtMS0xLTY2OTUx_6616b77a-3b46-474f-80e2-a4dc5f01b8c8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i61fa110baf414adaa0600566a4e1d29a_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i5ddbaf2eacf744cf8db218d9a7266fc8_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i844ff7c88dde44c69fc24bd464b96f11_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyNw_8c90302e-5d65-4068-882b-93af76900292">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i867abfb9e1064a1ba6d0d1fa85686b18_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1MQ_814ddb0b-d044-4453-9608-47383f7c1878">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504" decimals="4" name="tars:PostemploymentBenefitsPercentOfAnnualBonusPaidOut" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF85MjEvZnJhZzo0YjQwM2Y5YTU0MGY0ODJjYjhlZDg5YThjZjg5N2MxMS90YWJsZTo1ZTdlNGI0NTljOTc0NjBmOGVhNjk1ZWQzN2M3M2IzYi90YWJsZXJhbmdlOjVlN2U0YjQ1OWM5NzQ2MGY4ZWE2OTVlZDM3YzczYjNiXzAtMS0xLTEtODM2Mjg_8c970f81-ed89-4035-81d8-90895722174d">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tars-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd94dd3746b44e8a0edbb9d88cbd6b6_I20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i20710df36adc404dad2e0ed426a82823_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ife6229fc8e68402f9b920eda1e0e260c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1a56ba171f3b48d49d64d6e0307a3072_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7392f7324e42b08828f273ba9f2c0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97e1a9cf5d64176b102a3410a4d3b35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8211b2209a124db8ba40846a6c3b2773_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib338de9842274a3cbb24a9dc2f5a75cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib389bf866d074c89b3498200f9bad100_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96634ffd5e2b456d91f2981b30790819_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184b2fe780564e698be7796aef221da3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2cb096252d467081badd94de5d94ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d842f7924da4f698cc36d3101b1ff1f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32855a1e027f4f2e92ff4d299c365316_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67692224fc6f4b78971fb14dc911e44f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3e982e36134221a56256dedf94650e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4728d2434f4cb3a885b91a7a39402e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a8d5e87bdf4552b41bd69d53f4778e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c86944e64a841aeaa619bae42c25b4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida561c34d05744459e3a6ba53e5082ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2356c7fef74c498e1b3064e427a7c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c2701f525a41e5aba1d5d4441c2fbd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff9bfcac8dd149bfa9f2b65537c92af8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>tars:segment</xbrli:measure></xbrli:unit><xbrli:context id="i61fa110baf414adaa0600566a4e1d29a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff1c597f3fd4a3c9576292df2860f68_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5ddbaf2eacf744cf8db218d9a7266fc8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ea086e3521419c9e262a45add82d46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e869641ee94a998264205f21fc8531_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9425df31da3a481584b439067cf07700_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibab9f798f0c849b6b6e313512298cd23_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3636234782064fa8a83fa7367952b887_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b552e3d3e6478a9f79127736c53136_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8a90c2600d4884b61ed721cf411567_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354a2222e5704982adaad60e04689993_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3fb4c1d1b74fc7bb77555b5885dcfc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144d9ee39e514d3c9f20ae2686e700bc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826796d58f43453bbe3a4e4f0df2dade_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ead24808e6418abe1c6285968f2a8e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7489f1c01f4040fa9027f3139aa5b960_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892be22603d64788b51cf55111b69eba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed0e212cc8b4b7aa51ff422f461de73_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida739d9e492041df8abac70acd6a4018_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7494a6d8c7fb4ce19624be505d391926_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd774b344c242018371671a89a14ad3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad928b2f434a4f91881e16edfff1f575_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f154f954b443e482459e699ab62660_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8b670522cf45f8ab84db74558ab9c2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ed5a6a9e3a45528f0d3c03542d3548_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78155dab98245379b7409e98a4d0db2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95392055c6c4c689895a8ec69851578_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f413bfd9e1344f194608ea5c75f1b14_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37bbb85698e4468e92bffdf013a05804_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ecb831e068f4e4eba5855f83c097192_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed529994d5a489a923621611c8dd9e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1488cc93f0044561a3bd35cf45b241cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0256b4f7bc471698e819ba39b63c4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc742ef4d3f499281a5e3db27036808_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b127b6e20648509ccfc27bc1d93571_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30727f2c96b341fe911ef415de4c348f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5597704788449bbbcea9eba34b39aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55798f7922ed4f90b40cf890e7c58539_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb0218825134bd9b61163220979283d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd8a154fb694ad786f8c8da8d391a16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3631e96ef564c579622dff441e974e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f2b2e02b4b45fea07db876890aa3d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73e18a89cf74db4b49c5a7a82c5d5de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b81c93d9584d62b21986ea577e3937_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe3af3744bea4434818663e6ea1800b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2171876554134f82b5a5cea826938d46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33af9a3f4c25435dae84fc4f1bab1c97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae22aa8959ba409fbcfaf7febb83d253_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id293f7748a664952b30b29710a563efc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6154a4280d4f41f784fb63374be71d6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f86d28e0b24020a867c02990388aa1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12fdf79c65a44bde92634bea4639cc61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>tars:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="warrant"><xbrli:measure>tars:warrant</xbrli:measure></xbrli:unit><xbrli:context id="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>tars:security</xbrli:measure></xbrli:unit><xbrli:context id="i844ff7c88dde44c69fc24bd464b96f11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02393f415335453b90d7884e68e659ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i533c566d81f044ba9eae18e652238819_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867abfb9e1064a1ba6d0d1fa85686b18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54617256e4f143fc8a0b0c96a6a280ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762203c8d41341b6a256214747c9a07c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61cebed72353446c84a867bf93927fcb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b89b78a42a4429a8d3f77392ce80a4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9112849a364d638fb3efe500b2b222_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd02acbbe7a4774a2097f5656e5f09d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8f8b00797641848f2b5a4b1b905ee3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie853a328a5ec41d3972f307e7901c482_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ff25d218e04f7a9b1566f714bb8346_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db3a5e7cdb34537b766bd622dc616b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917bf9bfe034449b834be912de58d1fa_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e27f78c37544ca1b323673fc30d9a3b_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac59350831b24dfdacee66f79da8ab72_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4149d89cf8448a9a0e2ea0b40d6ac4c_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4416d2143c4221be97d977037586b4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>tars:vote</xbrli:measure></xbrli:unit><xbrli:context id="i47bc68703c824e77bffd6af8ae80c0f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6729c6febce8422b827027ebc9a6d64e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2fca5aed6f4a76b7dd655630e82a4b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95cb4582644f423d9136ef1e85e60b7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8503e32597854aa6a46c8b8515cc5b3d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514d107167894741a8b7f284d591b2b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3558f809862443fe9aaf961e3fe46862_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68cb6ee1927b4f99ada59e4d064573f2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ded64e9a23d4e3ebbacb7b216bb928a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b81ae74dba9486c9d47805cc82049c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88f78cb86a54bd88f68fd667ba9bf91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1f95855536428d8e7258cfd624dd7c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0991bb1e26c40059e9714e160dcd466_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e64247629bd49ad88f0a146a9a98bde_D20190101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1eebcc98854765b87cca237a5b757f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859b21f6d2d440d78aeb12f136556886_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd840a9974534e8a86fb288669a39d26_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7122162b9e8442fb9dbe528f8bf4e6db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6d21b9d0b1d41519dfdd05a63606147_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76624ba745b8460b9f60a3265e3b69fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662dee756fdb482ab237e7e724a9180c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>tars:contract</xbrli:measure></xbrli:unit><xbrli:context id="ifc838841c8c34d339322513ad5186477_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42809a841f17475d971438d5fe3366fb_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5bc0dd6d674c43a5676efe1c51dae5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fdb0d02a3f4465f9adaa728283ff184_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4deb7fc864cf40d58681297bddbc56fc_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69314c7f4594e288ffe725501411cd7_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:MilestoneDeterminedByTheCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8637cc436fcd44d58ba1f8037dad5983_D20210326-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7350246746e45e096c4b5c05592d2bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fc38686769463e89dccae19d75a856_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d63e21c49245618766f49acefdeffc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb291c31a4554839b5b0b66a4fe2675f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f0b2c2b8d64ed1aed8211167ca0c9f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9982c244cae049c2b927906df44008a4_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbbc17db51145c1b3991110981ecf19_I20230105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6757e8b476a41fd8f001984f0e90cab_I20230105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityFirstAmendmentTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ab2b8124224aeeaacabd23e0670fc6_D20230315-20230315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead63404689e4c9fb5d3dd9c7e44eb93_D20230315-20230315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib138596b65dc49378e26b8bcfa849a7c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57aedd3d329a44348c333722afc8f2da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12dac813311e4f7c9349b2c69b102372_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7de7306a164d21817ad5a9f76cd054_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde37c43b07847328ecd4970539db537_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb591f932524f878ed995d1d169d6e6_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63781028d94a4277a261f195f03cebe0_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af35563ebb945b9a4b563b46884004c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5516daf64a47d4948fc6884c6bf78b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80393f9b040b4bbdbc5232b580944b52_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:110%">FORM <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUx_d4ba5aac-a5f8-45a2-8c6c-896e5ba7c582">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6Y2Q0NWFmNDBhZjQ5NGU0MmJlMDlmOTFlZjQ0NDVlMjcvdGFibGVyYW5nZTpjZDQ1YWY0MGFmNDk0ZTQyYmUwOWY5MWVmNDQ0NWUyN18wLTAtMS0xLTY2OTUx_a7dd8c85-2e31-4c5b-b960-08082d08ebb9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:15pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the quarterly period ended <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xMjk_e19dc56d-eeab-468f-a19f-9fb38ccf66db">March&#160;31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZDg4NmI3MDEwYzFhNGU4MmJjNDVmN2M1NGY4ZDY3OWIvdGFibGVyYW5nZTpkODg2YjcwMTBjMWE0ZTgyYmM0NWY3YzU0ZjhkNjc5Yl8wLTAtMS0xLTY2OTUx_f829cce6-24c7-4182-bb6b-bd07a7e1c8ee">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from _____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">to ____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#160;</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:  <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUy_8e6859ef-365d-4853-9771-b04ebb4f940f">001-39614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ2_82af8ba5-75b3-4eb9-a6e2-09df1296449a">TARSUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6OTNhZmY5Y2E4N2MyNDRiMzg2ZjRmZWNkNjdlMmJkZjEvdGFibGVyYW5nZTo5M2FmZjljYTg3YzI0NGIzODZmNGZlY2Q2N2UyYmRmMV8wLTAtMS0xLTY2OTUx_24d0a5d5-2614-43c9-bf76-488fe03420ee">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6OTNhZmY5Y2E4N2MyNDRiMzg2ZjRmZWNkNjdlMmJkZjEvdGFibGVyYW5nZTo5M2FmZjljYTg3YzI0NGIzODZmNGZlY2Q2N2UyYmRmMV8wLTItMS0xLTY2OTUx_5604e237-7d5d-4bba-bb69-efd2e70d72ff">81-4717861</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8wLTAtMS0xLTY2OTUx_26a75991-450d-4452-87dd-ae026474a367">15440 Laguna Canyon Road, Suite 160</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTAtMS0xLTY2OTUxL3RleHRyZWdpb246OTQwMmEyMDJhOWUwNDAxZWFiNmU4ZDRlODQzZmM1M2JfNA_cd0f6f62-0ef5-4e5d-8373-af7dc0d92c3c">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTAtMS0xLTY2OTUxL3RleHRyZWdpb246OTQwMmEyMDJhOWUwNDAxZWFiNmU4ZDRlODQzZmM1M2JfOA_245b9beb-7a40-4f5e-9743-678b069112fc">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTItMS0xLTY2OTUx_7192b4c6-5d8f-4f09-9e25-499de257760f">92618</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ4_8a02fe19-b6d3-4547-a494-dceccc892cc6">(949)</ix:nonNumeric> <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ3_65d3da87-cd4f-4a35-af5f-61d285601e97">409-9820</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"></td><td style="width:40.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTAtMS0xLTY2OTUx_2bc95a33-e536-4993-b0fc-4c0f1fc0fda4">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTEtMS0xLTY2OTUx_ac6097bc-8364-48e8-b865-1a4ddf207a11">TARS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Nasdaq Global Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTItMS0xLTY2OTUxL3RleHRyZWdpb246MmZhMjk2ODFlZGM5NDU4ODk5Y2JhNDQyZjQ3ZDM1MGRfMzQ_c9675e55-222f-4d33-bb15-1766f81e9a98">Nasdaq Global Select Market</ix:nonNumeric>)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQz_71426472-4917-4793-a7a1-3ce501ff1e4c">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ5_496e5fb4-d79c-47d1-934a-8383bd9082d0">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8xLTAtMS0xLTY2OTUx_cbfac32f-c9a8-46f1-a405-893e1350a78e">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8xLTQtMS0xLTY2OTUx_4e7c9658-c9af-48f7-9ddb-ac3456f2af18">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8yLTQtMS0xLTY2OTUx_bda9497e-f2b9-4402-9330-3c2c29956da3">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUw_0680ced2-8c92-4124-aa77-78bef7d87b7a">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ1_f4d3649c-07bb-4b98-917b-365936c4f527">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May 4, 2023, the number of outstanding shares of the registrant's common stock, par value $0.0001 per share, was <ix:nonFraction unitRef="shares" contextRef="i7cd94dd3746b44e8a0edbb9d88cbd6b6_I20230504" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xODYy_f023dec3-a00a-4b7a-bb4e-87664fa97985">26,803,733</ix:nonFraction>.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_10">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_13">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_70">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_70">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_76">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_76">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_79">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_79">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_82">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_82">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_85">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_85">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_88">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_91">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_91">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_94">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_94">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_97">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_97">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_100">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_100">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_103">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_103">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_106">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_106">39</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_13"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item I. Financial Statements (Unaudited)</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pages</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_22">Condensed Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNS0xLTEtMS02Njk1MQ_2cc2dcac-d04f-4431-b039-5c1f5822c1c8">65,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNS0zLTEtMS02Njk1MQ_e84f2389-b301-4ea3-9115-6788009a966d">71,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNy0xLTEtMS02Njk1MQ_cb3f632f-534d-4274-bddc-753c9182fe0f">135,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNy0zLTEtMS02Njk1MQ_76405fb7-2a34-4453-aeb5-4cb738f8b823">145,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOC0xLTEtMS04MTUzNg_05478df5-0292-4b1d-8049-77b191cdbd14">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOC0zLTEtMS04MTUzNg_b87a36c9-2bfe-4194-9405-5d5f39b91f60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOS0xLTEtMS02Njk1MQ_7c2a792f-53a2-4997-a35a-40564957fafb">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOS0zLTEtMS02Njk1MQ_37282ba8-cd3f-426d-8848-492748ba9650">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTAtMS0xLTEtNjY5NTE_81131d9f-ddf4-468e-91b0-09d4e3e24e49">4,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTAtMy0xLTEtNjY5NTE_70cb851f-0b44-4eab-b8bb-276ef422d312">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTEtMS0xLTEtNjY5NTE_fe7a49e4-ff9f-4689-a68a-23dd433c6930">208,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTEtMy0xLTEtNjY5NTE_c936797b-5ffb-421e-a518-898f95a69c22">225,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTItMS0xLTEtNjY5NTE_75bd4cb4-b148-473f-bd8c-1f63afe659fa">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTItMy0xLTEtNjY5NTE_612347cf-9799-4fa2-9e67-c8a9507fea2c">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTMtMS0xLTEtNjY5NTE_887bc4ab-60bd-464b-acb9-d6fc41f23b53">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTMtMy0xLTEtNjY5NTE_98e24475-5312-4a19-bd63-de82298a5dfc">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTQtMS0xLTEtNjY5NTE_70c4c656-9786-446b-9f33-f084e9608ab7">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTQtMy0xLTEtNjY5NTE_4dabb98d-0823-4334-a5b2-3f374df6f69e">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTUtMS0xLTEtNjY5NTE_f185566f-d9fd-468f-8521-b80ffff3ceac">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTUtMy0xLTEtNjY5NTE_4858469e-b72c-48b1-8daf-50f7d85525bd">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTYtMS0xLTEtNjY5NTE_d961d1f5-0b26-470c-8fea-dcd4eac58adb">211,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTYtMy0xLTEtNjY5NTE_c9d874d8-7f5e-45a5-bca1-1a41fa88bac0">227,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTktMS0xLTEtNjY5NTE_ff44d029-9136-4d00-a8f9-1340f3f497ba">9,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTktMy0xLTEtNjY5NTE_b3bf5b4e-2119-4a94-bea8-2f71eb864d24">9,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjAtMS0xLTEtNjY5NTE_23a86544-07be-43ef-bc5b-27e39e808c0d">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjAtMy0xLTEtNjY5NTE_0c731f3b-f636-42cc-90ec-b4c5c3dc7ccb">5,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjEtMS0xLTEtNjY5NTE_ea94e11e-ab1c-4f5e-a7c7-5583c526c3b3">13,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjEtMy0xLTEtNjY5NTE_6bd98e45-35b5-4619-81fd-c606b23df9b4">15,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjItMS0xLTEtNjY5NTE_c780d3c7-fe26-45d5-a3a4-9499ad8a8c2e">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjItMy0xLTEtNjY5NTE_30fc9ffd-a941-423f-8edd-2a9aecd3ff66">19,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjMtMS0xLTEtNjY5NTE_5e14c633-806d-4080-b06c-f4e48fe491d4">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjMtMy0xLTEtNjY5NTE_5df973b5-dfa9-4bac-b997-83ed94ff37da">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjQtMS0xLTEtNjY5NTE_a6c3d71b-d628-4517-9a5d-ce333dd432f9">37,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjQtMy0xLTEtNjY5NTE_6413b796-5bc1-49c1-882e-5f49c3f9ca98">34,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjUtMS0xLTEtNjY5NTE_374454e6-9f56-49c6-a932-8c5f157b32d5"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjUtMy0xLTEtNjY5NTE_305c8f29-e8c9-4d78-92fe-c7b62871265f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8yMQ_19c2190b-cf04-4d20-8120-2220b9fe8cfa"><ix:nonFraction unitRef="usdPerShare" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8yMQ_59fe0a18-e2ce-4406-95d2-b99cad822138">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8zNQ_00465234-2423-4038-8268-8a96e103278c"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8zNQ_1bf53a97-6759-4d70-bb64-50f540eda860">10,000,000</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_267973d6-35b1-411e-9833-5dc1bd9b1716"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_34ce7ea7-184a-49be-a8cc-03412fc0ad94"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_5d72218e-019e-4a52-8cc4-e16b44008521"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_696448d1-622f-4a4b-a793-a037245babe5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMS0xLTEtNjY5NTE_34db3254-dc23-47d8-94cd-0004dae57fd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMy0xLTEtNjY5NTE_96bc3c39-fb66-4330-addf-7b1612d93200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xOA_715f3be8-225c-4430-b76a-bcafa4ddc9bf"><ix:nonFraction unitRef="usdPerShare" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xOA_8f15f898-2965-4108-80e8-0f6d0a40c50e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8zMg_6c0b2016-45d7-41d4-8b34-81d763c4be13"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8zMg_f1fac91c-c3e6-452d-92ab-fafb4eec4cb1">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF81NA_90ca5f3c-0e24-46d5-86d0-3ec1c689a551"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF81NA_a0f73516-9ec0-4520-bb1b-ec4f2008db01">26,800,512</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 (unaudited); <ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xMDY_68271d12-9837-4f4a-b385-87dc007e529e"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xMDY_f3633c2f-6b5a-4d61-9e58-a56d759f7757">26,727,458</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMS0xLTEtNjY5NTE_3df39f80-2902-431f-a789-5c2c0c9de694">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMy0xLTEtNjY5NTE_a01c78e7-2271-4fec-a8cc-6931b8a257e6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjktMS0xLTEtNjY5NTE_7679df40-e459-4a6a-a19d-e6db0f7581ec">305,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjktMy0xLTEtNjY5NTE_9f7c481b-b59c-4361-ac00-1858746d81e7">301,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzAtMS0xLTEtNjY5NTE_10c886b6-db7e-479a-913e-1be57ef67a9b">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzAtMy0xLTEtNjY5NTE_6e357353-3a92-42a7-aba4-68b79ee163d6">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzEtMS0xLTEtNjY5NTE_e275293e-6665-4e33-84ac-aa10f278c4a5">132,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzEtMy0xLTEtNjY5NTE_104a57f7-c448-477a-b0d0-0e655de6a858">108,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzItMS0xLTEtNjY5NTE_0c72cb62-7e39-4aef-9797-b4b54ba5ca51">173,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzItMy0xLTEtNjY5NTE_42ad23d5-fd2c-4da8-8f63-799b07d55622">192,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzMtMS0xLTEtNjY5NTE_d7014b79-3b16-44af-a14b-5edadd0f7c5f">211,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzMtMy0xLTEtNjY5NTE_cf773dfb-bb8a-4f5b-9781-0690146e9498">227,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:68.752%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ba171f3b48d49d64d6e0307a3072_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNC01LTEtMS02Njk1MQ_aa4e43d1-df33-4b7a-bf04-045e0a1c47e2">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7392f7324e42b08828f273ba9f2c0a_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNC03LTEtMS02Njk1MQ_697d4a9b-aea6-44d2-a9ac-75135b9e23ce">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 31pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNy01LTEtMS02Njk1MQ_b46d58cd-2e7d-41b2-9236-089dd7bce262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNy03LTEtMS02Njk1MQ_026c50d1-b9ce-4607-bf1e-2d944b7db253">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOC01LTEtMS02Njk1MQ_f5db4dd5-1b86-43e8-983b-cc5c47e210a9">12,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOC03LTEtMS02Njk1MQ_ec9af996-2909-4419-8874-8ee2a80521b1">12,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOS01LTEtMS02Njk1MQ_7b312c1b-5e80-4d75-a21d-6d39b7d6bdf0">15,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOS03LTEtMS02Njk1MQ_1592642e-e69f-48ea-a8c3-12615ac75bd9">7,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTAtNS0xLTEtNjY5NTE_f9a28f9e-0c0b-483a-9bef-b4ef43f5a155">27,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTAtNy0xLTEtNjY5NTE_a294a426-fafb-4dac-81e0-56a99efcf2eb">20,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations before other income (expense) and income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTEtNS0xLTEtNjY5NTE_c6164e7b-218c-4f95-afa3-0bfd2b522f67">24,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTEtNy0xLTEtNjY5NTE_5f4a9bf6-ef3b-4852-9a2a-4307b828b5d0">19,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTMtNS0xLTEtNjY5NTE_e9fc68bf-b252-4c85-adec-5f28549325af">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTMtNy0xLTEtNjY5NTE_2050ea2d-ede1-4c90-b0b6-f71b8749488b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTQtNS0xLTEtNjY5NTE_c82a49a0-d2b0-4338-9ef7-7364e93dd0b3">684</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTQtNy0xLTEtNjY5NTE_8a365875-257d-4a0b-a88f-46ff0ee10c05">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTUtNS0xLTEtNjY5NTE_0d2c361c-0e0d-4759-a6b8-13cad0808564">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTUtNy0xLTEtNjY5NTE_3dff302d-96f1-4198-9e25-2f4621379a84">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTYtNS0xLTEtNjY5NTE_dbc3bb5a-2dfa-4273-976f-17fc3cb0ca93">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTYtNy0xLTEtNjY5NTE_cf6b6899-dff1-4cb4-8ce6-fce00bd7763e">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTctNS0xLTEtNjY5NTE_b0b7e373-8c6d-487c-9a00-736fd09e4c15">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTctNy0xLTEtNjY5NTE_bf26f916-613a-4348-a660-477d2ac47cb5">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTgtNS0xLTEtNjY5NTE_126c38e6-92d3-4bbb-b527-ab693eb6570a">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTgtNy0xLTEtNjY5NTE_7e9a1f1b-175e-4a85-91f1-bed31b9dd0f6">716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTktNS0xLTEtNjY5NTE_4e0c0e4c-cff4-4d8a-ac84-0c936503daa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTktNy0xLTEtNjY5NTE_7022e640-ec7f-4d63-93d8-d60751f98b7c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjAtNS0xLTEtNjY5NTE_01f7a7bf-8d8b-4c2f-aed5-b2d6394ad908">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjAtNy0xLTEtNjY5NTE_b1eafd46-cbea-48d3-958c-1dcb31b38296">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjMtNS0xLTEtNjY5NTE_c43247c9-996b-4cba-a570-5492d325e719">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjMtNy0xLTEtNjY5NTE_73d406bd-b209-47db-9075-8eaa3a4d7b85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjQtNS0xLTEtNjY5NTE_5733be68-e16f-48e5-91a1-ce72039d6416">23,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjQtNy0xLTEtNjY5NTE_3ce441c6-eb9a-4607-93d1-54a43b71aa73">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjYtNS0xLTEtNjY5NTE_42f56405-3d96-4b14-8c34-5e46285d810f">0.88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjYtNy0xLTEtNjY5NTE_8de7a5bb-48ae-4864-b0ae-de063462f43d">0.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjctNS0xLTEtNjY5NTE_6c3a8a9a-4422-41bc-b82f-5a345f2e532a">0.88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjctNy0xLTEtNjY5NTE_388011a4-f20b-45ef-8adc-35df31a60db1">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjktNS0xLTEtNjY5NTE_ac7e199f-ddc3-45a6-b1a7-040e6c1177a5">26,742,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjktNy0xLTEtNjY5NTE_8cb483d7-5cb7-4da5-be03-34fafaf8eecd">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMzAtNS0xLTEtNjY5NTE_468620d0-ae07-4067-9449-7de02b6afe98">26,742,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMzAtNy0xLTEtNjY5NTE_6ccf02b5-4123-408e-a9a8-d5a924ee0484">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.715%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xLTEtMS02Njk1MQ_4225c28e-91c7-4b1d-8be0-8b2695475ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0zLTEtMS02Njk1MQ_03a62270-6842-43a5-8a6d-8b605ef65bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id97e1a9cf5d64176b102a3410a4d3b35_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi01LTEtMS02Njk1MQ_cd6c43f2-e90a-4679-a3c9-8c6d690e7f9f">26,727,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97e1a9cf5d64176b102a3410a4d3b35_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi03LTEtMS02Njk1MQ_9747fc93-c782-4ddc-902f-191ea236305b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8211b2209a124db8ba40846a6c3b2773_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi05LTEtMS02Njk1MQ_f4e9e47c-d3b0-4d9b-b970-73f582dc6000">301,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib338de9842274a3cbb24a9dc2f5a75cf_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xMS0xLTEtNjY5NTE_243102b8-44bd-4c0c-b897-084eff5f1b49">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib389bf866d074c89b3498200f9bad100_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xMy0xLTEtNjY5NTE_e0cc4991-2625-44c7-826f-a148019158b1">108,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xNS0xLTEtNjY5NTE_72f04ea2-db84-47a0-b46b-ada63e567d72">192,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96634ffd5e2b456d91f2981b30790819_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMy0xMy0xLTEtNjY5NTE_476dbb44-48e2-40c3-ac6f-b969399ee8b4">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMy0xNS0xLTEtNjY5NTE_a49d9ae1-67b3-4c3a-b75a-630d5dff6983">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNC05LTEtMS02Njk1MQ_f2082ea0-7c1b-43f9-ba15-dad47c1c640f">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNC0xNS0xLTEtNjY5NTE_d3c6d230-f225-4be2-8e02-1aa10a631247">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i184b2fe780564e698be7796aef221da3_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS01LTEtMS02Njk1MQ_94bd6d9d-1145-4443-96c5-4d335f7e9d98">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS05LTEtMS02Njk1MQ_da2b17e1-01b9-4305-a1eb-5aba8f5235e7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS0xNS0xLTEtNjY5NTE_ec2c4269-efe3-4957-b610-140945a67e71">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i184b2fe780564e698be7796aef221da3_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNi01LTEtMS02Njk1MQ_6e941e50-75d0-4f17-88fa-1b4ddcc2a108">66,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2cb096252d467081badd94de5d94ce_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNy0xMS0xLTEtNjY5NTE_d4cf39f1-342f-41b5-8894-8ebb844d4019">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNy0xNS0xLTEtNjY5NTE_f56dc50e-9896-4027-afd7-e0eab9800ef3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xLTEtMS02Njk1MQ_e64838b7-a9d3-4d85-aa11-72b9eefee0cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0zLTEtMS02Njk1MQ_e23a2a79-bb84-4ca8-a6fe-cb0ec2c639cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d842f7924da4f698cc36d3101b1ff1f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC01LTEtMS02Njk1MQ_bf2c74be-e3e2-499f-8c29-da5395e90437">26,800,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d842f7924da4f698cc36d3101b1ff1f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC03LTEtMS02Njk1MQ_c1061e9a-00f5-4fa1-9cfc-eadea06ba107">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32855a1e027f4f2e92ff4d299c365316_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC05LTEtMS02Njk1MQ_7e74660a-5f64-47a2-a29c-af7415803824">305,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67692224fc6f4b78971fb14dc911e44f_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xMS0xLTEtNjY5NTE_e78588a4-5bd5-4e97-a344-42d15ae61254">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c3e982e36134221a56256dedf94650e_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xMy0xLTEtNjY5NTE_6ff2dda5-8949-4a89-a1d0-3b4aa665fcc0">132,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xNS0xLTEtNjY5NTE_f5a38ee7-88c6-46b8-b887-06353de24fdb">173,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.780%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xLTEtMS02Njk1MQ_2e57ef24-e7f7-4567-8b7c-4a968219c00a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0zLTEtMS02Njk1MQ_cf5ec9f7-467b-44d5-98c1-d788978642aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e4728d2434f4cb3a885b91a7a39402e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi01LTEtMS02Njk1MQ_6b3dee49-ca2a-4b93-9c72-60cabc5e6359">20,698,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4728d2434f4cb3a885b91a7a39402e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi03LTEtMS02Njk1MQ_5c8c757f-345f-46ae-997a-5a38d032ba75">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a8d5e87bdf4552b41bd69d53f4778e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi05LTEtMS02Njk1MQ_7a1143cb-01c0-44bf-85e1-f56b6ad0669b">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c86944e64a841aeaa619bae42c25b4d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xMS0xLTEtNjY5NTE_c2e8db0f-e9be-47bb-9d08-a763f1d7616d">46,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xMy0xLTEtNjY5NTE_b304e423-1256-49dc-8325-8c82487c05ab">166,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida561c34d05744459e3a6ba53e5082ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMy0xMS0xLTEtNjY5NTE_8370c260-d6c7-4504-a5ad-a78d68016209">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMy0xMy0xLTEtNjY5NTE_8f0a6f80-27f4-412b-8806-5d2612fbf758">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNC05LTEtMS02Njk1MQ_213f1e0a-8574-410d-aff0-5ff680443526">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNC0xMy0xLTEtNjY5NTE_f8ef1cdf-7cf7-4f89-bf9f-512cbb8bcfb0">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNS01LTEtMS02Njk1MQ_4d6cbf89-13cf-40d1-b43f-53f245509ca7">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi01LTEtMS04MTcxNQ_5937f566-8d13-4f5a-b15d-d9bbcf976fb0">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of repurchase obligation for stock option exercises, prior to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331" decimals="INF" name="tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi01LTEtMS02Njk1MQ_82e4ec66-4576-418a-8b15-f8978358ec4b">15,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi05LTEtMS02Njk1MQ_373894d6-be1b-41e8-95b0-01b6473ba402">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi0xMy0xLTEtNjY5NTE_5aeddbe9-fe1b-47f2-b24d-d037cf270e4c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xLTEtMS02Njk1MQ_573f1f7d-f639-4f87-acb6-54ce3348f9e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0zLTEtMS02Njk1MQ_7b5d4c25-a5f5-480e-b94c-d20f412c3aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d2356c7fef74c498e1b3064e427a7c3_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy01LTEtMS02Njk1MQ_ba014a94-fd71-4672-bfa4-58961cc7bb25">20,718,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2356c7fef74c498e1b3064e427a7c3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy03LTEtMS02Njk1MQ_bbb40c1f-a73b-4fc2-b7fb-e0475d29934d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c2701f525a41e5aba1d5d4441c2fbd_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy05LTEtMS02Njk1MQ_1a5b3d67-ea11-4673-9faa-faa306dc131a">216,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff9bfcac8dd149bfa9f2b65537c92af8_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xMS0xLTEtNjY5NTE_946c4b88-9f2c-48a5-8c0d-3d836d86afc9">66,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xMy0xLTEtNjY5NTE_eddb4306-08d0-48a1-a732-f9eb1e81619a">149,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMy0xLTEtMS02Njk1MQ_9f41d87a-18fa-478a-8f9e-5a11e02579e6">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMy0zLTEtMS02Njk1MQ_c6ace51a-741e-4ee7-823e-d298c9e664f3">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNS0xLTEtMS02Njk1MQ_03461dc0-10c4-407f-a0f9-d1cc97b0f7e9">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNS0zLTEtMS02Njk1MQ_4a6a2186-ed14-44f7-b3e8-17b4104f90ea">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of term loan-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNi0xLTEtMS02Njk1MQ_58053673-d3de-46e5-9500-9ae9b99cd263">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNi0zLTEtMS02Njk1MQ_ac2d526d-37bb-40a3-89aa-66d7a984ee30">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNy0xLTEtMS02Njk1MQ_142c7347-13cd-4d29-af50-a55779b75d57">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNy0zLTEtMS02Njk1MQ_59a4d055-3e84-4ba9-95d4-11c49397bf75">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfOC0xLTEtMS02Njk1MQ_9cfc8946-f1b6-434e-9a18-ca52713e7bb7">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfOC0zLTEtMS02Njk1MQ_7530d6a7-fc74-41a8-b52c-d263e4687617">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTEtMS0xLTEtNjY5NTE_8011f8ae-967d-4113-8900-b8d1aa3aaf4b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTEtMy0xLTEtNjY5NTE_f154779b-47ad-4833-a197-20099b26d1ae">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of discount on available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTItMS0xLTEtNjY5NTE_c0de0ee0-d975-4d67-867a-b28881eeaa83">1,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTItMy0xLTEtNjY5NTE_b6066561-2e06-4036-bf4b-17602c1a85b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTMtMS0xLTEtNjY5NTE_9fb1cb8c-7a02-494a-8cef-2599c4aa83b3">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTMtMy0xLTEtNjY5NTE_f3e810e9-2950-4108-98e7-8b9006123405">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain from transactions denominated in a foreign currency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTUtMS0xLTEtNjY5NTE_1873ee3f-e4dc-44ba-84bf-717612403c9b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTUtMy0xLTEtNjY5NTE_f4679b38-d223-41ef-a2ac-79d0bb85f65b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTgtMS0xLTEtNjY5NTE_adfe12af-3b9f-40c7-aee7-f4b2d7f70792">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTgtMy0xLTEtNjY5NTE_6c90b37d-6dd3-4203-ab0d-a40fd0d03433">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjAtMS0xLTEtNjY5NTE_b9cddd33-cbd6-4daa-8df9-61eed9473a11">3,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjAtMy0xLTEtNjY5NTE_8d6e1dfb-a44c-4ed5-ac62-d48d76da064c">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjEtMS0xLTEtNjY5NTE_4f5a0a69-4238-4c32-9325-0fd764988f13">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjEtMy0xLTEtNjY5NTE_22d4595e-f7de-4dc8-8a29-e43bb3b83585">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjItMS0xLTEtNjY5NTE_63e4e55c-de01-458d-b848-7a88e4ab527a">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjItMy0xLTEtNjY5NTE_6543960e-3986-4b7e-9774-3abdff21aa4e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjMtMS0xLTEtNjY5NTE_582ad61d-8962-44a6-b660-57716f4ff901">1,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjMtMy0xLTEtNjY5NTE_8a4a7842-7338-486f-8772-0035819c323b">1,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjQtMS0xLTEtNjY5NTE_2201b37c-9cbc-48a3-bd66-a432090ffaae">1,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjQtMy0xLTEtNjY5NTE_6ea25003-0d68-49d1-b84a-62f55b5939a3">993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjUtMS0xLTEtNjY5NTE_a43387c9-1ae2-4d0c-b95c-7ce090a2dd45">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjUtMy0xLTEtNjY5NTE_347d1a4f-a395-4021-b579-3363cf95be80">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjYtMS0xLTEtNjY5NTE_7985c28c-ed82-4793-9876-7cb55c5abb5e">21,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjYtMy0xLTEtNjY5NTE_1e5c9545-64c3-4c28-ba94-df8c36c37f6f">15,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjktMS0xLTEtNjY5NTE_1dbd4d59-b0d5-431f-addb-09490b38c257">40,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjktMy0xLTEtNjY5NTE_06b2173c-a87f-4ca5-ae12-fcd9ef38b267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMS0xLTEtODA0NDM_a095ecd2-f4d2-4551-8a36-934c51b0a43c">28,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMy0xLTEtODA0NDM_f0eb45fd-adb1-4f4f-a3d8-684cb017f027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMS0xLTEtNjY5NTE_a47b7ace-1a9f-4367-9bb3-3ca95e5a6e42">340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMy0xLTEtNjY5NTE_3a368476-99db-434a-b906-6d2467494152">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzEtMS0xLTEtNjY5NTE_e773fd4f-fb5b-47a7-8323-9f18250ccaad">11,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzEtMy0xLTEtNjY5NTE_79b09d1b-fc9f-4c7d-880f-ab76ac0e2856">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMS0xLTEtNjgzNDc_c7522a27-ceb0-42da-a275-b2082332f7a3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMy0xLTEtNjgzNDc_ca685ab7-53fa-4f95-a211-71e94c292227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzgtMS0xLTEtNjg0MTU_e25e2195-6cd5-46b5-b597-df714eefbb1c">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzgtMy0xLTEtNjg0MTU_25dc8411-9850-4348-9973-5d4b851a0f20">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of term loan issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzktMS0xLTEtNjg0MjI_f5afccf2-0ef5-4f99-907c-66e6b49abe94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzktMy0xLTEtNjg0MjI_0af79df7-d562-4636-a4c3-e37823f4f887">815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of deferred offering costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="tars:PaymentsOfDeferredStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMS0xLTEtNjY5NTE_dac50a4b-5c1b-43a8-8614-41c9d04ca008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="tars:PaymentsOfDeferredStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMy0xLTEtNjY5NTE_eca49071-e14d-4661-a013-6f4616600009">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDItMS0xLTEtNjY5NTE_c473dfab-d0f4-40d6-8a6b-15b3f4b98748">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDItMy0xLTEtNjY5NTE_1f307768-65be-4429-b2da-f542d9f0b938">19,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDMtMS0xLTEtNjY5NTE_6149f366-6d30-4000-8c27-efc8f598e8cf">5,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDMtMy0xLTEtNjY5NTE_cc421ae9-c28a-427a-ac05-dd71b03edf4b">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents &#8212; beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDQtMS0xLTEtNjY5NTE_8e9fc490-4196-47d0-911b-c83389b1f672">71,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDQtMy0xLTEtNjY5NTE_7a993087-27a2-49de-8604-e546d975737b">171,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents &#8212; end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDUtMS0xLTEtNjY5NTE_5e043622-741e-416e-b7a1-886f6d98dd3e">65,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDUtMy0xLTEtNjY5NTE_7850014c-db76-4786-8579-0e519ef358c9">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosures Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTEtMS0xLTEtNjY5NTE_01395023-2071-493a-b64d-953c5af46783">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTEtMy0xLTEtNjY5NTE_e2967be6-ef28-4bb2-967b-b2bdaeb7fbfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense paid in cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTItMS0xLTEtNjY5NTE_91d145ca-de78-4938-a684-f8980269cd4c">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTItMy0xLTEtNjY5NTE_4df08eae-8f9c-4e96-805e-f5a5662cabd8">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions of property and equipment included within accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTMtMS0xLTEtNjY5NTE_3a38b2b2-2623-4fe5-a418-5fe7c13c9f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTMtMy0xLTEtNjY5NTE_022cd54e-13e0-451e-b428-06adbe882d92">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred offering costs included within accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTgtMS0xLTEtNjY5NTE_908ddd35-7564-4a5f-88be-0662e8024fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTgtMy0xLTEtNjY5NTE_4341b296-7d6b-4acf-8bca-d184fd0ff371">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_882"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_31"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfNDM3NA_f4c301b3-f0c6-4e02-b6e4-4c0004abba83" continuedAt="i32b7f493a5d041bcb6eef3500acd2136" escape="true">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i32b7f493a5d041bcb6eef3500acd2136"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company&#8217;s operations currently consist of its preclinical and clinical studies, corporate administration and commercial leadership supporting planned business growth. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a limited operating history, no product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offering completed in May 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), proceeds from its out-license agreement, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfNDM3NQ_d8ba76fd-4c12-46ae-8554-201274f92522" escape="true">To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company&#8217;s management determined that it operates <ix:nonFraction unitRef="segment" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfMzU4MA_01c96ea5-365b-4eac-8a2a-0300ec507b0b"><ix:nonFraction unitRef="segment" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfMzU4MA_f35442e1-db7f-44d3-8cc8-6298122d8895">one</ix:nonFraction></ix:nonFraction> reportable operating segment.</ix:nonNumeric> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div></ix:continuation><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTM_e544a001-e6fb-4765-83bc-d514d8f2e352" continuedAt="ia8e592e9bc0e4b42b8b47d9d12a36420" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES</ix:nonNumeric></span></div><ix:continuation id="ia8e592e9bc0e4b42b8b47d9d12a36420" continuedAt="i3f1b8df1f1654c3690c7462b138dfe1a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTQ_3d0d5e48-3a5d-45d0-a34e-a250fc7e1da4" continuedAt="i35f633cf4b404b9e8bb0664ffde79ab9" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="i35f633cf4b404b9e8bb0664ffde79ab9" continuedAt="ic74d9429c006468db30df39c8c9d6b56"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.</span></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3f1b8df1f1654c3690c7462b138dfe1a" continuedAt="i338f2b42bb1d46e09841017ef49b777f"><ix:continuation id="ic74d9429c006468db30df39c8c9d6b56" continuedAt="ib2eeb3ca178946a494c0a9f144fd33e4"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders&#8217; Equity, and the interim Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023 or any other interim or annual period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial statements as of and for the year ended December&#160;31, 2022, reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div></ix:continuation><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><ix:continuation id="ib2eeb3ca178946a494c0a9f144fd33e4" continuedAt="ib9663cf11e4b488e9abed2807313c9aa"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ib9663cf11e4b488e9abed2807313c9aa"> license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss.</ix:continuation> </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2023, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;17, 2023, except as discussed below. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(ii) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODY_0ecf87ae-b8bd-4b0b-a0b9-445a5394d7fa" continuedAt="ib04f980a1368430186e8a8583827e867" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ib04f980a1368430186e8a8583827e867">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTU_0ff7cb9f-c300-4c0c-86ec-92e5b184626b" continuedAt="ib2096c0c99a047a0bbdb141e5b602467" escape="true">Marketable Securities and Long-Term Investments</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="ib2096c0c99a047a0bbdb141e5b602467" continuedAt="i44d6444c9892436eb6a8c26afee3a4c1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations. </span></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i338f2b42bb1d46e09841017ef49b777f" continuedAt="ib1fa4c8ab5cd4065bebde833a6199621"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i44d6444c9892436eb6a8c26afee3a4c1" continuedAt="i2b7960569da848d2b76865b154cbfe3a">Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</ix:continuation></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i2b7960569da848d2b76865b154cbfe3a">Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0NA_407bac6c-d97c-4ee1-ae52-cc80787b9f5a" continuedAt="i40895e17a5844b4db5c2411d39ed5bf0" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i40895e17a5844b4db5c2411d39ed5bf0"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Ng_8dd3a0b4-c4c1-4899-a654-8159f10738b8" continuedAt="if2b2276537d941f6bc6a7b1a174f1d61" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if2b2276537d941f6bc6a7b1a174f1d61" continuedAt="i096e4d818c87485888bc7c53ffbfddd7">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0">three</span> to <ix:nonNumeric contextRef="icff1c597f3fd4a3c9576292df2860f68_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU1OA_736bd0e4-9202-4676-a1d3-f9a84183c241">five years</ix:nonNumeric>. Leasehold </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib1fa4c8ab5cd4065bebde833a6199621" continuedAt="ib2da79db37f64013a4e94a0db64fb769"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i096e4d818c87485888bc7c53ffbfddd7">improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2023 and 2022.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vi) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTY_065befe8-c772-43fe-9c65-bcacb81e0d03" continuedAt="i672039e931e34164a83b993c185c73c1" escape="true">Concentration of Credit Risk and Other Risks and Uncertainties</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="i672039e931e34164a83b993c185c73c1"><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-5" name="us-gaap:DepositsAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODcwNg_4dcdc3d0-9d30-416a-ba4a-4ded0e2da082">8.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-5" name="us-gaap:DepositsAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODcyMA_9bfd03d1-3919-4ac0-8ee5-f61ad9c7164a">15.0</ix:nonFraction>&#160;million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#8217;s deposits and substantially all of SVB&#8217;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#8220;SVBB&#8221;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#8217;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#8217;s receivership.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODc_1b6a6285-a102-47d7-9336-031dbe43314d" continuedAt="i514182d61c804f7ea9e178308f075cdb" escape="true">Revenue Recognition for Out-License Arrangements</ix:nonNumeric></span></div><ix:continuation id="i514182d61c804f7ea9e178308f075cdb" continuedAt="i6be27cbd043d4f0a8376f4640cf8ea18"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib2da79db37f64013a4e94a0db64fb769" continuedAt="ice72959e59a246788affaa7d5470d932"><ix:continuation id="i6be27cbd043d4f0a8376f4640cf8ea18" continuedAt="i068d783941aa4bf1aa79586b3ced86c7"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ice72959e59a246788affaa7d5470d932" continuedAt="ie944ae61560b492597e51ae019f1b793"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i068d783941aa4bf1aa79586b3ced86c7" continuedAt="id5d311a0c3ed42e18b26005605d8de40">or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5d311a0c3ed42e18b26005605d8de40">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(viii) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODk_cdbfff3c-bdc0-427e-aa67-e051a2fa4788" continuedAt="ic2c18926fb4e44b887c04e033c59b39e" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ic2c18926fb4e44b887c04e033c59b39e">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODg_842eb305-8ae2-44f1-b3aa-419bd7cd045d" continuedAt="iedf906197f184a9ba659ca42701ea63d" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="iedf906197f184a9ba659ca42701ea63d" continuedAt="i478f95263afa49849592436be25fe227"><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than <ix:nonFraction unitRef="number" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3NA_9e64487a-3e1d-499b-88f3-55b8e9233e1f">100</ix:nonFraction>% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639">one</span> to <ix:nonNumeric contextRef="i53ea086e3521419c9e262a45add82d46_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU5OA_b53c7dca-40ee-4f44-a920-09b4ec9a847b">four-year</ix:nonNumeric> service conditions and a contractual term of <ix:nonNumeric contextRef="id8e869641ee94a998264205f21fc8531_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODc0Mg_f706a2c4-9884-41a8-8596-df3ac8ed9011">10</ix:nonNumeric> years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie944ae61560b492597e51ae019f1b793"><ix:continuation id="i478f95263afa49849592436be25fe227" continuedAt="i8f4bff26144d46769fdb217c2f7e220d"><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&#160;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i8f4bff26144d46769fdb217c2f7e220d" continuedAt="i65033402dd6a4a52a8a3d4f1c5015cd9">Dividend Yield</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i65033402dd6a4a52a8a3d4f1c5015cd9"> &#8212; The Company&#8217;s expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMTkxMTQ_291e095d-709e-4850-9ace-debf139c539e">zero</ix:nonFraction> because it has never paid cash dividends and does not expect to for the foreseeable future.</ix:continuation>  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTA_9d88ccda-3fbc-455b-9edd-0ac02f7afa0d" continuedAt="i870b30929c6e493b8c2eaf0df77f4240" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="i870b30929c6e493b8c2eaf0df77f4240"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss  per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTI_f1568308-d1b8-4ef3-871a-d9add910a4c6" continuedAt="ic3a454514da2470ba6ada15dcaa05562" escape="true">Comprehensive Loss </ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3a454514da2470ba6ada15dcaa05562">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xii) <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODU_890520a4-8a80-4acb-a621-67a1498d1c70" continuedAt="i30b7cdd130df421395f35f96722dcfc1" escape="true">Recently Issued or Effective Accounting Standards</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30b7cdd130df421395f35f96722dcfc1">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</ix:continuation></span></div></ix:continuation><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyNg_00db4e77-4904-4d2b-96f7-c40e43afe635" continuedAt="i85c41e83e556420bb7f06a294de3e385" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="i85c41e83e556420bb7f06a294de3e385" continuedAt="id0635ac8abbb4004a9d6a641ae24dd28"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyNw_e22f1b8a-fe85-4de8-8f63-087b0f2b03cf" continuedAt="i2476b5bf84ae4389a3e2de04dec9ab88" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="id0635ac8abbb4004a9d6a641ae24dd28" continuedAt="iae67fbffcdbe47b28b13d563fc39271c"><div style="margin-top:12pt;text-align:center"><ix:continuation id="i2476b5bf84ae4389a3e2de04dec9ab88"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9425df31da3a481584b439067cf07700_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0xLTEtMS03ODUyMQ_46c9e842-b7c0-4162-ada2-4eec08d0d1ed">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab9f798f0c849b6b6e313512298cd23_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0zLTEtMS03ODUyMQ_3ef1c19d-ebda-47b3-bb74-077c09cad76c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3636234782064fa8a83fa7367952b887_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy01LTEtMS03ODUyMQ_564538eb-ed2e-40e4-a5bd-d453b40e6309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy03LTEtMS03ODUyMQ_47242759-7374-498d-a623-626a4737207f">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8a90c2600d4884b61ed721cf411567_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0xLTEtMS02Njk1MQ_28d0ce96-ebb7-456a-8d52-cd9b2ee2ee16">65,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354a2222e5704982adaad60e04689993_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0zLTEtMS02Njk1MQ_6d47358d-acd2-48df-bd64-22fd1ed8db00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3fb4c1d1b74fc7bb77555b5885dcfc_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy01LTEtMS02Njk1MQ_52c58dab-4086-40f2-a2be-a635b75fa097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d9ee39e514d3c9f20ae2686e700bc_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy03LTEtMS02Njk1MQ_55de26aa-ce0e-411a-9944-ddbd077618fd">65,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826796d58f43453bbe3a4e4f0df2dade_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC0xLTEtMS02Njk1MQ_4346ccd7-be67-467d-a5fd-b1d6acf03e9a">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ead24808e6418abe1c6285968f2a8e_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC0zLTEtMS02Njk1MQ_a05fb42e-2ec3-4abe-addf-8bbbaa2e572c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7489f1c01f4040fa9027f3139aa5b960_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC01LTEtMS02Njk1MQ_513fa19b-79f5-4cd5-8f19-b4e8a8882ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC03LTEtMS02Njk1MQ_6389828f-5d83-451a-b363-3ec18f79b451">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892be22603d64788b51cf55111b69eba_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS0xLTEtMS02Njk1MQ_2e8ebc04-06d2-44ab-8bfb-5eec2b30a007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed0e212cc8b4b7aa51ff422f461de73_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS0zLTEtMS02Njk1MQ_9528d293-fb60-4c53-a5e7-3baaedeb9629">65,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida739d9e492041df8abac70acd6a4018_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS01LTEtMS02Njk1MQ_b49a9abe-f26c-4565-ae1e-7c9b6a865dce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS03LTEtMS02Njk1MQ_0c89eebd-3dde-4a33-bd0e-02ceeac8c795">65,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd774b344c242018371671a89a14ad3_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi0xLTEtMS02Njk1MQ_409085fc-6df2-4c1e-8bd1-fe1fa0732391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad928b2f434a4f91881e16edfff1f575_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi0zLTEtMS02Njk1MQ_1549ef4f-6b44-4b1a-a3ba-9fab2d64bcc9">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f154f954b443e482459e699ab62660_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi01LTEtMS02Njk1MQ_7ed6ce88-c05e-4fc3-9551-7bc8770e624a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi03LTEtMS02Njk1MQ_9f26ba85-1085-49a9-96ea-f19f4d63884b">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8b670522cf45f8ab84db74558ab9c2_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0xLTEtMS02OTE5MQ_53932f95-069f-4d40-8d91-5a3a24c0318a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ed5a6a9e3a45528f0d3c03542d3548_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0zLTEtMS02OTE5MQ_32c99069-a3ef-4ede-8877-e1a1edbf00c5">8,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78155dab98245379b7409e98a4d0db2_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy01LTEtMS02OTE5MQ_45288d03-37a8-4529-8390-c9c5085896e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy03LTEtMS02OTE5MQ_34e03dc6-15b5-496c-94a2-97639c913374">8,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95392055c6c4c689895a8ec69851578_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0xLTEtMS02Njk1MQ_d5323b5e-25b4-445d-bbbb-aa20b9edbba4">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0zLTEtMS02Njk1MQ_af7d3eae-f091-4c8e-8947-e734b8b12678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy01LTEtMS02Njk1MQ_3c22c962-9d88-41a4-8434-c4baaca613f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy03LTEtMS02Njk1MQ_670eff98-237a-4329-af5d-77033403fcc2">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95392055c6c4c689895a8ec69851578_I20230331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC0xLTEtMS02Njk1MQ_344e1540-4184-4195-8d5e-f839cfd73105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC0zLTEtMS02Njk1MQ_e19f6155-9fef-44d7-a5c0-f5e67c618b8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC01LTEtMS02Njk1MQ_b7383fda-03dc-49e2-9916-d6ab59486e60">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC03LTEtMS02Njk1MQ_d3f55986-2818-416f-8802-f860239736cb">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95392055c6c4c689895a8ec69851578_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS0xLTEtMS02Njk1MQ_b9a9c626-41c8-43c3-87cf-0d82793fee6b">115,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS0zLTEtMS02Njk1MQ_84eb693b-233b-4c12-9e39-9b12050578cb">86,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS01LTEtMS02Njk1MQ_47681152-c3fb-4997-b5f6-77c966ac2d9c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS03LTEtMS02Njk1MQ_119b7308-b2b3-497e-bc29-1d8ef29257de">201,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecb831e068f4e4eba5855f83c097192_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtMS0xLTEtNjY5NTE_4093f8f0-bd24-4469-b809-34acb927eec5">64,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed529994d5a489a923621611c8dd9e7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtMy0xLTEtNjY5NTE_99f63f26-89a9-403a-ad98-cbe91a1d1ea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1488cc93f0044561a3bd35cf45b241cd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtNS0xLTEtNjY5NTE_7a20825a-20cf-4c7e-8a2e-d1a35d078e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtNy0xLTEtNjY5NTE_7a21151d-1a22-43ba-bbcb-628b1f13e439">64,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc742ef4d3f499281a5e3db27036808_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMS0xLTEtNjkyMDE_b234f13a-5613-4668-aece-0e54c19eefce">69,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b127b6e20648509ccfc27bc1d93571_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMy0xLTEtNjkyMDE_739f6411-2a9e-4347-bf20-ed6200815632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30727f2c96b341fe911ef415de4c348f_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNS0xLTEtNjkyMDE_dc34e73e-42c0-4e92-9016-436658cf27c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNy0xLTEtNjkyMDE_70c66290-b57c-4dd2-a927-3277dc1a0c2f">69,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55798f7922ed4f90b40cf890e7c58539_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMS0xLTEtNjkyMDE_001a9cbe-4fec-4cf5-bda0-f07d8416b21f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb0218825134bd9b61163220979283d_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMy0xLTEtNjkyMDE_2627830c-3837-4271-807c-984c7c87dffd">60,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd8a154fb694ad786f8c8da8d391a16_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNS0xLTEtNjkyMDE_49353904-81b6-434f-bcd8-dd5ba75695f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNy0xLTEtNjkyMDE_9ba64abe-0278-4709-8bf5-ba36aed64cb0">60,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f2b2e02b4b45fea07db876890aa3d5_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtMS0xLTEtNjkyMDE_e3243a25-f293-4c5c-a337-06311e97d335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73e18a89cf74db4b49c5a7a82c5d5de_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtMy0xLTEtNjkyMDE_d55770a6-2fd9-45a7-9a5b-30167625eff8">11,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b81c93d9584d62b21986ea577e3937_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtNS0xLTEtNjkyMDE_fb4481a0-6d43-43e0-a42e-890f373d2841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtNy0xLTEtNjkyMDE_824b5ea4-f5b9-4ccb-b29a-d624314a7b81">11,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2171876554134f82b5a5cea826938d46_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktMS0xLTEtNjkyMDE_4e254b9d-b0b7-4827-bf90-0f64d9d82eca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33af9a3f4c25435dae84fc4f1bab1c97_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktMy0xLTEtNjkyMDE_b841bf77-742e-430b-8377-e85ec471eb8d">10,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae22aa8959ba409fbcfaf7febb83d253_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktNS0xLTEtNjkyMDE_a49c2dda-ecff-498e-b79d-3fa6b3b0a78d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktNy0xLTEtNjkyMDE_40b06e9a-d871-45d8-bba9-a2478516d239">10,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtMS0xLTEtNjY5NTE_d245bc7b-5173-4efa-b980-68d38a6d34c9">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtMy0xLTEtNjY5NTE_193c6a3b-39b8-4397-95f7-7b757b7b5874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtNS0xLTEtNjY5NTE_ed66b8c6-17fa-4d0f-a985-5d5b3e2dbe8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtNy0xLTEtNjY5NTE_e3a6e222-896c-4c7e-a99f-53193e773e73">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMS0xLTEtNjY5NTE_5721436b-95b7-4ca9-ab72-9d7f9ebadcff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMy0xLTEtNjY5NTE_206c1643-b961-4efb-90b3-4c2d55f92d40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNS0xLTEtNjY5NTE_be481568-2e34-4839-b77c-f9389c7e17ae">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNy0xLTEtNjY5NTE_aae0445d-94aa-4b5f-add5-7b8281bd35cd">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMS0xLTEtNjY5NTE_2682de70-7edc-4ec2-a363-a68bc2a02f73">134,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMy0xLTEtNjY5NTE_a441f44b-9b6f-4ce0-9e9f-edfd70d450c1">82,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNS0xLTEtNjY5NTE_a8a48069-985a-4c2c-89a1-0d1e6c383362">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNy0xLTEtNjY5NTE_02fed893-5968-4344-9195-fdf00ece87ac">217,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds and U.S. Treasury Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper, Corporate Debt Securities and Government-related Debt Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LianBio Common Stock and Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio, executed a warrant agreement for the Company to purchase, in <ix:nonFraction unitRef="tranche" contextRef="i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331" decimals="INF" name="tars:WarrantAgreementNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTEyOA_6878dc39-3a00-4c34-ae7b-0de923957657">three</ix:nonFraction> tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first <ix:nonFraction unitRef="warrant" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:NumberOfVestedWarrants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2Mjc2OA_ba5aa2ab-4ae7-4d85-aa2d-a0a626000689">two</ix:nonFraction> tranches were vested and exercised as of December 31, 2022 and converted into <ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="0" name="tars:EquitySecuritiesFVNINumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2Mjc2MA_85c1c2c5-7916-45f5-8c52-b8fc981d4a66">156,746</ix:nonFraction> shares of LianBio common stock as recognized at fair value within long-term investments on the Condensed Balance Sheets as of March&#160;31, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iae67fbffcdbe47b28b13d563fc39271c" continuedAt="i69436fdcd0b84df6b49ed4ba33cc0b9a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of regulatory milestone achievement for vesting, and the application of an assumed discount rate.</span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyOA_285a9734-699c-4b17-b66f-8393b0bcff0f" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfMS0xLTEtMS02Njk1MQ_241c2a62-a81d-4625-ae5e-0b27b19e2f9d">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfMy0xLTEtMS02Njk1MQ_36a313b3-b4e2-44f7-95cd-1ae11636398c">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfNC0xLTEtMS02Njk1MQ_72f45a41-34e3-4935-902b-c0aec6fbbbb8">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfMS0xLTEtMS02Njk1MQ_c27da141-ea13-43e8-9d2c-955c8c4eb7ab">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfMy0xLTEtMS02Njk1MQ_bd0c71fb-75f5-4a56-86b3-6fcd7e1827d8">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfNC0xLTEtMS02Njk1MQ_713d18b4-5d81-4f6b-9b53-f03f051c24b2">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyOQ_5ecafd93-066a-4b84-b524-b4bb6cd4d98b" continuedAt="i31ecf888e01f479cb9e2ee85079ace27" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy0xLTEtMS03ODQ5NQ_6bd65590-9b5c-4548-83e8-62e99f8302c9">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy03LTEtMS03ODQ5NQ_f78329a3-ad5b-43a8-b1ad-7288d6d4e6a4">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy0xLTEtMS02Njk1MQ_fb14c47d-1c8a-470b-91bf-8f783ea3e108">65,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy03LTEtMS02Njk1MQ_99bb6e18-93d6-4aa5-bca3-f67f2005cb78">65,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfNi0xLTEtMS02Njk1MQ_63999868-d800-4169-ad3b-c6edd49e4f79">65,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfNi03LTEtMS02Njk1MQ_71978a06-5206-43f1-85c6-9f5acf5242be">65,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS0xLTEtMS02Njk1MQ_f5ad4d08-06c5-468c-b108-406e848b273a">49,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS0zLTEtMS02Njk1MQ_e633a758-164e-45b5-b5df-6f416d06a8bf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS01LTEtMS02Njk1MQ_1a278e55-9c17-497b-bceb-0571b2f2738c">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS03LTEtMS02Njk1MQ_aede23dd-b22a-421a-ad35-0624c20baece">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtMS0xLTEtNjY5NTE_b3803539-e3c8-47d9-b9b0-6492b71af579">65,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtMy0xLTEtNjY5NTE_3c319261-2cd4-4b27-bab4-25b66f4a2745">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtNS0xLTEtNjY5NTE_b1231e53-1ad3-48ce-8722-e4d53caa9c03">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtNy0xLTEtNjY5NTE_3608e7b7-7732-4ea9-92fc-cb3a8fc8836d">65,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMS0xLTEtNjkyODQ_7ed5f3b9-8ec9-40d7-a18e-7103f54cec4a">12,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMy0xLTEtNjkyODQ_df049489-bc5d-488d-a73f-e2cb6be24487">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNS0xLTEtNjkyODQ_4aae7040-bfe4-4b31-8469-0fe3961a8e95">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNy0xLTEtNjkyODQ_ba5b001e-fe11-46cf-9750-97baf727bfb2">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMS0xLTEtNjY5NTE_9dc33b52-f1e0-4fe8-bb17-fbf2f168c9bb">8,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMy0xLTEtNjY5NTE_a291950c-0319-41fe-8775-e1cd2184f0b7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNS0xLTEtNjY5NTE_fccc1d2e-6156-41b5-b0c6-88d21c17a901">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNy0xLTEtNjY5NTE_706bed7e-d833-446e-9fe2-3902d7fc9f2a">8,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItMS0xLTEtNjY5NTE_ff95fb69-ba61-4828-9307-f9ecb92aab3f">135,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItMy0xLTEtNjY5NTE_d810a9c0-57c0-42c0-ae27-f829b049b987">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItNS0xLTEtNjY5NTE_97d605e8-d7bb-4d74-abbe-ea709824733c">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItNy0xLTEtNjY5NTE_acad9997-18f4-476f-b8e9-80bd83a01b8b">135,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtMS0xLTEtNjY5NTE_570d6cd3-b532-4e52-8139-7ab011c3fa43">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtMy0xLTEtNjY5NTE_1c302268-9210-4e0b-9990-237ddb1f1bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtNS0xLTEtNjY5NTE_05838f07-cbd1-4715-8cae-6eb7cc34ddc0">925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtNy0xLTEtNjY5NTE_4e888692-16d3-4fdc-a581-2b1051a7b494">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtMS0xLTEtNjY5NTE_6c57a98d-5807-4c76-b464-a4aeee91353e">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtMy0xLTEtNjY5NTE_1086b238-8394-48d9-9677-f10ac62a3637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtNS0xLTEtNjY5NTE_62f84c83-0342-48c2-bf39-7d62339c7fc4">925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtNy0xLTEtNjY5NTE_59bf1cb8-896b-4ff3-9cdf-2e50dcd1eb40">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i69436fdcd0b84df6b49ed4ba33cc0b9a"><div style="margin-top:12pt"><ix:continuation id="i31ecf888e01f479cb9e2ee85079ace27"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMy0xLTEtMS02Njk1MQ_baf2ce28-a17e-4028-8243-50bf27dd52c4">64,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMy03LTEtMS02Njk1MQ_1fd75e58-f50c-4e6a-a7be-8ff9b9aa4359">64,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC0xLTEtMS02OTI0OQ_7b606e82-346a-493a-a868-2152eb1d1d47">4,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC03LTEtMS02OTI0OQ_18f56de4-625a-4a0d-bbfe-3d62ddeac753">4,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNS0xLTEtMS02OTI0OQ_8977159c-b7aa-492b-be26-8ad51e89ec1f">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNS03LTEtMS02OTI0OQ_956ae68e-6160-4f5a-8170-8d32f08cfa01">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC0xLTEtMS02Njk1MQ_e9a907cf-8f77-4b76-8898-48bb0c11bbd9">71,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC03LTEtMS02Njk1MQ_4eddb5a0-3793-42af-a50d-9aca48d468a7">71,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS0xLTEtMS02OTI1Nw_a2839c9a-d06d-4c3f-92e1-d34dafa3d890">69,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS0zLTEtMS02OTI1Nw_43a00a3c-7772-401d-a694-590085e5d1df">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS01LTEtMS02OTI1Nw_44a64aa8-5b13-4310-9862-50d97feca8bd">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS03LTEtMS02OTI1Nw_e8f12a8d-192e-4a53-96f4-6f5957cd29ee">69,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtMS0xLTEtNjkyNTc_59db50d0-56e4-4c4f-8f78-d7693ca4099e">58,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtMy0xLTEtNjkyNTc_31e897ee-a5a0-4032-86bf-9b7f06a16f7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtNS0xLTEtNjkyNTc_07979a51-9123-4841-8beb-77ed75428cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3631e96ef564c579622dff441e974e0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtNy0xLTEtNjkyNTc_19255677-e322-4acb-8cc6-35cff4a2d1c4">58,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtMS0xLTEtNjkyNTc_009f2ad2-7b72-4c5f-bcaa-fc46cdc3cd7a">11,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtMy0xLTEtNjkyNTc_833a1911-52c5-42a6-8a05-029746b2b22d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtNS0xLTEtNjkyNTc_f236a1a8-d496-49a0-8e9d-bc8a047c3a55">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtNy0xLTEtNjkyNTc_ac677b4b-e6da-4bfd-a250-08f16f89dee8">11,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy0xLTEtMS02Njk1MQ_8aacd49a-5f15-4703-a4a0-56b180f05892">5,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy0zLTEtMS02Njk1MQ_86532237-7b98-407b-9aec-b3d7b82273ae">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy01LTEtMS02Njk1MQ_84d7ccd0-d20d-4144-8168-1a7688e725a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id293f7748a664952b30b29710a563efc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy03LTEtMS02Njk1MQ_2b4fd838-da8d-4827-851f-1081a5e579fd">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC0xLTEtMS02Njk1MQ_ba6e864c-635e-40a4-acbe-1e3220b3261e">145,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC0zLTEtMS02Njk1MQ_ccf04d75-0cf0-4718-b694-a7bbb0bb2560">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC01LTEtMS02Njk1MQ_9de899ab-5af0-426d-a100-d637c5612400">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC03LTEtMS02Njk1MQ_03d85b46-13e5-4e26-99ce-ad185a7fcbb7">145,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtMS0xLTEtNjkyNzI_1e1d32ac-acfc-4fca-b7cb-a581f9f30d60">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtMy0xLTEtNjkyNzI_f446c52a-c8ce-49ca-ae97-4e210c689876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtNS0xLTEtNjkyNzI_34669c40-93b5-40f3-9c44-feed00468035">860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtNy0xLTEtNjkyNzI_fea0266e-e846-40bc-a470-dc601491f737">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctMS0xLTEtNjkyNzI_06627abb-d8e1-49e9-b69b-d19640b57fcc">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctMy0xLTEtNjkyNzI_a0da8017-2041-4a7f-97a6-209214e3a764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctNS0xLTEtNjkyNzI_0546b9bb-fdc6-4d4e-a709-8e7c157285f7">860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctNy0xLTEtNjkyNzI_de60fe7f-6d74-4f04-a7bd-552a68bee8d3">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. <ix:nonFraction unitRef="security" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ2MQ_e618bfc9-6cea-4c83-9f56-ab42500c1c74">Four</ix:nonFraction> securities have a contractual maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyNw_8c90302e-5d65-4068-882b-93af76900292">one</span> and <ix:nonNumeric contextRef="i02393f415335453b90d7884e68e659ee_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyOA_075ea64b-0b7b-4f54-aa3a-d9a2ddf10e3b">four years</ix:nonNumeric>, with an estimated fair market value of $<ix:nonFraction unitRef="usd" contextRef="i533c566d81f044ba9eae18e652238819_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDUyNg_0f67f7f9-5673-4a8d-87be-384c8a68c4c3">5.8</ix:nonFraction>&#160;million and amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i533c566d81f044ba9eae18e652238819_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDU0NQ_88d57da0-d9e7-413f-8b2c-597c8eea951e">5.7</ix:nonFraction>&#160;million. As of December&#160;31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. <ix:nonFraction unitRef="security" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ2OQ_550f1354-0860-454e-b333-862747d01fec">Three</ix:nonFraction> securities have a contractual maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1MQ_814ddb0b-d044-4453-9608-47383f7c1878">one</span> and <ix:nonNumeric contextRef="i54617256e4f143fc8a0b0c96a6a280ce_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1Mg_63742686-f6b6-4673-974e-f9a51c15ad74">five years</ix:nonNumeric>, with an estimated fair market value of $<ix:nonFraction unitRef="usd" contextRef="i762203c8d41341b6a256214747c9a07c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ4NA_e67d9b32-a5f3-4b13-8806-1916653dce8e">4.6</ix:nonFraction>&#160;million and amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i762203c8d41341b6a256214747c9a07c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDUwNw_f14a08e5-6768-4537-88ad-8a729706b90b">4.6</ix:nonFraction>&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, all available-for-sale debt securities have gross unrealized losses in a continuous loss position for less than one year. As of March&#160;31, 2023 and December&#160;31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.</span></div></ix:continuation><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyOA_4727c24a-3589-4122-804a-28378e123d2a" continuedAt="ifc9dedfbb19442719409e406ddfdb1d3" escape="true">BALANCE SHEET ACCOUNT DETAIL</ix:nonNumeric></span></div><ix:continuation id="ifc9dedfbb19442719409e406ddfdb1d3" continuedAt="i9dff884486ce49df9750a239a3c9c735"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyNA_f63e3c9b-f2a5-4385-bf15-3c63e4df14d9" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61cebed72353446c84a867bf93927fcb_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMS0xLTEtMS02Njk1MQ_af6e0aa6-feeb-4b11-85fa-7d0467b57fda">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89b78a42a4429a8d3f77392ce80a4a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMS0zLTEtMS02Njk1MQ_347d56de-674d-4d2e-b8ce-e52c0e37b836">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9112849a364d638fb3efe500b2b222_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMi0xLTEtMS02Njk1MQ_21628c24-aa22-4189-b036-c5422fb85d11">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd02acbbe7a4774a2097f5656e5f09d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMi0zLTEtMS02Njk1MQ_e04fd966-c685-4a29-9469-debd63427ca1">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8f8b00797641848f2b5a4b1b905ee3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMy0xLTEtMS02Njk1MQ_75852bac-69b4-4ea9-807e-f706a65c394f">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie853a328a5ec41d3972f307e7901c482_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMy0zLTEtMS02Njk1MQ_816a8a5b-89df-4184-b96f-7a5440721784">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ff25d218e04f7a9b1566f714bb8346_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNC0xLTEtMS02Njk1MQ_b339ac11-716a-4bd5-a8fe-5d2c378ab859">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db3a5e7cdb34537b766bd622dc616b9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNC0zLTEtMS02Njk1MQ_877d59a7-3a9a-4ce4-8f11-b8801898010b">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNS0xLTEtMS02Njk1MQ_e49f3b44-36ac-47bb-b049-7b0bd137ee68">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNS0zLTEtMS02Njk1MQ_85b82105-15a0-44e3-9847-dd4d6749ebfe">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNi0xLTEtMS02Njk1MQ_12ba27e5-4cfe-4356-b098-f186595c1aa1">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNi0zLTEtMS02Njk1MQ_d0c4c518-5866-47ec-932d-79eee0128401">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNy0xLTEtMS02Njk1MQ_2cb1c2df-7902-4178-bfe5-7e26bc51236b">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNy0zLTEtMS02Njk1MQ_7591c593-9300-4a1c-a08e-95ff75ed63da">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfODY1_103390f3-8998-4c42-a547-38c5e7dc2192">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMjE5OTAyMzI1ODA1Mg_a0de1c74-9da2-4e21-9e58-79458f4cd7fc">0.1</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9dff884486ce49df9750a239a3c9c735"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Other Accrued Liabilities&#160;</span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyNg_1b5f6ac2-af40-492a-9b7e-837140b5e647" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMS0xLTEtMS02Njk1MQ_5a1de8ee-2208-4374-a089-acf657727c2d">7,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMS0zLTEtMS02Njk1MQ_b990fb05-2f82-4d1b-936b-76cfd7f610e6">5,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMi0xLTEtMS02OTY5NQ_c0a80a0b-bcb2-4d4b-b2ee-93034e84323d">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMi0zLTEtMS02OTY5NQ_28f1d87e-cf1e-410f-a5f4-59b81e6f72ca">3,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMy0xLTEtMS02Njk1MQ_e7006865-a42d-4755-b6d3-a30cabce120e">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMy0zLTEtMS02Njk1MQ_507f3f41-4c9c-4921-aa9f-e2670abf577c">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNi0xLTEtMS02Njk1MQ_1f461dcc-98d2-409a-90fd-4c190b64430b">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNi0zLTEtMS02Njk1MQ_a0cfdf65-c670-470b-986c-e41dce918870">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNy0xLTEtMS02Njk1MQ_7f5d88b6-6cb4-46fc-8eeb-6d514820165d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNy0zLTEtMS02Njk1MQ_c48da500-7be5-4e31-93b8-90f931e39385">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfOS0xLTEtMS02Njk1MQ_7061ee9e-2475-4a79-8a69-559d5d7ec10b">9,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfOS0zLTEtMS02Njk1MQ_39937816-3f7d-4322-9e43-c180fb43e1bc">9,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTE3OA_ebf82b81-0bb1-4df3-86be-abcd68df8498" continuedAt="i1d1a6a584d644734b01f4a30a742d364" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="i1d1a6a584d644734b01f4a30a742d364"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offering</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an  initial underwritten sale of <ix:nonFraction unitRef="shares" contextRef="i917bf9bfe034449b834be912de58d1fa_D20220501-20220531" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDQ1OA_ba22c99f-59e2-43ab-9f00-30b3693821d6">5,600,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e27f78c37544ca1b323673fc30d9a3b_I20220531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDUwMw_94c510e5-de20-43ae-a72b-b919ad5b8b56">13.50</ix:nonFraction> per share. The Company also granted the underwriters a 30-day option to purchase up to <ix:nonFraction unitRef="shares" contextRef="iac59350831b24dfdacee66f79da8ab72_D20220501-20220531" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDU5NA_5a4ba64e-39a9-4203-81c8-2832a74dc7ad">840,000</ix:nonFraction> additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of additional <ix:nonFraction unitRef="shares" contextRef="ib4149d89cf8448a9a0e2ea0b40d6ac4c_D20220601-20220630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDc2Ng_8e5175b6-1321-49a1-b928-dc33d392dbd8">289,832</ix:nonFraction> shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="ide4416d2143c4221be97d977037586b4_I20220630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDc4MA_1dcd61dc-f24a-4e0c-9115-b06f587cc613">13.50</ix:nonFraction> per share was concurrently completed. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross proceeds from this offering were $<ix:nonFraction unitRef="usd" contextRef="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630" decimals="-5" name="tars:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDg2OA_e4b328a0-5e5e-4ccd-b953-59d29e3a2e76">79.5</ix:nonFraction>&#160;million (before underwriting discounts, commissions and other estimated offering expenses), resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDk4NQ_7cbb183a-5f3a-4cdb-bf06-08eb36d09d67">74.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE4ODA2_97dcfbe2-d4b3-428d-b769-315f54dd1172"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE4ODA2_b948f31c-7fcc-40da-95a2-a0bfe9a3c1e8">26.8</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE3MTMx_5b1054ab-f1d2-4101-bade-5b989bbf2788"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE3MTMx_df551c2b-4088-4310-b3ad-befd0ae00834">26.7</ix:nonFraction></ix:nonFraction> million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:CommonStockNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMjkx_f373f1dc-0e59-489a-a181-d9ce0ad00422">one</ix:nonFraction> vote. </span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTE3OQ_d1c6a39b-7681-4dfa-9569-4aa0e4178708" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMS0xLTEtMS02Njk1MQ_895e2e64-a9b4-4688-a591-64e9469e3fcb">8,068,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMS0zLTEtMS02Njk1MQ_408f4d5d-5a5e-483a-b633-46da2645c6a3">8,346,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMi0xLTEtMS02Njk1MQ_399d934f-d33b-44c1-b1b9-695c8436fc06">2,930,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMi0zLTEtMS02Njk1MQ_4cfda4ea-0c62-459c-9084-8ac9e63a6ff7">2,663,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMy0xLTEtMS02Njk1MQ_da0bdc20-08a9-4fd1-a2fc-1a17bd43dbdf">4,596,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMy0zLTEtMS02Njk1MQ_51d94538-2dcd-4cfe-acb1-700535698063">3,899,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNC0xLTEtMS02Njk1MQ_1c085c6e-6cb7-469f-a476-58b5295366cb">1,128,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNC0zLTEtMS02Njk1MQ_a16aeb7e-fe87-4051-8082-27ba01029d7f">551,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNS0xLTEtMS02Njk1MQ_09fa9596-35de-4237-833d-30e216b2a135">16,723,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNS0zLTEtMS02Njk1MQ_588c4597-62bc-45ff-874a-e7274b6c5838">15,460,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_46"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjI5_c051f2a4-004e-448a-97ad-e2b1e51b5f81" continuedAt="i6f7e31269b0e45a79d03f575211df0f9" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i6f7e31269b0e45a79d03f575211df0f9" continuedAt="i9a5ecf6c22f6415a908a428992f222db"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjMw_3f4dde1c-a2d2-4fed-b080-920f775eb529" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:70.728%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bc68703c824e77bffd6af8ae80c0f5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMi01LTEtMS02Njk1MQ_40aa455c-5a4f-4236-b941-82b6a4b809b9">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6729c6febce8422b827027ebc9a6d64e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMi03LTEtMS02Njk1MQ_7c116d60-86df-47ae-a681-cc51ad82aeed">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fca5aed6f4a76b7dd655630e82a4b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMy01LTEtMS02Njk1MQ_b29dd3f8-4329-402d-8766-5a670b38f102">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cb4582644f423d9136ef1e85e60b7a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMy03LTEtMS02Njk1MQ_caf0a46d-3096-49bb-926e-87291e591893">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfNC01LTEtMS02Njk1MQ_4ba7861d-fa52-448b-b0e4-4c989ea31ce4">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfNC03LTEtMS02Njk1MQ_0d57066b-1e32-4cb8-b15b-b1ecca92afc2">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNA_3e53ce49-d794-46f9-a2c2-e539c4518cce" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMi0yLTEtMS04MjUzMA_ec94107c-fbc7-4604-b637-2a0f2ea144a0">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMi00LTEtMS04MjUzMA_522ba851-756c-45da-969a-251e2689cf35">1.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMy0yLTEtMS04MjUzMA_d1608c70-46d0-49fc-b100-af3af70ed682">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMy00LTEtMS04MjUzMA_3fa60cc3-c7e5-443a-8928-3794c2b625d7">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNC0yLTEtMS04MjUzMA_4c98719f-9312-4b43-8015-e72a0739b01d">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNC00LTEtMS04MjUzMA_0a42475c-a470-4ab4-b672-665811851098">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNS0yLTEtMS04MjUzMA_e9724514-afbc-4153-b722-9f2e2f3a455d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNS00LTEtMS04MjUzMA_48378622-c600-4688-a981-18b70f7558ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNi0yLTEtMS04MjUzMA_a2c047c0-ce3a-4641-a892-511e7cb185fd">15.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNi00LTEtMS04MjUzMA_c0ae970d-26e0-4313-8d69-91f3351a1927">19.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNQ_dd4e2f01-4a70-4c12-84e8-f82c77ce757b" continuedAt="i493a4ae65b3c4e99a04cb8a357090a5e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2023 was as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS0xLTEtMS04MjMyMQ_f32470d5-92ba-4c6b-b4c6-62e7f92ecd09">3,899,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS0zLTEtMS04MjMyMQ_4ea0ca74-6169-4283-a607-563b555c326b">16.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS01LTEtMS04MjMyMQ_7a654af0-4ece-4fa3-aea2-0c360a42cc4c">8.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS03LTEtMS04MjMyMQ_dcb6231b-a8c4-4f5d-873e-fcbf956b754a">19,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMi0xLTEtMS04MjMyMQ_305241dc-c732-416a-b67d-b82308517c72">728,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMi0zLTEtMS04MjMyMQ_881aae5d-024a-46af-9274-8ab09015c2f3">15.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMy0xLTEtMS04MjMyMQ_8913c474-df77-42f0-8156-bd8364b13d5b">6,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMy0zLTEtMS04MjMyMQ_5049415e-2def-486c-8cf1-3386e07c8788">2.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNC0xLTEtMS04MjMyMQ_ecebb086-e1da-4c9e-9a71-dd585e8afef1">24,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNC0zLTEtMS04MjMyMQ_f9ca758e-ec28-4e60-9450-e384086100c0">21.19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS0xLTEtMS04MjMyMQ_82f8ee3a-12c9-4c23-91b4-769d6d2c9346">4,596,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS0zLTEtMS04MjMyMQ_b2e682b4-69f5-4eed-8ae0-88a67520b256">16.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS01LTEtMS04MjMyMQ_ac8252bc-341a-42a3-971c-1542b6195379">8.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS03LTEtMS04MjMyMQ_35c8b8bd-fc48-496d-ad6b-2693192c4715">15,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi0xLTEtMS04MjMyMQ_7082884c-2d1f-4074-bb3b-a8ff00cf88fd">2,028,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi0zLTEtMS04MjMyMQ_cb637966-0fee-48c0-a6ea-02f093587e68">14.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi01LTEtMS04MjMyMQ_3e0f4937-878b-4a3b-a96e-19a6d65863dd">7.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi03LTEtMS04MjMyMQ_dfa959a9-d943-4432-9849-808a3954724a">12,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy0xLTEtMS04MjMyMQ_06d5090a-b169-4c05-b11d-e53bd97550e4">2,568,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy0zLTEtMS04MjMyMQ_1a42233c-94ff-4a17-afe6-60d5301ae343">18.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy01LTEtMS04MjMyMQ_bd84ba47-a22a-46c3-be33-44ce6c677eaf">8.83</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy03LTEtMS04MjMyMQ_700048cb-72eb-4ae3-8d65-9017a48b94ee">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:continuation id="i493a4ae65b3c4e99a04cb8a357090a5e" continuedAt="ice3f3722695245379bc2fc84b2f96ef4">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ice3f3722695245379bc2fc84b2f96ef4"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2023.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4Mjg2_8d8825d0-0498-490c-a212-a62681db0566">29.8</ix:nonFraction>&#160;million of unrecorded compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of <ix:nonNumeric contextRef="i8503e32597854aa6a46c8b8515cc5b3d_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzIw_5d4f1ba7-9b31-45da-a96a-ff8f85e8502b">2.5</ix:nonNumeric> years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNw_e1b152f3-c5b0-48d5-ab5e-c6246f4fd024" continuedAt="i000d6c33885348d38a70dad2c8619928" escape="true">Restricted stock unit activity during the three months ended March 31, 2023 was as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><ix:continuation id="i9a5ecf6c22f6415a908a428992f222db" continuedAt="i1a4da0b3917747e688f04ef1e6f0daae"><ix:continuation id="i000d6c33885348d38a70dad2c8619928"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i514d107167894741a8b7f284d591b2b0_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMS0yLTEtMS04MjQwMA_698d3245-521f-4c05-8a3f-6062be64dfb0">551,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i514d107167894741a8b7f284d591b2b0_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMS00LTEtMS04MjQwMA_efdbdc4f-4616-4975-96e3-f3f99fc9b5d9">17.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMi0yLTEtMS04MjQwMA_ecc7594e-4141-4cf4-94b0-a1e07b2b9ad9">647,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMi00LTEtMS04MjQwMA_308398bc-4dcf-4e37-b2ff-5f9840d5a1a3">15.24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMy0yLTEtMS04MjQwMA_5cdfc6ff-6238-4d04-88aa-54e6590c599d">66,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMy00LTEtMS04MjQwMA_56acb146-d5fe-4e44-8f75-142adc412027">19.15</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNC0yLTEtMS04MjQwMA_d795517c-6883-4344-9455-50fe83394c75">4,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNC00LTEtMS04MjQwMA_73c92fde-c773-4266-a2e5-db10723c0609">19.40</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNS0yLTEtMS04MjQwMA_fe473699-fcc0-4f56-8fe2-8863267a6358">1,128,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNS00LTEtMS04MjQwMA_2035e6f9-e239-4a68-81f4-1a656dc0993d">16.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1a4da0b3917747e688f04ef1e6f0daae">As of March&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzA1_f034d1b1-6643-42c9-a6b2-e1b3bdddff23">16.8</ix:nonFraction>&#160;million of unrecorded compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of <ix:nonNumeric contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzMz_80ec5ddb-6abb-441d-9ba7-fbb4ac0d1960">3.5</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDA2_ce9b38e9-afaa-40e7-b5df-f2a3fadaddbd" continuedAt="i4bcd64ead5494dd1aff90238b7187d6a" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i4bcd64ead5494dd1aff90238b7187d6a"><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDAz_c722b0f5-b623-467b-a851-d854ee345fb5" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:70.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfMy01LTEtMS02Njk1MQ_fdc71e83-a940-4584-a433-63f96c290c57">23,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfMy03LTEtMS02Njk1MQ_8514c88b-c44e-4267-b2af-c28243183e5a">20,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC01LTEtMS02Njk1MQ_a77ce0ed-98e4-45ae-91b2-38eea7fc43f5"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC01LTEtMS02Njk1MQ_f03200f5-b735-4dc8-b206-0854392918e0">26,742,023</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC03LTEtMS02Njk1MQ_6ee8f735-49fc-4282-9758-397f1aa86a7c"><ix:nonFraction unitRef="shares" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC03LTEtMS02Njk1MQ_890e09c7-e1e7-4ab8-a1e0-21bd517337e0">20,710,224</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS01LTEtMS02Njk1MQ_d87b9876-305e-445c-b58d-6bfe40d86635"><ix:nonFraction unitRef="usdPerShare" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS01LTEtMS02Njk1MQ_edf5e02d-854d-4360-bf13-432f6a11b3c6">0.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS03LTEtMS02Njk1MQ_5a418156-65b9-4a9e-adf3-5c1419319887"><ix:nonFraction unitRef="usdPerShare" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS03LTEtMS02Njk1MQ_9f17b9a8-3620-453c-8bf9-8a0a6be5d2ab">0.98</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDA0_fc033449-51e4-4758-8544-49058822dfe2" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68cb6ee1927b4f99ada59e4d064573f2_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMi01LTEtMS02Njk1MQ_990991af-75ae-4bda-9426-e3a9637bdec0">4,596,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ded64e9a23d4e3ebbacb7b216bb928a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMi03LTEtMS02Njk1MQ_0de931eb-8196-4edb-9cc3-722b1d61d300">3,561,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b81ae74dba9486c9d47805cc82049c8_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy01LTEtMS03MTM5Nw_0ed69497-0304-4663-b657-eeda1bbb2c2c">1,128,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie88f78cb86a54bd88f68fd667ba9bf91_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy03LTEtMS03MTM5Nw_4cb1bc6a-bd3b-446a-acfd-7d938d7296ec">351,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised prior to vesting&#8212; remaining unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e1f95855536428d8e7258cfd624dd7c_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy01LTEtMS02Njk1MQ_b6ee0282-0c6d-4de8-accd-e16d6f53bfa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0991bb1e26c40059e9714e160dcd466_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy03LTEtMS02Njk1MQ_a09d635d-4740-4c3f-999e-e4f6708562e5">12,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfNS01LTEtMS02Njk1MQ_f8fe3128-d67b-4aae-99f8-adef0a26c372">5,724,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfNS03LTEtMS02Njk1MQ_cfe89a74-6c02-4bf6-b72c-1e4c8dadbf14">3,925,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNzk4Mw_3e82c049-7e5d-4412-be0e-de01591a9e81" continuedAt="ie32830f4b8174cfbb79da6c37f54ee22" escape="true">COMMITMENTS&#160;&amp; CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ie32830f4b8174cfbb79da6c37f54ee22" continuedAt="if575b0773aee40dc80df15239c11babe"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements for Lotilaner</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">January 2019 Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's made cash payments to Elanco under the Eye and Derm Agreement comprised of $<ix:nonFraction unitRef="usd" contextRef="i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODMyNTQz_08c93b81-11af-4cec-b059-84d9071d6245">1.0</ix:nonFraction>&#160;million upfront upon contract execution in January 2019 and a total of $<ix:nonFraction unitRef="usd" contextRef="i0e64247629bd49ad88f0a146a9a98bde_D20190101-20230331" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODMyODA5_15c62973-db81-4e3f-b147-061092631c24">3.0</ix:nonFraction>&#160;million for two specified clinical milestone achievements in September 2020 and April 2021, respectively. </span></div></ix:continuation><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if575b0773aee40dc80df15239c11babe" continuedAt="i2dae421d971f486b944d04622666036c"><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone of $<ix:nonFraction unitRef="usd" contextRef="i2d1eebcc98854765b87cca237a5b757f_D20230101-20230331" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzMjA3_94f6567f-5994-468e-b1b7-8fd766f7c6dc">1.0</ix:nonFraction>&#160;million was included in research and development expense on the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2023. The milestone achievement fully offset a $<ix:nonFraction unitRef="usd" contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331" decimals="-5" sign="-" name="tars:CollaborativeArrangementRightsAndObligationsRemainingPrepayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzNDEx_18064412-a30c-41ac-8b23-511e93360b9b">0.6</ix:nonFraction>&#160;million remaining prepayment and $<ix:nonFraction unitRef="usd" contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzNDQw_d65ea3e3-e41e-4c3c-85f8-507a7d80e2a1">0.4</ix:nonFraction>&#160;million was recognized in accounts payable and other accrued liabilities on the accompanying Condensed Balance Sheets as of March&#160;31, 2023. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2023, the Company is obligated to make further cash payments to Elanco of $<ix:nonFraction unitRef="usd" contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331" decimals="-5" name="tars:CollaborativeArrangementFutureCashPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQxMzgz_dcc0758c-82c6-4684-850c-ac4116ab4d3a">2.4</ix:nonFraction> million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $<ix:nonFraction unitRef="usd" contextRef="ifd840a9974534e8a86fb288669a39d26_I20230331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODM0Mzc5_e5a8dec0-3781-4331-a283-c48306f83567">79.0</ix:nonFraction> million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">September 2020 Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco <ix:nonFraction unitRef="shares" contextRef="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTE1Ng_a890570d-cb34-4e61-b8b0-1460838b69ae">222,460</ix:nonFraction> shares of its common stock with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTI3NA_941ee0bd-c22f-40c3-af61-801d4e9ad8df">3.1</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="i7122162b9e8442fb9dbe528f8bf4e6db_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTI3OA_301f917a-135c-4e6c-af0e-87b0009aabbb">14.0003</ix:nonFraction> per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's made cash payments under the All Human Uses Elanco Agreement of $<ix:nonFraction unitRef="usd" contextRef="ib6d21b9d0b1d41519dfdd05a63606147_D20221201-20221231" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMjY0_11e33250-1807-4302-8613-4bdb3c6af9b3">0.5</ix:nonFraction> million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i76624ba745b8460b9f60a3265e3b69fc_I20230331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMTA0_82f90eda-8083-44f7-98a7-3c2ea1562408">4.0</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i662dee756fdb482ab237e7e724a9180c_I20230331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMjE3_1cfa5dc2-f818-449e-b699-8979df0b6a2b">77.0</ix:nonFraction> million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with <ix:nonFraction unitRef="contract" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="INF" name="tars:NumberOfEmploymentArrangementsWithExecutiveOfficers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMxMDg2OA_2e4b8b1c-2ba2-403f-982a-10b55ab7ce6f">seven</ix:nonFraction> of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a preexisting consulting agreement with a board member that was appointed in December 2021. This consulting agreement provides for annual cash compensation of approximately $<ix:nonFraction unitRef="usd" contextRef="ifc838841c8c34d339322513ad5186477_I20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzEzNA_61e55797-2d0b-410c-abae-f5b9bb110384">0.2</ix:nonFraction>&#160;million and option grants to purchase <ix:nonFraction unitRef="shares" contextRef="i42809a841f17475d971438d5fe3366fb_D20211231-20211231" decimals="0" name="tars:RelatedPartyTransactionOptionToPurchaseShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE2Mw_76d3af9a-bc30-4f95-90c1-68575bb2808a">45,134</ix:nonFraction> shares of the Company&#8217;s common stock, with exercise prices ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d5bc0dd6d674c43a5676efe1c51dae5_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE0OA_0b7e24da-eff5-4355-9242-6a4e64b580d1">2.01</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i7fdb0d02a3f4465f9adaa728283ff184_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE1NQ_dde9460b-742f-4809-a805-27a7e2749e94">34.72</ix:nonFraction> per share. This consulting agreement may be terminated by either party with ten days notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, the Company entered into a separation and severance agreement with its former Chief Financial Officer, which provides for the following benefits effective upon and after June 15, 2023: severance payments equal to <ix:nonNumeric contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504" name="tars:PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODcxNw_71df504f-56c1-4fbd-a7ac-79453653bced">nine months</ix:nonNumeric> of base salary and <ix:nonNumeric contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504" name="tars:PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODcxOA_4882864b-9f53-414c-87ec-e90daedb2e9f">10</ix:nonNumeric> months of company-paid continued benefits coverage, a lump sum bonus payment payable in 2024 equal to one-third of the former Chief Financial Officer's 2023 annual target bonus adjusted based on the 2023 Company performance score,  accelerated vesting of options in <ix:nonFraction unitRef="shares" contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODY5Mg_9fb8b6b4-34c3-4ea2-8160-2f463b53dbee">40,744</ix:nonFraction> shares of the Company&#8217;s common stock, and an option exercise </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i2dae421d971f486b944d04622666036c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period extension for certain options, in exchange for a release and waiver of claims and continued compliance with his confidentiality obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div></ix:continuation><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMTkzNg_554af217-543c-4f21-ae2f-dcab3e999913" continuedAt="i16404300889c4c68afb7e4b0ff852b37" escape="true">OUT-LICENSE AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="i16404300889c4c68afb7e4b0ff852b37" continuedAt="id6d3cc1c696f40898df203b41440765f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in the China Territory in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into The China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assessed this arrangement in accordance with ASC 606 and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory, and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTExMA_6338e673-f513-4ad0-8361-5f1ca694f1f1">15.0</ix:nonFraction>&#160;million, (ii) a second cash payment of $<ix:nonFraction unitRef="usd" contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326" decimals="-5" name="tars:RevenueRemainingPerformanceObligationAdditionalCashPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA2Ng_fd18e552-95f3-4cfd-8dbe-d29f9bdc3028">10.0</ix:nonFraction>&#160;million, (iii) a $<ix:nonFraction unitRef="usd" contextRef="if69314c7f4594e288ffe725501411cd7_I20210326" decimals="-5" name="tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA4MQ_362af494-8277-46c5-99f2-feacf19ef9b8">10.0</ix:nonFraction>&#160;million milestone that was determined to be within the control of the Company, and (iv) $<ix:nonFraction unitRef="usd" contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA5Ng_335c10f1-4f31-482e-9925-fba1531076e0">1.2</ix:nonFraction>&#160;million representing the initial fair value of the equity warrant. </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounted for each performance obligation as follows: </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Out-License</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Services </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="id6d3cc1c696f40898df203b41440765f" continuedAt="ied9f822057d04aaa9a5e7ba9e8bc2bd9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2023, a specified milestone event was triggered resulting in $<ix:nonFraction unitRef="usd" contextRef="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NTQ5_a04aa0b7-b019-461f-9697-2341c1296e77">2.5</ix:nonFraction>&#160;million recognized as license fees and collaboration revenue in the Condensed Statements of Operations for the three months ended March&#160;31, 2023. This cash payment was received in the second quarter of 2023. Through March&#160;31, 2023, the Company had received payments from LianBio totaling $<ix:nonFraction unitRef="usd" contextRef="i8637cc436fcd44d58ba1f8037dad5983_D20210326-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTkw_40269d31-bf96-44db-84dc-9d6074fd09c8">80.0</ix:nonFraction>&#160;million, comprised of initial consideration of $<ix:nonFraction unitRef="usd" contextRef="id7350246746e45e096c4b5c05592d2bf_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NDc1_b1ab55b5-2052-40fb-8e55-16cca389f634">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331" decimals="-5" name="tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NTE0_c2ba87f2-58e3-4e79-ab76-1b833093205e">65.0</ix:nonFraction>&#160;million for the achievement of specified milestones. </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestone and one-time payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfOTEx_b8d9ec27-8b41-411f-878e-631b89dfce31">25.0</ix:nonFraction>&#160;million (including the $<ix:nonFraction unitRef="usd" contextRef="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTEyNQ_c6209683-b26e-4cf0-85d8-86635a3514d1">2.5</ix:nonFraction>&#160;million cash payment received in the second quarter of 2023), (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="id7350246746e45e096c4b5c05592d2bf_I20230331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMTA5MQ_447139b1-2a65-4094-914d-aac1913f4e47">100.0</ix:nonFraction>&#160;million, (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales, and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss relates to the satisfaction of performance obligations including (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the completion of U.S. clinical activities and then providing LianBio with the related data to supplement its local pivotal trial package for TP-03 in the treatment of Demodex blepharitis. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the China Out-License with LianBio the Company granted Elanco an additional <ix:nonFraction unitRef="shares" contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331" decimals="INF" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzMjA3_02a2fa2b-a376-48a7-aca1-417766dc6123">187,500</ix:nonFraction> shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $<ix:nonFraction unitRef="usd" contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331" decimals="-5" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzNDQx_af3ef857-c04c-42cf-982b-c0d5575890be">5.5</ix:nonFraction> million, based on the Company's closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331" decimals="INF" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzNDky_5ee0561c-4135-4e96-b79c-0b65e2a70cf0">29.30</ix:nonFraction> per share on the date this issuance became contractually required.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company made a contractual payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="i20fc38686769463e89dccae19d75a856_D20210401-20210630" decimals="-5" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ2NA_d47c614b-1692-4c17-9f28-7092991eeba0">2.5</ix:nonFraction>&#160;million to Elanco following the receipt of $<ix:nonFraction unitRef="usd" contextRef="i93d63e21c49245618766f49acefdeffc_D20210401-20210630" decimals="-6" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ3OA_b3837877-cf3a-4cd0-8177-59169bdbd6b6">25</ix:nonFraction>&#160;million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ifb291c31a4554839b5b0b66a4fe2675f_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ5MQ_eedf8a70-8d12-45d6-acdb-1e5fc9bd270d">0.4</ix:nonFraction>&#160;million of cost of license fees and collaboration revenue upon receipt of $<ix:nonFraction unitRef="usd" contextRef="i08f0b2c2b8d64ed1aed8211167ca0c9f_D20230101-20230331" decimals="-6" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTUwNQ_0511d698-ed06-4fd7-ae1e-ecbc571b162f">10</ix:nonFraction>&#160;million of cash proceeds from LianBio for the achievement of a clinical development milestone.</span></div></ix:continuation><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ied9f822057d04aaa9a5e7ba9e8bc2bd9">The expenses recognized under the China-Out License were not material for the three month periods ended March 31, 2023 and 2022.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 10. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMQ_0f7f78ed-636b-4779-a35a-592a82259979" continuedAt="i55d6d6f3dac44eff9a1ede1246825e18" escape="true">CREDIT FACILITY AGREEMENT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i55d6d6f3dac44eff9a1ede1246825e18" continuedAt="ifdef1b9a1bba43e5b2c6241dae99c5e7"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i9982c244cae049c2b927906df44008a4_D20220202-20220202" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODExOQ_f87f03e1-2e89-438c-b0fc-915d74bc25b7">20.0</ix:nonFraction>&#160;million draw.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $<ix:nonFraction unitRef="usd" contextRef="i5bbbc17db51145c1b3991110981ecf19_I20230105" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODEzNA_f3d569ff-6720-4f10-a4d8-bf0775ca1a68">25.0</ix:nonFraction>&#160;million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $<ix:nonFraction unitRef="usd" contextRef="ic6757e8b476a41fd8f001984f0e90cab_I20230105" decimals="-5" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE0OQ_b7cff1ff-287b-4be5-abac-aadb3de4dc2f">5.0</ix:nonFraction>&#160;million was drawn on or before March 15, 2023 and at least an additional $<ix:nonFraction unitRef="usd" contextRef="ic6757e8b476a41fd8f001984f0e90cab_I20230105" decimals="-6" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI4MTIyNg_510cb86e-8880-44fd-ad6b-9d0dc62768db">5</ix:nonFraction>&#160;million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 15, 2023, the Company made a $<ix:nonFraction unitRef="usd" contextRef="ib5ab2b8124224aeeaacabd23e0670fc6_D20230315-20230315" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE5Mw_44631f35-76d0-4650-86f7-f1582e9fdbaa">5.0</ix:nonFraction>&#160;million draw (including SVB's commitment of $<ix:nonFraction unitRef="usd" contextRef="iead63404689e4c9fb5d3dd9c7e44eb93_D20230315-20230315" decimals="-4" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE3OA_3278eb15-dba3-411a-9309-efc2acbeda50">1.25</ix:nonFraction>&#160;million) from the $<ix:nonFraction unitRef="usd" contextRef="i5bbbc17db51145c1b3991110981ecf19_I20230105" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE2Mw_64047ee2-031e-4dbc-b4b8-c619552a92c6">25.0</ix:nonFraction>&#160;million tranche that became available upon submission of the NDA. As of March&#160;31, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1ODc5_d1d094d6-7ebd-48a1-8cfb-f5a1033e940e">130.0</ix:nonFraction>&#160;million with tranched availability as follows: $<ix:nonFraction unitRef="usd" contextRef="ib138596b65dc49378e26b8bcfa849a7c_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTE1_437a2476-df78-4d5a-a80e-4e6582e07405">20.0</ix:nonFraction>&#160;million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022, $<ix:nonFraction unitRef="usd" contextRef="i57aedd3d329a44348c333722afc8f2da_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTQ5_2d3b9eeb-28c8-42a5-95c6-5679cc2c8582">35.0</ix:nonFraction>&#160;million available upon FDA approval of TP-03, $<ix:nonFraction unitRef="usd" contextRef="i12dac813311e4f7c9349b2c69b102372_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTgz_7ddb0457-6d22-445c-910e-1dab3f956299">50.0</ix:nonFraction>&#160;million available upon achievement of product net revenue thresholds, and $<ix:nonFraction unitRef="usd" contextRef="iea7de7306a164d21817ad5a9f76cd054_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI2MDE3_3b67b219-661b-48a9-a789-be408f705974">25.0</ix:nonFraction>&#160;million available upon lender approval.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-indent:54pt"><span><br/></span></div><ix:continuation id="ifdef1b9a1bba43e5b2c6241dae99c5e7"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these tranches may be drawn down in $<ix:nonFraction unitRef="usd" contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202" decimals="-5" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTk0_939649cf-feed-4a41-b24c-f3c8f480eb64">5.0</ix:nonFraction>&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.  </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus <ix:nonFraction unitRef="number" contextRef="idde37c43b07847328ecd4970539db537_D20220202-20220202" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMTc2_ecc4e645-2ff6-4a54-b5cf-30d3756586fc">4.45</ix:nonFraction>% with an aggregate cap of <ix:nonFraction unitRef="number" contextRef="iefb591f932524f878ed995d1d169d6e6_D20220202-20220202" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMTk4_72a2c7d3-d735-463d-84b3-e16a43153387">11.45</ix:nonFraction>%, or (ii) <ix:nonFraction unitRef="number" contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMjAy_585a2dd1-4425-4383-a404-54af880ab5cc">8.45</ix:nonFraction>%. At the execution date of the Credit Facility, the WSJ prime rate was <ix:nonFraction unitRef="number" contextRef="i9982c244cae049c2b927906df44008a4_D20220202-20220202" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTIxOA_be8e17c8-f04c-4d58-9c46-68a2a4d13a8a">3.25</ix:nonFraction>% and increased to <ix:nonFraction unitRef="number" contextRef="i63781028d94a4277a261f195f03cebe0_D20220930-20220930" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTI2NQ_4fcf10ae-7204-4627-b7c0-76fb8ddc2ed7">8.00</ix:nonFraction>% as of March&#160;31, 2023.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $<ix:nonFraction unitRef="usd" contextRef="i9af35563ebb945b9a4b563b46884004c_D20230101-20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTU0MA_40bed852-4f64-4d5f-9de6-105bd90158ef">1.2</ix:nonFraction> million was derived by multiplying <ix:nonFraction unitRef="number" contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202" decimals="4" name="tars:LineOfCreditFacilityPeriodicPaymentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTYxMA_0d093cae-1701-48e3-887d-60d99e8ee3ad">4.75</ix:nonFraction>% by the $<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODM2OTA0_a6652ad4-c43a-4ee1-b632-3432100b8fb0">25.0</ix:nonFraction>&#160;million outstanding principal balance as of March&#160;31, 2023 and is accreted to interest expense through maturity.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March&#160;31, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was <ix:nonFraction unitRef="number" contextRef="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI5Njg0_099a9e94-90e3-4118-9041-f1ccb8714556">12.12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2f5516daf64a47d4948fc6884c6bf78b_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI5Njk0_51442d25-7de9-47ed-b81b-75bcc5294ec6">9.66</ix:nonFraction>%, respectively. </span></div><div style="text-indent:54pt"><span><br/></span></div><ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMg_6169de50-302c-4786-9955-e0162c3bf4df" escape="true"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the three months ended March&#160;31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMS0xLTEtMS02Njk1MQ_73ea9813-ef09-40c0-b843-a263dded0963">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMS0zLTEtMS02Njk1MQ_39f0f97b-f2fb-4982-8cc3-05ae2c98deef">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMi0xLTEtMS02Njk1MQ_7028e32d-82a8-4ac9-87fb-d16aa1d06fa0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMi0zLTEtMS02Njk1MQ_f3c0164c-07e1-492e-8e47-4fdd36d7f1ec">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMy0xLTEtMS02Njk1MQ_66467b24-4a3a-415e-b96f-caf6c9aca959">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMy0zLTEtMS02Njk1MQ_882de72d-7c07-4398-8f79-273cf6c4e327">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfNC0xLTEtMS02Njk1MQ_efee62a7-09a9-453c-8a82-d8df9709006f">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfNC0zLTEtMS02Njk1MQ_a32d6690-d80d-4410-85a9-d7dacde7f7d0">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMA_b38a122c-2428-4d47-8d54-94fb73e7a270" continuedAt="ic91fc3bbfbfb4b7aa23758513eb26aae" escape="true">The principal balance of this Credit Facility and related accretion and amortization as of March&#160;31, 2023 and December&#160;31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:</ix:nonNumeric></span></div><div style="text-indent:54pt"><span><br/></span></div><div><ix:continuation id="ic91fc3bbfbfb4b7aa23758513eb26aae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMS0xLTEtMS02Njk1MQ_a6652ad4-c43a-4ee1-b632-3432100b8fb0">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMS0zLTEtMS03MTAxMQ_d117ce95-50f4-4dc8-966b-8dca8227efe8">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMi0xLTEtMS02Njk1MQ_e89b4af0-a0cf-4046-a1ba-b0cf772553bd">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMi0zLTEtMS03MTAxMQ_31632d73-8424-4d9d-9556-60d562549f0b">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMy0xLTEtMS02Njk1MQ_a1e95aa0-016d-44fd-8199-4fbd64454d15">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMy0zLTEtMS03MTAxMQ_7ee6c600-e487-40a0-afc8-e42f8df554d9">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNC0xLTEtMS02Njk1MQ_2819b6b7-5911-4c87-a93d-e63da4c54237">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNC0zLTEtMS03MTAxMQ_ebb8321d-90e3-4879-9242-9c97b0abf8e0">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20710df36adc404dad2e0ed426a82823_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNS0xLTEtMS02Njk1MQ_c851b001-8a61-4794-8106-fe29ad77a7b3">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNS0zLTEtMS03MTAxMQ_f6ae9249-d814-43a8-ace4-4bfd008101ff">19,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_890"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF84OTAvZnJhZzplNzQ4NDM0OWIxYmE0ZmZlYWY5MTc4NDVhYjg0ZmJkYi90ZXh0cmVnaW9uOmU3NDg0MzQ5YjFiYTRmZmVhZjkxNzg0NWFiODRmYmRiXzIxOTkwMjMyNTU2OTc_cfc81a94-68d1-40fd-8796-e0b3d9177527" continuedAt="i784b89adfdbf48309a4243f168be148b" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i784b89adfdbf48309a4243f168be148b">On May 2, 2023 the Company amended the existing facilities lease, extending the term for <ix:nonNumeric contextRef="i80393f9b040b4bbdbc5232b580944b52_I20230502" name="tars:LesseeOperatingLeaseRemainingLeaseTermExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF84OTAvZnJhZzplNzQ4NDM0OWIxYmE0ZmZlYWY5MTc4NDVhYjg0ZmJkYi90ZXh0cmVnaW9uOmU3NDg0MzQ5YjFiYTRmZmVhZjkxNzg0NWFiODRmYmRiXzU0OTc1NTgxNDAwNA_d2babe77-b257-4c85-b519-199dde0bb085">three years</ix:nonNumeric> through January 31, 2027.</ix:continuation> </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ from expected results, include, among others:</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approval and successfully commercialize TP-03 for the treatment of Demodex blepharitis;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and progress of our current clinical trials and timing of initiation of our future clinical trials, and the reporting of data from our current and future trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the clinical development of our current and future product candidates, including the size, number and disease areas to be evaluated;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence of Demodex blepharitis and the size of the market opportunity for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including sales strategy;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of health epidemics, including COVID-19, on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of unfavorable global economic conditions on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States ("U.S.") or globally, as applicable, who suffer from Demodex blepharitis, Meibomian Gland Disease ("MGD"), rosacea, Lyme disease and malaria and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates and our product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including additional indications for which we may pursue;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third-party collaborators to commercialize our product candidates in the territories under license) and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the U.S. and other jurisdictions;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, in particular sales personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and</span></div><div style="padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from our Initial Public Offering (&#8220;IPO&#8221;) and our subsequent follow-on public offering in May 2022 (the &#8220;Follow-On Public Offering&#8221;), and credit facility.</span></div><div style="margin-top:3pt;padding-left:20.25pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and growth prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Our lead product candidate, TP-03 (lotilaner ophthalmic solution, 0.25%), is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis ("Blephar" is a reference to eyelid and &#8220;itis&#8221; is a reference to inflammation) is an ophthalmic lid margin disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. Poorly controlled and progressive blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There are an estimated 25&#160;million people in the U.S. who suffer from Demodex blepharitis.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We designed TP-03 to target and eradicate the root cause of Demodex blepharitis &#8212; Demodex mite infestation. The active pharmaceutical ingredient ("API") of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GABA-Cl") channels.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have completed seven clinical trials that include a Phase 3 Saturn-2 trial, a Phase 2b/3 Saturn-1 trial, four Phase 2 trials, and a Phase 1 trial for TP-03 in Demodex blepharitis, all of which met their primary, secondary and/or certain exploratory endpoints, with the drug well tolerated throughout each trial. In November 2022, we announced the New Drug Application ("NDA") submission package for TP-03 for the treatment of Demodex blepharitis was accepted by the U.S. Food and Drug Administration ("FDA") with a PDUFA decision date of August 25, 2023. We believe TP-03 has the potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to be the first therapeutic approved by the FDA and become the definitive standard of care for the treatment of Demodex blepharitis. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to further advance our pipeline with the lotilaner API to address several diseases across therapeutic and/or prophylactic categories in human medicine, including eye care, dermatology, and other diseases. We are investigating the development of product candidates to address targeted diseases with high unmet medical needs, which currently include TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Business and Clinical Highlights </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 Demodex Blepharitis, PDUFA August 25, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: Our sales force leadership infrastructure is in place for the potential upcoming commercial launch of TP-03 for the treatment of Demodex blepharitis, including the Vice President of Sales, two regional directors and eleven district managers. The sales force will be focused on targeting approximately 15,000 optometrists and ophthalmologists, which represents greater than 80% of the market. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In March 2023, the Demodex Expert Panel on Treatment and Eyelid Health (&#8220;DEPTH&#8221;) published two papers on the importance of diagnosis and management of Demodex blepharitis Eye; https://doi.org/10.1038/s41433-023-02500-4, which showed the following:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Clinical diagnosis and management of Demodex blepharitis established consensus about the disease, including signs, symptoms and diagnosis;</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">DEPTH consensus regarding current clinical practice management options for Demodex blepharitis showed collarettes are pathognomonic, patients with greater than 10 collarettes should be treated even in the absence of symptoms and efficacy can be tracked by collarette resolution; and</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">DEPTH panel consensus was obtained by using the Delphi methodology, an approach that allows experts to achieve consensus by performing qualitative and quantitative analyses and utilizing sequential surveys.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In March 2023, we presented health economics data at the Academy of Managed Care Pharmacy 2023, which suggests a costly, substantial burden of illness in patients with Demodex blepharitis and the need for a safe and effective FDA-approved treatment. The data presented included:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Ongoing disease impact and additional office visits are potentially driving up healthcare resource utilization;</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Patients reported having delayed diagnosis, multiple office visits, unresolved Demodex blepharitis and high costs of disease management; and</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Current non-FDA approved therapies to manage Demodex blepharitis do not address the root problem nor provide satisfactory relief for most patients.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">An Awareness, Trial and Usage (ATU) market research survey of approximately 250 optometrists and ophthalmologists was conducted to capture and analyze awareness and the likelihood to prescribe a potential prescription therapeutic for Demodex blepharitis, including:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Growing confidence in making a diagnosis with 68% believing collarettes are pathognomonic to Demodex blepharitis and 66% recognizing the importance of screening patients for the presence of collarettes during eye exams; and</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">93% indicated they would prescribe an FDA-approved therapeutic for Demodex blepharitis.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We have raised awareness on the prevalence and impact of Demodex blepharitis through launching disease education campaigns, including:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The &#8220;Look at the Lids&#8221; disease education campaign, which generated nearly 200,000 unique website visits, up from 125,000 during the quarter ended December 31, 2022 and more than 2.3 million digital/media impressions, an increase of 300,000 impressions from the quarter ended December 31, 2022; and</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The &#8220;Don&#8217;t Freak Out. Get Checked Out.&#8221; disease education campaign, which was designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 Meibomian Gland Disease, Ersa Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: In August 2022, we announced the enrollment of our first patient in the Phase 2a Ersa clinical trial studying TP-03 for the treatment of MGD. We expect to report topline data during the second half of 2023.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-04 Rosacea, Galatea Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: In March 2023, we initiated the Galatea trial, a Phase 2a trial evaluating TP-04, a novel gel formulation of lotilaner, for the treatment of rosacea. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-05 Lyme Disease, Callisto and Carpo Trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2022, we announced positive topline results from the completed Phase 1 Callisto trial and enrollment of the first patient in the Phase 2a Carpo trial. The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral, non-vaccine pharmacological prophylactic for the potential prevention of Lyme disease. The Callisto Phase 1 trial was a randomized, double-blind, single and multiple-ascending dose trial that evaluated the safety, tolerability, and PK of TP-05 in healthy subjects. Results from the trial showed that TP-05 was well tolerated with no dose-related or drug-related serious adverse events. Pharmacokinetic data from the trial demonstrated rapid absorption and an extended half-life of TP-05 that potentially supports a convenient oral therapy regimen, supporting its potential as a rapid onset, prophylactic therapy for Lyme disease. Additionally, exploratory ex-vivo tick kill modeling utilizing serum from TP-05 treated subjects demonstrated potent, rapid killing of adult and nymph ticks. The Carpo trial, evaluating TP-05 for the potential prevention of Lyme disease in humans, is a randomized, double-blind trial that will evaluate the efficacy of TP-05 in killing lab grown, non-disease carrying ticks after they have attached to the skin of healthy volunteers, as well as confirm the safety, tolerability, and blood concentration of TP-05. We expect to report topline data from the Phase 2a Carpo trial during the second half of 2023.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe TP-05 is currently the only non-vaccine, drug-based prophylaxis in development that targets the ticks, and potentially prevents Lyme disease transmission. It is designed to rapidly and durably provide systemic blood levels of lotilaner potentially sufficient to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 China Territory Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: In March 2021, we executed an out-license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), granting exclusive commercial rights to TP-03 for the treatment of Demodex blepharitis and MGD within The People&#8217;s Republic of China, Macau, Hong Kong, and Taiwan (the "China Territory"). </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2023, a specified milestone was triggered resulting in $2.5&#160;million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations for the three months ended March&#160;31, 2023. This cash payment was received in the second quarter of 2023. As of the date of this filing, we have received contractual cash proceeds from LianBio of $82.5&#160;million (including the $2.5&#160;million received in the second quarter of 2023), representing initial consideration of $15.0&#160;million and $67.5&#160;million for the achievement of specified milestone events. We also received equity in LianBio as part of this China Out-License, a portion of which remains subject to a China-based regulatory vesting provision.   </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Credit Facility with Hercules Capital and Silicon Valley Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2022, we executed a loan and security agreement with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank ("SVB") (the "Credit Facility). On January 5, 2023, we entered into an amendment to the loan and security agreement, which set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions. On March 15, 2023, we made a $5.0 million draw (including SVB's commitment of $1.25 million) from the $25.0 million tranche that became available upon submission of the NDA. As of March&#160;31, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $130.0&#160;million (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). As further described below in the section titled &#8220;Impact of the COVID-19 Pandemic and the Macroeconomic Environment,&#8221; SVBB (as defined below) assumed the obligations and commitments of SVB, and subsequently, on March 27, 2023, First-Citizens Bank &amp; Trust Company (&#8220;First Citizens Bank&#8221;) assumed all of SVBB&#8217;s obligations and commitments and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate and Financial Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as a Delaware corporation in November 2016, and our headquarters is located in Irvine, California. Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquiring intellectual property, clinical development of our product candidates, building our research and development capabilities, raising capital, and enhancing our corporate infrastructure. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have financed our operations through private placements of preferred stock, convertible promissory notes, the net proceeds from issuance of common stock in our IPO and Follow-On Public Offering, cash proceeds from our China Out-License, and draw-downs from our Credit Facility. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant operating expenses and, other than the effect of license fees and collaboration revenue from the China Out-License, increasing operating losses for the foreseeable future. Our net loss was $23.4 million and $20.2 million for the three months ended March 31, 2023 and 2022, respectively. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. We anticipate that our operating expenses will increase significantly as we:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for TP-03 and other product candidates that successfully complete clinical development, if any;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the clinical development of TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme prophylaxis;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish our own sales force in the U.S. to commercialize TP-03 upon regulatory approval and our other products for which we obtain such approvals;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage with contract manufacturers to ensure a sufficient supply chain capacity to provide commercial quantities of any products for which we may obtain marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, scientific, technical, regulatory, marketing, operations, financial, and other support personnel, to execute our business plan; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have revenue from product sales. Our reported revenue within license fees and collaboration revenue is from our China Out-License; we expect to report additional revenue under this caption in future periods.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenues from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate and commercially launch such product. Until such time as we can generate significant revenue from product sales and achieve profitability, if ever, we expect to finance our operations through private or public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital or enter into such agreements as and when needed, we could be forced to significantly delay, scale back, or discontinue our product development and/or commercialization plans, which would negatively and adversely affect our financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug product development, we are unable to accurately forecast the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our aggregate cash, cash equivalents and marketable securities was $201.2 million &#8211; see the section below titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic and Macroeconomic Environment</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been monitoring the COVID-19 pandemic and its potential impact on our business. To date, we have been able to continue our key business activities and advance our clinical programs. However, in the future, it is possible that our clinical development timelines and business plans could be adversely affected. We maintain regular communication with our vendors and clinical sites to appropriately plan for, and mitigate, the impact of the COVID-19 pandemic on our operations. While the pandemic has begun to subside, a resurgence in the COVID-19 pandemic, or other health epidemics or outbreaks in the future, could have a material, adverse impact on our commercialization and development timelines for our products and product candidates.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the economic downturn resulting from the COVID-19 pandemic precipitated a global recession, and together with high rates of inflation and energy supply issues experienced in certain regions, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). We are monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#8217;s deposits and substantially all of SVB&#8217;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#8220;SVBB&#8221;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB; commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#8217;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, we do not believe we have exposure to loss as a result of SVB&#8217;s receivership.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See the section titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;17, 2023 and in this Quarterly Report, for a further discussion of the potential adverse impact of COVID-19 and unfavorable global economic conditions on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2023&#160;and 2022</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations before other income (expense) and income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,431)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,181)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees and Collaboration Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, we recognized $2.5 million and $0.5 million, respectively, of license fees and collaboration revenue under the China Out-License. These amounts represent the contractual milestones achieved or allocated under the China Out-License that have been fully or partially completed by the period end. These allocated amounts represented the satisfaction of the transfer of license rights to LianBio and the completion of related performance obligations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize additional license fees and collaboration revenue to the extent other events occur, specifically related to (i) milestone achievement of an additional drug supply agreement execution, (ii) milestone achievement of certain regulatory events in the China Territory, and (iii) royalties and milestones from our licensee's product sales of TP-03 in the China Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of license fees and collaboration revenue was $33 thousand for the three months ended March&#160;31, 2022. This amount relates to our contractual payment obligations to Elanco, in proportion to our recognized license fees and collaboration revenue in the same period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct external expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-03 program</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-04 program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-05 program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other early-stage programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indirect expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and personnel-related </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elanco milestone expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,356&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $0.3 million for the three months ended March&#160;31, 2023, as compared to the prior year period. This increase was primarily due to (i) $2.8 million of increased indirect expenses related to payroll and personnel-related costs (including stock-based compensation) for 28 employee additions period over period to drive our product development initiatives, (ii) $1.0 million of milestone expense related to our in-license agreement with Elanco, and (iii) $1.8 million of increased TP-05 program expenses primarily related to a new food effect study that was initiated during the three months ended March&#160;31, 2023 and other clinical trial initiatives. These increases were partially offset by decreases in direct external spend for the TP-03 and TP-04 programs of $4.9 million and $0.5 million, respectively. The decrease in our TP-03 program expenses was primarily due to significantly reduced clinical trial costs given the completion of our Saturn-2 trial in the first half of 2022. The decrease in our TP-04 program expenses were primarily due to decreases in preclinical costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $7.2 million for the three months ended March&#160;31, 2023, as compared to the prior year period. The increase was primarily due to (i) $3.7 million of increased payroll and personnel-related costs (including stock-based compensation) for 31 corporate employee additions, period over period, to support our business growth and commercial leadership hires for readiness of our anticipated commercial launch of TP-03 in the second half of 2023, and (ii) $2.9 million of increased commercial and market research costs as we continue our commercial expansion and prepare for the potential launch of TP-03 in the second half of 2023, (iii) $0.2 million of increased IT application expenses to support the continued growth and expansion of our corporate infrastructure, and (iv) $0.2 million of increased facilities and other office and administrative expenses. We expect sales and marketing headcount and associated vendor expenses to meaningfully increase during 2023 as part of our TP-03 commercial launch-related activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income (expense), net increased by $2.2 million primarily due to (i) $2.3 million of increased interest income earned on our cash, cash equivalents and marketable securities, (ii) $0.2 million change in estimated fair value of the LianBio equity warrants we received as part of our China Out-License in March 2021, and (iii) $0.1 million change in fair value of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LianBio common stock. These increases were partially offset by a decrease of interest expense of $0.4 million on the Credit Facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a valuation allowance against our net deferred tax assets as of March&#160;31, 2023 and 2022 due to the uncertainty that such assets will be realized. We evaluate the recoverability of our deferred tax assets on at least an annual basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and marketable securities of $201.2&#160;million. Since our inception, our operations have been substantially financed by cash proceeds of private placements of preferred stock, IPO proceeds from the issuance of common stock, China Out-License consideration, Credit Facility draws, and the Follow-On Public Offering. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO and Follow-On Public Offering</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our October 2020 IPO, we sold 6,325,000 shares of our common stock (inclusive of the full exercise of the underwriters&#8217; option to purchase 825,000 shares of common stock). After deducting underwriting discounts, commissions and other related expenses, our IPO proceeds were $91.7 million.  In May 2022, we completed the Follow-On Public Offering. We also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. In June 2022, the underwriters partially exercised their option to purchase an additional 289,832 shares of common stock at the offering price of $13.50 per share, before underwriting discounts and commissions. After giving effect to the exercise of the underwriters&#8217; option, we sold 5,889,832 shares for total gross proceeds of $79.5&#160;million, before underwriting discounts, commissions and other estimated offering expenses for total net proceeds received of $74.3&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, we have received $82.5&#160;million of total proceeds in connection with our China Out-License. We expect to receive an additional $2.5&#160;million during 2023 for the achievement of a specific milestone, for cumulative milestone receipts of $85.0&#160;million through December 2023. The remaining $120.0&#160;million of available milestones under this arrangement will potentially be received upon future regulatory and sales achievements all within the China Territory. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, we drew $20.0&#160;million from our Credit Facility with Hercules and SVB. Capital draws are at our election and are in $5.0 million increments. This Credit Facility was amended in January 2023. The Credit Facility, as amended, includes an extended period to draw down the tranche associated with the NDA submission, from March 15, 2023 to March 15, 2024 provided at least $5 million was drawn on or before March 15, 2023 and at least an additional $5 million is drawn on or before September 15, 2023. On March 15, 2023 we made a $5.0 million draw (including SVB's commitment of $1.25 million) from the $25.0&#160;million tranche associated with the NDA submission of TP-03. The Credit Facility includes four-year period of interest-only payments and is extendable for a fifth year to February 2027 maturity, upon our expected achievement of required conditions. We currently have no other financing commitments, such as lines of credit or guarantees. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of this filing, we have $130.0&#160;million of tranched availability as follows: </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $20.0&#160;million, which became available in September 2022 upon our NDA submission of TP-03 to the FDA;</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $35.0&#160;million available upon FDA approval of TP-03;</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $50.0&#160;million available upon achievement of certain quarterly revenue thresholds; and</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $25.0&#160;million available with lender approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenditures currently consist of research and development costs (including activities within our preclinical, clinical, regulatory, and drug manufacturing initiatives) and general and administrative costs. Our use of cash is impacted by the timing and extent of payments for each of these activities and other business requirements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our cash and investments of $201.2&#160;million as of March&#160;31, 2023 is sufficient to fund our current and planned operations for at least the next twelve months from the date of this filing on Form 10-Q. Based upon this plan, we anticipate these funds in combination with our Credit Facility, revenues generated from TP-03, and milestones from the China Out-License to fund our commercial launch of TP-03 in Demodex blepharitis and advance our pipeline through Phase 2 studies in MGD, Lyme disease and rosacea. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We anticipate having at least $55.0&#160;million of available capital from our Credit Facility through March 2024 and an additional $75.0&#160;million of additional tranched availability through December 2024. The Credit Facility requires interest-only debt service payments that are expected to remain through its maturity in February 2027 and its remaining tranches are subject to undrawn expiry in either March 2024 or December 2024 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash runway estimate is predicated on current assumptions for future revenue, operating expenses, and debt availability and may require future adjustments. Accordingly, we may be required to raise additional capital earlier than we currently expect based on our cash requirements and market dynamics. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 1, 2021, we filed a shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 (the &#8220;Shelf Registration Statement&#8221;), which permitted us to offer up to $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. We have approximately $220 million remaining under our Shelf Registration Statement, after giving effect to the Follow-On Public Offering (but inclusive of the sales agreement prospectus described below). Our Shelf Registration Statement is intended to provide us with additional flexibility to access capital markets for general corporate expenses and acquisitions of complementary products, technologies, or businesses. We completed the Follow-On Public Offering under this Shelf Registration Statement.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, as part of this Shelf Registration Statement, we concurrently filed a sales agreement prospectus covering the sale of up to $100.0 million of our common stock pursuant to an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (the &#8220;ATM  Agreement&#8221;) with Jefferies LLC. Through the date of this filing, we have not sold any shares of our common stock under the ATM Agreement. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Liquidity Risks</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any product sales, though we have recognized revenue and cash receipts from our China Out-License. We do not expect to report any product revenue unless and until we (i)&#160;complete development of any of our product candidates; (ii)&#160;obtain applicable regulatory approvals; and then (iii)&#160;successfully commercialize our product candidates or enter into other collaborative agreements for our product candidates with third parties. We do not know with certainty when, or if, any of these items will ultimately occur.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant operating losses for the foreseeable future, and expect these losses to further increase, as we expand our clinical development programs and as we prepare for the potential commercial launch of TP-03. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional capital to fully develop our product candidates and to execute our business strategy. Our requirements of a future capital raise will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of development and commercial manufacturing activities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time and availability of our Credit Facility;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our implementation of various computerized information systems;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of health epidemics, including COVID-19, on our clinical development or operations; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section titled &#8220;Risk Factors&#8221; in this report for additional risks associated with our substantial capital requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Statements of Cash Flows</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,970)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,663)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.0 million for the three months ended March 31, 2023, which primarily consisted of our net loss of $23.4 million partially offset by stock-based compensation of $3.9 million. For the three months ended March 31, 2023, our cash payments to vendors totaled $15.2 million and payroll-related cash payments (inclusive of 2022 bonus payouts) totaled $10.4 million. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by operating activities was $15.3 million for the three months ended March 31, 2022. Though we recognized $0.5 million of license fee and collaboration revenue, no corresponding cash was received in connection with our China Out-License. In the prior year period, our cash payments to vendors for our operating activities totaled $10.1 million and payroll-related cash payments (inclusive of 2021 bonus payouts) totaled $5.2 million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $11.3 million for the three months ended March 31, 2023, and primarily relates to $40.3 million of proceeds from maturities of investments, partially offset by $28.7 million of purchased investments and $0.3 million of purchased furniture, fixtures and leasehold improvements for our laboratory and administrative offices.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three months ended March&#160;31, 2022, which consisted of leasehold improvements for our laboratory and administrative offices and various purchases of computer hardware and office equipment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $5.0 million and $19.1 million for the three months ended March 31, 2023 and 2022, respectively, which substantially relates to proceeds from our Credit Facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management's discussion and analysis of financial condition and results of operations is based on our Condensed Financial Statements, which have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of these condensed financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in our filed Annual Report on Form 10-K for the year ended December&#160;31, 2022.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no material changes to our previously reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Critical Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> during the three months ended March 31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows are disclosed in the footnote to which each relates within these accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of March&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">earliest of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;December 31, 2025, which is the last day of our first fiscal year following the fifth anniversary of the completion of our IPO, (2) the last day of our first fiscal year (a)&#160;in which we have total annual gross revenues of at least $1.235&#160;billion or (b)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million, as of the prior June 30th and (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March&#160;31, 2023, we had cash, cash equivalents, and marketable securities of $201.2 million, consisting of interest-bearing money market accounts, U.S. Treasury securities, commercial paper, corporate debt securities and government-related debt securities for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low-risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash, cash equivalents and marketable securities. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $25.0 million of debt principal outstanding. Our Credit Facility bears interest at an annual rate equal to the greater of (i) the prime rate as reported in the Wall Street Journal plus 4.45% with an aggregate cap of 11.45% or (ii) 8.45%. A hypothetical interest rate of 20% would have resulted in reported interest expense of $1.3 million for the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe inflation, interest rate changes, and foreign currency exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein. However, with further inflationary pressures, certain significant increased costs could have an adverse impact on the results of our operations.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_85"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_88"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of this filing, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Proceeds from Initial Public Offering</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There has been no material change in the planned use of proceeds from our IPO as described in the Registration Statement on Form S-1 (File No. 333-249076), declared effective by the SEC on October 15, 2020, and the related final prospectus, dated October 15, 2020, filed with the SEC on October 16, 2020, pursuant to Rule 424(b) of the Securities Act of 1933, as amended.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in our Current Report on Form 8-K filed with the SEC on April 24, 2023, we announced that Leonard Greenstein would be leaving his role as the Company&#8217;s Chief Financial Officer (the &#8220;Transition&#8221;), effective as of April 24, 2023 (the &#8220;Transition Date&#8221;) and leaving his employment with the Company on June 15, 2023 (the &#8220;Separation Date&#8221;).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Transition and Mr. Greenstein&#8217;s termination of employment, on May 4, 2023, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a separation and severance agreement with Mr. Greenstein, which provides for the following benefits effective upon and after the Separation Date: severance payments equal to nine months of base salary and 10 months of company-paid continued benefits coverage, a lump sum bonus payment payable in 2024 equal to one-third of his 2023 annual target bonus adjusted based on the 2023 Company performance score,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated vesting of options for 40,744 shares of our common stock, and an option exercise period extension for certain options, in exchange for a release and waiver of claims and continued compliance with his confidentiality obligations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing summary of the terms of the Separation Agreement is qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which will be filed with the Company&#8217;s Quarterly Report on 10-Q for the quarter ending June 30, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1819790/000181979023000007/tarsuslsafirstamendment1.htm">First Amendment to Loan and Security Agreement, dated as of January 5, 2023, by and among Registrant, Hercules Capital, Inc. and Silicon Valley Bank.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-396147</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 17, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-33123.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-33123.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-33123.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-33123.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Tarsus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i2779edde9dc94c55bb7cd8d1f6f5224d_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2779edde9dc94c55bb7cd8d1f6f5224d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TARSUS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Chairman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Director)</span></td></tr></table></div><div style="margin-top:12pt;text-align:right;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Farrow</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Farrow</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Strategy Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-33123.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id58b05137510443cb3302daeeb81a8f6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Bobak Azamian, M.D., Ph.D., certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-33123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4afa18d276ea4bbab0f45600635d0c18_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Jeffrey Farrow, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Jeffrey Farrow</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Jeffrey Farrow</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Financial Officer and Chief Strategy Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-33123.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i951aa96bd63c42bcb210d0d99ab9fbc1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.1 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">results of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-33123.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i42d8db38be4e461cbfc4cf0516976bfa_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Farrow, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">results of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jeffrey Farrow</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Farrow</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer and Chief Strategy Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tars-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tars="http://tarsusrx.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tarsusrx.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://tarsusrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://tarsusrx.com/role/CondensedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersEquity" roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatements" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements">
        <link:definition>0000007 - Disclosure - Description of Business and Presentation of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimates" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://tarsusrx.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetail" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail">
        <link:definition>0000010 - Disclosure - Balance Sheet Account Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://tarsusrx.com/role/StockholdersEquity">
        <link:definition>0000011 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://tarsusrx.com/role/StockBasedCompensation">
        <link:definition>0000012 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://tarsusrx.com/role/NetLossPerShare">
        <link:definition>0000013 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingencies" roleURI="http://tarsusrx.com/role/CommitmentContingencies">
        <link:definition>0000014 - Disclosure - Commitment &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreement" roleURI="http://tarsusrx.com/role/OutLicenseAgreement">
        <link:definition>0000015 - Disclosure - Out-License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreement" roleURI="http://tarsusrx.com/role/CreditFacilityAgreement">
        <link:definition>0000016 - Disclosure - Credit Facility Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://tarsusrx.com/role/SubsequentEvent">
        <link:definition>0000017 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies">
        <link:definition>0000018 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables">
        <link:definition>0000019 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailTables" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables">
        <link:definition>0000020 - Disclosure - Balance Sheet Account Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://tarsusrx.com/role/StockholdersEquityTables">
        <link:definition>0000021 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://tarsusrx.com/role/StockBasedCompensationTables">
        <link:definition>0000022 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://tarsusrx.com/role/NetLossPerShareTables">
        <link:definition>0000023 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementTables" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables">
        <link:definition>0000024 - Disclosure - Credit Facility Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatementsDetails" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails">
        <link:definition>0000025 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
        <link:definition>0000027 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails">
        <link:definition>0000029 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails">
        <link:definition>0000030 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
        <link:definition>0000031 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000032 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharesReservedforIssuanceDetails" roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails">
        <link:definition>0000034 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>0000035 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsofStockOptionsDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails">
        <link:definition>0000036 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000038 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://tarsusrx.com/role/NetLossPerShareDetails">
        <link:definition>0000040 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>0000041 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesInLicenseAgreementforLotilanerDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
        <link:definition>0000042 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesEmploymentArrangementsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails">
        <link:definition>0000043 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreementDetails" roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails">
        <link:definition>0000044 - Disclosure - Out-License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails">
        <link:definition>0000045 - Disclosure - Credit Facility Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementSummaryofInterestExpenseDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails">
        <link:definition>0000046 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails">
        <link:definition>0000047 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://tarsusrx.com/role/SubsequentEventDetails">
        <link:definition>0000048 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="tars_CreditFacilityTrancheOneMember" abstract="true" name="CreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" abstract="false" name="PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" abstract="false" name="PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CreditFacilityTrancheThreeMember" abstract="true" name="CreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_MilestoneDeterminedByTheCompanyMember" abstract="true" name="MilestoneDeterminedByTheCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClinicalMilestonesMember" abstract="true" name="ClinicalMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_DevelopmentAndRegulatoryMilestoneMember" abstract="true" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="tars_CommonStockNumberOfVotes" abstract="false" name="CommonStockNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseRemainingLeaseTermExtension" abstract="false" name="LesseeOperatingLeaseRemainingLeaseTermExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_LineOfCreditSVBMember" abstract="true" name="LineOfCreditSVBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AccruedClinicalStudiesCurrent" abstract="false" name="AccruedClinicalStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_EquitySecuritiesFVNINumberOfShares" abstract="false" name="EquitySecuritiesFVNINumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodValueLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityFirstAmendmentTrancheTwoMember" abstract="true" name="CreditFacilityFirstAmendmentTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CreditFacilityTrancheTwoMember" abstract="true" name="CreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsRemainingPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LineOfCreditFacilityPeriodicPaymentInterestRate" abstract="false" name="LineOfCreditFacilityPeriodicPaymentInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" abstract="false" name="DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" abstract="false" name="PostemploymentBenefitsPercentOfAnnualBonusPaidOut" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_LianBioMember" abstract="true" name="LianBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ElancoMember" abstract="true" name="ElancoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_RelatedPartyTransactionOptionToPurchaseShares" abstract="false" name="RelatedPartyTransactionOptionToPurchaseShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" abstract="true" name="AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CollaborativeArrangementFutureCashPayments" abstract="false" name="CollaborativeArrangementFutureCashPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_EquityWarrantsFairValueDisclosure" abstract="false" name="EquityWarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LineOfCreditFacilityDrawDownIncrements" abstract="false" name="LineOfCreditFacilityDrawDownIncrements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" abstract="false" name="RevenueRemainingPerformanceObligationAdditionalCashPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommercialAndSalesMilestonesMember" abstract="true" name="CommercialAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_WarrantAgreementNumberOfTranches" abstract="false" name="WarrantAgreementNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" abstract="true" name="ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CollaborativeArrangementMaximumMilestonePayment" abstract="false" name="CollaborativeArrangementMaximumMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" abstract="false" name="DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityTrancheFourMember" abstract="true" name="CreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_EquityIncentivePlan2016Member" abstract="true" name="EquityIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LicenseAndCollaborationMember" abstract="true" name="LicenseAndCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_NumberOfVestedWarrants" abstract="false" name="NumberOfVestedWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" abstract="true" name="ShareBasedPaymentArrangementEarlyExercisedOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" abstract="false" name="NumberOfEmploymentArrangementsWithExecutiveOfficers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_PaymentsOfDeferredStockIssuanceCosts" abstract="false" name="PaymentsOfDeferredStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>tars-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_735ccd78-80a7-4b51-8311-ba551c7360cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_810704b6-5a01-46fd-9aaa-dd038b317ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_735ccd78-80a7-4b51-8311-ba551c7360cb" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_810704b6-5a01-46fd-9aaa-dd038b317ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55233e63-4ec0-4682-a8c6-4d15bd4a412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_735ccd78-80a7-4b51-8311-ba551c7360cb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_55233e63-4ec0-4682-a8c6-4d15bd4a412b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b785fab9-ecbc-445c-bf81-b64a33533103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b785fab9-ecbc-445c-bf81-b64a33533103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9cb90afd-306d-4fe0-a9c5-19c6f2794742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9cb90afd-306d-4fe0-a9c5-19c6f2794742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_13fa47b4-b346-4001-bbf7-28c74c9901c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_13fa47b4-b346-4001-bbf7-28c74c9901c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3647806c-89b6-4d45-9293-192dd7c87463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3647806c-89b6-4d45-9293-192dd7c87463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e6685702-4db7-4871-8794-b65af62d269a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_125ef937-9a33-45a5-85bd-d5912b06f19e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e6685702-4db7-4871-8794-b65af62d269a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32fea4dc-1f7d-433f-b80b-1911865ab01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9cd260d9-9442-4cc7-b52e-231fd7824b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_32fea4dc-1f7d-433f-b80b-1911865ab01b" xlink:to="loc_us-gaap_Liabilities_9cd260d9-9442-4cc7-b52e-231fd7824b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bb1e8f6-8878-484e-ab33-44f0468ed4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_32fea4dc-1f7d-433f-b80b-1911865ab01b" xlink:to="loc_us-gaap_StockholdersEquity_5bb1e8f6-8878-484e-ab33-44f0468ed4a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5baa4b3b-1720-4615-b986-ee779eeadaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_32fea4dc-1f7d-433f-b80b-1911865ab01b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5baa4b3b-1720-4615-b986-ee779eeadaa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9cc17ff-c68d-4b6a-9343-c4c40cd6ab61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9cc17ff-c68d-4b6a-9343-c4c40cd6ab61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b604d81e-b7d2-4979-8f24-519afc2a75f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:to="loc_us-gaap_CommonStockValue_b604d81e-b7d2-4979-8f24-519afc2a75f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_88d5b96c-797e-48ac-849d-1b083b162658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:to="loc_us-gaap_PreferredStockValue_88d5b96c-797e-48ac-849d-1b083b162658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f997fdeb-3bed-4855-9d0d-8d0937bac695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f997fdeb-3bed-4855-9d0d-8d0937bac695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b0d59fba-05e8-49f5-9e46-80ffa8d0a398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d7445132-6c65-4609-99dd-8f9290608e58" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b0d59fba-05e8-49f5-9e46-80ffa8d0a398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4136eadc-65f1-478e-b907-9d3fbca619a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_915b9ca7-c1f3-4859-aab3-0190298a0cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4136eadc-65f1-478e-b907-9d3fbca619a2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_915b9ca7-c1f3-4859-aab3-0190298a0cea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0e9b37d7-2138-4bd0-b9e7-e191b2542d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4136eadc-65f1-478e-b907-9d3fbca619a2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0e9b37d7-2138-4bd0-b9e7-e191b2542d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e9443df4-23d1-4a33-846c-fe77288cacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4136eadc-65f1-478e-b907-9d3fbca619a2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e9443df4-23d1-4a33-846c-fe77288cacbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f5cece80-4a7e-4282-885c-84b0042f0281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:to="loc_us-gaap_AssetsCurrent_f5cece80-4a7e-4282-885c-84b0042f0281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eb166dd7-3080-4d34-b24a-119b14ed3e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eb166dd7-3080-4d34-b24a-119b14ed3e31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_57110d65-a982-4bf3-b651-6aaba9ee1934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_57110d65-a982-4bf3-b651-6aaba9ee1934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_23d1f9cd-3f18-45ac-997c-323d8881c57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_23d1f9cd-3f18-45ac-997c-323d8881c57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_e651ff54-222c-4695-9d54-f8d66267c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b95a9957-a572-4bfb-bb8d-88308259f336" xlink:to="loc_us-gaap_LongTermInvestments_e651ff54-222c-4695-9d54-f8d66267c174" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d141f52-4252-4601-8938-24184be6dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e827ed2-e9da-484d-b9f3-c7cf3fa071a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d141f52-4252-4601-8938-24184be6dee9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e827ed2-e9da-484d-b9f3-c7cf3fa071a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_653d9eb4-b8f7-4633-887e-ba8edbf8f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d141f52-4252-4601-8938-24184be6dee9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_653d9eb4-b8f7-4633-887e-ba8edbf8f80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_454c2648-ed34-4995-a216-710cfe1ffe00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d141f52-4252-4601-8938-24184be6dee9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_454c2648-ed34-4995-a216-710cfe1ffe00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4395eb13-9a61-49f7-9eed-3eaf533fddae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3d592db-4ada-4fbf-b284-94a0f5303118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4395eb13-9a61-49f7-9eed-3eaf533fddae" xlink:to="loc_us-gaap_CostsAndExpenses_c3d592db-4ada-4fbf-b284-94a0f5303118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_236aea02-e4a1-435e-8109-1d728089ef57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4395eb13-9a61-49f7-9eed-3eaf533fddae" xlink:to="loc_us-gaap_Revenues_236aea02-e4a1-435e-8109-1d728089ef57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_0f4043dc-37b4-4776-84a7-92e15758771a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:to="loc_us-gaap_InterestIncomeOther_0f4043dc-37b4-4776-84a7-92e15758771a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_57ca2afe-c24d-4cb2-b763-0790d411cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_57ca2afe-c24d-4cb2-b763-0790d411cdcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_356c3453-b430-406d-8c80-e7b9dc1b13b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_356c3453-b430-406d-8c80-e7b9dc1b13b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e1198e5-880c-42e2-9fdd-41cda91e8d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e1198e5-880c-42e2-9fdd-41cda91e8d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a4508669-5ea1-442f-bb3a-cf54c986caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_45d9db14-36b5-4d2e-8155-408806929196" xlink:to="loc_us-gaap_InterestExpense_a4508669-5ea1-442f-bb3a-cf54c986caa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3530b6b3-99ff-459b-86ec-ded05b224966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f213729a-a517-4227-ac49-639f8a0727b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3530b6b3-99ff-459b-86ec-ded05b224966" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f213729a-a517-4227-ac49-639f8a0727b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_013daf0d-0f21-4e9b-91bc-43741f94137a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3530b6b3-99ff-459b-86ec-ded05b224966" xlink:to="loc_us-gaap_NetIncomeLoss_013daf0d-0f21-4e9b-91bc-43741f94137a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd430fcc-9421-4192-932e-4fdd6119d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d3abe236-c95e-420b-9037-0847ae3365a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd430fcc-9421-4192-932e-4fdd6119d0f6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d3abe236-c95e-420b-9037-0847ae3365a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0c877178-afb2-4214-9a6f-ca46a17c5ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd430fcc-9421-4192-932e-4fdd6119d0f6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0c877178-afb2-4214-9a6f-ca46a17c5ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_520bb3c4-46e0-4bc9-be87-9efa389c4313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd430fcc-9421-4192-932e-4fdd6119d0f6" xlink:to="loc_us-gaap_OperatingIncomeLoss_520bb3c4-46e0-4bc9-be87-9efa389c4313" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_7ebfc7bd-31fd-463c-943f-138002d8facd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_7ebfc7bd-31fd-463c-943f-138002d8facd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4b45f42-4418-460c-af16-7c04f966aa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4b45f42-4418-460c-af16-7c04f966aa2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e4d8155-da1b-45f2-bb50-80e7b2e4f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_NetIncomeLoss_6e4d8155-da1b-45f2-bb50-80e7b2e4f8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_05e2a25e-2c66-4721-939b-a0446124e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_05e2a25e-2c66-4721-939b-a0446124e8ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7328a60d-0264-4fe6-96fe-3102f9b4e548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7328a60d-0264-4fe6-96fe-3102f9b4e548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ba57045f-a67a-4a42-85df-a48469edaea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ba57045f-a67a-4a42-85df-a48469edaea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_1e8a7121-b6f2-4073-bf4b-6ba4ccd87aa5" xlink:href="tars-20230331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_tars_OperatingLeaseNoncashExpense_1e8a7121-b6f2-4073-bf4b-6ba4ccd87aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f7568a1b-1dba-4b90-a4b5-4e070a1b60af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f7568a1b-1dba-4b90-a4b5-4e070a1b60af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_10270abd-025f-4460-a494-55a7e00fcea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_10270abd-025f-4460-a494-55a7e00fcea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_64b29b39-a01b-4766-94ba-ccf985acbd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_ShareBasedCompensation_64b29b39-a01b-4766-94ba-ccf985acbd29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_814b28c5-a86f-4844-b7fa-a440c460caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_814b28c5-a86f-4844-b7fa-a440c460caac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_62b315ee-970b-4a62-a7e3-22d07af45265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_62b315ee-970b-4a62-a7e3-22d07af45265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47045eb3-70dc-4f93-a196-11fe57aaa875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47045eb3-70dc-4f93-a196-11fe57aaa875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_875412cd-a5c2-43ee-8348-6517808ffbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_875412cd-a5c2-43ee-8348-6517808ffbcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dca7b45-0506-4769-a27c-c277e89b0343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dca7b45-0506-4769-a27c-c277e89b0343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1b26e32c-0703-42c3-9768-643afa9b72b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_601ee746-00db-4bc1-8fde-350687b70726" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1b26e32c-0703-42c3-9768-643afa9b72b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28a82bb3-da58-4ccf-b620-58ce255e3360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4fd7227f-ebb9-4587-9983-e09454621ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28a82bb3-da58-4ccf-b620-58ce255e3360" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4fd7227f-ebb9-4587-9983-e09454621ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b4661933-4dd0-41a2-bdef-d3c620eaecee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28a82bb3-da58-4ccf-b620-58ce255e3360" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b4661933-4dd0-41a2-bdef-d3c620eaecee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11ca1781-dae8-4543-a355-36406f22427d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28a82bb3-da58-4ccf-b620-58ce255e3360" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11ca1781-dae8-4543-a355-36406f22427d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b97a1ea2-3603-4084-a770-1d963c61acdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77754b6f-23cd-4ba2-9143-282659cfdf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b97a1ea2-3603-4084-a770-1d963c61acdd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77754b6f-23cd-4ba2-9143-282659cfdf4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9687b0-92a7-44a2-8f74-f7c6d9f54fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b97a1ea2-3603-4084-a770-1d963c61acdd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a9687b0-92a7-44a2-8f74-f7c6d9f54fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04575b9b-c5cc-4715-8eec-e4d047b8b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b97a1ea2-3603-4084-a770-1d963c61acdd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04575b9b-c5cc-4715-8eec-e4d047b8b667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e6204d6-caf6-44a2-9f4e-7c5c30e3b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts_865d1431-8dc4-4e10-b377-37e19ae5c32a" xlink:href="tars-20230331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e6204d6-caf6-44a2-9f4e-7c5c30e3b3a8" xlink:to="loc_tars_PaymentsOfDeferredStockIssuanceCosts_865d1431-8dc4-4e10-b377-37e19ae5c32a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_76b3c5d5-5f62-4779-a12a-d42b07e98dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e6204d6-caf6-44a2-9f4e-7c5c30e3b3a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_76b3c5d5-5f62-4779-a12a-d42b07e98dad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_29e741fe-56a4-42c5-a594-5460511c7f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e6204d6-caf6-44a2-9f4e-7c5c30e3b3a8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_29e741fe-56a4-42c5-a594-5460511c7f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7c123c52-457b-49e1-adbd-4955e1ac919d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e6204d6-caf6-44a2-9f4e-7c5c30e3b3a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7c123c52-457b-49e1-adbd-4955e1ac919d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9270b764-00e4-47f2-8eb9-40e18af78a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9270b764-00e4-47f2-8eb9-40e18af78a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_f0388576-ac4a-4399-8312-16dc39d76607" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_f0388576-ac4a-4399-8312-16dc39d76607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b8026b37-f9cb-4bc5-898d-301f599c65e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b8026b37-f9cb-4bc5-898d-301f599c65e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_85ebf057-d559-40d1-897d-798393b71898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_85ebf057-d559-40d1-897d-798393b71898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_9adf7b56-10aa-4ede-8eaf-44deff8cec3b" xlink:href="tars-20230331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d9aa2b72-b3a1-43f5-8b00-7897915cae62" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_9adf7b56-10aa-4ede-8eaf-44deff8cec3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c2c7ebed-5805-4807-857a-ee5c575e080c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a209c46b-c47c-40c2-aa2f-f698c947d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c2c7ebed-5805-4807-857a-ee5c575e080c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a209c46b-c47c-40c2-aa2f-f698c947d1fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22c9b7e2-01f2-4ef0-9f58-98cd8aac593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c2c7ebed-5805-4807-857a-ee5c575e080c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22c9b7e2-01f2-4ef0-9f58-98cd8aac593b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ba530a3-8195-4a46-a38a-ffcccf8be4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c2c7ebed-5805-4807-857a-ee5c575e080c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ba530a3-8195-4a46-a38a-ffcccf8be4f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f35a66ce-9658-40e7-a3bb-171a9d8b260f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_940ebeb2-dbc3-4bca-adf5-d57f5fc0b4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f35a66ce-9658-40e7-a3bb-171a9d8b260f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_940ebeb2-dbc3-4bca-adf5-d57f5fc0b4c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0f68f0b3-0446-4966-818d-64d390efea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f35a66ce-9658-40e7-a3bb-171a9d8b260f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0f68f0b3-0446-4966-818d-64d390efea97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_eb644634-a1cd-4706-a3ae-5ea1e5e7ad30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_eb644634-a1cd-4706-a3ae-5ea1e5e7ad30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_8b0196d4-2263-446e-b3f9-5700d705d1a6" xlink:href="tars-20230331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_8b0196d4-2263-446e-b3f9-5700d705d1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_c1c96232-72d3-400f-b928-9412ae93ae44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_c1c96232-72d3-400f-b928-9412ae93ae44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a17a81f-86a5-434a-befb-bdc98a2320d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a17a81f-86a5-434a-befb-bdc98a2320d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_aab2a56c-9eca-49ab-bc94-049750f47171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cd9364a5-f2f4-4d76-b810-e956e9146af3" xlink:to="loc_us-gaap_InterestPayableCurrent_aab2a56c-9eca-49ab-bc94-049750f47171" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquitySharesReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_61921954-682b-4960-bc5b-19efba0df4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_0c48c3c1-124b-4465-b54f-e8c32eb87344" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_61921954-682b-4960-bc5b-19efba0df4a6" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_0c48c3c1-124b-4465-b54f-e8c32eb87344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_cd111e27-0f17-4531-baf2-569576146318" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_61921954-682b-4960-bc5b-19efba0df4a6" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_cd111e27-0f17-4531-baf2-569576146318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_bbf82767-aa09-4b7a-8ef3-36025a78137b" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_61921954-682b-4960-bc5b-19efba0df4a6" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_bbf82767-aa09-4b7a-8ef3-36025a78137b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_d6f63304-35b1-4313-ae6c-53f84d0ca5b4" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_61921954-682b-4960-bc5b-19efba0df4a6" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_d6f63304-35b1-4313-ae6c-53f84d0ca5b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_d978433f-0cc9-4abe-9bb9-0d0299f6fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_960f6813-85fd-4a3f-b62c-877ddd3b6159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_d978433f-0cc9-4abe-9bb9-0d0299f6fb7a" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_960f6813-85fd-4a3f-b62c-877ddd3b6159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d5a4602e-3b27-473d-aa4e-03484ffc17b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_d978433f-0cc9-4abe-9bb9-0d0299f6fb7a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d5a4602e-3b27-473d-aa4e-03484ffc17b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_092ee047-668d-4064-be16-3515d41ee49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_d978433f-0cc9-4abe-9bb9-0d0299f6fb7a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_092ee047-668d-4064-be16-3515d41ee49a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fd078fc6-4114-4d84-91c8-c44a5369a5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3012607b-b692-4c08-9d6f-937ec14c645b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd078fc6-4114-4d84-91c8-c44a5369a5bd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3012607b-b692-4c08-9d6f-937ec14c645b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_a1abe9b6-e1ee-40b3-9380-2cf1a3c0ebc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd078fc6-4114-4d84-91c8-c44a5369a5bd" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_a1abe9b6-e1ee-40b3-9380-2cf1a3c0ebc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_3a35bfe9-17e9-422b-8e53-b7e7157f6382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd078fc6-4114-4d84-91c8-c44a5369a5bd" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_3a35bfe9-17e9-422b-8e53-b7e7157f6382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_930514a4-2814-4e95-9ece-374e493b6be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd078fc6-4114-4d84-91c8-c44a5369a5bd" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_930514a4-2814-4e95-9ece-374e493b6be1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>tars-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i475b2b38aeee4ddab140253ec559d056_CondensedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3696262e-c255-468a-9a41-6bbfb42b96fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:to="loc_us-gaap_Revenues_3696262e-c255-468a-9a41-6bbfb42b96fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_921f2a91-308b-44de-945e-b2344acbbc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_921f2a91-308b-44de-945e-b2344acbbc3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b42cfee5-6970-4a52-a021-a623df67e974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b42cfee5-6970-4a52-a021-a623df67e974" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bc9d6325-ae81-42a2-a989-dc1bf7efd79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bc9d6325-ae81-42a2-a989-dc1bf7efd79e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_be7b9510-499a-4c96-b9a8-91569b861a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_CostsAndExpenses_be7b9510-499a-4c96-b9a8-91569b861a7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4ea6191d-f927-40aa-8689-13373146172f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OperatingIncomeLoss_4ea6191d-f927-40aa-8689-13373146172f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_27c8605b-20c5-449e-b8c1-20300efc3017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_InterestIncomeOther_27c8605b-20c5-449e-b8c1-20300efc3017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_df96242f-daad-45ed-a8cc-93a9eb48c963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_InterestExpense_df96242f-daad-45ed-a8cc-93a9eb48c963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36c5192c-54b5-4bc4-b78b-97ab9352fa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36c5192c-54b5-4bc4-b78b-97ab9352fa2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3466974f-dc94-44cb-bcb5-bc1ecdd1d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3466974f-dc94-44cb-bcb5-bc1ecdd1d47b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a0e2d031-5d79-47c4-a86f-88f1178d75a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a0e2d031-5d79-47c4-a86f-88f1178d75a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aeb78aad-f47f-45ca-bab8-e87e7afa64d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aeb78aad-f47f-45ca-bab8-e87e7afa64d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47d38659-fdc2-432b-9157-795a5ce4a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47d38659-fdc2-432b-9157-795a5ce4a608" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97a26a7b-8f94-4f4a-860d-33e75383e578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_NetIncomeLoss_97a26a7b-8f94-4f4a-860d-33e75383e578" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cc44fb7b-7622-4c33-a891-93fbdbbd5f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cc44fb7b-7622-4c33-a891-93fbdbbd5f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2af217b-6aee-4a71-a596-09cd96f165b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2af217b-6aee-4a71-a596-09cd96f165b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c33bd77e-fc1f-487b-8b05-ea30b8408566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:to="loc_us-gaap_EarningsPerShareBasic_c33bd77e-fc1f-487b-8b05-ea30b8408566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_93aff632-8a8a-4caf-912f-45b2571d5107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_93aff632-8a8a-4caf-912f-45b2571d5107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1aa1fd54-6f75-4673-ae23-6fe19f8e7645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1aa1fd54-6f75-4673-ae23-6fe19f8e7645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e96f330e-74a5-48f6-a5bb-756f126ca12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e96f330e-74a5-48f6-a5bb-756f126ca12e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:to="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_100a0bee-1473-43c2-bc2e-9cd6dee9f513_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:to="loc_srt_ProductsAndServicesDomain_100a0bee-1473-43c2-bc2e-9cd6dee9f513_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:to="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_fbf89b3c-aaea-42ec-a250-04449a5fcd1d" xlink:href="tars-20230331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:to="loc_tars_LicenseAndCollaborationMember_fbf89b3c-aaea-42ec-a250-04449a5fcd1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="extended" id="i722e1c3d788644b5a881d115fea748a7_CondensedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_199a6713-0f45-4e69-9238-9f7e06693539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_199a6713-0f45-4e69-9238-9f7e06693539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5f8905e6-8731-43b5-bdd4-9ed1661beb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_07a64a5d-953c-456a-9b20-888bd26443e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_07a64a5d-953c-456a-9b20-888bd26443e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e6538515-d90a-4a90-a0b6-1af5e9bc50e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28636726-fd7b-4176-b037-4956f9f32b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28636726-fd7b-4176-b037-4956f9f32b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bc4c114-cca7-4061-ba48-aa4adcebc9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockholdersEquity_5bc4c114-cca7-4061-ba48-aa4adcebc9c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9be073f6-3d80-47b0-981d-89e1cc3e9bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_NetIncomeLoss_9be073f6-3d80-47b0-981d-89e1cc3e9bcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9183ddcf-bf05-4d48-850b-4a1827d812d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9183ddcf-bf05-4d48-850b-4a1827d812d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_610d8939-5447-48f4-8d2a-4aaeeb3862de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_610d8939-5447-48f4-8d2a-4aaeeb3862de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c1d6e8f-671d-48d1-bfb7-696e970072f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c1d6e8f-671d-48d1-bfb7-696e970072f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_141247fd-d3e3-4349-aeef-65cab9ac91ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_141247fd-d3e3-4349-aeef-65cab9ac91ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_90ba40ba-5d5b-4b07-b7dc-ebca0eb6859b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_90ba40ba-5d5b-4b07-b7dc-ebca0eb6859b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_a6bd96c7-952d-414e-b1b9-6b644ea1fdd6" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_a6bd96c7-952d-414e-b1b9-6b644ea1fdd6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_8e7617dd-a68e-4147-90f3-f510ef2fcd95" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_8e7617dd-a68e-4147-90f3-f510ef2fcd95" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c570bea8-c25f-4583-9c8e-1c7d6c594027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7929d48-663d-456a-b890-2680125c8dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:to="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_18125637-2481-4e3b-9b8d-50d044fd7165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:to="loc_us-gaap_EquityComponentDomain_18125637-2481-4e3b-9b8d-50d044fd7165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:to="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_983ecc87-ecfa-426c-84d0-305c77868aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_CommonStockMember_983ecc87-ecfa-426c-84d0-305c77868aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_57122d83-4d9e-4c41-8172-e2dfc0cbb894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_57122d83-4d9e-4c41-8172-e2dfc0cbb894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2153b115-8569-437b-91fa-df58efb996df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2153b115-8569-437b-91fa-df58efb996df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bcf84f7a-a0e7-400d-b871-f6ee6b34d51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_RetainedEarningsMember_bcf84f7a-a0e7-400d-b871-f6ee6b34d51b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="extended" id="if878cd1973d748509a7193cf4d420516_SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3bca4f7a-9192-4e81-855f-d3f87577a4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3bca4f7a-9192-4e81-855f-d3f87577a4fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssets_f3616372-6c98-4350-9109-073e510e77d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_DepositsAssets_f3616372-6c98-4350-9109-073e510e77d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_097d5eca-2526-4fca-9e3c-716a1e853fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_097d5eca-2526-4fca-9e3c-716a1e853fc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0c56f194-f786-4712-85ed-7e4717abf083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0c56f194-f786-4712-85ed-7e4717abf083" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0f1445dc-09fa-4d1d-9e23-c614118a744c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0f1445dc-09fa-4d1d-9e23-c614118a744c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a1d2692-a597-4895-bf06-9ebabd7e0615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a1d2692-a597-4895-bf06-9ebabd7e0615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:to="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89494aa5-f62e-4e4d-9e30-3c3727a9df49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:to="loc_srt_RangeMember_89494aa5-f62e-4e4d-9e30-3c3727a9df49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:to="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_304e66e3-52f8-41e0-9d0a-33e987f794f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:to="loc_srt_MinimumMember_304e66e3-52f8-41e0-9d0a-33e987f794f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5842bbf3-912e-47c8-9ccd-06410eba435f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:to="loc_srt_MaximumMember_5842bbf3-912e-47c8-9ccd-06410eba435f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:to="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ed6be0ce-4f40-443f-b764-4c8a717e64db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:to="loc_us-gaap_PlanNameDomain_ed6be0ce-4f40-443f-b764-4c8a717e64db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:to="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_78c23642-f751-4268-90c3-0c7f4f3ea14b" xlink:href="tars-20230331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:to="loc_tars_EquityIncentivePlan2016Member_78c23642-f751-4268-90c3-0c7f4f3ea14b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended" id="id65329426e3744e3aad078e8cf2972f8_FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:to="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f91ce10d-d57b-433f-8908-3ac43928dee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f91ce10d-d57b-433f-8908-3ac43928dee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_c0d4cf5f-d85a-45de-9099-95b84db763dd" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_c0d4cf5f-d85a-45de-9099-95b84db763dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d704f8d-a2ad-4714-a33f-ff98ac8a0c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d704f8d-a2ad-4714-a33f-ff98ac8a0c40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fe2ea468-4a35-40d1-be3d-be364c83de08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fe2ea468-4a35-40d1-be3d-be364c83de08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_38d2e637-3b0d-488d-9aa1-ccf80e70c757" xlink:href="tars-20230331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_38d2e637-3b0d-488d-9aa1-ccf80e70c757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_32ab0ed0-3c60-44c1-af56-4ce1c67ed2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_32ab0ed0-3c60-44c1-af56-4ce1c67ed2ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5219b6de-d829-441e-b915-5516f4f5dbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5219b6de-d829-441e-b915-5516f4f5dbe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d031be49-733b-42e5-87b1-64282eb25344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d031be49-733b-42e5-87b1-64282eb25344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6d1392b6-499c-477e-a7e6-b20837b4db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6d1392b6-499c-477e-a7e6-b20837b4db6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8caabcf-652d-4f0b-b414-321ae03067bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8caabcf-652d-4f0b-b414-321ae03067bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_b1252013-6617-4b34-9728-a1bb6ea508b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CashMember_b1252013-6617-4b34-9728-a1bb6ea508b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7d60c474-a60c-4efd-bba2-4cf8f2c91f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7d60c474-a60c-4efd-bba2-4cf8f2c91f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_865c0fc3-5308-4d18-af65-c5f091c1f92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_865c0fc3-5308-4d18-af65-c5f091c1f92a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a19082aa-f19a-4a9f-aa5d-e1b882e947ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CommercialPaperMember_a19082aa-f19a-4a9f-aa5d-e1b882e947ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_20dc132c-832d-461d-99d8-606f37329d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_20dc132c-832d-461d-99d8-606f37329d37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e8e4a959-cf23-4dfa-a2a7-336f626196d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e8e4a959-cf23-4dfa-a2a7-336f626196d0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i081d6aa505dc47f2ade4cca90f3a3652_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches_9f9d644b-e0f3-4020-99e8-7cd3243875e2" xlink:href="tars-20230331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_WarrantAgreementNumberOfTranches_9f9d644b-e0f3-4020-99e8-7cd3243875e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants_c56efa8e-982e-47b1-986b-b98b9d8da5c0" xlink:href="tars-20230331.xsd#tars_NumberOfVestedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_NumberOfVestedWarrants_c56efa8e-982e-47b1-986b-b98b9d8da5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares_3533bd0b-d556-4289-b247-bd936cdff3ab" xlink:href="tars-20230331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_EquitySecuritiesFVNINumberOfShares_3533bd0b-d556-4289-b247-bd936cdff3ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_d95f8764-b78a-43f2-9ae6-2800927d23cf" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_d95f8764-b78a-43f2-9ae6-2800927d23cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_e988977a-af9b-4527-af13-7286f4835e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_e988977a-af9b-4527-af13-7286f4835e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef862783-f877-4876-92a8-b95a755e77ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef862783-f877-4876-92a8-b95a755e77ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9bef5247-c320-4e99-9370-92c983da2ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9bef5247-c320-4e99-9370-92c983da2ddf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:to="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f10114cf-3758-40c4-a55a-d4f95f074d6e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:to="loc_srt_RangeMember_f10114cf-3758-40c4-a55a-d4f95f074d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:to="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfca97f8-cff9-4e6f-a3de-e5b339158d22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:to="loc_srt_MinimumMember_cfca97f8-cff9-4e6f-a3de-e5b339158d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee23c2ea-3b4f-4f7e-a12c-222d95b99513" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:to="loc_srt_MaximumMember_ee23c2ea-3b4f-4f7e-a12c-222d95b99513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cc5e714-163d-4104-a068-92d49ee91859_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cc5e714-163d-4104-a068-92d49ee91859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_f8baf80e-c5d1-44dc-a560-6b52afd1f7a8" xlink:href="tars-20230331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:to="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_f8baf80e-c5d1-44dc-a560-6b52afd1f7a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended" id="i7e7a5aaad2d24dbb9c899a3d09eac68c_FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05b602ca-97ce-4338-af5f-038059b6639c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05b602ca-97ce-4338-af5f-038059b6639c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09b45884-d013-4e04-a429-1126e91c389b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09b45884-d013-4e04-a429-1126e91c389b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f763e7c-aa2e-494a-913a-7d0931b73837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f763e7c-aa2e-494a-913a-7d0931b73837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b842cdab-2dc8-4403-bad7-7f2796dc6764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b842cdab-2dc8-4403-bad7-7f2796dc6764" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c7297da-8e1e-4eeb-8e97-f652ac2dd7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c7297da-8e1e-4eeb-8e97-f652ac2dd7a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b807ff28-cca0-4ade-8e68-b7c7b858bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b807ff28-cca0-4ade-8e68-b7c7b858bb18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_46ee237e-25a3-444e-be99-ab77d55cc1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_46ee237e-25a3-444e-be99-ab77d55cc1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_49787e83-8af4-43e2-b7dd-c47d5f77951a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_49787e83-8af4-43e2-b7dd-c47d5f77951a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1f0ec97b-4d27-4848-bbc4-e3d545ac68ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1f0ec97b-4d27-4848-bbc4-e3d545ac68ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_30cd32f8-caa4-45cb-b6be-a57b1cf2e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_30cd32f8-caa4-45cb-b6be-a57b1cf2e517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_112388f5-99f1-4077-8231-68967d680ba1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_112388f5-99f1-4077-8231-68967d680ba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05d9d9dd-5d05-4901-8dee-6a64df3edffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05d9d9dd-5d05-4901-8dee-6a64df3edffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1705b933-537c-4491-b334-563943b44484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1705b933-537c-4491-b334-563943b44484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5b5029c7-4df2-4dfe-ae05-b61e761384b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CommercialPaperMember_5b5029c7-4df2-4dfe-ae05-b61e761384b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_9d543db9-1f67-40ce-b02e-d862115d7915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_9d543db9-1f67-40ce-b02e-d862115d7915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2b122936-bf11-46a9-a21b-30c7c7b4102e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2b122936-bf11-46a9-a21b-30c7c7b4102e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_29ca2d44-c7b9-4518-a34f-ef57d5d00745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CashMember_29ca2d44-c7b9-4518-a34f-ef57d5d00745" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended" id="ibfe5bdefeef145c09cd3d9f41d1ae27f_BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8731fa93-f09d-497e-87bc-c628a1509a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8731fa93-f09d-497e-87bc-c628a1509a03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d28a4b21-848c-4918-96fc-4c2b461e5437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d28a4b21-848c-4918-96fc-4c2b461e5437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1644182a-b2e6-4bae-b9bb-bab3b8fbdf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1644182a-b2e6-4bae-b9bb-bab3b8fbdf09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5fe172de-2132-42c8-b6df-f2762cf0a22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_Depreciation_5fe172de-2132-42c8-b6df-f2762cf0a22a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a4edfe3d-4c88-426d-8aee-7f336834db4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a4edfe3d-4c88-426d-8aee-7f336834db4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e567409a-73e3-4ed7-abdb-e24faf0bdcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e567409a-73e3-4ed7-abdb-e24faf0bdcc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a549eca2-309f-4899-bd91-1f035693bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_OfficeEquipmentMember_a549eca2-309f-4899-bd91-1f035693bfcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_9ade8091-e727-4338-b825-62483863c698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_9ade8091-e727-4338-b825-62483863c698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0a3d35ff-5301-4f18-9913-b8e58a0bd821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0a3d35ff-5301-4f18-9913-b8e58a0bd821" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i1dea305f0f6749819707af4153ff69a0_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_861bd062-ab28-4b93-b7a9-5e1b707fee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_861bd062-ab28-4b93-b7a9-5e1b707fee9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c6f61d32-2d81-408b-ad87-2743e200fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c6f61d32-2d81-408b-ad87-2743e200fe18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_9a8c7d52-77a6-4e2a-a1a1-23ada3796dc7" xlink:href="tars-20230331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_9a8c7d52-77a6-4e2a-a1a1-23ada3796dc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aa2767d8-fb05-4a22-96bc-3544274d223b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aa2767d8-fb05-4a22-96bc-3544274d223b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1c6139e8-7745-4eea-a12a-3173faf468b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1c6139e8-7745-4eea-a12a-3173faf468b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a1f0ca95-072f-4c6e-9f73-c4541881453e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_CommonStockSharesIssued_a1f0ca95-072f-4c6e-9f73-c4541881453e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_4cfee92b-19ca-4d95-ac53-fdd14a519fa0" xlink:href="tars-20230331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_tars_CommonStockNumberOfVotes_4cfee92b-19ca-4d95-ac53-fdd14a519fa0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a7d13c0d-93d1-4116-9648-bafb4633b11f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a7d13c0d-93d1-4116-9648-bafb4633b11f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember_ea18d682-b7f1-466d-844d-f43d15bacc9e" xlink:href="tars-20230331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:to="loc_tars_FollowOnPublicOfferingMember_ea18d682-b7f1-466d-844d-f43d15bacc9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d3de7cc9-7897-4e96-9d15-563b03cc4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d3de7cc9-7897-4e96-9d15-563b03cc4e3d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="i94108b86d1e141bba3b5bb25294086c5_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_600642e4-507b-4aeb-93b8-65244e6fe981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_600642e4-507b-4aeb-93b8-65244e6fe981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_49034ba2-754b-4015-9690-9742683ecb6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_49034ba2-754b-4015-9690-9742683ecb6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ed954a-15fa-4559-b8d4-3b0a434cb3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ed954a-15fa-4559-b8d4-3b0a434cb3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bbb5334-e683-4eb3-bfb7-04821ad37d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bbb5334-e683-4eb3-bfb7-04821ad37d50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ifa1c5aebbe7a44788f00a29ac6e388b8_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6e4208fe-703f-4353-b3f0-efea372a7873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6e4208fe-703f-4353-b3f0-efea372a7873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a7a1130-c37e-46ac-bea8-a871b7dfdfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a7a1130-c37e-46ac-bea8-a871b7dfdfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b1169074-a878-41cf-9fbc-42b5dfa5e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b1169074-a878-41cf-9fbc-42b5dfa5e3df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:to="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bfbff5f-2198-4445-a2fc-8422eae17721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bfbff5f-2198-4445-a2fc-8422eae17721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4fc7ebcd-0c0f-4ebb-8164-65790dbf96b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4fc7ebcd-0c0f-4ebb-8164-65790dbf96b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d67cca26-dc82-4cf5-8765-b17fe5b7a964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d67cca26-dc82-4cf5-8765-b17fe5b7a964" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i98519595d90a4778a5af1c585bd8f9a4_StockBasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_362d0066-5777-42b1-82aa-788295c08453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_362d0066-5777-42b1-82aa-788295c08453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e257d2bd-2199-44f5-99d3-9b51a63bac80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e257d2bd-2199-44f5-99d3-9b51a63bac80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1dd1dbcf-dff6-49f7-ab1d-448b891bcc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1dd1dbcf-dff6-49f7-ab1d-448b891bcc98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07afb6f7-3f3a-4de3-8bb1-da8f71488ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07afb6f7-3f3a-4de3-8bb1-da8f71488ee3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e0c0562-f6c0-4064-9195-c6272164fd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c910904-e952-41aa-877e-b883c713057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c910904-e952-41aa-877e-b883c713057b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d01cc823-f37e-427b-92b4-8d146f96b016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d01cc823-f37e-427b-92b4-8d146f96b016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f7d4870a-9570-4fb2-90f8-faa04ad40e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f7d4870a-9570-4fb2-90f8-faa04ad40e84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61b16872-b7de-47f2-9aeb-6f879c7d9cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61b16872-b7de-47f2-9aeb-6f879c7d9cd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd7356e6-e796-423b-b143-48e963c99a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:to="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a6be0f33-247c-41b6-b992-f04162309db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a6be0f33-247c-41b6-b992-f04162309db5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i7820dd14219d41dc8b5cb9cd09eb0499_NetLossPerShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ef878d5-05c3-4aed-bf61-58d6b54932fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ef878d5-05c3-4aed-bf61-58d6b54932fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4543072c-9531-41fd-8685-320bbee034cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4543072c-9531-41fd-8685-320bbee034cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8cda10e-afd1-4dec-a31b-e44c123abdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8cda10e-afd1-4dec-a31b-e44c123abdd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_075c1fd3-fb17-4341-bc36-85fa93c3e678" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_075c1fd3-fb17-4341-bc36-85fa93c3e678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_1ceafb0b-851f-4d9e-bc00-eab2e50aa379" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_1ceafb0b-851f-4d9e-bc00-eab2e50aa379" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended" id="i09bb8a6e452241af9d326acb9b138877_CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4fad684a-57a5-4bf9-be23-7515f14f7919" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4fad684a-57a5-4bf9-be23-7515f14f7919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_18b89e9f-b3eb-4203-922b-2acd5938c4c1" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_18b89e9f-b3eb-4203-922b-2acd5938c4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_04415995-b87b-4709-bda6-834c1b46c6fd" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_04415995-b87b-4709-bda6-834c1b46c6fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_70d0f05d-b953-428e-b248-32c61cf0376b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_70d0f05d-b953-428e-b248-32c61cf0376b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments_a171e2b0-a724-43e5-a181-8b36b886b0c2" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementFutureCashPayments_a171e2b0-a724-43e5-a181-8b36b886b0c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_ff85407a-030b-4213-8751-86e3dff44156" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_ff85407a-030b-4213-8751-86e3dff44156" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_c05df83f-48c1-480d-a021-c84d5245d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_c05df83f-48c1-480d-a021-c84d5245d8fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2b3edf56-f180-4ced-a4c5-c60e5315b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2b3edf56-f180-4ced-a4c5-c60e5315b9a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5b13cb7a-4c2e-4d6f-b6e9-509f6b90d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_SharePrice_5b13cb7a-4c2e-4d6f-b6e9-509f6b90d92f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d89dd862-845f-48fa-9882-6ccfec6851c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d89dd862-845f-48fa-9882-6ccfec6851c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:to="loc_srt_ProductsAndServicesDomain_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:to="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_9596f07b-f3f3-4e4d-8aaf-7ea9856d8ea5" xlink:href="tars-20230331.xsd#tars_ClinicalMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:to="loc_tars_ClinicalMilestonesMember_9596f07b-f3f3-4e4d-8aaf-7ea9856d8ea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_a25c51b2-78cc-4ec2-9a86-dfc9d2cac859" xlink:href="tars-20230331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_a25c51b2-78cc-4ec2-9a86-dfc9d2cac859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe8a8b40-c2c8-43c6-a7a3-791d6212e223_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe8a8b40-c2c8-43c6-a7a3-791d6212e223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_e6a87a02-f900-45b6-be10-61754f3b4e5d" xlink:href="tars-20230331.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:to="loc_tars_ElancoMember_e6a87a02-f900-45b6-be10-61754f3b4e5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CommitmentContingenciesEmploymentArrangementsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="extended" id="i02675334622d49e6ad8cb74471817897_CommitmentContingenciesEmploymentArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_dd19d233-68ab-4485-8f85-13443adfa76b" xlink:href="tars-20230331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_dd19d233-68ab-4485-8f85-13443adfa76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_40137f72-4cb8-42d3-b396-957404c5de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_40137f72-4cb8-42d3-b396-957404c5de8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionOptionToPurchaseShares_0bb9916c-9768-4056-8697-425fa1cc825c" xlink:href="tars-20230331.xsd#tars_RelatedPartyTransactionOptionToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_RelatedPartyTransactionOptionToPurchaseShares_0bb9916c-9768-4056-8697-425fa1cc825c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9c22d1db-72e6-4261-918c-85a5d2d6f1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9c22d1db-72e6-4261-918c-85a5d2d6f1b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_e0103309-1b9d-4a1e-835f-86007ad004ff" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_e0103309-1b9d-4a1e-835f-86007ad004ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_617f427c-b071-43f7-b263-dee56804dbf6" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_617f427c-b071-43f7-b263-dee56804dbf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_0a206e6d-df53-48ca-95b1-dea0cfa6f9d0" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_0a206e6d-df53-48ca-95b1-dea0cfa6f9d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_4231c645-65a0-4127-8f0d-98abd0c14005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_4231c645-65a0-4127-8f0d-98abd0c14005" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9b937503-516b-42f6-9cff-5da5ac325264_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:to="loc_us-gaap_RelatedPartyDomain_9b937503-516b-42f6-9cff-5da5ac325264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:to="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c47fbf12-027c-4615-8a2e-bbce3839a73d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:to="loc_srt_DirectorMember_c47fbf12-027c-4615-8a2e-bbce3839a73d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b81a0da-ece8-4416-b706-6e440581af6c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:to="loc_srt_RangeMember_9b81a0da-ece8-4416-b706-6e440581af6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:to="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61326e99-9669-4b46-b555-b4863688452c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:to="loc_srt_MinimumMember_61326e99-9669-4b46-b555-b4863688452c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bcb7b47-61b7-435d-9ef9-3fff1e9eca2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:to="loc_srt_MaximumMember_1bcb7b47-61b7-435d-9ef9-3fff1e9eca2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_a355ddd7-66d3-457f-b1ec-19722f3bd05c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:to="loc_srt_ChiefFinancialOfficerMember_a355ddd7-66d3-457f-b1ec-19722f3bd05c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2de0f3e5-7e37-47dc-8a92-9451f64acfeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2de0f3e5-7e37-47dc-8a92-9451f64acfeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1eaf1e3-dbcb-4200-a0a5-e5055e7eae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:to="loc_us-gaap_SubsequentEventMember_e1eaf1e3-dbcb-4200-a0a5-e5055e7eae4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#OutLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended" id="i4dac2f2372b94c79844d084885cae2ed_OutLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e0a7e697-3941-405e-aedc-de75d341a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e0a7e697-3941-405e-aedc-de75d341a0c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_544de824-d4b1-42c8-b1be-675a2eb2c535" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_544de824-d4b1-42c8-b1be-675a2eb2c535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_6bacc7c8-d784-4eea-83f6-62fbe054ba89" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_6bacc7c8-d784-4eea-83f6-62fbe054ba89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_4e1dd798-f20e-49d2-813a-483ee76041e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_4e1dd798-f20e-49d2-813a-483ee76041e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b85f5b1b-69f9-4687-b0fa-19997ae65d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b85f5b1b-69f9-4687-b0fa-19997ae65d49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_f0527796-e07c-45c6-ae66-abc32593c1b9" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_f0527796-e07c-45c6-ae66-abc32593c1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_8c711577-01a3-483d-adf5-a85c4f7a8871" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_8c711577-01a3-483d-adf5-a85c4f7a8871" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3f745bc0-499c-4e8e-8c06-842cc3a95b2c" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3f745bc0-499c-4e8e-8c06-842cc3a95b2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_daab0dbb-bd63-4505-857e-7e767e556143" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_daab0dbb-bd63-4505-857e-7e767e556143" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_8f1ce0d1-834b-4912-be10-1866f93cf579" xlink:href="tars-20230331.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_UpfrontPayment_8f1ce0d1-834b-4912-be10-1866f93cf579" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fb92fafa-eaa1-4941-baa6-53721347523a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fb92fafa-eaa1-4941-baa6-53721347523a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b6f4109-1671-4861-b0ae-c86583499693_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b6f4109-1671-4861-b0ae-c86583499693_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5ad2beb3-2998-4b91-b017-378def93918a" xlink:href="tars-20230331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:to="loc_tars_LianBioMember_5ad2beb3-2998-4b91-b017-378def93918a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_1244b2e3-dabf-4ca1-98e1-ba133be2a2e9" xlink:href="tars-20230331.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:to="loc_tars_ElancoMember_1244b2e3-dabf-4ca1-98e1-ba133be2a2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50a2adf0-2b0f-472f-8b20-69f897b7f64d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50a2adf0-2b0f-472f-8b20-69f897b7f64d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ccdefa55-9129-4d7d-9868-d8442007d5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ccdefa55-9129-4d7d-9868-d8442007d5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbe48d95-7daf-4e48-acda-03e994fca51e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:to="loc_srt_ProductsAndServicesDomain_bbe48d95-7daf-4e48-acda-03e994fca51e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:to="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember_c6e329d3-5aa0-4a90-9568-f6760252de04" xlink:href="tars-20230331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:to="loc_tars_MilestoneDeterminedByTheCompanyMember_c6e329d3-5aa0-4a90-9568-f6760252de04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_c2294396-e306-41d8-b2d6-128173a99a74" xlink:href="tars-20230331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_c2294396-e306-41d8-b2d6-128173a99a74" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended" id="ibcdf0ef5264342d1887d0aa0fb5bbff6_CreditFacilityAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_6ca9c676-fd1b-4c7e-8d49-450c859f16d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_6ca9c676-fd1b-4c7e-8d49-450c859f16d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f4c940f-1f74-4c70-a08f-5276f6843385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f4c940f-1f74-4c70-a08f-5276f6843385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_03a511e9-bdff-4cfb-9392-c52244379666" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_03a511e9-bdff-4cfb-9392-c52244379666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_966d165a-ae46-4f44-a927-915bbaad2adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_966d165a-ae46-4f44-a927-915bbaad2adc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ee23dd5-67cf-42c5-acee-980a5716f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ee23dd5-67cf-42c5-acee-980a5716f78e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_7e14de92-7008-4d9d-8ff6-0162b3884447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_7e14de92-7008-4d9d-8ff6-0162b3884447" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_8eb65998-404c-4e34-90d8-92a2a0da3977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_8eb65998-404c-4e34-90d8-92a2a0da3977" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_6af48ef0-93e4-4c0d-ad35-3c2457fb72f9" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_6af48ef0-93e4-4c0d-ad35-3c2457fb72f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_86fba6b3-ec51-439f-a76e-117a928ab77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_86fba6b3-ec51-439f-a76e-117a928ab77f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5c01f96a-9af4-4183-a808-1c1166a197fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5c01f96a-9af4-4183-a808-1c1166a197fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a21e0835-30c3-4027-916f-2b61414f70eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a21e0835-30c3-4027-916f-2b61414f70eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1be50320-d164-4ea4-9b94-601a054adb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:to="loc_us-gaap_LineOfCreditMember_1be50320-d164-4ea4-9b94-601a054adb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember_2adc1167-1c7e-4fb3-9e15-0917b7d91c82" xlink:href="tars-20230331.xsd#tars_LineOfCreditSVBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:to="loc_tars_LineOfCreditSVBMember_2adc1167-1c7e-4fb3-9e15-0917b7d91c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_323bbe62-cecd-4c56-84e4-24cac295c160_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_323bbe62-cecd-4c56-84e4-24cac295c160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_f2388746-918d-4910-907b-01add2e7eeaa" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheOneMember_f2388746-918d-4910-907b-01add2e7eeaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_e7894bae-97e4-43e5-86ac-19f654ffac5d" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_e7894bae-97e4-43e5-86ac-19f654ffac5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_f479ac72-85e8-4d0f-bcfe-53423742c103" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_f479ac72-85e8-4d0f-bcfe-53423742c103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_6b621eeb-b71d-4fd5-af1e-591b1333efb4" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheFourMember_6b621eeb-b71d-4fd5-af1e-591b1333efb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_98902892-6501-4f0f-aa75-cf20138fa6d3" xlink:href="tars-20230331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_98902892-6501-4f0f-aa75-cf20138fa6d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0b04a433-2868-4a90-93da-fa87469175b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:to="loc_us-gaap_VariableRateDomain_0b04a433-2868-4a90-93da-fa87469175b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:to="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f25622b3-d060-470f-b773-ccab65e10552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:to="loc_us-gaap_PrimeRateMember_f25622b3-d060-470f-b773-ccab65e10552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f5767783-38f3-4daa-8b61-65791d3aac28_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:to="loc_srt_RangeMember_f5767783-38f3-4daa-8b61-65791d3aac28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:to="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da78a69b-1da7-4455-bf11-5c2c168e8b20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:to="loc_srt_MaximumMember_da78a69b-1da7-4455-bf11-5c2c168e8b20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended" id="ib58707e1caef4614b5618874eb818888_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_0732bf05-5217-4de9-9503-6f6560dd34d9" xlink:href="tars-20230331.xsd#tars_LesseeOperatingLeaseRemainingLeaseTermExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:to="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_0732bf05-5217-4de9-9503-6f6560dd34d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:to="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5d5213a-e9f6-4452-bb95-19f7b897d59d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5d5213a-e9f6-4452-bb95-19f7b897d59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e76db9ba-71db-44a0-9850-db146d038561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:to="loc_us-gaap_SubsequentEventMember_e76db9ba-71db-44a0-9850-db146d038561" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>tars-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_41fdcdfe-7390-43ba-83cf-1b332bf027f9_negatedTerseLabel_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_label_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_documentation_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Deferred Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:href="tars-20230331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:to="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e624994d-facc-4863-9977-4fd1b7d63cb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d6a0707e-cb9d-43b1-9be0-4e1903a017ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f523931f-61a9-4bae-a9f5-09f1922e3b15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6f186002-f8ef-41bb-b964-c667a21ebf56_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f9d18548-9a5b-4312-83d6-3a16e9a8b804_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_020a8dba-d395-43d6-84be-88462de2557b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_be54c06c-aebe-4045-be09-ea2c8266a359_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheThreeMember" xlink:to="lab_tars_CreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_d65fd93a-428d-4573-8385-188c6327e81c_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a8667980-9549-43ab-bbc5-b9dd7b894cd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_4412c7f5-dd81-4d41-9ae5-8b409e94934f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_648a81f9-ea38-4771-a88e-b979129b75b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_56e19a20-6506-4de8-8db3-6ff68e7ea60d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_5371f9c0-4d33-4487-acc6-19c9af4dd95d_terseLabel_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Months of base salary payments</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_label_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Duration of Base Salary Severance Payments</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_documentation_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Duration of Base Salary Severance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:to="lab_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_22e0610b-4994-416c-998e-9c804c13459a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78f753ae-01e0-4d0c-aa8f-a1f10746e820_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_fb7faeba-a7dc-42a3-b0fb-f5ae4357e522_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b577cc93-9e3e-439f-bc6f-adc2aa1d1ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d6b007b7-0368-42df-a9ac-0eef7176aad1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d1a283a8-2e1d-45ab-95a9-65b9b805fc2c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e1595a9-64fc-4667-9d5e-f309ab205e63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43b25dcb-c474-4dfe-81f4-3af98a24b8cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_2aa2272a-8b3a-4cce-aae1-14cd716d2b71_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense for term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c41feffd-dc9d-4dfb-8e15-a3bbcf6d33b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_0665c6f6-7547-493e-b37a-bd56513332f4_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member" xlink:href="tars-20230331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2016Member" xlink:to="lab_tars_EquityIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_1cbe51ed-b65b-4fd9-83a8-ec3286a2066f_terseLabel_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, gross proceeds</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="tars-20230331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_e23e7761-f838-429a-ad58-9cc09cc9fbbd_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_b3696d7d-9f36-4da4-a580-7ef450e8058e_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8a06c550-273d-4725-b5fc-6fe43112c52a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1ed0d0f8-1c44-4cbf-841b-c3a1e533212b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_275c2a41-e3f6-4063-b4ef-3cbafd3ff76d_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9458db0c-a6bc-4d5b-af89-5a0bfdc76aca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ce0376e8-e5f7-406d-b0ab-6bb32166acc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4ba4b3f3-d38a-41fd-995b-724831eaa3a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f54ff8a7-7893-4e44-8c60-ae3f2210385c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_66d46f0c-1f1a-4251-8fc5-deadb331dd9a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b316ceb3-11a9-4d85-9f5b-bdc057149cc0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_46f230f8-899b-4bcb-8bfc-d442c220f2d7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_dca9efd3-5a12-4490-9d4e-3af519b11653_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2c1a49cb-1ed2-42a2-9ef3-91b919ea9327_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_52b83e57-51fc-414b-baf5-be2ba6a6dac4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00ba3314-7248-4f17-9cdf-eb68c9e5a949_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_9b1927e6-6b10-41aa-a0df-ed3da48e3043_terseLabel_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense" xlink:href="tars-20230331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_OperatingLeaseNoncashExpense" xlink:to="lab_tars_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b5074dba-96f8-41c5-a958-2042931621e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_442fb94f-1f27-407b-94c5-17cbd36ab814_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_de330b52-2671-4a18-9db3-88ff6a8708c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e7a7a798-8444-48fc-a67a-8e03ecd1ceb8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_37fbf401-8451-4c5b-95e1-35e887b9cd62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9c4f6125-1834-46ad-9c8f-084ca463e66d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_93a13acf-5c3d-4d8f-aeae-3ab97ed89599_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d517b3eb-4ff0-4dcf-a9b6-57cbd65f6cc3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RelatedPartyTransactionOptionToPurchaseShares_b5b27b7a-8355-4b34-9e6a-760534bbf7b7_terseLabel_en-US" xlink:label="lab_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to purchase shares for consulting agreement (shares)</link:label>
    <link:label id="lab_tars_RelatedPartyTransactionOptionToPurchaseShares_label_en-US" xlink:label="lab_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Option to Purchase Shares</link:label>
    <link:label id="lab_tars_RelatedPartyTransactionOptionToPurchaseShares_documentation_en-US" xlink:label="lab_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Option to Purchase Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:href="tars-20230331.xsd#tars_RelatedPartyTransactionOptionToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:to="lab_tars_RelatedPartyTransactionOptionToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_38d5e5fa-27bd-4479-965c-07d63fb15f2b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_682ed117-b59c-49a9-99a5-85b43d474c0f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c00670d8-ba08-4562-8d80-376044ae10f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_024dee86-be20-4212-aaa6-ebd4ebba08d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_7eb8636f-648f-4125-a9de-de9a37ab01a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bab8b695-306c-4109-bde1-6ffbe5b37860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7eea673b-43f9-4dd3-b8a6-ec4b84f2d2df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_d9db913d-3fd4-4cdf-b5e7-2bb6bc5d4888_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_56cbd793-c336-47ed-ac9c-7018f666bfc0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_78a64126-fd8f-4906-9ac9-327bdfdbab53_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04dc861-6243-4ebd-a8ab-e73afeaa1147_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12c05c5d-b3c7-407e-af4b-0e7ed21ce968_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_ca648065-5913-4b85-9bca-950c76f996ba_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options reserved for future grant (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_2f31291b-dd10-406f-a14c-5912ad4a7a84_terseLabel_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Determined by the Company</link:label>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_label_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Determined by the Company [Member]</link:label>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_documentation_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Determined by the Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember" xlink:href="tars-20230331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_MilestoneDeterminedByTheCompanyMember" xlink:to="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6d5fc653-9720-427f-8a16-f02f4d4ea88a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6e8caa6f-17ad-434b-98e8-f91dbe77cd92_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bcd577a-fb89-4e17-8d36-0d16944f9d07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ec8f079f-76c7-41b8-bb6c-c87d4b7e762c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bd3040f1-3d42-443c-8088-ce2b78246889_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e6c78b7d-d77e-44ce-b7d0-e09c6a063e67_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_79319c8e-d8d2-4a02-9d6d-3973343c95c4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b09d8c6a-80a2-46ab-99e4-ca96bc44f867_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_75a5f195-337d-42f6-a914-81c476718dfc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8706fd85-c3b9-4911-9426-0863732f8ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_7414b08a-4351-45f1-88cf-25c11d2513e5_terseLabel_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash payment</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_label_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Additional Cash Payment</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_documentation_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Additional Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:to="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab0bdc2a-8762-4410-8b4d-cf583e792352_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48f84acf-27b0-4bed-b697-43931cd4c302_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_41b11203-983a-4b48-a177-3a55796daea3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e984d109-538c-422e-b3e8-49ee04d825a1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3484ae61-181a-4fbf-ba36-3b1ff21d4caf_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfVestedWarrants_3b5e8bbe-f176-4170-899a-6c9d75b3aa78_terseLabel_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vested warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_label_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_documentation_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants" xlink:href="tars-20230331.xsd#tars_NumberOfVestedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfVestedWarrants" xlink:to="lab_tars_NumberOfVestedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_19a5b64d-f081-4a5a-8426-5678b4063ec2_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term charge, interest rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:to="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d503a80f-e995-4194-a8af-d2e0bdafc7b8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e5debcce-4623-40ec-b71d-4988798adc37_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_67f52226-e894-42b7-8dc6-1dcd483cebd1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_f6739c53-003c-45bc-9866-c9e5a3b8c287_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised prior to vesting&#8212; remaining unvested</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_3a72290d-879b-4e52-88e0-6276ca3dd45c_terseLabel_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering [Member]</link:label>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember" xlink:href="tars-20230331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_FollowOnPublicOfferingMember" xlink:to="lab_tars_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5373d724-0465-4ea7-9d55-eb276be88889_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_05374780-2fcb-4961-8aef-9b459af99389_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ba54e3a7-5c18-49b9-a8e8-fa74292a1a3c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_36e5d570-45e3-45ec-b946-ab670583fd17_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_57d4a724-4dfc-4374-87e2-f48069f2384a_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_361bfe92-2d26-463b-87c8-77869bf9eb3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2366e67-b001-4a48-adcc-1c4fc4c3fafe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_3783ba90-89b2-4e28-b2a0-a244e9595bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_fb44abf6-5f23-4585-b484-d505deeb5109_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab37ed71-a697-4341-897b-3f1222183a02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_50498482-3be3-4375-8583-a1096e4bc36f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_283c7270-1b33-42d2-91bf-fe410b979f94_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_64a64859-3744-43b3-b2ca-0e73c1730195_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_21d1cdc3-336c-4ef0-9e45-daa725f5f9ff_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense related to term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_84954441-cceb-4c0e-a8a3-450038274561_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_4fb10eb8-e266-4b73-8616-ec0d09420c6f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9d504e52-3d1a-486f-86bc-720aef7a92b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4cf206d4-293c-4511-8b0d-4b721d3b3fe1_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a6f725c4-8316-41da-81ea-e021e6f2e5a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_18ee5755-aff3-4371-bf13-d49a9afe7c7f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of term loan-related costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bc4a2516-afb9-4143-a9ba-c141d2ef7271_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d3786755-9b16-4e65-bbd7-b830c2396c61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation assumptions of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8acb9782-89c5-4ea0-ad5c-c44c7970a717_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Detail</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f59f760-be8b-491f-9ae2-84ca17bf721a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_f9112bc8-1042-4a08-9912-cce80817fd36_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_666eb60b-0cef-4a9b-8e55-ee400b2dda97_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, weighted average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ee3f0b66-9e5f-4543-82e9-05367fc189aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_6d9fcbb2-c7b3-48ca-97c3-1ef5f9436336_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future cash payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_label_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Future Cash Payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Future Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementFutureCashPayments" xlink:to="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_d9840ed9-c091-4911-84f3-a13933d6b38e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_12a6c99f-765c-4fb6-bb6a-99e177633b13_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ef989594-54a0-4fb2-b0a4-d3e4d4705594_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e48184a4-fed7-4f60-9dcb-638f84a0c662_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d98ef70b-6bbd-403c-b72c-2f92b63fb05d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8f5e5ee1-7a01-4033-8d18-2e74f524c270_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_4c24cd1c-f7fe-4181-b809-6bc9449ecdde_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cc9892db-9958-4bff-9f21-7a3bf9e6cafb_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_21cb9693-acf1-4b1b-ade0-2702b4caf3db_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0dc0fe0f-8ac2-450a-8edc-79af2a0c9e84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_421abfcb-2ef0-4449-aba2-3a6d10310628_terseLabel_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities (in shares)</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_label_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_documentation_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:href="tars-20230331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:to="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_63802412-9e00-4a89-8a49-75aab8669c23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_0f6a2a5b-4677-4768-acf4-35bccde249fd_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a4b9f8fc-2bb3-408a-b012-9f064da4d661_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c04f9282-a9a8-46d3-bc3d-29c15cd8586a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_bbf73c1e-249f-427c-92dd-1575305e904b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_069aad94-cb66-48be-8949-7cd4e3fe29f3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest, current</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_990ab5c9-9767-485b-a409-cec61e72855c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_be2828ad-6f6c-4c3e-a0d0-cc066fa3dfde_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_679b5d22-462c-427f-aff1-3559acdb871b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_dbbc235b-7525-4704-adaf-518a7829f20d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_bd636fef-13bd-4a7c-9ad3-f30c3cb7e0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Draw on credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_939b7e99-6929-490e-ba5e-670d2e240d39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dd9298a8-b8a4-447e-b0fb-d241186f35b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_9bbd776f-e0a0-49de-a828-531c80f8b55b_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5f6c84fd-a0a5-421a-9907-89909475dc05_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LianBioMember_295452cd-9d63-4669-a24f-e4fbe2acdde0_terseLabel_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:label id="lab_tars_LianBioMember_label_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio [Member]</link:label>
    <link:label id="lab_tars_LianBioMember_documentation_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember" xlink:href="tars-20230331.xsd#tars_LianBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LianBioMember" xlink:to="lab_tars_LianBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_6274f87c-7bd2-4d61-b90d-9ffc99e87dd6_terseLabel_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included within accounts payable and accrued liabilities</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_documentation_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:href="tars-20230331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_86938c5e-1aa7-4cb9-aa1c-d917e4347d21_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b3b2407d-17ac-4a75-b242-4e7d6cb0a8e4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense paid in cash</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_e93d0266-dcea-41b3-8dbc-e86f9f3c3b4c_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase obligation for stock option exercises, prior to vesting</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b1bb87cb-4502-43b5-85ce-3438eee94684_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7e401fd9-d884-4a00-b14a-da117ffee4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service condition period for full vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_ba8a1aee-a32c-438b-babc-cbb170e73a49_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash compensation for consulting agreement</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_90c6647f-78ff-4455-a0f8-b0b79cb78be4_terseLabel_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_label_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Agreement, Number of Tranches</link:label>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_documentation_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Agreement, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches" xlink:href="tars-20230331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_WarrantAgreementNumberOfTranches" xlink:to="lab_tars_WarrantAgreementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_210dc33b-4169-4e33-a035-89347c2b7580_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_913415c2-fd44-4df9-981b-abfd709f84bb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c229ac96-ef10-404f-9ab1-a6907210e69c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d01dfe79-66a4-44a1-9cb6-6a9ad1faa3b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_ddf71a52-7049-42e5-ace7-bb766f995802_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_9989dbc2-312b-4e94-b24f-270956c7fc78_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3cb1b72d-0c72-4f25-8425-5eab7ffbcd5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_25f90d64-83ad-47e5-aaea-946423bceb0c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_880a29bc-cecd-4d0e-aae5-2b53e307668e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_4490a8ee-93f3-4661-b0f7-317362019a00_terseLabel_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities with contractual maturity between one and five years</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_label_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_documentation_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:to="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_405c989b-d026-494f-a844-65aae3dcc107_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb2425f3-04af-44c2-a55c-aea52133530a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e46ebbb9-d9cb-4b7b-8fa0-e778a5b32452_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_23b53e39-ad64-4822-92ea-c4acf4290d66_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a2858a48-4f62-4360-8f98-43ce76a8151e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06f10862-3bef-451f-908d-69303660a1be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d8f9b167-53b8-4d53-a926-9c988aa72ca7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_11f3db23-0a14-494b-a466-58b512e4ec37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_db8c46eb-9fcc-45bd-a52b-033cde31198f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_b0df4a1f-cb56-4983-b6d8-a0526f3ebed8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_92189287-7650-484b-a189-8763a8247efc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Long-Term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a1889758-c6b4-43f5-8cfa-42dccf6ce4c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_376855a1-4ec0-4b68-9d22-12bc9fc02f4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9e7b671-cccb-4080-a960-165577d65c5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_db104713-d261-4c25-aa22-53e418c26d6f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_9ec5163b-8aca-493b-9651-768f2f8c87e2_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3de18219-a1b7-4355-98db-068437729dc6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_84ed7493-7dd8-45e9-8f91-610ef2274e59_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_83b25559-1624-49ee-b748-829daf87e53d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_588549e9-dee1-4681-87da-74b908360acd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_49b8dc77-702f-4a21-b43a-b0f2ee743af8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6fc501b2-33c4-4d4f-a54a-934340b05475_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_d2f15b52-db34-4761-9146-7c82c6229f7f_terseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term, Extension</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term, Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:href="tars-20230331.xsd#tars_LesseeOperatingLeaseRemainingLeaseTermExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:to="lab_tars_LesseeOperatingLeaseRemainingLeaseTermExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4af06232-17a3-4f53-978b-88c419fbc5ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5d5274c2-8837-4967-8641-8b8fbc9d145d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8bc36474-26c7-4c38-9a17-054f79da9b8f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bb3cd65a-3834-42e1-a68f-2085339a96ca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_847867e5-f238-4312-9015-47d0416a83da_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_623ad98b-f979-40c2-9551-14569e6fe46f_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_06bb4ffc-d4b1-48df-9343-b40735279034_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2b81f18c-5a0b-46e3-aee5-cf80e2a03fd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_bdfe0d5f-80fd-4b4f-a313-60f4bfad5e41_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f87bef00-8f7d-4822-9046-2ebf221cad3e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d44e645b-d4fb-45a7-ad81-39d5c00f37bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c7adface-675c-43b0-bdf5-75ea8c18932a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d38686ab-e492-411d-a89c-034b14230b11_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a2aabc37-8ca1-4b7f-87a8-31c2f8a0d4c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_0aea9d1d-71f5-49d3-b2aa-27f63c55a1e0_terseLabel_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:href="tars-20230331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fdc76aee-a1b6-440a-b0e3-f3eeff633495_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_068a149d-81fe-4e58-a081-ef6a53486757_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fe4ce017-c3f5-4f40-bbd6-744fa1864ab8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditSVBMember_a35fbdf3-a6a3-459a-b548-4d4c7702f407_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, SVB</link:label>
    <link:label id="lab_tars_LineOfCreditSVBMember_label_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, SVB [Member]</link:label>
    <link:label id="lab_tars_LineOfCreditSVBMember_documentation_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, SVB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember" xlink:href="tars-20230331.xsd#tars_LineOfCreditSVBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditSVBMember" xlink:to="lab_tars_LineOfCreditSVBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_e0089323-cc87-4eac-a352-a019f914f776_terseLabel_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Months of continued benefits coverage</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_label_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Duration of Company-Paid Benefits Coverage</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_documentation_en-US" xlink:label="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Duration of Company-Paid Benefits Coverage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:to="lab_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_49e45a67-af8b-4edd-a53e-5d2ac83d3f1e_terseLabel_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and sales milestones</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_label_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones [Member]</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember" xlink:href="tars-20230331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommercialAndSalesMilestonesMember" xlink:to="lab_tars_CommercialAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_43fe5787-aa60-497f-bc2f-7b17322879bc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_506868c1-a097-48b0-94cf-41a5297c0240_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2c3369f4-c134-4e74-9b9b-407bffe29eba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b25879f9-eedc-436c-891a-e62cf1d2cde2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations before other income (expense) and income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fe810afd-76cc-457d-b211-9f65558fd965_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Effective Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_ca5356f1-16c6-4efc-975f-e3f325c37c63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of end of term charge</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_8fe657f6-1cf2-4a9d-b2fc-fad9d3a060d1_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheFourMember" xlink:to="lab_tars_CreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7cfe6df0-3ed3-4c1a-8413-d9123e6b0324_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3bb495df-30a5-4e33-8af5-c23346cd3e4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ab8a1206-5f4a-41b4-ba1a-8d87e9886dd2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_f25816f3-24ce-44a9-a48a-a8b2941013d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8531e2b3-74c1-479f-8c03-618d2e569099_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_145903f8-5566-4a54-9485-4c9f6df70c86_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_326432d5-fbdc-4d2d-9eab-fcfb64a89d64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d39097ba-c051-4801-9094-9d8e9ef6fe25_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf93c26a-fe46-4733-ac21-027c50adacf4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_f446f6e3-d3b7-410d-9bb7-7f493398783f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4cf6cbe9-2255-42f9-93d3-1e18327c340a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09fafeae-01e8-406a-b64d-3aa262bb1351_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockNumberOfVotes_1becb94e-4011-4715-a5fd-31739d85c2d5_terseLabel_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_label_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_documentation_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes" xlink:href="tars-20230331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockNumberOfVotes" xlink:to="lab_tars_CommonStockNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_94f5ceaa-150e-44c8-a101-765edbaa966e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_062227c7-792f-4503-bb57-dd38763a316b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50be10c7-0e4f-4d8c-8e06-55cc25a8bf36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7351c21b-a4c3-4fe7-87c3-bde8cd58626a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3775eeb2-808c-4e81-ae67-45158843b53d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_12c565e8-f88b-41cb-a174-57e0359b0010_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_acf9f177-0c52-4422-a8d5-e3f5cbf8bb8b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of license fees and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_e36186ab-1565-4e0d-a73c-b5a1652aa57f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_3d6bbddb-9e73-4bee-8c24-1cf0fd93c8d3_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c42bd4ca-5297-4877-8a33-e813e54333b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_96bf0d2d-4144-43eb-b2d0-ddb0d7977445_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_57ccf727-a753-4132-9c15-1176b7c64e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Less): Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_da4d569d-da2b-4978-b6eb-f543b3dae2c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41f50fbc-f347-4f48-8216-3b6a81358c74_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_a24d65d2-1ff4-4f52-8c70-857a712ecd51_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock in LianBio</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d6767896-bf15-4387-bd96-72c6dfaf0da5_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01c7bd70-dc69-44cd-ae21-f4f4e6d45448_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_3da20164-446b-4ad2-b376-5748b99f63f6_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssets_5c983b19-5f22-4b46-86f3-43f4cabc24ad_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held in depository accounts</link:label>
    <link:label id="lab_us-gaap_DepositsAssets_label_en-US" xlink:label="lab_us-gaap_DepositsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssets" xlink:to="lab_us-gaap_DepositsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a606d540-ba89-4cf3-928c-a368d970ca3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,800,512 shares issued and outstanding at March&#160;31, 2023 (unaudited); 26,727,458 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_48c28e99-ffd4-488f-8fd7-e5a216f4d9db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_32037733-7252-42d9-9816-a3e42741b596_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9fa96729-6b4c-4e6c-9a14-200b7009edec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the vesting of restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1e920b72-7a92-47ce-9e81-0b79847b8f84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8fd56982-0458-4f34-91e8-f2bf757aa2db_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ab8f7c19-3c3b-45ad-a0cd-1b46d565df35_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b75e758f-0fd7-4862-aa99-4802afbbc815_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e073b4c6-eb22-4cc3-9a4c-47be73ce35b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_890b1c0b-2bda-4f67-b881-79c3e3e1708d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment &amp; Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_407c75df-5aa9-4469-8787-5cd868436a63_terseLabel_en-US" xlink:label="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of annual target bonus</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_label_en-US" xlink:label="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Percent of Annual Bonus Paid Out</link:label>
    <link:label id="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_documentation_en-US" xlink:label="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits, Percent of Annual Bonus Paid Out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:to="lab_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_46d6e06c-ed31-4311-a17d-2a7e64f28d5a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_81b286a2-7bb8-4ba6-b665-62630e6199dd_terseLabel_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical studies</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_label_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_documentation_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent" xlink:href="tars-20230331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AccruedClinicalStudiesCurrent" xlink:to="lab_tars_AccruedClinicalStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5ee5c646-797a-4095-ab8a-82c3eca91c86_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1d88a4d8-8009-4301-bed4-cecfeb21b815_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_0a0a4256-6cf1-4f7d-b334-c0dcb07dad97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_0058b4e8-1590-42f0-9ba8-e28dd26771f2_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, value</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d509332d-3302-4b4b-983b-fe066d56656a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a215b56-379e-459b-a1d2-661e049021d0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of property and equipment included within accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_aa333506-9fec-4d98-9ea0-93c53e4a5768_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_36ff7543-a5c3-4df7-91a8-80828c57afae_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3945eb7b-6377-4f03-b062-fc2d8af4a606_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_d9609307-901b-4d94-95f3-9dce2ab01296_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_72b03a47-7e28-4eaf-8606-6fbefa70a271_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ee9d92ba-75f4-4590-8293-487b36c3c1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of equity awards</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_615a3513-f959-42bf-a345-cf90262d3267_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f3d90afd-9780-4f08-8295-2b77239c0548_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5580256d-e42f-4427-90d9-d756a9fa7b3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_dc0a57eb-8faf-4d06-a18c-62d45f7aa8ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9e82fd43-94ba-4bae-a46e-5de25817aa69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ec0f4592-4c2a-4bfb-a9da-29f443dbba6a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2c71ba4a-129d-4931-a561-4b40e44e75a1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_810660f4-e096-4d13-b3af-ee7c7f70047e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37fc77b2-9777-41ec-a9e4-cf5dcb0e1cc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_aa28d889-a5e7-40cb-a0f1-e2f0b5ca7615_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c8f43e79-9f46-44ef-9a80-d37c0b1fd207_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_952fc343-c55d-49c2-a5a4-014f55119ec8_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two</link:label>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_label_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:href="tars-20230331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:to="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3bbcd7ea-8b73-4ede-baee-9330f4905ea0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_908588a7-1d24-46da-bd5d-b55ab511998a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9d0ded71-b4fe-4a12-af08-38d6e03bf945_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_beec8fb1-5a47-4417-9092-89c1bdb0ae4a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_646d0390-e3b5-4867-a273-0944089b679e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_abca8a2f-2e75-4ef0-b77e-fe5699cef1ee_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining prepayment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Remaining Prepayment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Remaining Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:to="lab_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_ad0c4b6f-cdc3-4e58-a09d-27ab5b8679d2_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d3f96a32-7328-49b9-b6f4-6a0787e12d3a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_aff9c511-a14c-4756-9891-fe1d6e2c94c9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unexercised&#8212;vested and unvested</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_89982e0a-5614-490d-9e9a-efdcf3776fba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0abae8e1-3c07-4d81-b83b-656bd561a49c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ef4d80e8-10de-4d53-92df-c377f9d04088_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c84608b4-fde9-40cb-a365-4ccabf8feb60_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2045e321-b26b-458d-b46c-0a5c79b7db5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_64cc1edd-f942-447d-88bf-835c2fc2f487_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a9d36630-88a8-4025-8214-3b1308148bea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on marketable securities and cash equivalents</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bf2e6777-d41f-4a3f-a4b8-efbaaea165d2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ada0d1de-e5c5-4cd5-9500-c42907610f95_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original issue price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_818a89b4-171c-4e09-b40a-d97c7f32a5c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_61ada142-b03a-46f8-866e-f17d416a6797_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrants issued by licensee</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1c8730e7-f751-4253-9bc3-e7932fe99620_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrants issued by licensee</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_c67e8b00-78b2-4ddd-9c32-01422506b973_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bef0b4db-9e18-4ace-90bc-f2684e905ed9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_5781d42b-b192-41ec-b400-009d3dc0c0c1_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units&#8212;unvested</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617e567d-a45e-4631-a059-29508128cf95_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2214654d-2ea5-4d44-8089-f79b1d650be1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LicenseAndCollaborationMember_f1242ceb-9564-4e7e-8fef-d9c00bb6cdc1_terseLabel_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees and Collaboration</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_label_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration [Member]</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_documentation_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember" xlink:href="tars-20230331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LicenseAndCollaborationMember" xlink:to="lab_tars_LicenseAndCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_5394002e-f9a4-47a2-bd2a-cdcdc1529d56_terseLabel_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</link:label>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_label_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member]</link:label>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_documentation_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:href="tars-20230331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:to="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_59bddb61-5e95-4dc4-bbdf-778dff1ce54a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_881ff5d8-4b26-42a1-a948-12ec9e32412a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_08376912-3a1b-4a06-84de-8d2db31a301b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_81ae16de-1c04-46bd-aadd-2110f285bb51_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d2855945-4e7c-45a8-b429-64cd58b100fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_02d4c0ec-0fa5-4292-b8f2-adc37e4ee097_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0fcef33b-2a17-494b-b11e-39162c7eac16_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_6c6bca97-7b4b-4bba-ab64-2557b9d1b245_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheTwoMember" xlink:to="lab_tars_CreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClinicalMilestonesMember_01501092-ba39-4dfc-a06d-3be58daa18c3_terseLabel_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical milestones</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_label_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones [Member]</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_documentation_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember" xlink:href="tars-20230331.xsd#tars_ClinicalMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClinicalMilestonesMember" xlink:to="lab_tars_ClinicalMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e68c9da0-dcde-4880-a4e9-0ef3abebc03d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec9cd14c-8a71-451c-9794-eebb73f4aa21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_c1d8985f-c7fd-4755-a83c-d5ef8755f648_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of end of term charge</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d50f63f4-21dc-480c-90d8-db2c463f157f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c6f7eff-0e59-4a1b-92aa-958fc703ad78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_24293fc8-a911-461c-a332-0ca8ccb17dcb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fb84cd8c-d82f-4e31-97de-14cfe002f6be_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_28b7e7b9-ba7d-4f50-afc8-5236152f34bf_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3aadd2c9-ad5f-4e1e-a18f-795826c14f2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2706a571-60fc-4f5e-8ff8-a5b25204e83c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_ee216ad0-7f9f-4a7b-8c7e-0e28ffa99578_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of term loan issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_333558fc-af54-4dab-8f82-8857cecbaced_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c37a459e-51c5-4019-87a4-e2a2ce340343_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b122ac4-6421-4d09-b479-740bea2d56fd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0b4bdee4-084b-4af9-8555-a2f555b93025_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46bbe4f2-ff8e-4dd8-a23c-c2409aa4bac0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_71ebf02f-3dfa-4f59-b8cc-79c08d88c56b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_21398782-8a52-4b5a-b261-4bec33e09782_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aa97009a-7590-42d2-b1e9-1a94f8bbd564_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f8efd552-4870-48e7-ba02-7bb65a54f655_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNIAbstract_69f6c46e-ef6b-4720-9bb2-d0a66e32b654_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNIAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_4f6fb8e6-f72c-4708-9bf1-f8338a966dda_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_f0c7affc-ba44-4276-9ac9-8397465fcc25_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_339aeb26-3169-4459-a38a-f87d191bbf17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1d99c1b9-a7eb-46ec-a1f0-820821897abb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ElancoMember_a3a93d28-2b27-48a0-abb3-57670e59661e_terseLabel_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_tars_ElancoMember_label_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco [Member]</link:label>
    <link:label id="lab_tars_ElancoMember_documentation_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember" xlink:href="tars-20230331.xsd#tars_ElancoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ElancoMember" xlink:to="lab_tars_ElancoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_83508925-f769-4b22-b1ce-687ef864be1b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_16cd989f-ec39-495a-95ea-a0dc99fea98f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_87278058-c809-4035-8b20-cac15e03505e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_931b2645-1c0e-405f-b729-ef448c9dd52e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_426e99a7-9297-43bb-956d-9bb77cac4851_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_08b68d1b-5f14-4816-a05f-f59be4f6e361_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4cbcc62-f399-4daa-bc1d-6440c6a3095e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_18d13453-9b69-4147-9d3e-331362b45a0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8c21befa-ba31-4f35-9851-155d946c43ab_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_80efb328-e2ee-4e11-beb6-a1224f4798a8_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheOneMember" xlink:to="lab_tars_CreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_83d52f68-ad90-4453-b6a6-d7ff2b1bdd91_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3e7a04b0-3298-44cb-bfaf-8a3de1073c4c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_345d3a2b-c87b-405b-b18c-072eaa4b0aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39423612-6274-40f3-98d5-bd954e5f3ada_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e58a1878-a97c-4656-a21a-e74980e559e3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc1aeb9e-e4a1-4728-9bbb-836a6f9f9057_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock reserved (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2ce05b60-3eb7-4101-a2da-670268404885_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_732676f9-38ad-4784-b9d4-c72196f3c456_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e5611f29-5ebc-4130-83ea-5bb069c43c4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_UpfrontPayment_e8ef5898-219b-4d0a-8db7-7f14d90846da_terseLabel_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_UpfrontPayment_label_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_tars_UpfrontPayment_documentation_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment" xlink:href="tars-20230331.xsd#tars_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_UpfrontPayment" xlink:to="lab_tars_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bcf7e3a1-8a3a-4fa2-a814-1c82c3469174_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_f4562d58-63cd-4e21-bccc-dc2f8bbbccf7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_ed8ef637-c0d6-4964-ad37-1fe0fff17f2f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-related debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c09143bd-d7e7-402b-8034-9306b39f4802_terseLabel_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments to be achieved</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Amount</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4b09db44-b01f-4333-8320-547a9d06756c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_da4c4775-bb24-4f61-8d49-842ae8aed5ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5fd58c22-5598-4e68-95fb-26015d9b9f8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain from transactions denominated in a foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_28d8a821-988e-4a5c-82ec-0f707d5e5340_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7892bca3-f928-4868-8635-09de920cd98c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_087ef450-fe98-4af8-8df1-4976066a60e6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5cff1d6-849b-4a50-87ad-539b934d78d8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e299522-868f-402f-96ab-3ab8d1ef6b75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_20afd0b8-a22e-4924-8247-7f23814c011e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_302b24c7-ba5c-4d69-9529-35edcb31046f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_287f30c9-e244-4e22-8818-9370e326282a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_689f3f2e-901a-451d-8d64-2148ad28e7c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4a966863-b784-455a-a164-96a8db19b5f0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_efa1561f-303e-4995-8368-d5cfcc427929_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a747b65d-d54a-4b8f-9930-2b7e6fcb456c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e25eddee-ee08-4aa8-b568-184690498b30_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_412ecf1c-57c3-4a2e-94d6-88ef91091802_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e7a0f02b-2787-4fa7-a941-425425295351_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4501369a-9fb9-4d5c-8e81-982e018dadf9_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_fb5d3e6f-ae16-4613-aa7f-d70364e26835_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a65d6c68-f545-49e6-bf93-f07b0f5dc700_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_54c3ac30-79b3-4eb9-be66-b1f2c812c40e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e17bdf59-8ddf-4d4a-a990-194b942c71ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5f97e634-b021-449f-9b61-a3a740ccf259_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1239e6d1-91a4-4d16-90d1-dae123817f78_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3ab1f10d-2e07-4913-8633-dd22fe853215_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f4fe7ad6-fffb-49ec-a9da-d37f14e3bde9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_0b7af440-5b7c-420c-aad9-c9cf3c9ed96e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_e4538b39-0115-43f4-b63b-2d400522f5de_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual milestone payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5b45d636-bbe4-4ddc-af40-673578048ae6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7156bd5e-eec6-4ecf-95b7-e5ac8a6bf064_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_8836022d-2b58-4337-9b4f-5f2d38f3cec0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_6d29e120-abc6-4546-938d-44b9f69ba9c8_terseLabel_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale and cash and cash equivalents</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_label_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale And Cash And Cash Equivalents</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_documentation_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale And Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:to="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_83c1f91e-60b6-4448-b065-892006f21e13_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_c7e29ffa-83cb-40e0-b20d-c76b88dd26a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a9cc5274-e2e0-43d8-b85a-0b6bd1096d43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_6b271d66-6516-4059-b0e1-31e8d11dc8f9_terseLabel_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employment arrangements with executive officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_label_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_documentation_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:href="tars-20230331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:to="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ed2d473-3b53-46e1-ba83-950bc53e9536_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_aa8a32a5-01d8-4941-a695-0c44cd9e3379_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_4a4d2306-12b4-4126-b9e7-eabf001b60af_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increments to draw on credit facility at company's election</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:to="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_91faca57-6cf4-4641-a786-05dd28f43ce8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_29a802b5-6ae9-42e6-9924-dd214e06a887_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b4efa9a3-fac5-46e8-bbf0-95cf9b367046_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b3926fc-0674-47c9-adfa-a9cef64904c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5010504-8283-459b-82e2-897cc2a9646e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7179ad3d-acdd-4558-a5ae-891e0b359e8a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_42f3e8a7-b362-44c0-9efb-5a05bfefd677_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_26d9b274-9b1c-4fc0-bea1-592725578535_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9917146d-53ee-4fa3-bc52-5d88e356d6c3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_458da76b-a508-4128-8623-89ec90f17687_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e224fb6d-6b4c-4518-80e5-9b92dbc30c97_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5abdf1c8-55fc-467d-b34b-a99ef76e5916_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_e5ac0cb3-e9ee-4a34-b5a1-dc96506a464f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_834974e4-0cf4-409c-be7d-52af8103c464_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_3e5d86be-c5b9-40be-bd3c-d6a69357c3d3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term charge</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_8bc69d76-b9cf-413b-ae81-fb230b577714_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_09255886-1109-42a0-8401-c598cc2bac9c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1bdba5e8-1eea-4ee8-aa3c-01c3bf6f8ca5_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e64b59ed-1c21-4a9e-9558-db54aa3dc44a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_91b25fa9-6e73-4c9e-8b56-9c42153e17e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fbc1aa1a-67df-409c-8215-dc79e9fcf99f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e96ad4ab-3e2a-4dfa-b15b-fc9d8ae10f82_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_212813ed-83fa-4806-bb0c-1eed25497a2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a828da58-2a80-4bc1-aaf7-bf08e6747039_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per stock option (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ccc38866-7851-4dd7-b4e6-f17886836867_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0503cb1c-923f-41c6-b1a3-952b15762f36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db777c9d-4aba-4c10-8b95-a6b07c787f95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_841125ef-b6d6-4f77-ae4e-1bede0e5b02e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_58598c7d-ca14-4dd5-9353-0c8261bf76c4_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity warrants (for LianBio shares)</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_label_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure" xlink:href="tars-20230331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantsFairValueDisclosure" xlink:to="lab_tars_EquityWarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_576a872d-1f7f-4baa-b722-e490123f505a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, basis and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_afea16c3-8a97-48fc-8c3c-9c0c8586684d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b60deec7-fd21-494d-b7de-51e72e451d26_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>tars-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:99ca3187-00ae-4c91-9c08-02c6f0ff14d6,g:8e56a9dc-09d0-48b7-af10-186125bae8bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/Cover" xlink:type="simple" xlink:href="tars-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d485b25c-d100-4346-898b-636a6abb5365" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentType_d485b25c-d100-4346-898b-636a6abb5365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f1641c2e-2a6f-46d2-b58a-4cb415fb8e4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentQuarterlyReport_f1641c2e-2a6f-46d2-b58a-4cb415fb8e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cb32072d-ccc0-479d-8c7b-feb9dced2dad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentPeriodEndDate_cb32072d-ccc0-479d-8c7b-feb9dced2dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1338ce09-268e-4c2d-8a01-d64742155d82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentTransitionReport_1338ce09-268e-4c2d-8a01-d64742155d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_31b78264-0cf4-436a-9dc2-1b99625b425e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityFileNumber_31b78264-0cf4-436a-9dc2-1b99625b425e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e6ff57f-d3de-4f9a-9b7f-e07132217187" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityRegistrantName_1e6ff57f-d3de-4f9a-9b7f-e07132217187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8c520c29-821d-4bf3-9a17-07052cb48d1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8c520c29-821d-4bf3-9a17-07052cb48d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_50e421a8-712c-446a-a99a-8634d826124f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityTaxIdentificationNumber_50e421a8-712c-446a-a99a-8634d826124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_570839c0-f1ca-407a-b030-50b8bd8a3996" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityAddressAddressLine1_570839c0-f1ca-407a-b030-50b8bd8a3996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7e5092cd-098d-45cb-a6fc-c26c599129bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityAddressCityOrTown_7e5092cd-098d-45cb-a6fc-c26c599129bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c2844367-d22d-4d36-8411-b7448b93a935" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityAddressStateOrProvince_c2844367-d22d-4d36-8411-b7448b93a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fd296e27-7bca-4f24-a0a1-9b1a3aafd462" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityAddressPostalZipCode_fd296e27-7bca-4f24-a0a1-9b1a3aafd462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c6faef5c-0913-46fc-bc8d-1324a231fad2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_CityAreaCode_c6faef5c-0913-46fc-bc8d-1324a231fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88b2f8ff-6761-4d65-ac84-9488c8112100" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_LocalPhoneNumber_88b2f8ff-6761-4d65-ac84-9488c8112100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_07464456-ac07-43f9-83c3-9b6283d4e5df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_Security12bTitle_07464456-ac07-43f9-83c3-9b6283d4e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_314768e7-2541-41e5-82f8-0b9adb2367b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_TradingSymbol_314768e7-2541-41e5-82f8-0b9adb2367b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b01cdb24-3462-481e-8a13-5e2a5a89874f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_SecurityExchangeName_b01cdb24-3462-481e-8a13-5e2a5a89874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ec2268e0-fde4-487c-af95-67c02553b867" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityCurrentReportingStatus_ec2268e0-fde4-487c-af95-67c02553b867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e9c862e4-767e-417b-b0dd-0f4a246b8dd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityInteractiveDataCurrent_e9c862e4-767e-417b-b0dd-0f4a246b8dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_95ed6cdf-c8e5-4188-a4c8-49c4a7e54d11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityFilerCategory_95ed6cdf-c8e5-4188-a4c8-49c4a7e54d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_61de4046-09c1-41a6-ba54-a50bd29fec11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntitySmallBusiness_61de4046-09c1-41a6-ba54-a50bd29fec11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_768698af-75f6-4138-9d29-1b6df8d41e5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityEmergingGrowthCompany_768698af-75f6-4138-9d29-1b6df8d41e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e7e03f4c-646c-4792-b506-946c6827e9eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityExTransitionPeriod_e7e03f4c-646c-4792-b506-946c6827e9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6c2cea09-d3aa-4b3f-82bc-2b91c464cbc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityShellCompany_6c2cea09-d3aa-4b3f-82bc-2b91c464cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d6e43b7a-87d6-4ff9-9c32-75094ae4086d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d6e43b7a-87d6-4ff9-9c32-75094ae4086d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c6709575-0907-425b-9665-3e18cfd3b683" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_AmendmentFlag_c6709575-0907-425b-9665-3e18cfd3b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_27152fcc-f89a-4ea6-8307-116e82c4cadc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_EntityCentralIndexKey_27152fcc-f89a-4ea6-8307-116e82c4cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f3f2bf80-3d8f-4967-95fc-e5ba70610e69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_CurrentFiscalYearEndDate_f3f2bf80-3d8f-4967-95fc-e5ba70610e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d6ff414a-d863-4a8f-b71b-b80f676eeed6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentFiscalYearFocus_d6ff414a-d863-4a8f-b71b-b80f676eeed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_42e89a20-c81c-4845-b8e9-f18e9cea1217" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbbcbe63-8d7a-4740-a22c-851d3e3e648d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_42e89a20-c81c-4845-b8e9-f18e9cea1217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9225052d-2928-47a4-b431-faf1eddced2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9225052d-2928-47a4-b431-faf1eddced2e" xlink:to="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebfd6653-6e44-4fb0-b3fc-2f7d5b341e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebfd6653-6e44-4fb0-b3fc-2f7d5b341e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_87d1c15e-81c0-4541-a63c-708999835f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_87d1c15e-81c0-4541-a63c-708999835f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d0603a89-961d-4c72-a6db-d3eea0b57d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d0603a89-961d-4c72-a6db-d3eea0b57d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_61341d6d-203d-4d84-b1ff-4102e8f5d8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_61341d6d-203d-4d84-b1ff-4102e8f5d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_717b33bb-ed70-4595-a566-f52c84b2b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_717b33bb-ed70-4595-a566-f52c84b2b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_be0683f6-be68-42d2-ba4e-ab725b66c980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8a8e3867-41be-493c-b25a-81661c0511d3" xlink:to="loc_us-gaap_AssetsCurrent_be0683f6-be68-42d2-ba4e-ab725b66c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d0f24dfc-d68d-4613-8ce4-dcfb0bb9f8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d0f24dfc-d68d-4613-8ce4-dcfb0bb9f8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac5b36c2-0f19-4005-9aec-a6b907ff152d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac5b36c2-0f19-4005-9aec-a6b907ff152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_659fa311-bed8-4a07-a928-cf1815dc9d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_LongTermInvestments_659fa311-bed8-4a07-a928-cf1815dc9d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_275a1529-c508-4aa8-9795-6448f3baf7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_275a1529-c508-4aa8-9795-6448f3baf7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8e4361ed-f255-4af6-894c-6bf9b6ff9875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85a4bdfe-d411-40b2-8816-416fe0a99d21" xlink:to="loc_us-gaap_Assets_8e4361ed-f255-4af6-894c-6bf9b6ff9875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9225052d-2928-47a4-b431-faf1eddced2e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_422b7aaa-f72c-46fb-aec9-1cfc1cd48a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_422b7aaa-f72c-46fb-aec9-1cfc1cd48a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6552b933-262b-477e-aa2a-675716a36d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_422b7aaa-f72c-46fb-aec9-1cfc1cd48a39" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6552b933-262b-477e-aa2a-675716a36d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19adb278-12a5-43c9-be74-236e22a20add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_422b7aaa-f72c-46fb-aec9-1cfc1cd48a39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19adb278-12a5-43c9-be74-236e22a20add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_781319c3-24cf-4da8-95c7-cebf6bc1e396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_422b7aaa-f72c-46fb-aec9-1cfc1cd48a39" xlink:to="loc_us-gaap_LiabilitiesCurrent_781319c3-24cf-4da8-95c7-cebf6bc1e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_50edee89-0155-4caa-a975-a7a347154ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_50edee89-0155-4caa-a975-a7a347154ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_95d0814a-ab61-46c3-8447-66752fbb206d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_95d0814a-ab61-46c3-8447-66752fbb206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b3c61b3d-20f0-4419-902e-d5df61d0edff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_Liabilities_b3c61b3d-20f0-4419-902e-d5df61d0edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03489b63-1f21-41e6-a43c-3f8594aca554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03489b63-1f21-41e6-a43c-3f8594aca554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1f444049-e27a-405c-bd01-5a177abcfb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_PreferredStockValue_1f444049-e27a-405c-bd01-5a177abcfb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b81ae63d-b679-4ec5-89cc-e1d06adbf0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_CommonStockValue_b81ae63d-b679-4ec5-89cc-e1d06adbf0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1642cf55-4251-4b7c-afbd-734ee5534fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1642cf55-4251-4b7c-afbd-734ee5534fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0815a9e-2869-4409-9f12-835549493e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0815a9e-2869-4409-9f12-835549493e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3057ff9-9a18-4955-8f03-1d596ea17fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3057ff9-9a18-4955-8f03-1d596ea17fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_11b947cf-7e03-4cea-8572-6741b2656a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3719d014-3909-40b9-948a-c8a5a2bb6c2b" xlink:to="loc_us-gaap_StockholdersEquity_11b947cf-7e03-4cea-8572-6741b2656a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c69d6f0-79ca-49a2-866a-4f1c04a07ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf4806f7-1e82-40e0-bdeb-6405567637bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c69d6f0-79ca-49a2-866a-4f1c04a07ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1de7c350-8c2f-4e7f-9af7-0b4c87e62478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1de7c350-8c2f-4e7f-9af7-0b4c87e62478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b61c05b7-7ace-4ae6-b538-b33ba3af80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b61c05b7-7ace-4ae6-b538-b33ba3af80b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9c6af78a-4c3a-4813-b241-436cfcf1f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9c6af78a-4c3a-4813-b241-436cfcf1f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2b2c47c8-c2a3-43b7-bb1f-dd81a63c7973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2b2c47c8-c2a3-43b7-bb1f-dd81a63c7973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40568a77-6bae-4825-805a-68d850da8a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40568a77-6bae-4825-805a-68d850da8a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_53af3d9e-e0b7-4fcd-ab4f-ba8fe65ae03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_53af3d9e-e0b7-4fcd-ab4f-ba8fe65ae03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e7327c24-3fb1-4dd7-b686-c4225fd9d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_CommonStockSharesIssued_e7327c24-3fb1-4dd7-b686-c4225fd9d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c69135bf-b114-42ab-93e3-8a91ef82917f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0db3857-aa12-42a9-b86f-d0a352fcedf2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c69135bf-b114-42ab-93e3-8a91ef82917f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_080fc5f6-621a-4614-9f3e-bf8c3f647516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_080fc5f6-621a-4614-9f3e-bf8c3f647516" xlink:to="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:to="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_100a0bee-1473-43c2-bc2e-9cd6dee9f513" xlink:to="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_fbf89b3c-aaea-42ec-a250-04449a5fcd1d" xlink:href="tars-20230331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_efd502a9-03da-4616-93bf-0110a5993a26" xlink:to="loc_tars_LicenseAndCollaborationMember_fbf89b3c-aaea-42ec-a250-04449a5fcd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827f5881-aa23-46f3-a79d-7319a5943e30" xlink:to="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3696262e-c255-468a-9a41-6bbfb42b96fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ca7e10f7-8157-41a4-bb62-3e09ba923e53" xlink:to="loc_us-gaap_Revenues_3696262e-c255-468a-9a41-6bbfb42b96fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_921f2a91-308b-44de-945e-b2344acbbc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_921f2a91-308b-44de-945e-b2344acbbc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b42cfee5-6970-4a52-a021-a623df67e974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b42cfee5-6970-4a52-a021-a623df67e974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bc9d6325-ae81-42a2-a989-dc1bf7efd79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bc9d6325-ae81-42a2-a989-dc1bf7efd79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_be7b9510-499a-4c96-b9a8-91569b861a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e6f4d88e-4297-46c4-8aa5-f6a621fed638" xlink:to="loc_us-gaap_CostsAndExpenses_be7b9510-499a-4c96-b9a8-91569b861a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4ea6191d-f927-40aa-8689-13373146172f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OperatingIncomeLoss_4ea6191d-f927-40aa-8689-13373146172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_27c8605b-20c5-449e-b8c1-20300efc3017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_InterestIncomeOther_27c8605b-20c5-449e-b8c1-20300efc3017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_df96242f-daad-45ed-a8cc-93a9eb48c963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_InterestExpense_df96242f-daad-45ed-a8cc-93a9eb48c963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36c5192c-54b5-4bc4-b78b-97ab9352fa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36c5192c-54b5-4bc4-b78b-97ab9352fa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3466974f-dc94-44cb-bcb5-bc1ecdd1d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3466974f-dc94-44cb-bcb5-bc1ecdd1d47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a0e2d031-5d79-47c4-a86f-88f1178d75a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a0e2d031-5d79-47c4-a86f-88f1178d75a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aeb78aad-f47f-45ca-bab8-e87e7afa64d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_749a42f7-301b-405a-9aa6-08b32905973e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aeb78aad-f47f-45ca-bab8-e87e7afa64d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47d38659-fdc2-432b-9157-795a5ce4a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47d38659-fdc2-432b-9157-795a5ce4a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97a26a7b-8f94-4f4a-860d-33e75383e578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_NetIncomeLoss_97a26a7b-8f94-4f4a-860d-33e75383e578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cc44fb7b-7622-4c33-a891-93fbdbbd5f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cc44fb7b-7622-4c33-a891-93fbdbbd5f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2af217b-6aee-4a71-a596-09cd96f165b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_303b84f9-e36c-4028-9b39-3e1595eb90a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2af217b-6aee-4a71-a596-09cd96f165b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c33bd77e-fc1f-487b-8b05-ea30b8408566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:to="loc_us-gaap_EarningsPerShareBasic_c33bd77e-fc1f-487b-8b05-ea30b8408566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_93aff632-8a8a-4caf-912f-45b2571d5107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a56ad7f7-1ebb-4991-96b0-6db4394ba45d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_93aff632-8a8a-4caf-912f-45b2571d5107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55165200-c414-41ee-a63c-8a442314980a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1aa1fd54-6f75-4673-ae23-6fe19f8e7645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1aa1fd54-6f75-4673-ae23-6fe19f8e7645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e96f330e-74a5-48f6-a5bb-756f126ca12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_607c9b4e-9b09-43c1-9c0c-bededa50e982" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e96f330e-74a5-48f6-a5bb-756f126ca12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9f5e1466-8a6b-4b01-9aa1-ebda564afb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9f5e1466-8a6b-4b01-9aa1-ebda564afb4f" xlink:to="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18125637-2481-4e3b-9b8d-50d044fd7165" xlink:to="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_983ecc87-ecfa-426c-84d0-305c77868aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_CommonStockMember_983ecc87-ecfa-426c-84d0-305c77868aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_57122d83-4d9e-4c41-8172-e2dfc0cbb894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_57122d83-4d9e-4c41-8172-e2dfc0cbb894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2153b115-8569-437b-91fa-df58efb996df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2153b115-8569-437b-91fa-df58efb996df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bcf84f7a-a0e7-400d-b871-f6ee6b34d51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3ed7219-a8bc-4963-98ed-2f3375918f23" xlink:to="loc_us-gaap_RetainedEarningsMember_bcf84f7a-a0e7-400d-b871-f6ee6b34d51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c214a52-a2d7-4775-8c57-5158a984f7d6" xlink:to="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_199a6713-0f45-4e69-9238-9f7e06693539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_199a6713-0f45-4e69-9238-9f7e06693539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5f8905e6-8731-43b5-bdd4-9ed1661beb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_5f8905e6-8731-43b5-bdd4-9ed1661beb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_07a64a5d-953c-456a-9b20-888bd26443e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_07a64a5d-953c-456a-9b20-888bd26443e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e6538515-d90a-4a90-a0b6-1af5e9bc50e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_25bf7677-f5e0-4552-bc8b-a93d78584a66" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e6538515-d90a-4a90-a0b6-1af5e9bc50e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5f1b9435-558c-426a-9205-1d157ab75dd3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28636726-fd7b-4176-b037-4956f9f32b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28636726-fd7b-4176-b037-4956f9f32b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bc4c114-cca7-4061-ba48-aa4adcebc9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockholdersEquity_5bc4c114-cca7-4061-ba48-aa4adcebc9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9be073f6-3d80-47b0-981d-89e1cc3e9bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_NetIncomeLoss_9be073f6-3d80-47b0-981d-89e1cc3e9bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9183ddcf-bf05-4d48-850b-4a1827d812d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9183ddcf-bf05-4d48-850b-4a1827d812d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_610d8939-5447-48f4-8d2a-4aaeeb3862de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_610d8939-5447-48f4-8d2a-4aaeeb3862de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c1d6e8f-671d-48d1-bfb7-696e970072f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c1d6e8f-671d-48d1-bfb7-696e970072f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_141247fd-d3e3-4349-aeef-65cab9ac91ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_141247fd-d3e3-4349-aeef-65cab9ac91ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_90ba40ba-5d5b-4b07-b7dc-ebca0eb6859b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_90ba40ba-5d5b-4b07-b7dc-ebca0eb6859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_a6bd96c7-952d-414e-b1b9-6b644ea1fdd6" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_a6bd96c7-952d-414e-b1b9-6b644ea1fdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_8e7617dd-a68e-4147-90f3-f510ef2fcd95" xlink:href="tars-20230331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_8e7617dd-a68e-4147-90f3-f510ef2fcd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c570bea8-c25f-4583-9c8e-1c7d6c594027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c570bea8-c25f-4583-9c8e-1c7d6c594027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7929d48-663d-456a-b890-2680125c8dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4ebf0c1c-1874-4896-9715-ba2ae5db630f" xlink:to="loc_us-gaap_StockholdersEquity_a7929d48-663d-456a-b890-2680125c8dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20230331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e5a1335-0246-4085-945a-68cbb85443bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e5a1335-0246-4085-945a-68cbb85443bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cee60a10-07b7-4a37-a029-f460e454be98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e5a1335-0246-4085-945a-68cbb85443bd" xlink:to="loc_us-gaap_NetIncomeLoss_cee60a10-07b7-4a37-a029-f460e454be98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e5a1335-0246-4085-945a-68cbb85443bd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_4b860c24-aa57-4682-a463-ab5bde14f566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_4b860c24-aa57-4682-a463-ab5bde14f566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eef513f0-7df7-4c28-9b8e-acbff8d5bcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eef513f0-7df7-4c28-9b8e-acbff8d5bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bdfe5dac-32c4-4276-9e07-880bf23497cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_ShareBasedCompensation_bdfe5dac-32c4-4276-9e07-880bf23497cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_ab678e70-6fa0-4ac9-bb4e-b16bf9554490" xlink:href="tars-20230331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_tars_OperatingLeaseNoncashExpense_ab678e70-6fa0-4ac9-bb4e-b16bf9554490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0068140d-18ce-4e86-8d9d-d8e2df1d5871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0068140d-18ce-4e86-8d9d-d8e2df1d5871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ad8bfd2a-f0bd-4397-b363-3c68a1b68be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ad8bfd2a-f0bd-4397-b363-3c68a1b68be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_aad0c3a8-bcb7-41b7-803c-494ae07f2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_aad0c3a8-bcb7-41b7-803c-494ae07f2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a5c646aa-82f7-45a7-8b1f-e17fdf96df38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a5c646aa-82f7-45a7-8b1f-e17fdf96df38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc879654-5d68-4777-ba02-d1afbb9041e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85766691-fe5e-40c5-a25c-88c3672d54f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85766691-fe5e-40c5-a25c-88c3672d54f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_1187471d-6d7f-43a5-9aa2-898229697ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_1187471d-6d7f-43a5-9aa2-898229697ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1576598-cbb8-4a8a-bd8d-03f673425bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1576598-cbb8-4a8a-bd8d-03f673425bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_11f643e5-1957-4fcb-80b6-65daf4d73dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_11f643e5-1957-4fcb-80b6-65daf4d73dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7652e14f-f419-4624-914d-9330c9be49b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7652e14f-f419-4624-914d-9330c9be49b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fea2e9ad-76b4-482c-92c0-16746d21b0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fea2e9ad-76b4-482c-92c0-16746d21b0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1ebed76-5afd-49d9-a12d-c0653fa3a5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bf1c2b4-8f0a-4541-a457-ed769becb935" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1ebed76-5afd-49d9-a12d-c0653fa3a5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ab2ea99-6a9d-4d29-ad63-5f1e480b3f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e5a1335-0246-4085-945a-68cbb85443bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ab2ea99-6a9d-4d29-ad63-5f1e480b3f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4d50f15c-8ef8-417d-85c8-9349297d254d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4d50f15c-8ef8-417d-85c8-9349297d254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_559b08a5-d57f-489f-a869-3d5e41cf9789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_559b08a5-d57f-489f-a869-3d5e41cf9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ee0ea83-30e1-4ebd-9233-14cd8b132fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ee0ea83-30e1-4ebd-9233-14cd8b132fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_072b6de8-28d5-4bc7-aba7-9edf4aeb96d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5cb5693e-5ae6-4cef-a81a-bfaa97a0159b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_072b6de8-28d5-4bc7-aba7-9edf4aeb96d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_70d36530-bd56-4d33-9827-fdcd6ce7288f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_70d36530-bd56-4d33-9827-fdcd6ce7288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c974c207-f24b-4dc3-911d-199b0c51d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c974c207-f24b-4dc3-911d-199b0c51d187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b1c5244a-6d62-45ad-bfa0-dbaf624b1813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b1c5244a-6d62-45ad-bfa0-dbaf624b1813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts_2ccd7600-3641-4d97-a11c-4c324ad8caad" xlink:href="tars-20230331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:to="loc_tars_PaymentsOfDeferredStockIssuanceCosts_2ccd7600-3641-4d97-a11c-4c324ad8caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c1e7090-765f-492f-880c-4eee9629e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9adee40-3669-4f9d-b778-a6b103257433" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c1e7090-765f-492f-880c-4eee9629e539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f331fb91-d7ce-4d03-8294-f5e95997f628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f331fb91-d7ce-4d03-8294-f5e95997f628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63780d08-3028-470d-a9bb-a4707995d19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63780d08-3028-470d-a9bb-a4707995d19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62d5cf68-cd92-47ad-823c-4af91bd4c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62d5cf68-cd92-47ad-823c-4af91bd4c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9311f429-a79e-414b-965e-3ce31afbb95c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b5ab1da3-8ada-447d-b5e8-5e8a9b1512ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b5ab1da3-8ada-447d-b5e8-5e8a9b1512ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ff869c06-0b8f-4d09-b88c-551a47dd8e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:to="loc_us-gaap_InterestPaidNet_ff869c06-0b8f-4d09-b88c-551a47dd8e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d511cfe0-7856-4d2f-87ad-f709c5c2de08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d511cfe0-7856-4d2f-87ad-f709c5c2de08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_71287c07-0e05-4b54-b9ef-92c3c8a621ec" xlink:href="tars-20230331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a269f8cb-f499-42af-8601-0bb59da16c66" xlink:to="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_71287c07-0e05-4b54-b9ef-92c3c8a621ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="simple" xlink:href="tars-20230331.xsd#DescriptionofBusinessandPresentationofFinancialStatements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8901353-013b-437c-8903-0edecd8b3c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bbd40cfa-ea6c-4b09-881b-f7ebd6b10ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8901353-013b-437c-8903-0edecd8b3c8d" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bbd40cfa-ea6c-4b09-881b-f7ebd6b10ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="simple" xlink:href="tars-20230331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimates"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d1eab58-1be1-4e71-a672-1f16bcfb414f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0bc530a5-470b-46d0-af36-34bf4a881389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d1eab58-1be1-4e71-a672-1f16bcfb414f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0bc530a5-470b-46d0-af36-34bf4a881389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3e3f8eef-ec8b-4975-85e0-e312469531fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_687282ee-c216-4a01-b9eb-c34390f18eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3e3f8eef-ec8b-4975-85e0-e312469531fa" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_687282ee-c216-4a01-b9eb-c34390f18eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetail"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0a39c17-690a-461e-8a31-5f8da0f37071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3aaa9c40-d6da-4119-aaf1-a45548da9531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0a39c17-690a-461e-8a31-5f8da0f37071" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3aaa9c40-d6da-4119-aaf1-a45548da9531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_004739a1-8443-4d40-8b5c-12bb1c33a9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_deab894c-ffc3-4db5-9d56-b423dbd36873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_004739a1-8443-4d40-8b5c-12bb1c33a9de" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_deab894c-ffc3-4db5-9d56-b423dbd36873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d3acdc8-360a-4e1a-8d4c-65ef89dda42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_337a0261-76ee-44cc-b8c4-2868ac1f7d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d3acdc8-360a-4e1a-8d4c-65ef89dda42d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_337a0261-76ee-44cc-b8c4-2868ac1f7d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="tars-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8d10fe88-7fbf-42c0-b34c-1b7a4e51b8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_54529223-1702-4aa8-b546-6c162047942c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8d10fe88-7fbf-42c0-b34c-1b7a4e51b8b7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_54529223-1702-4aa8-b546-6c162047942c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="simple" xlink:href="tars-20230331.xsd#CommitmentContingencies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_620e407f-9deb-49b9-beb5-02ba9af45fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_70e2f2a1-c620-45d4-bf08-300ddc3c6e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_620e407f-9deb-49b9-beb5-02ba9af45fb2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_70e2f2a1-c620-45d4-bf08-300ddc3c6e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="simple" xlink:href="tars-20230331.xsd#OutLicenseAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1748cbdb-2f7e-4d1f-981a-d313f90e3f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7e60ea2d-89e6-4efa-ba23-0f820a4fc4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1748cbdb-2f7e-4d1f-981a-d313f90e3f26" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7e60ea2d-89e6-4efa-ba23-0f820a4fc4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_58856f93-5fc7-4b90-9f69-1b33cd9438b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ddddb0b4-9496-4e22-a4a8-abb53d380fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_58856f93-5fc7-4b90-9f69-1b33cd9438b8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ddddb0b4-9496-4e22-a4a8-abb53d380fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEvent" xlink:type="simple" xlink:href="tars-20230331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4748fcab-7032-4a70-ab87-7aa231bdc56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ff698bf5-e0e9-48d7-8d56-98a86b54fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4748fcab-7032-4a70-ab87-7aa231bdc56a" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ff698bf5-e0e9-48d7-8d56-98a86b54fcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="simple" xlink:href="tars-20230331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_604a3e0e-d799-408e-a3e3-de6ab8a155f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_604a3e0e-d799-408e-a3e3-de6ab8a155f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82fb8ba4-98c3-4523-bad8-03aaea5cadc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82fb8ba4-98c3-4523-bad8-03aaea5cadc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_53e59293-b538-42da-bd5a-6f263eff6854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_53e59293-b538-42da-bd5a-6f263eff6854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_653060dc-c764-4e48-9e76-bc74cedb5dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_653060dc-c764-4e48-9e76-bc74cedb5dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_acbd0a93-f1bc-4ad6-ab8c-aeb0414d57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_acbd0a93-f1bc-4ad6-ab8c-aeb0414d57c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6ff4d557-3c51-4c92-b904-d3fe1581e42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6ff4d557-3c51-4c92-b904-d3fe1581e42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0060aa5f-e57a-4019-a580-d638328d28b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0060aa5f-e57a-4019-a580-d638328d28b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7d9fe626-88f0-432b-9a1f-56cbec37df7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7d9fe626-88f0-432b-9a1f-56cbec37df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7895b79b-8821-449b-8ec3-c8b4a1d0881a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7895b79b-8821-449b-8ec3-c8b4a1d0881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a310cf28-d55d-41de-8960-3e515dd6299c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a310cf28-d55d-41de-8960-3e515dd6299c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_28097b44-7bbc-465a-bead-fc0ba8bb4851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_28097b44-7bbc-465a-bead-fc0ba8bb4851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_17951880-9c13-441b-9535-b83e66c58194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_17951880-9c13-441b-9535-b83e66c58194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dd5704ed-d462-4348-bc80-0dbcc0974a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771ea125-89ef-4f39-97c1-31b0594cfc2f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dd5704ed-d462-4348-bc80-0dbcc0974a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_92e480a1-fa7a-4b6a-8598-9421c7df2a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_cbfc0d2a-b574-4aa5-958d-f0aecb07025f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92e480a1-fa7a-4b6a-8598-9421c7df2a5f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_cbfc0d2a-b574-4aa5-958d-f0aecb07025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7f4b19d8-adf6-4b45-aade-c3ae28e6618a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92e480a1-fa7a-4b6a-8598-9421c7df2a5f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7f4b19d8-adf6-4b45-aade-c3ae28e6618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e0c4c457-d8fe-4410-8a43-2cdaafe6374a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92e480a1-fa7a-4b6a-8598-9421c7df2a5f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e0c4c457-d8fe-4410-8a43-2cdaafe6374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4454107-a1d8-43ff-91b8-8f61da03b622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3bdbb623-b1d6-49ac-97c6-9339f2d259f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4454107-a1d8-43ff-91b8-8f61da03b622" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3bdbb623-b1d6-49ac-97c6-9339f2d259f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eebf44a5-465e-4e9f-a70a-08ceda6ff27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4454107-a1d8-43ff-91b8-8f61da03b622" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eebf44a5-465e-4e9f-a70a-08ceda6ff27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_124e438a-dced-416d-9c7b-12582cfd5a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_ae208a12-ae49-4ac5-8a25-cb86b25673c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_124e438a-dced-416d-9c7b-12582cfd5a55" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_ae208a12-ae49-4ac5-8a25-cb86b25673c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ff3d09d-4f56-4c29-94c6-011c902fc44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ae2b5d9b-6155-4002-9652-3627dc971f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ff3d09d-4f56-4c29-94c6-011c902fc44d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ae2b5d9b-6155-4002-9652-3627dc971f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb0bb314-64df-4f8c-a432-c5907f630a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ff3d09d-4f56-4c29-94c6-011c902fc44d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb0bb314-64df-4f8c-a432-c5907f630a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_717e8133-5a9f-407b-9712-9cd2d4009099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ff3d09d-4f56-4c29-94c6-011c902fc44d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_717e8133-5a9f-407b-9712-9cd2d4009099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d591731d-8666-41a8-8317-700d3373d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ff3d09d-4f56-4c29-94c6-011c902fc44d" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d591731d-8666-41a8-8317-700d3373d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="tars-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_07214d7f-ffb8-4279-bf98-099b6e4f1a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4cc2129a-5f00-4bd2-804c-a13eb85857e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07214d7f-ffb8-4279-bf98-099b6e4f1a19" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4cc2129a-5f00-4bd2-804c-a13eb85857e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6e9e4bc5-85c2-4f8d-a3e1-3abcaed52b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07214d7f-ffb8-4279-bf98-099b6e4f1a19" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6e9e4bc5-85c2-4f8d-a3e1-3abcaed52b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e808488-a5d7-4703-b4a1-6b6c81816c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_87d62d43-8618-4739-a45f-d09f928e3c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e808488-a5d7-4703-b4a1-6b6c81816c61" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_87d62d43-8618-4739-a45f-d09f928e3c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1404ba0f-d6bd-4ba0-8270-527c396c5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e808488-a5d7-4703-b4a1-6b6c81816c61" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1404ba0f-d6bd-4ba0-8270-527c396c5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e0276d5-e0c8-4904-a81e-9e1d62018634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f6dad984-9985-4655-b335-15124c473b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e0276d5-e0c8-4904-a81e-9e1d62018634" xlink:to="loc_us-gaap_NumberOfReportableSegments_f6dad984-9985-4655-b335-15124c473b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0b56dc85-5cb0-4fc4-b06f-d4bab9456d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e0276d5-e0c8-4904-a81e-9e1d62018634" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0b56dc85-5cb0-4fc4-b06f-d4bab9456d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_933549ea-212d-4413-8f28-ca5d37a9549e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_933549ea-212d-4413-8f28-ca5d37a9549e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:to="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89494aa5-f62e-4e4d-9e30-3c3727a9df49" xlink:to="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_304e66e3-52f8-41e0-9d0a-33e987f794f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:to="loc_srt_MinimumMember_304e66e3-52f8-41e0-9d0a-33e987f794f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5842bbf3-912e-47c8-9ccd-06410eba435f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33292250-da3c-40c5-8c01-36ea4e963223" xlink:to="loc_srt_MaximumMember_5842bbf3-912e-47c8-9ccd-06410eba435f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:to="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ed6be0ce-4f40-443f-b764-4c8a717e64db" xlink:to="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_78c23642-f751-4268-90c3-0c7f4f3ea14b" xlink:href="tars-20230331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4e1304c-40c5-492d-bc4f-d6f69959177a" xlink:to="loc_tars_EquityIncentivePlan2016Member_78c23642-f751-4268-90c3-0c7f4f3ea14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b0f2572-2b03-40a6-9fba-4ff966f8966a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3bca4f7a-9192-4e81-855f-d3f87577a4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3bca4f7a-9192-4e81-855f-d3f87577a4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssets_f3616372-6c98-4350-9109-073e510e77d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_DepositsAssets_f3616372-6c98-4350-9109-073e510e77d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_097d5eca-2526-4fca-9e3c-716a1e853fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_097d5eca-2526-4fca-9e3c-716a1e853fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0c56f194-f786-4712-85ed-7e4717abf083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0c56f194-f786-4712-85ed-7e4717abf083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0f1445dc-09fa-4d1d-9e23-c614118a744c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0f1445dc-09fa-4d1d-9e23-c614118a744c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a1d2692-a597-4895-bf06-9ebabd7e0615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b9255736-274b-4006-adb6-da939b6e0433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a1d2692-a597-4895-bf06-9ebabd7e0615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02a3eccf-2cb3-486c-a955-2058de49b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02a3eccf-2cb3-486c-a955-2058de49b5c3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ca41cd2-d8ce-43ba-9a72-3c91d5687eab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5219b6de-d829-441e-b915-5516f4f5dbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5219b6de-d829-441e-b915-5516f4f5dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d031be49-733b-42e5-87b1-64282eb25344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d031be49-733b-42e5-87b1-64282eb25344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6d1392b6-499c-477e-a7e6-b20837b4db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2873a406-deac-4ea9-89a3-beda7008c4cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6d1392b6-499c-477e-a7e6-b20837b4db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8caabcf-652d-4f0b-b414-321ae03067bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_b1252013-6617-4b34-9728-a1bb6ea508b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CashMember_b1252013-6617-4b34-9728-a1bb6ea508b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7d60c474-a60c-4efd-bba2-4cf8f2c91f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7d60c474-a60c-4efd-bba2-4cf8f2c91f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_865c0fc3-5308-4d18-af65-c5f091c1f92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_865c0fc3-5308-4d18-af65-c5f091c1f92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a19082aa-f19a-4a9f-aa5d-e1b882e947ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CommercialPaperMember_a19082aa-f19a-4a9f-aa5d-e1b882e947ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_20dc132c-832d-461d-99d8-606f37329d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_20dc132c-832d-461d-99d8-606f37329d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e8e4a959-cf23-4dfa-a2a7-336f626196d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ba5a029-df62-4e05-9e95-56c18b57e10c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e8e4a959-cf23-4dfa-a2a7-336f626196d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8ee6618b-02cf-4fae-9292-de9e11f42296" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9ddfcf7d-c83d-4c91-bd8b-4d3e218eb481" xlink:to="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f91ce10d-d57b-433f-8908-3ac43928dee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f91ce10d-d57b-433f-8908-3ac43928dee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_c0d4cf5f-d85a-45de-9099-95b84db763dd" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_c0d4cf5f-d85a-45de-9099-95b84db763dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d704f8d-a2ad-4714-a33f-ff98ac8a0c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d704f8d-a2ad-4714-a33f-ff98ac8a0c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fe2ea468-4a35-40d1-be3d-be364c83de08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fe2ea468-4a35-40d1-be3d-be364c83de08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_38d2e637-3b0d-488d-9aa1-ccf80e70c757" xlink:href="tars-20230331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_38d2e637-3b0d-488d-9aa1-ccf80e70c757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_32ab0ed0-3c60-44c1-af56-4ce1c67ed2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_037a8548-3708-4135-8eff-23e859bec874" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_32ab0ed0-3c60-44c1-af56-4ce1c67ed2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42ed60e7-4d68-4a75-8672-2b21dacd9906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_032c1270-6651-4a68-baa4-aadd1af218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42ed60e7-4d68-4a75-8672-2b21dacd9906" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_032c1270-6651-4a68-baa4-aadd1af218ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42ed60e7-4d68-4a75-8672-2b21dacd9906" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:to="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f10114cf-3758-40c4-a55a-d4f95f074d6e" xlink:to="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfca97f8-cff9-4e6f-a3de-e5b339158d22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:to="loc_srt_MinimumMember_cfca97f8-cff9-4e6f-a3de-e5b339158d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee23c2ea-3b4f-4f7e-a12c-222d95b99513" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_972c4ca6-019f-468a-bece-19ef15ce47c5" xlink:to="loc_srt_MaximumMember_ee23c2ea-3b4f-4f7e-a12c-222d95b99513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cc5e714-163d-4104-a068-92d49ee91859" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_f8baf80e-c5d1-44dc-a560-6b52afd1f7a8" xlink:href="tars-20230331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af5bb16f-587d-4f96-9cf0-02fdd43871ba" xlink:to="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_f8baf80e-c5d1-44dc-a560-6b52afd1f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46afbbdf-c2da-4e29-a849-1c9813d78f64" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches_9f9d644b-e0f3-4020-99e8-7cd3243875e2" xlink:href="tars-20230331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_WarrantAgreementNumberOfTranches_9f9d644b-e0f3-4020-99e8-7cd3243875e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants_c56efa8e-982e-47b1-986b-b98b9d8da5c0" xlink:href="tars-20230331.xsd#tars_NumberOfVestedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_NumberOfVestedWarrants_c56efa8e-982e-47b1-986b-b98b9d8da5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares_3533bd0b-d556-4289-b247-bd936cdff3ab" xlink:href="tars-20230331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_EquitySecuritiesFVNINumberOfShares_3533bd0b-d556-4289-b247-bd936cdff3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_d95f8764-b78a-43f2-9ae6-2800927d23cf" xlink:href="tars-20230331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_d95f8764-b78a-43f2-9ae6-2800927d23cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_e988977a-af9b-4527-af13-7286f4835e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_e988977a-af9b-4527-af13-7286f4835e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef862783-f877-4876-92a8-b95a755e77ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef862783-f877-4876-92a8-b95a755e77ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9bef5247-c320-4e99-9370-92c983da2ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6b93e99d-16a0-4318-952e-80f21b753953" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9bef5247-c320-4e99-9370-92c983da2ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d628af67-544e-4e30-982b-db6db31de96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_267a3d8f-910c-4930-8329-c6639bea82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d628af67-544e-4e30-982b-db6db31de96c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_267a3d8f-910c-4930-8329-c6639bea82b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cb3e70c0-02a4-4875-83a9-65d3ed5364ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_267a3d8f-910c-4930-8329-c6639bea82b5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cb3e70c0-02a4-4875-83a9-65d3ed5364ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_420092c7-6502-4de0-a189-5af3fa5bf4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_267a3d8f-910c-4930-8329-c6639bea82b5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_420092c7-6502-4de0-a189-5af3fa5bf4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80cde0ec-f452-43f5-8c63-37bfe1bbf711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_267a3d8f-910c-4930-8329-c6639bea82b5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80cde0ec-f452-43f5-8c63-37bfe1bbf711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d008a983-980b-4956-bdd8-899bd1e7bee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d008a983-980b-4956-bdd8-899bd1e7bee2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112388f5-99f1-4077-8231-68967d680ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05d9d9dd-5d05-4901-8dee-6a64df3edffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05d9d9dd-5d05-4901-8dee-6a64df3edffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1705b933-537c-4491-b334-563943b44484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1705b933-537c-4491-b334-563943b44484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5b5029c7-4df2-4dfe-ae05-b61e761384b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CommercialPaperMember_5b5029c7-4df2-4dfe-ae05-b61e761384b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_9d543db9-1f67-40ce-b02e-d862115d7915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_9d543db9-1f67-40ce-b02e-d862115d7915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2b122936-bf11-46a9-a21b-30c7c7b4102e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2b122936-bf11-46a9-a21b-30c7c7b4102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_29ca2d44-c7b9-4518-a34f-ef57d5d00745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54a668a3-3eb9-46b7-a9d6-981a699d16a9" xlink:to="loc_us-gaap_CashMember_29ca2d44-c7b9-4518-a34f-ef57d5d00745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f06e2025-2c74-4a29-aac6-cdcc596b44f7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05b602ca-97ce-4338-af5f-038059b6639c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05b602ca-97ce-4338-af5f-038059b6639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09b45884-d013-4e04-a429-1126e91c389b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7afe6f0a-0b73-4cdc-a862-fa688c11744f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09b45884-d013-4e04-a429-1126e91c389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f763e7c-aa2e-494a-913a-7d0931b73837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f763e7c-aa2e-494a-913a-7d0931b73837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b842cdab-2dc8-4403-bad7-7f2796dc6764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b842cdab-2dc8-4403-bad7-7f2796dc6764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c7297da-8e1e-4eeb-8e97-f652ac2dd7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c7297da-8e1e-4eeb-8e97-f652ac2dd7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b807ff28-cca0-4ade-8e68-b7c7b858bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f4d5e4a-d7f3-4e5f-b819-3b9675745b21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b807ff28-cca0-4ade-8e68-b7c7b858bb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fbfcd179-2b16-4fa5-a91c-c8d31ee18811" xlink:to="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_46ee237e-25a3-444e-be99-ab77d55cc1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_46ee237e-25a3-444e-be99-ab77d55cc1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_49787e83-8af4-43e2-b7dd-c47d5f77951a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_49787e83-8af4-43e2-b7dd-c47d5f77951a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1f0ec97b-4d27-4848-bbc4-e3d545ac68ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1f0ec97b-4d27-4848-bbc4-e3d545ac68ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_30cd32f8-caa4-45cb-b6be-a57b1cf2e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_dc3bea50-c289-4fbd-a33b-83f115f55e7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_30cd32f8-caa4-45cb-b6be-a57b1cf2e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a15f1e67-fbe0-4b3c-b8fe-6eb6445513ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a15f1e67-fbe0-4b3c-b8fe-6eb6445513ad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4edfe3d-4c88-426d-8aee-7f336834db4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e567409a-73e3-4ed7-abdb-e24faf0bdcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e567409a-73e3-4ed7-abdb-e24faf0bdcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a549eca2-309f-4899-bd91-1f035693bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_OfficeEquipmentMember_a549eca2-309f-4899-bd91-1f035693bfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_9ade8091-e727-4338-b825-62483863c698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_9ade8091-e727-4338-b825-62483863c698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0a3d35ff-5301-4f18-9913-b8e58a0bd821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dda6e50-57ad-42a8-ab68-705f48054858" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0a3d35ff-5301-4f18-9913-b8e58a0bd821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_030facfe-f48c-46f3-91f2-fe0805638063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8731fa93-f09d-497e-87bc-c628a1509a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8731fa93-f09d-497e-87bc-c628a1509a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d28a4b21-848c-4918-96fc-4c2b461e5437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d28a4b21-848c-4918-96fc-4c2b461e5437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1644182a-b2e6-4bae-b9bb-bab3b8fbdf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1644182a-b2e6-4bae-b9bb-bab3b8fbdf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5fe172de-2132-42c8-b6df-f2762cf0a22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bfa116bb-fc0f-4e40-b602-4745b93110dc" xlink:to="loc_us-gaap_Depreciation_5fe172de-2132-42c8-b6df-f2762cf0a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_dd1a5943-9721-45ec-9c96-06a516e3f3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_dd1a5943-9721-45ec-9c96-06a516e3f3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_5fc466b7-9e08-434b-b77e-033ea498f152" xlink:href="tars-20230331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_5fc466b7-9e08-434b-b77e-033ea498f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4b0c6c2a-8583-476b-a0cd-820f06a5139b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4b0c6c2a-8583-476b-a0cd-820f06a5139b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_1778aa4a-426f-4093-9521-67e5e87f5016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_us-gaap_InterestPayableCurrent_1778aa4a-426f-4093-9521-67e5e87f5016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_45e7a882-4426-489c-a15c-8f04464251a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_45e7a882-4426-489c-a15c-8f04464251a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e7c28788-36a5-4c7b-a417-78aa47c1fb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_781b5ce6-0dfb-4309-a06e-fb8ed6149ba1" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e7c28788-36a5-4c7b-a417-78aa47c1fb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_86127f35-0d09-4cfa-8261-e2f26a235138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_86127f35-0d09-4cfa-8261-e2f26a235138" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a7d13c0d-93d1-4116-9648-bafb4633b11f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember_ea18d682-b7f1-466d-844d-f43d15bacc9e" xlink:href="tars-20230331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:to="loc_tars_FollowOnPublicOfferingMember_ea18d682-b7f1-466d-844d-f43d15bacc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d3de7cc9-7897-4e96-9d15-563b03cc4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2634ea7-d341-4833-86a2-86325dc9ea18" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d3de7cc9-7897-4e96-9d15-563b03cc4e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b49c2346-88d1-4190-b2ea-2b7a5969fa0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_861bd062-ab28-4b93-b7a9-5e1b707fee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_861bd062-ab28-4b93-b7a9-5e1b707fee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c6f61d32-2d81-408b-ad87-2743e200fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c6f61d32-2d81-408b-ad87-2743e200fe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_9a8c7d52-77a6-4e2a-a1a1-23ada3796dc7" xlink:href="tars-20230331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_9a8c7d52-77a6-4e2a-a1a1-23ada3796dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aa2767d8-fb05-4a22-96bc-3544274d223b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aa2767d8-fb05-4a22-96bc-3544274d223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1c6139e8-7745-4eea-a12a-3173faf468b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1c6139e8-7745-4eea-a12a-3173faf468b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a1f0ca95-072f-4c6e-9f73-c4541881453e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_us-gaap_CommonStockSharesIssued_a1f0ca95-072f-4c6e-9f73-c4541881453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_4cfee92b-19ca-4d95-ac53-fdd14a519fa0" xlink:href="tars-20230331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e93f768b-617c-412a-a096-9afd913007c2" xlink:to="loc_tars_CommonStockNumberOfVotes_4cfee92b-19ca-4d95-ac53-fdd14a519fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockholdersEquitySharesReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_1576ec69-568d-407d-a453-9670eefa7234" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_1576ec69-568d-407d-a453-9670eefa7234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_d1172b1e-a818-449d-9ec6-13b0f1173487" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_d1172b1e-a818-449d-9ec6-13b0f1173487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_080a681d-58d7-493d-92e9-3f4e1e400f86" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_080a681d-58d7-493d-92e9-3f4e1e400f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_bbd5087f-bc61-486a-8197-da1901fbd96e" xlink:href="tars-20230331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_bbd5087f-bc61-486a-8197-da1901fbd96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd4e2c05-8f68-46ed-8055-8aca7173c67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a49d108-8c37-46b6-b8b1-e54d99fa540e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd4e2c05-8f68-46ed-8055-8aca7173c67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e92db37-1348-4ba1-acb0-da2889ddd964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e92db37-1348-4ba1-acb0-da2889ddd964" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49034ba2-754b-4015-9690-9742683ecb6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ed954a-15fa-4559-b8d4-3b0a434cb3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ed954a-15fa-4559-b8d4-3b0a434cb3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bbb5334-e683-4eb3-bfb7-04821ad37d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ecb2273-d895-41cb-9c00-cf7bc7702c9a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6bbb5334-e683-4eb3-bfb7-04821ad37d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23b0989b-b7e6-4e5e-81e0-29aac9543bab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_600642e4-507b-4aeb-93b8-65244e6fe981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23d888e5-fb5d-4b32-9e6f-ac282ec71f33" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_600642e4-507b-4aeb-93b8-65244e6fe981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationValuationAssumptionsofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f413877d-c064-49fb-b997-2037edb858a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f413877d-c064-49fb-b997-2037edb858a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e0c130ea-6443-4884-b626-33aaee05aba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e0c130ea-6443-4884-b626-33aaee05aba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8dd99869-b949-4dbc-9fab-5e122f3d58e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8dd99869-b949-4dbc-9fab-5e122f3d58e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bad6f1cc-87cb-4351-a05b-eff4a63fc03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bad6f1cc-87cb-4351-a05b-eff4a63fc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c57abea-2f29-4fce-aa11-2896efa0080b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6529dcb5-a9be-4636-acdf-a31cdcfd1dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c57abea-2f29-4fce-aa11-2896efa0080b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8571690c-8ade-4b94-8254-6f189f12ca6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8571690c-8ade-4b94-8254-6f189f12ca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b83a7f3a-663c-401c-a6b2-b9b25f7395dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b83a7f3a-663c-401c-a6b2-b9b25f7395dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a501476c-0736-42d7-92a5-ac79fbcb181e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a501476c-0736-42d7-92a5-ac79fbcb181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8588021d-ef6e-4fd5-b378-7add6b388679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8588021d-ef6e-4fd5-b378-7add6b388679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e066460d-91fb-4606-bc6b-1c3ca0006c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13d89563-f03b-4a56-a5e5-ec7794c6d6ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e066460d-91fb-4606-bc6b-1c3ca0006c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b3b1b1f-9f23-4ea8-b244-5817773972be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b3b1b1f-9f23-4ea8-b244-5817773972be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_bc3c34e0-f0d9-46ab-9269-ac53a7b3cff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_bc3c34e0-f0d9-46ab-9269-ac53a7b3cff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e895f983-7e07-48b5-9d5c-b3240c8ff659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e895f983-7e07-48b5-9d5c-b3240c8ff659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2ae0da82-a925-4196-8829-e8acdff85680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2ae0da82-a925-4196-8829-e8acdff85680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1b19b476-c584-494e-ad94-bc657e403c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1b19b476-c584-494e-ad94-bc657e403c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b5fbb915-acb0-4b76-b381-049ef517a509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b5fbb915-acb0-4b76-b381-049ef517a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7c07fe52-7e9b-4f79-9b14-0ec5a79beb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb07ad7-ccbd-41db-815f-b35ef40f9abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7c07fe52-7e9b-4f79-9b14-0ec5a79beb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_abeb7443-395a-4d53-a903-8386359d5b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_abeb7443-395a-4d53-a903-8386359d5b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_8f511800-e4a7-4256-8794-38d731ac530c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_8f511800-e4a7-4256-8794-38d731ac530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_c11fe7c2-7722-4c70-b930-cf520f208cb2" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_c11fe7c2-7722-4c70-b930-cf520f208cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_358f1601-a793-43cb-b524-b646e8aa870d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_c11fe7c2-7722-4c70-b930-cf520f208cb2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_358f1601-a793-43cb-b524-b646e8aa870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53f00ff7-da8f-4910-8083-4c3873580dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_c11fe7c2-7722-4c70-b930-cf520f208cb2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53f00ff7-da8f-4910-8083-4c3873580dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_e947ea46-b861-459d-a29a-0cf9aae3f75d" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_c11fe7c2-7722-4c70-b930-cf520f208cb2" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_e947ea46-b861-459d-a29a-0cf9aae3f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_99cd6e46-5520-4db2-9a69-b7d702ce99bd" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251d34ae-05da-4d11-b784-06ea3b60cbb5" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_99cd6e46-5520-4db2-9a69-b7d702ce99bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_547d101f-a282-4d8e-8480-f6a21686c883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_99cd6e46-5520-4db2-9a69-b7d702ce99bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_547d101f-a282-4d8e-8480-f6a21686c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_78ecb3e2-1252-4a9f-adb0-ad754b84f45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_99cd6e46-5520-4db2-9a69-b7d702ce99bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_78ecb3e2-1252-4a9f-adb0-ad754b84f45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_f1cd94ff-2d89-4b67-abd5-41b142f10e07" xlink:href="tars-20230331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_99cd6e46-5520-4db2-9a69-b7d702ce99bd" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_f1cd94ff-2d89-4b67-abd5-41b142f10e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f97be3a-88c7-4819-9915-dad795690304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f97be3a-88c7-4819-9915-dad795690304" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:to="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3bfbff5f-2198-4445-a2fc-8422eae17721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4fc7ebcd-0c0f-4ebb-8164-65790dbf96b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4fc7ebcd-0c0f-4ebb-8164-65790dbf96b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d67cca26-dc82-4cf5-8765-b17fe5b7a964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83de16aa-1b98-47f1-8b96-2ff1fea7f7c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d67cca26-dc82-4cf5-8765-b17fe5b7a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c2d9d6-4fee-41a1-8824-fecd2964837a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6e4208fe-703f-4353-b3f0-efea372a7873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6e4208fe-703f-4353-b3f0-efea372a7873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a7a1130-c37e-46ac-bea8-a871b7dfdfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a7a1130-c37e-46ac-bea8-a871b7dfdfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b1169074-a878-41cf-9fbc-42b5dfa5e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_403c1447-58ad-4f43-998e-bd4b466815e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b1169074-a878-41cf-9fbc-42b5dfa5e3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8204fc5-6bba-4140-aff2-375d1eae5d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8204fc5-6bba-4140-aff2-375d1eae5d0b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:to="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a5d08dd5-ff09-480f-ba28-3ff7b9a9d254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a6be0f33-247c-41b6-b992-f04162309db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3b918cf-f468-4641-8a10-6924b8401ef9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a6be0f33-247c-41b6-b992-f04162309db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b6e454-9e41-486b-85cf-3b4425e85dfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_362d0066-5777-42b1-82aa-788295c08453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_362d0066-5777-42b1-82aa-788295c08453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e257d2bd-2199-44f5-99d3-9b51a63bac80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e257d2bd-2199-44f5-99d3-9b51a63bac80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1dd1dbcf-dff6-49f7-ab1d-448b891bcc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1dd1dbcf-dff6-49f7-ab1d-448b891bcc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07afb6f7-3f3a-4de3-8bb1-da8f71488ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07afb6f7-3f3a-4de3-8bb1-da8f71488ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e0c0562-f6c0-4064-9195-c6272164fd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef1a0e00-37f3-4794-84f0-3c37313249ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e0c0562-f6c0-4064-9195-c6272164fd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9451fd16-c343-4206-9592-12d24a468ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c910904-e952-41aa-877e-b883c713057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c910904-e952-41aa-877e-b883c713057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d01cc823-f37e-427b-92b4-8d146f96b016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d01cc823-f37e-427b-92b4-8d146f96b016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f7d4870a-9570-4fb2-90f8-faa04ad40e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f7d4870a-9570-4fb2-90f8-faa04ad40e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61b16872-b7de-47f2-9aeb-6f879c7d9cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61b16872-b7de-47f2-9aeb-6f879c7d9cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd7356e6-e796-423b-b143-48e963c99a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62db0d2f-e455-47a5-a0ee-554c3325b463" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd7356e6-e796-423b-b143-48e963c99a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c445df9-5c42-4b01-80b4-fb68488bf603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c445df9-5c42-4b01-80b4-fb68488bf603" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_587af268-c3b9-48a2-9ec5-db265ebf2ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:to="loc_us-gaap_NetIncomeLoss_587af268-c3b9-48a2-9ec5-db265ebf2ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61ec79be-f870-4ef1-83ea-bfd4bf579dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61ec79be-f870-4ef1-83ea-bfd4bf579dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3dc6ea3-cff5-4528-8ebf-e0a48aa71e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3dc6ea3-cff5-4528-8ebf-e0a48aa71e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8348d3d1-4e9a-4bea-bf7d-a2d8dbeb5eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:to="loc_us-gaap_EarningsPerShareBasic_8348d3d1-4e9a-4bea-bf7d-a2d8dbeb5eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5aace9d6-6d40-4d48-9d3a-15db2306d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_581f778a-620d-4f0b-a419-b546075ee593" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5aace9d6-6d40-4d48-9d3a-15db2306d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f15a0dab-db96-44d6-8a97-4b7cd2db0b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f15a0dab-db96-44d6-8a97-4b7cd2db0b54" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4543072c-9531-41fd-8685-320bbee034cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8cda10e-afd1-4dec-a31b-e44c123abdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8cda10e-afd1-4dec-a31b-e44c123abdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_075c1fd3-fb17-4341-bc36-85fa93c3e678" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_075c1fd3-fb17-4341-bc36-85fa93c3e678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_1ceafb0b-851f-4d9e-bc00-eab2e50aa379" xlink:href="tars-20230331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fda066d5-f13a-4083-8be8-9e3816613e95" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_1ceafb0b-851f-4d9e-bc00-eab2e50aa379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2f59d11-35a2-4b16-9eec-192ccf5183c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ef878d5-05c3-4aed-bf61-58d6b54932fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6dee07f8-39ca-4215-b9ad-b12802add4b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ef878d5-05c3-4aed-bf61-58d6b54932fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7383903-cb77-4ca3-b9c3-025a4fda4b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7383903-cb77-4ca3-b9c3-025a4fda4b98" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fbbfb6b-74d8-47dd-a060-b85a101fe7e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d89dd862-845f-48fa-9882-6ccfec6851c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6c9f5d3-b13f-408f-9c46-3e7ad5da1493" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d89dd862-845f-48fa-9882-6ccfec6851c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ecfc4c8f-3dfd-4190-9c90-b1ba77e03b32" xlink:to="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_9596f07b-f3f3-4e4d-8aaf-7ea9856d8ea5" xlink:href="tars-20230331.xsd#tars_ClinicalMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:to="loc_tars_ClinicalMilestonesMember_9596f07b-f3f3-4e4d-8aaf-7ea9856d8ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_a25c51b2-78cc-4ec2-9a86-dfc9d2cac859" xlink:href="tars-20230331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feac0689-c8c3-42dd-b4f8-c1fa22908be6" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_a25c51b2-78cc-4ec2-9a86-dfc9d2cac859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fe8a8b40-c2c8-43c6-a7a3-791d6212e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_e6a87a02-f900-45b6-be10-61754f3b4e5d" xlink:href="tars-20230331.xsd#tars_ElancoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a98ee4-60b4-415c-9db2-ab1b6e313ef4" xlink:to="loc_tars_ElancoMember_e6a87a02-f900-45b6-be10-61754f3b4e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_128fbf4b-6dca-447d-97d4-0940c1a511f6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4fad684a-57a5-4bf9-be23-7515f14f7919" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4fad684a-57a5-4bf9-be23-7515f14f7919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_18b89e9f-b3eb-4203-922b-2acd5938c4c1" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_18b89e9f-b3eb-4203-922b-2acd5938c4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_04415995-b87b-4709-bda6-834c1b46c6fd" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment_04415995-b87b-4709-bda6-834c1b46c6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_70d0f05d-b953-428e-b248-32c61cf0376b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_70d0f05d-b953-428e-b248-32c61cf0376b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments_a171e2b0-a724-43e5-a181-8b36b886b0c2" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementFutureCashPayments_a171e2b0-a724-43e5-a181-8b36b886b0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_ff85407a-030b-4213-8751-86e3dff44156" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_ff85407a-030b-4213-8751-86e3dff44156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_c05df83f-48c1-480d-a021-c84d5245d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_c05df83f-48c1-480d-a021-c84d5245d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2b3edf56-f180-4ced-a4c5-c60e5315b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2b3edf56-f180-4ced-a4c5-c60e5315b9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5b13cb7a-4c2e-4d6f-b6e9-509f6b90d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44bc2506-2d61-43be-b9ae-1e8de5a83ad0" xlink:to="loc_us-gaap_SharePrice_5b13cb7a-4c2e-4d6f-b6e9-509f6b90d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CommitmentContingenciesEmploymentArrangementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a11f96-8654-471b-9b0b-243e8d435113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a11f96-8654-471b-9b0b-243e8d435113" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9b937503-516b-42f6-9cff-5da5ac325264" xlink:to="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c47fbf12-027c-4615-8a2e-bbce3839a73d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1fa16793-03f6-43c2-980c-4820aa968645" xlink:to="loc_srt_DirectorMember_c47fbf12-027c-4615-8a2e-bbce3839a73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b81a0da-ece8-4416-b706-6e440581af6c" xlink:to="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61326e99-9669-4b46-b555-b4863688452c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:to="loc_srt_MinimumMember_61326e99-9669-4b46-b555-b4863688452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bcb7b47-61b7-435d-9ef9-3fff1e9eca2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56d7bcd0-2884-4ee5-a0e2-4c67868e4e5c" xlink:to="loc_srt_MaximumMember_1bcb7b47-61b7-435d-9ef9-3fff1e9eca2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e7f9f0de-fd2d-46cb-a1b1-f13606d8b872" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_a355ddd7-66d3-457f-b1ec-19722f3bd05c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7e670e8e-45c1-4b24-a6cf-65f5967c18b0" xlink:to="loc_srt_ChiefFinancialOfficerMember_a355ddd7-66d3-457f-b1ec-19722f3bd05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2de0f3e5-7e37-47dc-8a92-9451f64acfeb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1eaf1e3-dbcb-4200-a0a5-e5055e7eae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d713d46b-a5b5-47a1-a226-62e5868d56ad" xlink:to="loc_us-gaap_SubsequentEventMember_e1eaf1e3-dbcb-4200-a0a5-e5055e7eae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de63f9b1-07c9-4ebe-a5f8-33e10e3dab03" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_dd19d233-68ab-4485-8f85-13443adfa76b" xlink:href="tars-20230331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_dd19d233-68ab-4485-8f85-13443adfa76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_40137f72-4cb8-42d3-b396-957404c5de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_40137f72-4cb8-42d3-b396-957404c5de8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionOptionToPurchaseShares_0bb9916c-9768-4056-8697-425fa1cc825c" xlink:href="tars-20230331.xsd#tars_RelatedPartyTransactionOptionToPurchaseShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_RelatedPartyTransactionOptionToPurchaseShares_0bb9916c-9768-4056-8697-425fa1cc825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9c22d1db-72e6-4261-918c-85a5d2d6f1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9c22d1db-72e6-4261-918c-85a5d2d6f1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_e0103309-1b9d-4a1e-835f-86007ad004ff" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments_e0103309-1b9d-4a1e-835f-86007ad004ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_617f427c-b071-43f7-b263-dee56804dbf6" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage_617f427c-b071-43f7-b263-dee56804dbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_0a206e6d-df53-48ca-95b1-dea0cfa6f9d0" xlink:href="tars-20230331.xsd#tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut_0a206e6d-df53-48ca-95b1-dea0cfa6f9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_4231c645-65a0-4127-8f0d-98abd0c14005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ce545772-f42d-44d8-8665-e6878d54b787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_4231c645-65a0-4127-8f0d-98abd0c14005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#OutLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce20558f-b332-4015-98b7-ec296b5c3e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce20558f-b332-4015-98b7-ec296b5c3e46" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6b6f4109-1671-4861-b0ae-c86583499693" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5ad2beb3-2998-4b91-b017-378def93918a" xlink:href="tars-20230331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:to="loc_tars_LianBioMember_5ad2beb3-2998-4b91-b017-378def93918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_1244b2e3-dabf-4ca1-98e1-ba133be2a2e9" xlink:href="tars-20230331.xsd#tars_ElancoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fedcd3c-c691-495c-a2d1-6d208f10b400" xlink:to="loc_tars_ElancoMember_1244b2e3-dabf-4ca1-98e1-ba133be2a2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50a2adf0-2b0f-472f-8b20-69f897b7f64d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ccdefa55-9129-4d7d-9868-d8442007d5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec719368-2ee7-42d8-a6a6-bf1f50b2eba0" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ccdefa55-9129-4d7d-9868-d8442007d5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bbe48d95-7daf-4e48-acda-03e994fca51e" xlink:to="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember_c6e329d3-5aa0-4a90-9568-f6760252de04" xlink:href="tars-20230331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:to="loc_tars_MilestoneDeterminedByTheCompanyMember_c6e329d3-5aa0-4a90-9568-f6760252de04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_c2294396-e306-41d8-b2d6-128173a99a74" xlink:href="tars-20230331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27d972a9-a209-4ddf-9e91-a295756111ac" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_c2294396-e306-41d8-b2d6-128173a99a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10f7b75b-433f-4194-ab57-d7e7907d955f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e0a7e697-3941-405e-aedc-de75d341a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e0a7e697-3941-405e-aedc-de75d341a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_544de824-d4b1-42c8-b1be-675a2eb2c535" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_544de824-d4b1-42c8-b1be-675a2eb2c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_6bacc7c8-d784-4eea-83f6-62fbe054ba89" xlink:href="tars-20230331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_6bacc7c8-d784-4eea-83f6-62fbe054ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_4e1dd798-f20e-49d2-813a-483ee76041e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_4e1dd798-f20e-49d2-813a-483ee76041e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b85f5b1b-69f9-4687-b0fa-19997ae65d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b85f5b1b-69f9-4687-b0fa-19997ae65d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_f0527796-e07c-45c6-ae66-abc32593c1b9" xlink:href="tars-20230331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_f0527796-e07c-45c6-ae66-abc32593c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_8c711577-01a3-483d-adf5-a85c4f7a8871" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_8c711577-01a3-483d-adf5-a85c4f7a8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3f745bc0-499c-4e8e-8c06-842cc3a95b2c" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3f745bc0-499c-4e8e-8c06-842cc3a95b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_daab0dbb-bd63-4505-857e-7e767e556143" xlink:href="tars-20230331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_daab0dbb-bd63-4505-857e-7e767e556143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_8f1ce0d1-834b-4912-be10-1866f93cf579" xlink:href="tars-20230331.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_tars_UpfrontPayment_8f1ce0d1-834b-4912-be10-1866f93cf579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fb92fafa-eaa1-4941-baa6-53721347523a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23608322-a6ad-4bb1-8bd9-6f01533ae195" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fb92fafa-eaa1-4941-baa6-53721347523a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d0442ae-d232-468e-9b0b-374d53e44070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d0442ae-d232-468e-9b0b-374d53e44070" xlink:to="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a21e0835-30c3-4027-916f-2b61414f70eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1be50320-d164-4ea4-9b94-601a054adb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:to="loc_us-gaap_LineOfCreditMember_1be50320-d164-4ea4-9b94-601a054adb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember_2adc1167-1c7e-4fb3-9e15-0917b7d91c82" xlink:href="tars-20230331.xsd#tars_LineOfCreditSVBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e23f7026-7918-42d4-9e9b-d19b16605b52" xlink:to="loc_tars_LineOfCreditSVBMember_2adc1167-1c7e-4fb3-9e15-0917b7d91c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_323bbe62-cecd-4c56-84e4-24cac295c160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_f2388746-918d-4910-907b-01add2e7eeaa" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheOneMember_f2388746-918d-4910-907b-01add2e7eeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_e7894bae-97e4-43e5-86ac-19f654ffac5d" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_e7894bae-97e4-43e5-86ac-19f654ffac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_f479ac72-85e8-4d0f-bcfe-53423742c103" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_f479ac72-85e8-4d0f-bcfe-53423742c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_6b621eeb-b71d-4fd5-af1e-591b1333efb4" xlink:href="tars-20230331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityTrancheFourMember_6b621eeb-b71d-4fd5-af1e-591b1333efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_98902892-6501-4f0f-aa75-cf20138fa6d3" xlink:href="tars-20230331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7acbac44-41be-418d-9c11-2ba81cb7afd4" xlink:to="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_98902892-6501-4f0f-aa75-cf20138fa6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_0b04a433-2868-4a90-93da-fa87469175b8" xlink:to="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f25622b3-d060-470f-b773-ccab65e10552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4b50ebc5-3f3a-49ac-8ee2-0b04710d9b20" xlink:to="loc_us-gaap_PrimeRateMember_f25622b3-d060-470f-b773-ccab65e10552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f5767783-38f3-4daa-8b61-65791d3aac28" xlink:to="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da78a69b-1da7-4455-bf11-5c2c168e8b20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cd2cf729-52c1-46b7-8b7b-1e4f2771c36d" xlink:to="loc_srt_MaximumMember_da78a69b-1da7-4455-bf11-5c2c168e8b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c0d3400-8600-4f66-a84d-eb75361d81cf" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_6ca9c676-fd1b-4c7e-8d49-450c859f16d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_6ca9c676-fd1b-4c7e-8d49-450c859f16d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f4c940f-1f74-4c70-a08f-5276f6843385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f4c940f-1f74-4c70-a08f-5276f6843385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_03a511e9-bdff-4cfb-9392-c52244379666" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_03a511e9-bdff-4cfb-9392-c52244379666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_966d165a-ae46-4f44-a927-915bbaad2adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_966d165a-ae46-4f44-a927-915bbaad2adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ee23dd5-67cf-42c5-acee-980a5716f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ee23dd5-67cf-42c5-acee-980a5716f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_7e14de92-7008-4d9d-8ff6-0162b3884447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_7e14de92-7008-4d9d-8ff6-0162b3884447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_8eb65998-404c-4e34-90d8-92a2a0da3977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_8eb65998-404c-4e34-90d8-92a2a0da3977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_6af48ef0-93e4-4c0d-ad35-3c2457fb72f9" xlink:href="tars-20230331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_6af48ef0-93e4-4c0d-ad35-3c2457fb72f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_86fba6b3-ec51-439f-a76e-117a928ab77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_86fba6b3-ec51-439f-a76e-117a928ab77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5c01f96a-9af4-4183-a808-1c1166a197fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f022727-2e9a-4216-aef4-f311eea1678a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5c01f96a-9af4-4183-a808-1c1166a197fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_536b7ab1-0e31-47ae-bc17-4dc3e605088a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_346c0f0d-70f4-4ac9-ab0a-8872c9be70c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_536b7ab1-0e31-47ae-bc17-4dc3e605088a" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_346c0f0d-70f4-4ac9-ab0a-8872c9be70c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_f637b46b-2199-4512-ba47-28df105025c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_536b7ab1-0e31-47ae-bc17-4dc3e605088a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_f637b46b-2199-4512-ba47-28df105025c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_fb5c0b57-53dc-41b8-a79e-de3d5daa9b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_536b7ab1-0e31-47ae-bc17-4dc3e605088a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_fb5c0b57-53dc-41b8-a79e-de3d5daa9b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_77c9f3cf-2267-45b0-9078-bb998c46dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_536b7ab1-0e31-47ae-bc17-4dc3e605088a" xlink:to="loc_us-gaap_InterestExpenseDebt_77c9f3cf-2267-45b0-9078-bb998c46dc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6484345f-88a3-4a9a-8516-7b35f8bfca4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6484345f-88a3-4a9a-8516-7b35f8bfca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_6fb5d6cd-b299-4628-b8c8-7069babed654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_6fb5d6cd-b299-4628-b8c8-7069babed654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_e1b07103-cf76-4063-975e-e45496db044b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_e1b07103-cf76-4063-975e-e45496db044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_098680e6-7aae-4c21-bcab-0f863727d569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_098680e6-7aae-4c21-bcab-0f863727d569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_42d3af32-2815-480b-b58d-a9bf2f87b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_262bad3f-8185-4583-b657-9cda784de21f" xlink:to="loc_us-gaap_LongTermDebt_42d3af32-2815-480b-b58d-a9bf2f87b24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20230331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0bc657a9-4e63-49c1-ae9d-890f85fdcdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0bc657a9-4e63-49c1-ae9d-890f85fdcdbc" xlink:to="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5d5213a-e9f6-4452-bb95-19f7b897d59d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e76db9ba-71db-44a0-9850-db146d038561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a57e38d-1ba0-4810-9bdc-ce3c02b195dc" xlink:to="loc_us-gaap_SubsequentEventMember_e76db9ba-71db-44a0-9850-db146d038561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d9f32bb2-f264-4d8b-8ba6-578085003519" xlink:to="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_0732bf05-5217-4de9-9503-6f6560dd34d9" xlink:href="tars-20230331.xsd#tars_LesseeOperatingLeaseRemainingLeaseTermExtension"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_77a38d76-ee13-47fa-8686-5d31216f9a91" xlink:to="loc_tars_LesseeOperatingLeaseRemainingLeaseTermExtension_0732bf05-5217-4de9-9503-6f6560dd34d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054559152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TARSUS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4717861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15440 Laguna Canyon Road, Suite 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">409-9820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,803,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054560048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,997<span></span>
</td>
<td class="nump">$ 71,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">135,222<span></span>
</td>
<td class="nump">145,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,509<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">208,646<span></span>
</td>
<td class="nump">225,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">211,214<span></span>
</td>
<td class="nump">227,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">9,049<span></span>
</td>
<td class="nump">9,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">5,519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,255<span></span>
</td>
<td class="nump">15,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net</a></td>
<td class="nump">24,515<span></span>
</td>
<td class="nump">19,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,810<span></span>
</td>
<td class="nump">34,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,800,512 shares issued and outstanding at March&#160;31, 2023 (unaudited); 26,727,458 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">305,651<span></span>
</td>
<td class="nump">301,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated deficit</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(132,182)<span></span>
</td>
<td class="num">(108,763)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">173,404<span></span>
</td>
<td class="nump">192,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 211,214<span></span>
</td>
<td class="nump">$ 227,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054541920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">26,800,512<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">26,800,512<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405055430352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license fees and collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,356<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,096<span></span>
</td>
<td class="nump">7,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">27,452<span></span>
</td>
<td class="nump">20,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations before other income (expense) and income taxes</a></td>
<td class="num">(24,952)<span></span>
</td>
<td class="num">(19,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(684)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity investments</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants issued by licensee</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(23,419)<span></span>
</td>
<td class="num">(20,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities and cash equivalents</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (23,415)<span></span>
</td>
<td class="num">$ (20,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (shares)</a></td>
<td class="nump">26,742,023<span></span>
</td>
<td class="nump">20,710,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (shares)</a></td>
<td class="nump">26,742,023<span></span>
</td>
<td class="nump">20,710,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember', window );">License fees and Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI https://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051933408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,698,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">166,730<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 213,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights', window );">Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights', window );">Lapse of repurchase obligation for stock option exercises, prior to vesting</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,718,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 149,197<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">216,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,910)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2022</a></td>
<td class="nump">26,727,458<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 192,900<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">301,732<span></span>
</td>
<td class="num">$ (74)<span></span>
</td>
<td class="num">(108,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">$ 3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">6,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive gain</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2023</a></td>
<td class="nump">26,800,512<span></span>
</td>
<td class="nump">26,800,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 173,404<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 305,651<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (132,182)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405055514496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,419)<span></span>
</td>
<td class="num">$ (20,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of term loan-related costs</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,906<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity investments</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on available-for-sale debt securities</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants issued by licensee</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized gain from transactions denominated in a foreign currency</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">3,165<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(1,046)<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and benefits</a></td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,970)<span></span>
</td>
<td class="num">(15,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">40,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(28,667)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(340)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">11,294<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of equity awards</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from term loan</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of term loan issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_PaymentsOfDeferredStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,013<span></span>
</td>
<td class="nump">19,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(5,663)<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8212; beginning of period</a></td>
<td class="nump">71,660<span></span>
</td>
<td class="nump">171,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8212; end of period</a></td>
<td class="nump">65,997<span></span>
</td>
<td class="nump">175,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid in cash</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions of property and equipment included within accounts payable and other accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities', window );">Deferred offering costs included within accounts payable and accrued liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_PaymentsOfDeferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of Deferred Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_PaymentsOfDeferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI https://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405056986000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Presentation of Financial Statements</a></td>
<td class="text">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company&#8217;s operations currently consist of its preclinical and clinical studies, corporate administration and commercial leadership supporting planned business growth. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a limited operating history, no product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offering completed in May 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), proceeds from its out-license agreement, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company&#8217;s management determined that it operates one reportable operating segment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405139760832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Use of Estimates</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders&#8217; Equity, and the interim Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023 or any other interim or annual period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial statements as of and for the year ended December&#160;31, 2022, reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2023, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;17, 2023, except as discussed below. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(ii) Cash and Cash Equivalents</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0">three</span> to five years. Leasehold </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vi) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $8.1&#160;million and $15.0&#160;million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#8217;s deposits and substantially all of SVB&#8217;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#8220;SVBB&#8221;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#8217;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#8217;s receivership.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) Revenue Recognition for Out-License Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(viii) Research and Development Costs</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) Stock-Based Compensation</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&#160;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss  per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xii) Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057021936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds and U.S. Treasury Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper, Corporate Debt Securities and Government-related Debt Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LianBio Common Stock and Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock as recognized at fair value within long-term investments on the Condensed Balance Sheets as of March&#160;31, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of regulatory milestone achievement for vesting, and the application of an assumed discount rate.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.941%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.941%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Four securities have a contractual maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyNw_8c90302e-5d65-4068-882b-93af76900292">one</span> and four years, with an estimated fair market value of $5.8&#160;million and amortized cost of $5.7&#160;million. As of December&#160;31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities have a contractual maturity between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1MQ_814ddb0b-d044-4453-9608-47383f7c1878">one</span> and five years, with an estimated fair market value of $4.6&#160;million and amortized cost of $4.6&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, all available-for-sale debt securities have gross unrealized losses in a continuous loss position for less than one year. As of March&#160;31, 2023 and December&#160;31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057089920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Detail</a></td>
<td class="text">BALANCE SHEET ACCOUNT DETAIL<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2023 and 2022 was $0.1 million and $0.1&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Other Accrued Liabilities&#160;</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057053664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offering</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an  initial underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of additional 289,832 shares at $13.50 per share was concurrently completed. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross proceeds from this offering were $79.5&#160;million (before underwriting discounts, commissions and other estimated offering expenses), resulting in net proceeds of $74.3&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had 26.8 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,068,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,346,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,930,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,723,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,460,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057021936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.728%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2023 was as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,028,011&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.26&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,045&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2023. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was approximately $29.8&#160;million of unrecorded compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.5 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the three months ended March 31, 2023 was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.24</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>As of March&#160;31, 2023, there was approximately $16.8&#160;million of unrecorded compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.5 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057044080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:70.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,742,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised prior to vesting&#8212; remaining unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,724,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057097120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment &amp; Contingencies</a></td>
<td class="text">COMMITMENTS&#160;&amp; CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements for Lotilaner</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">January 2019 Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0&#160;million upfront upon contract execution in January 2019 and a total of $3.0&#160;million for two specified clinical milestone achievements in September 2020 and April 2021, respectively. </span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone of $1.0&#160;million was included in research and development expense on the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2023. The milestone achievement fully offset a $0.6&#160;million remaining prepayment and $0.4&#160;million was recognized in accounts payable and other accrued liabilities on the accompanying Condensed Balance Sheets as of March&#160;31, 2023. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2023, the Company is obligated to make further cash payments to Elanco of $2.4 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $79.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">September 2020 Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a preexisting consulting agreement with a board member that was appointed in December 2021. This consulting agreement provides for annual cash compensation of approximately $0.2&#160;million and option grants to purchase 45,134 shares of the Company&#8217;s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This consulting agreement may be terminated by either party with ten days notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, the Company entered into a separation and severance agreement with its former Chief Financial Officer, which provides for the following benefits effective upon and after June 15, 2023: severance payments equal to nine months of base salary and 10 months of company-paid continued benefits coverage, a lump sum bonus payment payable in 2024 equal to one-third of the former Chief Financial Officer's 2023 annual target bonus adjusted based on the 2023 Company performance score,  accelerated vesting of options in 40,744 shares of the Company&#8217;s common stock, and an option exercise </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period extension for certain options, in exchange for a release and waiver of claims and continued compliance with his confidentiality obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057044080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Out-License Agreement</a></td>
<td class="text">OUT-LICENSE AGREEMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in the China Territory in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into The China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assessed this arrangement in accordance with ASC 606 and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory, and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0&#160;million, (ii) a second cash payment of $10.0&#160;million, (iii) a $10.0&#160;million milestone that was determined to be within the control of the Company, and (iv) $1.2&#160;million representing the initial fair value of the equity warrant. </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounted for each performance obligation as follows: </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Out-License</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Services </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2023, a specified milestone event was triggered resulting in $2.5&#160;million recognized as license fees and collaboration revenue in the Condensed Statements of Operations for the three months ended March&#160;31, 2023. This cash payment was received in the second quarter of 2023. Through March&#160;31, 2023, the Company had received payments from LianBio totaling $80.0&#160;million, comprised of initial consideration of $15.0&#160;million and $65.0&#160;million for the achievement of specified milestones. </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestone and one-time payments of up to an aggregate of $25.0&#160;million (including the $2.5&#160;million cash payment received in the second quarter of 2023), (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0&#160;million, (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales, and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss relates to the satisfaction of performance obligations including (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the completion of U.S. clinical activities and then providing LianBio with the related data to supplement its local pivotal trial package for TP-03 in the treatment of Demodex blepharitis. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company made a contractual payment in the amount of $2.5&#160;million to Elanco following the receipt of $25&#160;million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4&#160;million of cost of license fees and collaboration revenue upon receipt of $10&#160;million of cash proceeds from LianBio for the achievement of a clinical development milestone.</span></div>The expenses recognized under the China-Out License were not material for the three month periods ended March 31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057020352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility Agreement</a></td>
<td class="text">CREDIT FACILITY AGREEMENT<div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0&#160;million draw.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0&#160;million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0&#160;million was drawn on or before March 15, 2023 and at least an additional $5&#160;million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 15, 2023, the Company made a $5.0&#160;million draw (including SVB's commitment of $1.25&#160;million) from the $25.0&#160;million tranche that became available upon submission of the NDA. As of March&#160;31, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $130.0&#160;million with tranched availability as follows: $20.0&#160;million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022, $35.0&#160;million available upon FDA approval of TP-03, $50.0&#160;million available upon achievement of product net revenue thresholds, and $25.0&#160;million available upon lender approval.</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.  </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.00% as of March&#160;31, 2023.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.2 million was derived by multiplying 4.75% by the $25.0&#160;million outstanding principal balance as of March&#160;31, 2023 and is accreted to interest expense through maturity.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March&#160;31, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 12.12% and 9.66%, respectively. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the three months ended March&#160;31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization as of March&#160;31, 2023 and December&#160;31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:</span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057044080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">SUBSEQUENT EVENTOn May 2, 2023 the Company amended the existing facilities lease, extending the term for three years through January 31, 2027.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054616224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segment</a></td>
<td class="text">To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company&#8217;s management determined that it operates one reportable operating segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.</span><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders&#8217; Equity, and the interim Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023 or any other interim or annual period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s financial statements as of and for the year ended December&#160;31, 2022, reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span> license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities and Long-Term Investments</a></td>
<td class="text">Marketable Securities and Long-Term Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations. </span>Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, NetProperty and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2023 and 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">Concentration of Credit Risk and Other Risks and Uncertainties<div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $8.1&#160;million and $15.0&#160;million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#8217;s deposits and substantially all of SVB&#8217;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#8220;SVBB&#8221;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#8217;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#8217;s receivership.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text">Revenue Recognition for Out-License Arrangements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, </span></div>or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&#160;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div>Dividend Yield &#8212; The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss  per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive Loss Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Effective Accounting Standards</a></td>
<td class="text">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054259264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial instruments measured at fair value</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of equity warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.941%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.941%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057158432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405056977040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Stock details</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,068,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,346,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,930,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,723,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,460,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054500944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.728%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation assumptions of stock options</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2023 was as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,028,011&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.26&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,045&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted stock unit activity</a></td>
<td class="text">Restricted stock unit activity during the three months ended March 31, 2023 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.24</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405058540128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net (loss) income per share, basis and diluted</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:70.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,742,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding potentially dilutive securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised prior to vesting&#8212; remaining unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,724,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405057036288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the three months ended March&#160;31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</a></td>
<td class="text">The principal balance of this Credit Facility and related accretion and amortization as of March&#160;31, 2023 and December&#160;31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405139735408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051837216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Cash held in depository accounts</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Fair market value of common stock</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405053997888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,997<span></span>
</td>
<td class="nump">$ 71,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">135,222<span></span>
</td>
<td class="nump">145,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">201,616<span></span>
</td>
<td class="nump">217,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">64,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">65,148<span></span>
</td>
<td class="nump">60,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">65,148<span></span>
</td>
<td class="nump">58,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">11,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">11,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">4,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">8,297<span></span>
</td>
<td class="nump">10,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">8,297<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">115,303<span></span>
</td>
<td class="nump">134,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">64,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">86,222<span></span>
</td>
<td class="nump">82,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">65,148<span></span>
</td>
<td class="nump">60,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">11,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">8,297<span></span>
</td>
<td class="nump">10,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale And Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054156880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>security </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security </div>
<div>warrant</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_WarrantAgreementNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_NumberOfVestedWarrants', window );">Number of vested warrants | warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquitySecuritiesFVNINumberOfShares', window );">Equity securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities', window );">Number of securities with contractual maturity between one and five years | security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,222<span></span>
</td>
<td class="nump">$ 145,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,291<span></span>
</td>
<td class="nump">145,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember', window );">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquitySecuritiesFVNINumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquitySecuritiesFVNINumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfVestedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vested Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfVestedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_WarrantAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Agreement, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_WarrantAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405059370320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues', window );">Remeasurement of equity warrants</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054679792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">$ 65,997<span></span>
</td>
<td class="nump">$ 71,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,997<span></span>
</td>
<td class="nump">71,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">135,291<span></span>
</td>
<td class="nump">145,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">135,222<span></span>
</td>
<td class="nump">145,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNIAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(925)<span></span>
</td>
<td class="num">(860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Estimated fair value</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">64,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">49,037<span></span>
</td>
<td class="nump">69,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">65,188<span></span>
</td>
<td class="nump">58,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">65,148<span></span>
</td>
<td class="nump">58,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">4,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">65,812<span></span>
</td>
<td class="nump">4,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">8,293<span></span>
</td>
<td class="nump">5,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">8,297<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">12,773<span></span>
</td>
<td class="nump">11,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">$ 11,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNIAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNIAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054177200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 1,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">(Less): Accumulated depreciation and amortization</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051866144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable and other</a></td>
<td class="nump">$ 7,566<span></span>
</td>
<td class="nump">$ 5,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_AccruedClinicalStudiesCurrent', window );">Accrued clinical studies</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">3,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest, current</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">$ 9,049<span></span>
</td>
<td class="nump">$ 9,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AccruedClinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Studies, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AccruedClinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405050526272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800,512<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800,512<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockNumberOfVotes', window );">Common stock votes | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember', window );">Follow-On Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Original issue price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Stock issued, gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares)</a></td>
<td class="nump">289,832<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Original issue price (usd per share) | $ / shares</a></td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405059349984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant', window );">Stock options reserved for future grant (shares)</a></td>
<td class="nump">8,068,595<span></span>
</td>
<td class="nump">8,346,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan', window );">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">2,930,594<span></span>
</td>
<td class="nump">2,663,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding', window );">Stock options issued and outstanding (shares)</a></td>
<td class="nump">4,596,414<span></span>
</td>
<td class="nump">3,899,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant', window );">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</a></td>
<td class="nump">1,128,373<span></span>
</td>
<td class="nump">551,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (shares)</a></td>
<td class="nump">16,723,976<span></span>
</td>
<td class="nump">15,460,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405055117024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,906<span></span>
</td>
<td class="nump">$ 2,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,743<span></span>
</td>
<td class="nump">$ 1,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405055123728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average volatility</a></td>
<td class="nump">71.90%<span></span>
</td>
<td class="nump">77.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per stock option (usd per share)</a></td>
<td class="nump">$ 15.07<span></span>
</td>
<td class="nump">$ 19.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405052034832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (shares)</a></td>
<td class="nump">3,899,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">728,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(6,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(24,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (shares)</a></td>
<td class="nump">4,596,414<span></span>
</td>
<td class="nump">3,899,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="nump">2,028,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (shares)</a></td>
<td class="nump">2,568,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (usd per share)</a></td>
<td class="nump">$ 16.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">15.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (usd per share)</a></td>
<td class="nump">21.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (usd per share)</a></td>
<td class="nump">16.43<span></span>
</td>
<td class="nump">$ 16.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (usd per share)</a></td>
<td class="nump">14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (usd per share)</a></td>
<td class="nump">$ 18.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Unvested</a></td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 15,316<span></span>
</td>
<td class="nump">$ 19,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">12,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 3,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405053891712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 29.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period of recognition</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period of recognition</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051828512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (shares) | shares</a></td>
<td class="nump">551,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">647,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(66,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(4,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (shares) | shares</a></td>
<td class="nump">1,128,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 17.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">15.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">19.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">19.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 16.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405059374704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings Per Share, Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,419)<span></span>
</td>
<td class="num">$ (20,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (shares)</a></td>
<td class="nump">26,742,023<span></span>
</td>
<td class="nump">20,710,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (shares)</a></td>
<td class="nump">26,742,023<span></span>
</td>
<td class="nump">20,710,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051833008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">5,724,787<span></span>
</td>
<td class="nump">3,925,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options, unexercised&#8212;vested and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">4,596,414<span></span>
</td>
<td class="nump">3,561,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember', window );">Restricted stock units&#8212;unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">1,128,373<span></span>
</td>
<td class="nump">351,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember', window );">Stock options exercised prior to vesting&#8212; remaining unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054079024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details) - License agreement - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">51 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment', window );">Remaining prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Trade accounts payable and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementFutureCashPayments', window );">Future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for license agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued for license agreement, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Clinical milestones | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment', window );">Contractual milestone payment</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Commercial and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Commercial and sales milestones | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.0<span></span>
</td>
<td class="nump">$ 79.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Future Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Remaining Prepayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054725856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Employment Arrangements (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>May 04, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers', window );">Number of employment arrangements with executive officers | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments', window );">Months of base salary payments</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage', window );">Months of continued benefits coverage</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut', window );">Percent of annual target bonus</a></td>
<td class="nump">0.3333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (shares) | shares</a></td>
<td class="nump">40,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Cash compensation for consulting agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RelatedPartyTransactionOptionToPurchaseShares', window );">Option to purchase shares for consulting agreement (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price range (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price range (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Employment Arrangements With Executive Officers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfEmploymentArrangementsWithExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Postemployment Benefits, Duration of Base Salary Severance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Postemployment Benefits, Duration of Company-Paid Benefits Coverage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Postemployment Benefits, Percent of Annual Bonus Paid Out</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RelatedPartyTransactionOptionToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Option to Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RelatedPartyTransactionOptionToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051086432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,356<span></span>
</td>
<td class="nump">$ 12,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment', window );">Additional cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Milestone Determined by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Milestone payments to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Milestone payments to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_ElancoMember', window );">Elanco | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Additional Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RevenueRemainingPerformanceObligationAdditionalCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_MilestoneDeterminedByTheCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_MilestoneDeterminedByTheCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405051199360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest', window );">End of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate', window );">End of term charge, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.66%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, First Amendment, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember', window );">Line of Credit, SVB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityDrawDownIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Draw Down Increments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityDrawDownIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Periodic Payment, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityPeriodicPaymentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityFirstAmendmentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityFirstAmendmentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405059318288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement - Summary of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense for term loan</a></td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of end of term charge</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense related to term loan</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405054066192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan, gross</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Accretion of end of term charge</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Accumulated amortization of debt issuance costs</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="nump">$ 19,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140405139790208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details)<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LesseeOperatingLeaseRemainingLeaseTermExtension', window );">Lease term extension</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseRemainingLeaseTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Remaining Lease Term, Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseRemainingLeaseTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>tars-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:tars="http://tarsusrx.com/20230331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tars-20230331.xsd" xlink:type="simple"/>
    <context id="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7cd94dd3746b44e8a0edbb9d88cbd6b6_I20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="i20710df36adc404dad2e0ed426a82823_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife6229fc8e68402f9b920eda1e0e260c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a56ba171f3b48d49d64d6e0307a3072_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibf7392f7324e42b08828f273ba9f2c0a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id97e1a9cf5d64176b102a3410a4d3b35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8211b2209a124db8ba40846a6c3b2773_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib338de9842274a3cbb24a9dc2f5a75cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib389bf866d074c89b3498200f9bad100_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96634ffd5e2b456d91f2981b30790819_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i184b2fe780564e698be7796aef221da3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff2cb096252d467081badd94de5d94ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d842f7924da4f698cc36d3101b1ff1f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32855a1e027f4f2e92ff4d299c365316_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i67692224fc6f4b78971fb14dc911e44f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c3e982e36134221a56256dedf94650e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e4728d2434f4cb3a885b91a7a39402e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20a8d5e87bdf4552b41bd69d53f4778e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c86944e64a841aeaa619bae42c25b4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida561c34d05744459e3a6ba53e5082ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d7883646fff46a8b814bffcd6ed96c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5d2356c7fef74c498e1b3064e427a7c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i88c2701f525a41e5aba1d5d4441c2fbd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iff9bfcac8dd149bfa9f2b65537c92af8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61fa110baf414adaa0600566a4e1d29a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icff1c597f3fd4a3c9576292df2860f68_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ddbaf2eacf744cf8db218d9a7266fc8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i53ea086e3521419c9e262a45add82d46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8e869641ee94a998264205f21fc8531_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9425df31da3a481584b439067cf07700_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibab9f798f0c849b6b6e313512298cd23_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3636234782064fa8a83fa7367952b887_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if4b552e3d3e6478a9f79127736c53136_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c8a90c2600d4884b61ed721cf411567_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i354a2222e5704982adaad60e04689993_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f3fb4c1d1b74fc7bb77555b5885dcfc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i144d9ee39e514d3c9f20ae2686e700bc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i826796d58f43453bbe3a4e4f0df2dade_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i00ead24808e6418abe1c6285968f2a8e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7489f1c01f4040fa9027f3139aa5b960_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i892be22603d64788b51cf55111b69eba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ed0e212cc8b4b7aa51ff422f461de73_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida739d9e492041df8abac70acd6a4018_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7494a6d8c7fb4ce19624be505d391926_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifdd774b344c242018371671a89a14ad3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad928b2f434a4f91881e16edfff1f575_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i05f154f954b443e482459e699ab62660_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idd8b670522cf45f8ab84db74558ab9c2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16ed5a6a9e3a45528f0d3c03542d3548_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if78155dab98245379b7409e98a4d0db2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id95392055c6c4c689895a8ec69851578_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f413bfd9e1344f194608ea5c75f1b14_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i37bbb85698e4468e92bffdf013a05804_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ecb831e068f4e4eba5855f83c097192_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifed529994d5a489a923621611c8dd9e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1488cc93f0044561a3bd35cf45b241cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b0256b4f7bc471698e819ba39b63c4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1dc742ef4d3f499281a5e3db27036808_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05b127b6e20648509ccfc27bc1d93571_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30727f2c96b341fe911ef415de4c348f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf5597704788449bbbcea9eba34b39aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55798f7922ed4f90b40cf890e7c58539_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fb0218825134bd9b61163220979283d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecd8a154fb694ad786f8c8da8d391a16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3631e96ef564c579622dff441e974e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0f2b2e02b4b45fea07db876890aa3d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib73e18a89cf74db4b49c5a7a82c5d5de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07b81c93d9584d62b21986ea577e3937_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe3af3744bea4434818663e6ea1800b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2171876554134f82b5a5cea826938d46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33af9a3f4c25435dae84fc4f1bab1c97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae22aa8959ba409fbcfaf7febb83d253_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id293f7748a664952b30b29710a563efc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6154a4280d4f41f784fb63374be71d6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1f86d28e0b24020a867c02990388aa1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12fdf79c65a44bde92634bea4639cc61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i844ff7c88dde44c69fc24bd464b96f11_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i02393f415335453b90d7884e68e659ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i533c566d81f044ba9eae18e652238819_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i867abfb9e1064a1ba6d0d1fa85686b18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54617256e4f143fc8a0b0c96a6a280ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i762203c8d41341b6a256214747c9a07c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61cebed72353446c84a867bf93927fcb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b89b78a42a4429a8d3f77392ce80a4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d9112849a364d638fb3efe500b2b222_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iafd02acbbe7a4774a2097f5656e5f09d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb8f8b00797641848f2b5a4b1b905ee3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie853a328a5ec41d3972f307e7901c482_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8ff25d218e04f7a9b1566f714bb8346_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9db3a5e7cdb34537b766bd622dc616b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i917bf9bfe034449b834be912de58d1fa_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i7e27f78c37544ca1b323673fc30d9a3b_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="iac59350831b24dfdacee66f79da8ab72_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="ib4149d89cf8448a9a0e2ea0b40d6ac4c_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide4416d2143c4221be97d977037586b4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i47bc68703c824e77bffd6af8ae80c0f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6729c6febce8422b827027ebc9a6d64e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a2fca5aed6f4a76b7dd655630e82a4b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95cb4582644f423d9136ef1e85e60b7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8503e32597854aa6a46c8b8515cc5b3d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i514d107167894741a8b7f284d591b2b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3558f809862443fe9aaf961e3fe46862_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i68cb6ee1927b4f99ada59e4d064573f2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0ded64e9a23d4e3ebbacb7b216bb928a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b81ae74dba9486c9d47805cc82049c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie88f78cb86a54bd88f68fd667ba9bf91_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e1f95855536428d8e7258cfd624dd7c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if0991bb1e26c40059e9714e160dcd466_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0e64247629bd49ad88f0a146a9a98bde_D20190101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2d1eebcc98854765b87cca237a5b757f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i859b21f6d2d440d78aeb12f136556886_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd840a9974534e8a86fb288669a39d26_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7122162b9e8442fb9dbe528f8bf4e6db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib6d21b9d0b1d41519dfdd05a63606147_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76624ba745b8460b9f60a3265e3b69fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i662dee756fdb482ab237e7e724a9180c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc838841c8c34d339322513ad5186477_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42809a841f17475d971438d5fe3366fb_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d5bc0dd6d674c43a5676efe1c51dae5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fdb0d02a3f4465f9adaa728283ff184_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="i4deb7fc864cf40d58681297bddbc56fc_I20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="if69314c7f4594e288ffe725501411cd7_I20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:MilestoneDeterminedByTheCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="i8637cc436fcd44d58ba1f8037dad5983_D20210326-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id7350246746e45e096c4b5c05592d2bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20fc38686769463e89dccae19d75a856_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i93d63e21c49245618766f49acefdeffc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifb291c31a4554839b5b0b66a4fe2675f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i08f0b2c2b8d64ed1aed8211167ca0c9f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9982c244cae049c2b927906df44008a4_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i5bbbc17db51145c1b3991110981ecf19_I20230105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="ic6757e8b476a41fd8f001984f0e90cab_I20230105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityFirstAmendmentTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="ib5ab2b8124224aeeaacabd23e0670fc6_D20230315-20230315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="iead63404689e4c9fb5d3dd9c7e44eb93_D20230315-20230315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib138596b65dc49378e26b8bcfa849a7c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57aedd3d329a44348c333722afc8f2da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i12dac813311e4f7c9349b2c69b102372_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea7de7306a164d21817ad5a9f76cd054_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="idde37c43b07847328ecd4970539db537_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="iefb591f932524f878ed995d1d169d6e6_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i63781028d94a4277a261f195f03cebe0_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9af35563ebb945b9a4b563b46884004c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2f5516daf64a47d4948fc6884c6bf78b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i80393f9b040b4bbdbc5232b580944b52_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>tars:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>tars:tranche</measure>
    </unit>
    <unit id="warrant">
        <measure>tars:warrant</measure>
    </unit>
    <unit id="security">
        <measure>tars:security</measure>
    </unit>
    <unit id="vote">
        <measure>tars:vote</measure>
    </unit>
    <unit id="contract">
        <measure>tars:contract</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV8yLTEtMS0xLTY2OTUx_48310a2b-0ab4-4b1d-bff6-85e2346a15a8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV8zLTEtMS0xLTY2OTUx_ce2873bc-38a4-4a94-b6a5-7f95821965b9">0001819790</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV80LTEtMS0xLTY2OTUx_ab5c0290-fabb-452b-9534-8a8e0576117a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV81LTEtMS0xLTY2OTUx_28b3ec0a-ad5e-4d82-8b03-315e61003273">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80L2ZyYWc6NThmNjE0N2NkYTgyNDk1Y2IwZTQyMjBkMmM3NDE5YWIvdGFibGU6ZDlmNTQ3YzFjMjRlNGE3N2I5Y2E0NjQ0YTk0MTA1NGUvdGFibGVyYW5nZTpkOWY1NDdjMWMyNGU0YTc3YjljYTQ2NDRhOTQxMDU0ZV82LTEtMS0xLTY2OTUx_6616b77a-3b46-474f-80e2-a4dc5f01b8c8">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i61fa110baf414adaa0600566a4e1d29a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i5ddbaf2eacf744cf8db218d9a7266fc8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i844ff7c88dde44c69fc24bd464b96f11_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyNw_8c90302e-5d65-4068-882b-93af76900292">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i867abfb9e1064a1ba6d0d1fa85686b18_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1MQ_814ddb0b-d044-4453-9608-47383f7c1878">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <tars:PostemploymentBenefitsPercentOfAnnualBonusPaidOut
      contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF85MjEvZnJhZzo0YjQwM2Y5YTU0MGY0ODJjYjhlZDg5YThjZjg5N2MxMS90YWJsZTo1ZTdlNGI0NTljOTc0NjBmOGVhNjk1ZWQzN2M3M2IzYi90YWJsZXJhbmdlOjVlN2U0YjQ1OWM5NzQ2MGY4ZWE2OTVlZDM3YzczYjNiXzAtMS0xLTEtODM2Mjg_8c970f81-ed89-4035-81d8-90895722174d"
      unitRef="number">0.3333</tars:PostemploymentBenefitsPercentOfAnnualBonusPaidOut>
    <dei:DocumentType
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUx_d4ba5aac-a5f8-45a2-8c6c-896e5ba7c582">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6Y2Q0NWFmNDBhZjQ5NGU0MmJlMDlmOTFlZjQ0NDVlMjcvdGFibGVyYW5nZTpjZDQ1YWY0MGFmNDk0ZTQyYmUwOWY5MWVmNDQ0NWUyN18wLTAtMS0xLTY2OTUx_a7dd8c85-2e31-4c5b-b960-08082d08ebb9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xMjk_e19dc56d-eeab-468f-a19f-9fb38ccf66db">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZDg4NmI3MDEwYzFhNGU4MmJjNDVmN2M1NGY4ZDY3OWIvdGFibGVyYW5nZTpkODg2YjcwMTBjMWE0ZTgyYmM0NWY3YzU0ZjhkNjc5Yl8wLTAtMS0xLTY2OTUx_f829cce6-24c7-4182-bb6b-bd07a7e1c8ee">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUy_8e6859ef-365d-4853-9771-b04ebb4f940f">001-39614</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ2_82af8ba5-75b3-4eb9-a6e2-09df1296449a">TARSUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6OTNhZmY5Y2E4N2MyNDRiMzg2ZjRmZWNkNjdlMmJkZjEvdGFibGVyYW5nZTo5M2FmZjljYTg3YzI0NGIzODZmNGZlY2Q2N2UyYmRmMV8wLTAtMS0xLTY2OTUx_24d0a5d5-2614-43c9-bf76-488fe03420ee">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6OTNhZmY5Y2E4N2MyNDRiMzg2ZjRmZWNkNjdlMmJkZjEvdGFibGVyYW5nZTo5M2FmZjljYTg3YzI0NGIzODZmNGZlY2Q2N2UyYmRmMV8wLTItMS0xLTY2OTUx_5604e237-7d5d-4bba-bb69-efd2e70d72ff">81-4717861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8wLTAtMS0xLTY2OTUx_26a75991-450d-4452-87dd-ae026474a367">15440 Laguna Canyon Road, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTAtMS0xLTY2OTUxL3RleHRyZWdpb246OTQwMmEyMDJhOWUwNDAxZWFiNmU4ZDRlODQzZmM1M2JfNA_cd0f6f62-0ef5-4e5d-8373-af7dc0d92c3c">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTAtMS0xLTY2OTUxL3RleHRyZWdpb246OTQwMmEyMDJhOWUwNDAxZWFiNmU4ZDRlODQzZmM1M2JfOA_245b9beb-7a40-4f5e-9743-678b069112fc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6ZmE3MjUyYTRmNTJhNGNlNzgzMzIxODdkNzE1MGMwMDEvdGFibGVyYW5nZTpmYTcyNTJhNGY1MmE0Y2U3ODMzMjE4N2Q3MTUwYzAwMV8xLTItMS0xLTY2OTUx_7192b4c6-5d8f-4f09-9e25-499de257760f">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ4_8a02fe19-b6d3-4547-a494-dceccc892cc6">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ3_65d3da87-cd4f-4a35-af5f-61d285601e97">409-9820</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTAtMS0xLTY2OTUx_2bc95a33-e536-4993-b0fc-4c0f1fc0fda4">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTEtMS0xLTY2OTUx_ac6097bc-8364-48e8-b865-1a4ddf207a11">TARS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6NWMwODFmYjQ0YzIyNDI4MDllYWI0OWJmOTAwZGMyMTEvdGFibGVyYW5nZTo1YzA4MWZiNDRjMjI0MjgwOWVhYjQ5YmY5MDBkYzIxMV8xLTItMS0xLTY2OTUxL3RleHRyZWdpb246MmZhMjk2ODFlZGM5NDU4ODk5Y2JhNDQyZjQ3ZDM1MGRfMzQ_c9675e55-222f-4d33-bb15-1766f81e9a98">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQz_71426472-4917-4793-a7a1-3ce501ff1e4c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ5_496e5fb4-d79c-47d1-934a-8383bd9082d0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8xLTAtMS0xLTY2OTUx_cbfac32f-c9a8-46f1-a405-893e1350a78e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8xLTQtMS0xLTY2OTUx_4e7c9658-c9af-48f7-9ddb-ac3456f2af18">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGFibGU6MDc4ODQzMjRmZDkyNDIzODk0YjVjYzVhNDljOGI5NjUvdGFibGVyYW5nZTowNzg4NDMyNGZkOTI0MjM4OTRiNWNjNWE0OWM4Yjk2NV8yLTQtMS0xLTY2OTUx_bda9497e-f2b9-4402-9330-3c2c29956da3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTUw_0680ced2-8c92-4124-aa77-78bef7d87b7a">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xOTQ1_f4d3649c-07bb-4b98-917b-365936c4f527">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7cd94dd3746b44e8a0edbb9d88cbd6b6_I20230504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xL2ZyYWc6YjUzZWIyN2YyZTM4NGExNzg4YjFmOWY2YWQxMThhNmUvdGV4dHJlZ2lvbjpiNTNlYjI3ZjJlMzg0YTE3ODhiMWY5ZjZhZDExOGE2ZV8xODYy_f023dec3-a00a-4b7a-bb4e-87664fa97985"
      unitRef="shares">26803733</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNS0xLTEtMS02Njk1MQ_2cc2dcac-d04f-4431-b039-5c1f5822c1c8"
      unitRef="usd">65997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNS0zLTEtMS02Njk1MQ_e84f2389-b301-4ea3-9115-6788009a966d"
      unitRef="usd">71660000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNy0xLTEtMS02Njk1MQ_cb3f632f-534d-4274-bddc-753c9182fe0f"
      unitRef="usd">135222000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfNy0zLTEtMS02Njk1MQ_76405fb7-2a34-4453-aeb5-4cb738f8b823"
      unitRef="usd">145366000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOC0xLTEtMS04MTUzNg_05478df5-0292-4b1d-8049-77b191cdbd14"
      unitRef="usd">2500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOC0zLTEtMS04MTUzNg_b87a36c9-2bfe-4194-9405-5d5f39b91f60"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOS0xLTEtMS02Njk1MQ_7c2a792f-53a2-4997-a35a-40564957fafb"
      unitRef="usd">418000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfOS0zLTEtMS02Njk1MQ_37282ba8-cd3f-426d-8848-492748ba9650"
      unitRef="usd">3582000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTAtMS0xLTEtNjY5NTE_81131d9f-ddf4-468e-91b0-09d4e3e24e49"
      unitRef="usd">4509000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTAtMy0xLTEtNjY5NTE_70cb851f-0b44-4eab-b8bb-276ef422d312"
      unitRef="usd">4767000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTEtMS0xLTEtNjY5NTE_fe7a49e4-ff9f-4689-a68a-23dd433c6930"
      unitRef="usd">208646000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTEtMy0xLTEtNjY5NTE_c936797b-5ffb-421e-a518-898f95a69c22"
      unitRef="usd">225375000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTItMS0xLTEtNjY5NTE_75bd4cb4-b148-473f-bd8c-1f63afe659fa"
      unitRef="usd">1193000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTItMy0xLTEtNjY5NTE_612347cf-9799-4fa2-9e67-c8a9507fea2c"
      unitRef="usd">957000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTMtMS0xLTEtNjY5NTE_887bc4ab-60bd-464b-acb9-d6fc41f23b53"
      unitRef="usd">540000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTMtMy0xLTEtNjY5NTE_98e24475-5312-4a19-bd63-de82298a5dfc"
      unitRef="usd">575000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTQtMS0xLTEtNjY5NTE_70c4c656-9786-446b-9f33-f084e9608ab7"
      unitRef="usd">306000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTQtMy0xLTEtNjY5NTE_4dabb98d-0823-4334-a5b2-3f374df6f69e"
      unitRef="usd">371000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTUtMS0xLTEtNjY5NTE_f185566f-d9fd-468f-8521-b80ffff3ceac"
      unitRef="usd">529000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTUtMy0xLTEtNjY5NTE_4858469e-b72c-48b1-8daf-50f7d85525bd"
      unitRef="usd">585000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTYtMS0xLTEtNjY5NTE_d961d1f5-0b26-470c-8fea-dcd4eac58adb"
      unitRef="usd">211214000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTYtMy0xLTEtNjY5NTE_c9d874d8-7f5e-45a5-bca1-1a41fa88bac0"
      unitRef="usd">227863000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTktMS0xLTEtNjY5NTE_ff44d029-9136-4d00-a8f9-1340f3f497ba"
      unitRef="usd">9049000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMTktMy0xLTEtNjY5NTE_b3bf5b4e-2119-4a94-bea8-2f71eb864d24"
      unitRef="usd">9910000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjAtMS0xLTEtNjY5NTE_23a86544-07be-43ef-bc5b-27e39e808c0d"
      unitRef="usd">4206000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjAtMy0xLTEtNjY5NTE_0c731f3b-f636-42cc-90ec-b4c5c3dc7ccb"
      unitRef="usd">5519000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjEtMS0xLTEtNjY5NTE_ea94e11e-ab1c-4f5e-a7c7-5583c526c3b3"
      unitRef="usd">13255000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjEtMy0xLTEtNjY5NTE_6bd98e45-35b5-4619-81fd-c606b23df9b4"
      unitRef="usd">15429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjItMS0xLTEtNjY5NTE_c780d3c7-fe26-45d5-a3a4-9499ad8a8c2e"
      unitRef="usd">24515000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjItMy0xLTEtNjY5NTE_30fc9ffd-a941-423f-8edd-2a9aecd3ff66"
      unitRef="usd">19434000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjMtMS0xLTEtNjY5NTE_5e14c633-806d-4080-b06c-f4e48fe491d4"
      unitRef="usd">40000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjMtMy0xLTEtNjY5NTE_5df973b5-dfa9-4bac-b997-83ed94ff37da"
      unitRef="usd">100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjQtMS0xLTEtNjY5NTE_a6c3d71b-d628-4517-9a5d-ce333dd432f9"
      unitRef="usd">37810000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjQtMy0xLTEtNjY5NTE_6413b796-5bc1-49c1-882e-5f49c3f9ca98"
      unitRef="usd">34963000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjUtMS0xLTEtNjY5NTE_374454e6-9f56-49c6-a932-8c5f157b32d5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjUtMy0xLTEtNjY5NTE_305c8f29-e8c9-4d78-92fe-c7b62871265f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8yMQ_19c2190b-cf04-4d20-8120-2220b9fe8cfa"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8yMQ_59fe0a18-e2ce-4406-95d2-b99cad822138"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8zNQ_00465234-2423-4038-8268-8a96e103278c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV8zNQ_1bf53a97-6759-4d70-bb64-50f540eda860"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_267973d6-35b1-411e-9833-5dc1bd9b1716"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_34ce7ea7-184a-49be-a8cc-03412fc0ad94"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_5d72218e-019e-4a52-8cc4-e16b44008521"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo2MzcyNjVmMTkxNGI0ZmRhYWE3ZjVjODI4ZDAxZGNlOV81MA_696448d1-622f-4a4b-a793-a037245babe5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMS0xLTEtNjY5NTE_34db3254-dc23-47d8-94cd-0004dae57fd3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjctMy0xLTEtNjY5NTE_96bc3c39-fb66-4330-addf-7b1612d93200"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xOA_715f3be8-225c-4430-b76a-bcafa4ddc9bf"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xOA_8f15f898-2965-4108-80e8-0f6d0a40c50e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8zMg_6c0b2016-45d7-41d4-8b34-81d763c4be13"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8zMg_f1fac91c-c3e6-452d-92ab-fafb4eec4cb1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF81NA_90ca5f3c-0e24-46d5-86d0-3ec1c689a551"
      unitRef="shares">26800512</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF81NA_a0f73516-9ec0-4520-bb1b-ec4f2008db01"
      unitRef="shares">26800512</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xMDY_68271d12-9837-4f4a-b385-87dc007e529e"
      unitRef="shares">26727458</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMC0xLTEtNjY5NTEvdGV4dHJlZ2lvbjo3NDZiZDExYWExM2E0MjNmOGUyMWE4YjFmMTIzZTIzOF8xMDY_f3633c2f-6b5a-4d61-9e58-a56d759f7757"
      unitRef="shares">26727458</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMS0xLTEtNjY5NTE_3df39f80-2902-431f-a789-5c2c0c9de694"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjgtMy0xLTEtNjY5NTE_a01c78e7-2271-4fec-a8cc-6931b8a257e6"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjktMS0xLTEtNjY5NTE_7679df40-e459-4a6a-a19d-e6db0f7581ec"
      unitRef="usd">305651000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMjktMy0xLTEtNjY5NTE_9f7c481b-b59c-4361-ac00-1858746d81e7"
      unitRef="usd">301732000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzAtMS0xLTEtNjY5NTE_10c886b6-db7e-479a-913e-1be57ef67a9b"
      unitRef="usd">-70000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzAtMy0xLTEtNjY5NTE_6e357353-3a92-42a7-aba4-68b79ee163d6"
      unitRef="usd">-74000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzEtMS0xLTEtNjY5NTE_e275293e-6665-4e33-84ac-aa10f278c4a5"
      unitRef="usd">-132182000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzEtMy0xLTEtNjY5NTE_104a57f7-c448-477a-b0d0-0e655de6a858"
      unitRef="usd">-108763000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzItMS0xLTEtNjY5NTE_0c72cb62-7e39-4aef-9797-b4b54ba5ca51"
      unitRef="usd">173404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzItMy0xLTEtNjY5NTE_42ad23d5-fd2c-4da8-8f63-799b07d55622"
      unitRef="usd">192900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzMtMS0xLTEtNjY5NTE_d7014b79-3b16-44af-a14b-5edadd0f7c5f"
      unitRef="usd">211214000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8xOS9mcmFnOjFmMjMwM2M5ZThhNjRkYmE5Y2MyY2YxYzc1MGE4OTRjL3RhYmxlOmM3ZTk2MWUzNzcwNjQ1MDlhYzFhZDU1MDE3MzQ3NmU5L3RhYmxlcmFuZ2U6YzdlOTYxZTM3NzA2NDUwOWFjMWFkNTUwMTczNDc2ZTlfMzMtMy0xLTEtNjY5NTE_cf773dfb-bb8a-4f5b-9781-0690146e9498"
      unitRef="usd">227863000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i1a56ba171f3b48d49d64d6e0307a3072_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNC01LTEtMS02Njk1MQ_aa4e43d1-df33-4b7a-bf04-045e0a1c47e2"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf7392f7324e42b08828f273ba9f2c0a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNC03LTEtMS02Njk1MQ_697d4a9b-aea6-44d2-a9ac-75135b9e23ce"
      unitRef="usd">539000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNy01LTEtMS02Njk1MQ_b46d58cd-2e7d-41b2-9236-089dd7bce262"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfNy03LTEtMS02Njk1MQ_026c50d1-b9ce-4607-bf1e-2d944b7db253"
      unitRef="usd">33000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOC01LTEtMS02Njk1MQ_f5db4dd5-1b86-43e8-983b-cc5c47e210a9"
      unitRef="usd">12356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOC03LTEtMS02Njk1MQ_ec9af996-2909-4419-8874-8ee2a80521b1"
      unitRef="usd">12081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOS01LTEtMS02Njk1MQ_7b312c1b-5e80-4d75-a21d-6d39b7d6bdf0"
      unitRef="usd">15096000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfOS03LTEtMS02Njk1MQ_1592642e-e69f-48ea-a8c3-12615ac75bd9"
      unitRef="usd">7946000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTAtNS0xLTEtNjY5NTE_f9a28f9e-0c0b-483a-9bef-b4ef43f5a155"
      unitRef="usd">27452000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTAtNy0xLTEtNjY5NTE_a294a426-fafb-4dac-81e0-56a99efcf2eb"
      unitRef="usd">20060000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTEtNS0xLTEtNjY5NTE_c6164e7b-218c-4f95-afa3-0bfd2b522f67"
      unitRef="usd">-24952000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTEtNy0xLTEtNjY5NTE_5f4a9bf6-ef3b-4852-9a2a-4307b828b5d0"
      unitRef="usd">-19521000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTMtNS0xLTEtNjY5NTE_e9fc68bf-b252-4c85-adec-5f28549325af"
      unitRef="usd">2293000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTMtNy0xLTEtNjY5NTE_2050ea2d-ede1-4c90-b0b6-f71b8749488b"
      unitRef="usd">0</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTQtNS0xLTEtNjY5NTE_c82a49a0-d2b0-4338-9ef7-7364e93dd0b3"
      unitRef="usd">684000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTQtNy0xLTEtNjY5NTE_8a365875-257d-4a0b-a88f-46ff0ee10c05"
      unitRef="usd">316000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTUtNS0xLTEtNjY5NTE_0d2c361c-0e0d-4759-a6b8-13cad0808564"
      unitRef="usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTUtNy0xLTEtNjY5NTE_3dff302d-96f1-4198-9e25-2f4621379a84"
      unitRef="usd">37000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTYtNS0xLTEtNjY5NTE_dbc3bb5a-2dfa-4273-976f-17fc3cb0ca93"
      unitRef="usd">-65000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTYtNy0xLTEtNjY5NTE_cf6b6899-dff1-4cb4-8ce6-fce00bd7763e"
      unitRef="usd">-192000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTctNS0xLTEtNjY5NTE_b0b7e373-8c6d-487c-9a00-736fd09e4c15"
      unitRef="usd">-17000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTctNy0xLTEtNjY5NTE_bf26f916-613a-4348-a660-477d2ac47cb5"
      unitRef="usd">-245000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTgtNS0xLTEtNjY5NTE_126c38e6-92d3-4bbb-b527-ab693eb6570a"
      unitRef="usd">1533000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTgtNy0xLTEtNjY5NTE_7e9a1f1b-175e-4a85-91f1-bed31b9dd0f6"
      unitRef="usd">-716000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTktNS0xLTEtNjY5NTE_4e0c0e4c-cff4-4d8a-ac84-0c936503daa0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMTktNy0xLTEtNjY5NTE_7022e640-ec7f-4d63-93d8-d60751f98b7c"
      unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjAtNS0xLTEtNjY5NTE_01f7a7bf-8d8b-4c2f-aed5-b2d6394ad908"
      unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjAtNy0xLTEtNjY5NTE_b1eafd46-cbea-48d3-958c-1dcb31b38296"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjMtNS0xLTEtNjY5NTE_c43247c9-996b-4cba-a570-5492d325e719"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjMtNy0xLTEtNjY5NTE_73d406bd-b209-47db-9075-8eaa3a4d7b85"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjQtNS0xLTEtNjY5NTE_5733be68-e16f-48e5-91a1-ce72039d6416"
      unitRef="usd">-23415000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjQtNy0xLTEtNjY5NTE_3ce441c6-eb9a-4607-93d1-54a43b71aa73"
      unitRef="usd">-20238000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjYtNS0xLTEtNjY5NTE_42f56405-3d96-4b14-8c34-5e46285d810f"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjYtNy0xLTEtNjY5NTE_8de7a5bb-48ae-4864-b0ae-de063462f43d"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjctNS0xLTEtNjY5NTE_6c3a8a9a-4422-41bc-b82f-5a345f2e532a"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjctNy0xLTEtNjY5NTE_388011a4-f20b-45ef-8adc-35df31a60db1"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjktNS0xLTEtNjY5NTE_ac7e199f-ddc3-45a6-b1a7-040e6c1177a5"
      unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMjktNy0xLTEtNjY5NTE_8cb483d7-5cb7-4da5-be03-34fafaf8eecd"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMzAtNS0xLTEtNjY5NTE_468620d0-ae07-4067-9449-7de02b6afe98"
      unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yMi9mcmFnOmI5MzMwZTRlZDZjMTQ5NmY5MGJjOTg1NjU0NGYwYjhmL3RhYmxlOmY3ZWExMzU5N2YxNzQzMDRhOTI5ZmQ2OTljZjNjNDNmL3RhYmxlcmFuZ2U6ZjdlYTEzNTk3ZjE3NDMwNGE5MjlmZDY5OWNmM2M0M2ZfMzAtNy0xLTEtNjY5NTE_6ccf02b5-4123-408e-a9a8-d5a924ee0484"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xLTEtMS02Njk1MQ_4225c28e-91c7-4b1d-8be0-8b2695475ff5"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0zLTEtMS02Njk1MQ_03a62270-6842-43a5-8a6d-8b605ef65bf2"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id97e1a9cf5d64176b102a3410a4d3b35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi01LTEtMS02Njk1MQ_cd6c43f2-e90a-4679-a3c9-8c6d690e7f9f"
      unitRef="shares">26727458</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id97e1a9cf5d64176b102a3410a4d3b35_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi03LTEtMS02Njk1MQ_9747fc93-c782-4ddc-902f-191ea236305b"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8211b2209a124db8ba40846a6c3b2773_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi05LTEtMS02Njk1MQ_f4e9e47c-d3b0-4d9b-b970-73f582dc6000"
      unitRef="usd">301732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib338de9842274a3cbb24a9dc2f5a75cf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xMS0xLTEtNjY5NTE_243102b8-44bd-4c0c-b897-084eff5f1b49"
      unitRef="usd">-74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib389bf866d074c89b3498200f9bad100_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xMy0xLTEtNjY5NTE_e0cc4991-2625-44c7-826f-a148019158b1"
      unitRef="usd">-108763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMi0xNS0xLTEtNjY5NTE_72f04ea2-db84-47a0-b46b-ada63e567d72"
      unitRef="usd">192900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i96634ffd5e2b456d91f2981b30790819_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMy0xMy0xLTEtNjY5NTE_476dbb44-48e2-40c3-ac6f-b969399ee8b4"
      unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfMy0xNS0xLTEtNjY5NTE_a49d9ae1-67b3-4c3a-b75a-630d5dff6983"
      unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNC05LTEtMS02Njk1MQ_f2082ea0-7c1b-43f9-ba15-dad47c1c640f"
      unitRef="usd">3906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNC0xNS0xLTEtNjY5NTE_d3c6d230-f225-4be2-8e02-1aa10a631247"
      unitRef="usd">3906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i184b2fe780564e698be7796aef221da3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS01LTEtMS02Njk1MQ_94bd6d9d-1145-4443-96c5-4d335f7e9d98"
      unitRef="shares">6443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2cb40af467784ffc81229fc26b8c817e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS05LTEtMS02Njk1MQ_da2b17e1-01b9-4305-a1eb-5aba8f5235e7"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNS0xNS0xLTEtNjY5NTE_ec2c4269-efe3-4957-b610-140945a67e71"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i184b2fe780564e698be7796aef221da3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNi01LTEtMS02Njk1MQ_6e941e50-75d0-4f17-88fa-1b4ddcc2a108"
      unitRef="shares">66611</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iff2cb096252d467081badd94de5d94ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNy0xMS0xLTEtNjY5NTE_d4cf39f1-342f-41b5-8894-8ebb844d4019"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfNy0xNS0xLTEtNjY5NTE_f56dc50e-9896-4027-afd7-e0eab9800ef3"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xLTEtMS02Njk1MQ_e64838b7-a9d3-4d85-aa11-72b9eefee0cd"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0zLTEtMS02Njk1MQ_e23a2a79-bb84-4ca8-a6fe-cb0ec2c639cd"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0d842f7924da4f698cc36d3101b1ff1f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC01LTEtMS02Njk1MQ_bf2c74be-e3e2-499f-8c29-da5395e90437"
      unitRef="shares">26800512</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0d842f7924da4f698cc36d3101b1ff1f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC03LTEtMS02Njk1MQ_c1061e9a-00f5-4fa1-9cfc-eadea06ba107"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32855a1e027f4f2e92ff4d299c365316_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC05LTEtMS02Njk1MQ_7e74660a-5f64-47a2-a29c-af7415803824"
      unitRef="usd">305651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67692224fc6f4b78971fb14dc911e44f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xMS0xLTEtNjY5NTE_e78588a4-5bd5-4e97-a344-42d15ae61254"
      unitRef="usd">-70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c3e982e36134221a56256dedf94650e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xMy0xLTEtNjY5NTE_6ff2dda5-8949-4a89-a1d0-3b4aa665fcc0"
      unitRef="usd">-132182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOmM5ZTc4MmY3NWRkOTQ4MjZiNjRiYzY2YjNkYmM2NzA0L3RhYmxlcmFuZ2U6YzllNzgyZjc1ZGQ5NDgyNmI2NGJjNjZiM2RiYzY3MDRfOC0xNS0xLTEtNjY5NTE_f5a38ee7-88c6-46b8-b887-06353de24fdb"
      unitRef="usd">173404000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xLTEtMS02Njk1MQ_2e57ef24-e7f7-4567-8b7c-4a968219c00a"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0zLTEtMS02Njk1MQ_cf5ec9f7-467b-44d5-98c1-d788978642aa"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e4728d2434f4cb3a885b91a7a39402e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi01LTEtMS02Njk1MQ_6b3dee49-ca2a-4b93-9c72-60cabc5e6359"
      unitRef="shares">20698737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2e4728d2434f4cb3a885b91a7a39402e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi03LTEtMS02Njk1MQ_5c8c757f-345f-46ae-997a-5a38d032ba75"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20a8d5e87bdf4552b41bd69d53f4778e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi05LTEtMS02Njk1MQ_7a1143cb-01c0-44bf-85e1-f56b6ad0669b"
      unitRef="usd">213398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c86944e64a841aeaa619bae42c25b4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xMS0xLTEtNjY5NTE_c2e8db0f-e9be-47bb-9d08-a763f1d7616d"
      unitRef="usd">-46672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMi0xMy0xLTEtNjY5NTE_b304e423-1256-49dc-8325-8c82487c05ab"
      unitRef="usd">166730000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ida561c34d05744459e3a6ba53e5082ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMy0xMS0xLTEtNjY5NTE_8370c260-d6c7-4504-a5ad-a78d68016209"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfMy0xMy0xLTEtNjY5NTE_8f0a6f80-27f4-412b-8806-5d2612fbf758"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNC05LTEtMS02Njk1MQ_213f1e0a-8574-410d-aff0-5ff680443526"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNC0xMy0xLTEtNjY5NTE_f8ef1cdf-7cf7-4f89-bf9f-512cbb8bcfb0"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNS01LTEtMS02Njk1MQ_4d6cbf89-13cf-40d1-b43f-53f245509ca7"
      unitRef="shares">225</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi01LTEtMS04MTcxNQ_5937f566-8d13-4f5a-b15d-d9bbcf976fb0"
      unitRef="shares">4257</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights
      contextRef="i5bf55752ab874c7ba8fc49578c5eef66_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi01LTEtMS02Njk1MQ_82e4ec66-4576-418a-8b15-f8978358ec4b"
      unitRef="shares">15309</tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="ieec04c9c395a4d95a045182e0b345150_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi05LTEtMS02Njk1MQ_373894d6-be1b-41e8-95b0-01b6473ba402"
      unitRef="usd">31000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNi0xMy0xLTEtNjY5NTE_5aeddbe9-fe1b-47f2-b24d-d037cf270e4c"
      unitRef="usd">31000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xLTEtMS02Njk1MQ_573f1f7d-f639-4f87-acb6-54ce3348f9e4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0zLTEtMS02Njk1MQ_7b5d4c25-a5f5-480e-b94c-d20f412c3aa5"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5d2356c7fef74c498e1b3064e427a7c3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy01LTEtMS02Njk1MQ_ba014a94-fd71-4672-bfa4-58961cc7bb25"
      unitRef="shares">20718528</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5d2356c7fef74c498e1b3064e427a7c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy03LTEtMS02Njk1MQ_bbb40c1f-a73b-4fc2-b7fb-e0475d29934d"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88c2701f525a41e5aba1d5d4441c2fbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy05LTEtMS02Njk1MQ_1a5b3d67-ea11-4673-9faa-faa306dc131a"
      unitRef="usd">216103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff9bfcac8dd149bfa9f2b65537c92af8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xMS0xLTEtNjY5NTE_946c4b88-9f2c-48a5-8c0d-3d836d86afc9"
      unitRef="usd">-66910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yNS9mcmFnOjY1ZWJjMWNkMTdkNjQxZGU4MDdmNDJlZDNmNmI2ZjZkL3RhYmxlOjkwM2VlN2M1NWQ3ODQ3NjNiN2U5ZjRlNDZkNmIzODAxL3RhYmxlcmFuZ2U6OTAzZWU3YzU1ZDc4NDc2M2I3ZTlmNGU0NmQ2YjM4MDFfNy0xMy0xLTEtNjY5NTE_eddb4306-08d0-48a1-a732-f9eb1e81619a"
      unitRef="usd">149197000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMy0xLTEtMS02Njk1MQ_9f41d87a-18fa-478a-8f9e-5a11e02579e6"
      unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMy0zLTEtMS02Njk1MQ_c6ace51a-741e-4ee7-823e-d298c9e664f3"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNS0xLTEtMS02Njk1MQ_03461dc0-10c4-407f-a0f9-d1cc97b0f7e9"
      unitRef="usd">104000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNS0zLTEtMS02Njk1MQ_4a6a2186-ed14-44f7-b3e8-17b4104f90ea"
      unitRef="usd">41000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNi0xLTEtMS02Njk1MQ_58053673-d3de-46e5-9500-9ae9b99cd263"
      unitRef="usd">81000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNi0zLTEtMS02Njk1MQ_ac2d526d-37bb-40a3-89aa-66d7a984ee30"
      unitRef="usd">55000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNy0xLTEtMS02Njk1MQ_142c7347-13cd-4d29-af50-a55779b75d57"
      unitRef="usd">3906000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNy0zLTEtMS02Njk1MQ_59a4d055-3e84-4ba9-95d4-11c49397bf75"
      unitRef="usd">2674000</us-gaap:ShareBasedCompensation>
    <tars:OperatingLeaseNoncashExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfOC0xLTEtMS02Njk1MQ_9cfc8946-f1b6-434e-9a18-ca52713e7bb7"
      unitRef="usd">151000</tars:OperatingLeaseNoncashExpense>
    <tars:OperatingLeaseNoncashExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfOC0zLTEtMS02Njk1MQ_7530d6a7-fc74-41a8-b52c-d263e4687617"
      unitRef="usd">113000</tars:OperatingLeaseNoncashExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTEtMS0xLTEtNjY5NTE_8011f8ae-967d-4113-8900-b8d1aa3aaf4b"
      unitRef="usd">-65000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTEtMy0xLTEtNjY5NTE_f154779b-47ad-4833-a197-20099b26d1ae"
      unitRef="usd">-192000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTItMS0xLTEtNjY5NTE_c0de0ee0-d975-4d67-867a-b28881eeaa83"
      unitRef="usd">1484000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTItMy0xLTEtNjY5NTE_b6066561-2e06-4036-bf4b-17602c1a85b1"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTMtMS0xLTEtNjY5NTE_9fb1cb8c-7a02-494a-8cef-2599c4aa83b3"
      unitRef="usd">-17000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTMtMy0xLTEtNjY5NTE_f3e810e9-2950-4108-98e7-8b9006123405"
      unitRef="usd">-245000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTUtMS0xLTEtNjY5NTE_1873ee3f-e4dc-44ba-84bf-717612403c9b"
      unitRef="usd">-16000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTUtMy0xLTEtNjY5NTE_f4679b38-d223-41ef-a2ac-79d0bb85f65b"
      unitRef="usd">-1000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTgtMS0xLTEtNjY5NTE_adfe12af-3b9f-40c7-aee7-f4b2d7f70792"
      unitRef="usd">2500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMTgtMy0xLTEtNjY5NTE_6c90b37d-6dd3-4203-ab0d-a40fd0d03433"
      unitRef="usd">17000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjAtMS0xLTEtNjY5NTE_b9cddd33-cbd6-4daa-8df9-61eed9473a11"
      unitRef="usd">-3165000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjAtMy0xLTEtNjY5NTE_8d6e1dfb-a44c-4ed5-ac62-d48d76da064c"
      unitRef="usd">225000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjEtMS0xLTEtNjY5NTE_4f5a0a69-4238-4c32-9325-0fd764988f13"
      unitRef="usd">-257000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjEtMy0xLTEtNjY5NTE_22d4595e-f7de-4dc8-8a29-e43bb3b83585"
      unitRef="usd">-926000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjItMS0xLTEtNjY5NTE_63e4e55c-de01-458d-b848-7a88e4ab527a"
      unitRef="usd">-38000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjItMy0xLTEtNjY5NTE_6543960e-3986-4b7e-9774-3abdff21aa4e"
      unitRef="usd">-14000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjMtMS0xLTEtNjY5NTE_582ad61d-8962-44a6-b660-57716f4ff901"
      unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjMtMy0xLTEtNjY5NTE_8a4a7842-7338-486f-8772-0035819c323b"
      unitRef="usd">1969000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjQtMS0xLTEtNjY5NTE_2201b37c-9cbc-48a3-bd66-a432090ffaae"
      unitRef="usd">-1313000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjQtMy0xLTEtNjY5NTE_6ea25003-0d68-49d1-b84a-62f55b5939a3"
      unitRef="usd">-993000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjUtMS0xLTEtNjY5NTE_a43387c9-1ae2-4d0c-b95c-7ce090a2dd45"
      unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjUtMy0xLTEtNjY5NTE_347d1a4f-a395-4021-b579-3363cf95be80"
      unitRef="usd">-43000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjYtMS0xLTEtNjY5NTE_7985c28c-ed82-4793-9876-7cb55c5abb5e"
      unitRef="usd">-21970000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjYtMy0xLTEtNjY5NTE_1e5c9545-64c3-4c28-ba94-df8c36c37f6f"
      unitRef="usd">-15286000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjktMS0xLTEtNjY5NTE_1dbd4d59-b0d5-431f-addb-09490b38c257"
      unitRef="usd">40301000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMjktMy0xLTEtNjY5NTE_06b2173c-a87f-4ca5-ae12-fcd9ef38b267"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMS0xLTEtODA0NDM_a095ecd2-f4d2-4551-8a36-934c51b0a43c"
      unitRef="usd">28667000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMy0xLTEtODA0NDM_f0eb45fd-adb1-4f4f-a3d8-684cb017f027"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMS0xLTEtNjY5NTE_a47b7ace-1a9f-4367-9bb3-3ca95e5a6e42"
      unitRef="usd">340000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzAtMy0xLTEtNjY5NTE_3a368476-99db-434a-b906-6d2467494152"
      unitRef="usd">161000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzEtMS0xLTEtNjY5NTE_e773fd4f-fb5b-47a7-8323-9f18250ccaad"
      unitRef="usd">11294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzEtMy0xLTEtNjY5NTE_79b09d1b-fc9f-4c7d-880f-ab76ac0e2856"
      unitRef="usd">-161000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMS0xLTEtNjgzNDc_c7522a27-ceb0-42da-a275-b2082332f7a3"
      unitRef="usd">13000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMy0xLTEtNjgzNDc_ca685ab7-53fa-4f95-a211-71e94c292227"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzgtMS0xLTEtNjg0MTU_e25e2195-6cd5-46b5-b597-df714eefbb1c"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzgtMy0xLTEtNjg0MTU_25dc8411-9850-4348-9973-5d4b851a0f20"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzktMS0xLTEtNjg0MjI_f5afccf2-0ef5-4f99-907c-66e6b49abe94"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzktMy0xLTEtNjg0MjI_0af79df7-d562-4636-a4c3-e37823f4f887"
      unitRef="usd">815000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <tars:PaymentsOfDeferredStockIssuanceCosts
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMS0xLTEtNjY5NTE_dac50a4b-5c1b-43a8-8614-41c9d04ca008"
      unitRef="usd">0</tars:PaymentsOfDeferredStockIssuanceCosts>
    <tars:PaymentsOfDeferredStockIssuanceCosts
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfMzYtMy0xLTEtNjY5NTE_eca49071-e14d-4661-a013-6f4616600009"
      unitRef="usd">60000</tars:PaymentsOfDeferredStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDItMS0xLTEtNjY5NTE_c473dfab-d0f4-40d6-8a6b-15b3f4b98748"
      unitRef="usd">5013000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDItMy0xLTEtNjY5NTE_1f307768-65be-4429-b2da-f542d9f0b938"
      unitRef="usd">19125000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDMtMS0xLTEtNjY5NTE_6149f366-6d30-4000-8c27-efc8f598e8cf"
      unitRef="usd">-5663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDMtMy0xLTEtNjY5NTE_cc421ae9-c28a-427a-ac05-dd71b03edf4b"
      unitRef="usd">3678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDQtMS0xLTEtNjY5NTE_8e9fc490-4196-47d0-911b-c83389b1f672"
      unitRef="usd">71660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDQtMy0xLTEtNjY5NTE_7a993087-27a2-49de-8604-e546d975737b"
      unitRef="usd">171332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDUtMS0xLTEtNjY5NTE_5e043622-741e-416e-b7a1-886f6d98dd3e"
      unitRef="usd">65997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNDUtMy0xLTEtNjY5NTE_7850014c-db76-4786-8579-0e519ef358c9"
      unitRef="usd">175010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTEtMS0xLTEtNjY5NTE_01395023-2071-493a-b64d-953c5af46783"
      unitRef="usd">116000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTEtMy0xLTEtNjY5NTE_e2967be6-ef28-4bb2-967b-b2bdaeb7fbfb"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTItMS0xLTEtNjY5NTE_91d145ca-de78-4938-a684-f8980269cd4c"
      unitRef="usd">593000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTItMy0xLTEtNjY5NTE_4df08eae-8f9c-4e96-805e-f5a5662cabd8"
      unitRef="usd">127000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTMtMS0xLTEtNjY5NTE_3a38b2b2-2623-4fe5-a418-5fe7c13c9f82"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTMtMy0xLTEtNjY5NTE_022cd54e-13e0-451e-b428-06adbe882d92"
      unitRef="usd">41000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTgtMS0xLTEtNjY5NTE_908ddd35-7564-4a5f-88be-0662e8024fc3"
      unitRef="usd">0</tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities>
    <tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8yOC9mcmFnOjQyMWRkNDU1OTAzMDQzOWQ4MTAxOTVjMGE4ZTdiYmI3L3RhYmxlOjRiNmM3OTM4NmJkMDRkMTc4MDNjY2U0NzFmMDM2ZTYzL3RhYmxlcmFuZ2U6NGI2Yzc5Mzg2YmQwNGQxNzgwM2NjZTQ3MWYwMzZlNjNfNTgtMy0xLTEtNjY5NTE_4341b296-7d6b-4acf-8bca-d184fd0ff371"
      unitRef="usd">55000</tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfNDM3NA_f4c301b3-f0c6-4e02-b6e4-4c0004abba83">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tarsus Pharmaceuticals, Inc. (&#x201c;Tarsus&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company&#x2019;s operations currently consist of its preclinical and clinical studies, corporate administration and commercial leadership supporting planned business growth. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has a limited operating history, no product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offering completed in May 2022 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;), proceeds from its out-license agreement, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Segment  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company&#x2019;s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company&#x2019;s management determined that it operates one reportable operating segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfNDM3NQ_d8ba76fd-4c12-46ae-8554-201274f92522">To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company&#x2019;s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company&#x2019;s management determined that it operates one reportable operating segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfMzU4MA_01c96ea5-365b-4eac-8a2a-0300ec507b0b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNC9mcmFnOjA2MzU4NzBmMjE1NTQwMjNhM2Y0YmYzM2JjNjY0YWUzL3RleHRyZWdpb246MDYzNTg3MGYyMTU1NDAyM2EzZjRiZjMzYmM2NjRhZTNfMzU4MA_f35442e1-db7f-44d3-8cc8-6298122d8895"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTM_e544a001-e6fb-4765-83bc-d514d8f2e352">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders&#x2019; Equity, and the interim Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s financial statements as of and for the year ended December&#160;31, 2022, reflect the Company&#x2019;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There have been no significant changes in the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2023, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;17, 2023, except as discussed below. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;(ii) Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iii) Marketable Securities and Long-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iv) Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(v) Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0"&gt;three&lt;/span&gt; to five years. Leasehold &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(vi) Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $8.1&#160;million and $15.0&#160;million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#x2019;s deposits and substantially all of SVB&#x2019;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#x201c;SVBB&#x201d;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#x2019;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#x2019;s receivership.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(vii) Revenue Recognition for Out-License Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")&#x2014; see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;(viii) Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ix) Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#x2019;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock awards granted typically have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639"&gt;one&lt;/span&gt; to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Subsequent to the IPO, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(x) Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss  per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three months ended March&#160;31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xi) Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xii) Recently Issued or Effective Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTQ_3d0d5e48-3a5d-45d0-a34e-a250fc7e1da4">Basis of Presentation&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March&#160;17, 2023.&lt;/span&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders&#x2019; Equity, and the interim Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s financial statements as of and for the year ended December&#160;31, 2022, reflect the Company&#x2019;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt; license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODY_0ecf87ae-b8bd-4b0b-a0b9-445a5394d7fa">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTU_0ff7cb9f-c300-4c0c-86ec-92e5b184626b">Marketable Securities and Long-Term Investments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations. &lt;/span&gt;Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0NA_407bac6c-d97c-4ee1-ae52-cc80787b9f5a">Fair Value Measurements&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Ng_8dd3a0b4-c4c1-4899-a654-8159f10738b8">Property and Equipment, NetProperty and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU0Nw_2af45a19-cecf-405c-9096-e8aa0f014fc0"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2023 and 2022.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icff1c597f3fd4a3c9576292df2860f68_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU1OA_736bd0e4-9202-4676-a1d3-f9a84183c241">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTY_065befe8-c772-43fe-9c65-bcacb81e0d03">Concentration of Credit Risk and Other Risks and Uncertainties&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $8.1&#160;million and $15.0&#160;million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB&#x2019;s deposits and substantially all of SVB&#x2019;s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (&#x201c;SVBB&#x201d;). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB&#x2019;s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#x2019;s receivership.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DepositsAssets
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODcwNg_4dcdc3d0-9d30-416a-ba4a-4ded0e2da082"
      unitRef="usd">8100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODcyMA_9bfd03d1-3919-4ac0-8ee5-f61ad9c7164a"
      unitRef="usd">15000000</us-gaap:DepositsAssets>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODc_1b6a6285-a102-47d7-9336-031dbe43314d">Revenue Recognition for Out-License Arrangements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")&#x2014; see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, &lt;/span&gt;&lt;/div&gt;or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODk_cdbfff3c-bdc0-427e-aa67-e051a2fa4788">Research and Development CostsResearch and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODg_842eb305-8ae2-44f1-b3aa-419bd7cd045d">Stock-Based Compensation&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#x2019;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock awards granted typically have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3OQ_70c44df0-4546-4706-98e6-e2224b359639"&gt;one&lt;/span&gt; to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Subsequent to the IPO, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.&lt;/span&gt;&lt;/div&gt;Dividend Yield &#x2014; The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU3NA_9e64487a-3e1d-499b-88f3-55b8e9233e1f"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i53ea086e3521419c9e262a45add82d46_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMwMjU5OA_b53c7dca-40ee-4f44-a920-09b4ec9a847b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id8e869641ee94a998264205f21fc8531_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjE5OTAyMzMyODc0Mg_f706a2c4-9884-41a8-8596-df3ac8ed9011">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMTkxMTQ_291e095d-709e-4850-9ace-debf139c539e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTA_9d88ccda-3fbc-455b-9edd-0ac02f7afa0d">Net Loss per Share&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss  per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three months ended March&#160;31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzOTI_f1568308-d1b8-4ef3-871a-d9add910a4c6">Comprehensive Loss Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF8zNy9mcmFnOjU4MmZhMDk4ZTQ0MjQ2YTU4M2M0OGYzNjJlNWNkMzdhL3RleHRyZWdpb246NTgyZmEwOThlNDQyNDZhNTgzYzQ4ZjM2MmU1Y2QzN2FfMjQzODU_890520a4-8a80-4acb-a621-67a1498d1c70">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyNg_00db4e77-4904-4d2b-96f7-c40e43afe635">FAIR VALUE MEASUREMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Money Market Funds and U.S. Treasury Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Paper, Corporate Debt Securities and Government-related Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LianBio Common Stock and Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, contemporaneous with the China Out-License transaction (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock as recognized at fair value within long-term investments on the Condensed Balance Sheets as of March&#160;31, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of regulatory milestone achievement for vesting, and the application of an assumed discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March&#160;31, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Four securities have a contractual maturity between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyNw_8c90302e-5d65-4068-882b-93af76900292"&gt;one&lt;/span&gt; and four years, with an estimated fair market value of $5.8&#160;million and amortized cost of $5.7&#160;million. As of December&#160;31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities have a contractual maturity between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1MQ_814ddb0b-d044-4453-9608-47383f7c1878"&gt;one&lt;/span&gt; and five years, with an estimated fair market value of $4.6&#160;million and amortized cost of $4.6&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, all available-for-sale debt securities have gross unrealized losses in a continuous loss position for less than one year. As of March&#160;31, 2023 and December&#160;31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyNw_e22f1b8a-fe85-4de8-8f63-087b0f2b03cf">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9425df31da3a481584b439067cf07700_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0xLTEtMS03ODUyMQ_46c9e842-b7c0-4162-ada2-4eec08d0d1ed"
      unitRef="usd">185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibab9f798f0c849b6b6e313512298cd23_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0zLTEtMS03ODUyMQ_3ef1c19d-ebda-47b3-bb74-077c09cad76c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3636234782064fa8a83fa7367952b887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy01LTEtMS03ODUyMQ_564538eb-ed2e-40e4-a5bd-d453b40e6309"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy03LTEtMS03ODUyMQ_47242759-7374-498d-a623-626a4737207f"
      unitRef="usd">185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c8a90c2600d4884b61ed721cf411567_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0xLTEtMS02Njk1MQ_28d0ce96-ebb7-456a-8d52-cd9b2ee2ee16"
      unitRef="usd">65812000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i354a2222e5704982adaad60e04689993_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy0zLTEtMS02Njk1MQ_6d47358d-acd2-48df-bd64-22fd1ed8db00"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f3fb4c1d1b74fc7bb77555b5885dcfc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy01LTEtMS02Njk1MQ_52c58dab-4086-40f2-a2be-a635b75fa097"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i144d9ee39e514d3c9f20ae2686e700bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMy03LTEtMS02Njk1MQ_55de26aa-ce0e-411a-9944-ddbd077618fd"
      unitRef="usd">65812000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i826796d58f43453bbe3a4e4f0df2dade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC0xLTEtMS02Njk1MQ_4346ccd7-be67-467d-a5fd-b1d6acf03e9a"
      unitRef="usd">49000000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i00ead24808e6418abe1c6285968f2a8e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC0zLTEtMS02Njk1MQ_a05fb42e-2ec3-4abe-addf-8bbbaa2e572c"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i7489f1c01f4040fa9027f3139aa5b960_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC01LTEtMS02Njk1MQ_513fa19b-79f5-4cd5-8f19-b4e8a8882ad1"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNC03LTEtMS02Njk1MQ_6389828f-5d83-451a-b363-3ec18f79b451"
      unitRef="usd">49000000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i892be22603d64788b51cf55111b69eba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS0xLTEtMS02Njk1MQ_2e8ebc04-06d2-44ab-8bfb-5eec2b30a007"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i2ed0e212cc8b4b7aa51ff422f461de73_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS0zLTEtMS02Njk1MQ_9528d293-fb60-4c53-a5e7-3baaedeb9629"
      unitRef="usd">65148000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="ida739d9e492041df8abac70acd6a4018_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS01LTEtMS02Njk1MQ_b49a9abe-f26c-4565-ae1e-7c9b6a865dce"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNS03LTEtMS02Njk1MQ_0c89eebd-3dde-4a33-bd0e-02ceeac8c795"
      unitRef="usd">65148000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="ifdd774b344c242018371671a89a14ad3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi0xLTEtMS02Njk1MQ_409085fc-6df2-4c1e-8bd1-fe1fa0732391"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="iad928b2f434a4f91881e16edfff1f575_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi0zLTEtMS02Njk1MQ_1549ef4f-6b44-4b1a-a3ba-9fab2d64bcc9"
      unitRef="usd">12777000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i05f154f954b443e482459e699ab62660_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi01LTEtMS02Njk1MQ_7ed6ce88-c05e-4fc3-9551-7bc8770e624a"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNi03LTEtMS02Njk1MQ_9f26ba85-1085-49a9-96ea-f19f4d63884b"
      unitRef="usd">12777000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="idd8b670522cf45f8ab84db74558ab9c2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0xLTEtMS02OTE5MQ_53932f95-069f-4d40-8d91-5a3a24c0318a"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i16ed5a6a9e3a45528f0d3c03542d3548_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0zLTEtMS02OTE5MQ_32c99069-a3ef-4ede-8877-e1a1edbf00c5"
      unitRef="usd">8297000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="if78155dab98245379b7409e98a4d0db2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy01LTEtMS02OTE5MQ_45288d03-37a8-4529-8390-c9c5085896e1"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy03LTEtMS02OTE5MQ_34e03dc6-15b5-496c-94a2-97639c913374"
      unitRef="usd">8297000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="id95392055c6c4c689895a8ec69851578_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0xLTEtMS02Njk1MQ_d5323b5e-25b4-445d-bbbb-aa20b9edbba4"
      unitRef="usd">306000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy0zLTEtMS02Njk1MQ_af7d3eae-f091-4c8e-8947-e734b8b12678"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy01LTEtMS02Njk1MQ_3c22c962-9d88-41a4-8434-c4baaca613f5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfNy03LTEtMS02Njk1MQ_670eff98-237a-4329-af5d-77033403fcc2"
      unitRef="usd">306000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="id95392055c6c4c689895a8ec69851578_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC0xLTEtMS02Njk1MQ_344e1540-4184-4195-8d5e-f839cfd73105"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC0zLTEtMS02Njk1MQ_e19f6155-9fef-44d7-a5c0-f5e67c618b8b"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC01LTEtMS02Njk1MQ_b7383fda-03dc-49e2-9916-d6ab59486e60"
      unitRef="usd">91000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOC03LTEtMS02Njk1MQ_d3f55986-2818-416f-8802-f860239736cb"
      unitRef="usd">91000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id95392055c6c4c689895a8ec69851578_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS0xLTEtMS02Njk1MQ_b9a9c626-41c8-43c3-87cf-0d82793fee6b"
      unitRef="usd">115303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f413bfd9e1344f194608ea5c75f1b14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS0zLTEtMS02Njk1MQ_84eb693b-233b-4c12-9e39-9b12050578cb"
      unitRef="usd">86222000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37bbb85698e4468e92bffdf013a05804_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS01LTEtMS02Njk1MQ_47681152-c3fb-4997-b5f6-77c966ac2d9c"
      unitRef="usd">91000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfOS03LTEtMS02Njk1MQ_119b7308-b2b3-497e-bc29-1d8ef29257de"
      unitRef="usd">201616000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0ecb831e068f4e4eba5855f83c097192_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtMS0xLTEtNjY5NTE_4093f8f0-bd24-4469-b809-34acb927eec5"
      unitRef="usd">64685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifed529994d5a489a923621611c8dd9e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtMy0xLTEtNjY5NTE_99f63f26-89a9-403a-ad98-cbe91a1d1ea8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1488cc93f0044561a3bd35cf45b241cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtNS0xLTEtNjY5NTE_7a20825a-20cf-4c7e-8a2e-d1a35d078e4c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTQtNy0xLTEtNjY5NTE_7a21151d-1a22-43ba-bbcb-628b1f13e439"
      unitRef="usd">64685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i1dc742ef4d3f499281a5e3db27036808_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMS0xLTEtNjkyMDE_b234f13a-5613-4668-aece-0e54c19eefce"
      unitRef="usd">69644000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i05b127b6e20648509ccfc27bc1d93571_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMy0xLTEtNjkyMDE_739f6411-2a9e-4347-bf20-ed6200815632"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i30727f2c96b341fe911ef415de4c348f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNS0xLTEtNjkyMDE_dc34e73e-42c0-4e92-9016-436658cf27c2"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNy0xLTEtNjkyMDE_70c66290-b57c-4dd2-a927-3277dc1a0c2f"
      unitRef="usd">69644000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i55798f7922ed4f90b40cf890e7c58539_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMS0xLTEtNjkyMDE_001a9cbe-4fec-4cf5-bda0-f07d8416b21f"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i9fb0218825134bd9b61163220979283d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMy0xLTEtNjkyMDE_2627830c-3837-4271-807c-984c7c87dffd"
      unitRef="usd">60355000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="iecd8a154fb694ad786f8c8da8d391a16_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNS0xLTEtNjkyMDE_49353904-81b6-434f-bcd8-dd5ba75695f0"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNy0xLTEtNjkyMDE_9ba64abe-0278-4709-8bf5-ba36aed64cb0"
      unitRef="usd">60355000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="if0f2b2e02b4b45fea07db876890aa3d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtMS0xLTEtNjkyMDE_e3243a25-f293-4c5c-a337-06311e97d335"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="ib73e18a89cf74db4b49c5a7a82c5d5de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtMy0xLTEtNjkyMDE_d55770a6-2fd9-45a7-9a5b-30167625eff8"
      unitRef="usd">11521000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i07b81c93d9584d62b21986ea577e3937_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtNS0xLTEtNjkyMDE_fb4481a0-6d43-43e0-a42e-890f373d2841"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTgtNy0xLTEtNjkyMDE_824b5ea4-f5b9-4ccb-b29a-d624314a7b81"
      unitRef="usd">11521000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i2171876554134f82b5a5cea826938d46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktMS0xLTEtNjkyMDE_4e254b9d-b0b7-4827-bf90-0f64d9d82eca"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="i33af9a3f4c25435dae84fc4f1bab1c97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktMy0xLTEtNjkyMDE_b841bf77-742e-430b-8377-e85ec471eb8d"
      unitRef="usd">10821000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="iae22aa8959ba409fbcfaf7febb83d253_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktNS0xLTEtNjkyMDE_a49c2dda-ecff-498e-b79d-3fa6b3b0a78d"
      unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTktNy0xLTEtNjkyMDE_40b06e9a-d871-45d8-bba9-a2478516d239"
      unitRef="usd">10821000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtMS0xLTEtNjY5NTE_d245bc7b-5173-4efa-b980-68d38a6d34c9"
      unitRef="usd">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtMy0xLTEtNjY5NTE_193c6a3b-39b8-4397-95f7-7b757b7b5874"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtNS0xLTEtNjY5NTE_ed66b8c6-17fa-4d0f-a985-5d5b3e2dbe8e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTUtNy0xLTEtNjY5NTE_e3a6e222-896c-4c7e-a99f-53193e773e73"
      unitRef="usd">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMS0xLTEtNjY5NTE_5721436b-95b7-4ca9-ab72-9d7f9ebadcff"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtMy0xLTEtNjY5NTE_206c1643-b961-4efb-90b3-4c2d55f92d40"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNS0xLTEtNjY5NTE_be481568-2e34-4839-b77c-f9389c7e17ae"
      unitRef="usd">108000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTYtNy0xLTEtNjY5NTE_aae0445d-94aa-4b5f-add5-7b8281bd35cd"
      unitRef="usd">108000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6154a4280d4f41f784fb63374be71d6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMS0xLTEtNjY5NTE_2682de70-7edc-4ec2-a363-a68bc2a02f73"
      unitRef="usd">134700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1f86d28e0b24020a867c02990388aa1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctMy0xLTEtNjY5NTE_a441f44b-9b6f-4ce0-9e9f-edfd70d450c1"
      unitRef="usd">82697000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12fdf79c65a44bde92634bea4639cc61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNS0xLTEtNjY5NTE_a8a48069-985a-4c2c-89a1-0d1e6c383362"
      unitRef="usd">108000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmExOTNmMzFiZDE1YjQyMDdhZmU4ZTA2Mzg3MTQ5NThjL3RhYmxlcmFuZ2U6YTE5M2YzMWJkMTViNDIwN2FmZThlMDYzODcxNDk1OGNfMTctNy0xLTEtNjY5NTE_02fed893-5968-4344-9195-fdf00ece87ac"
      unitRef="usd">217505000</us-gaap:AssetsFairValueDisclosure>
    <tars:WarrantAgreementNumberOfTranches
      contextRef="i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTEyOA_6878dc39-3a00-4c34-ae7b-0de923957657"
      unitRef="tranche">3</tars:WarrantAgreementNumberOfTranches>
    <tars:NumberOfVestedWarrants
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2Mjc2OA_ba5aa2ab-4ae7-4d85-aa2d-a0a626000689"
      unitRef="warrant">2</tars:NumberOfVestedWarrants>
    <tars:EquitySecuritiesFVNINumberOfShares
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2Mjc2MA_85c1c2c5-7916-45f5-8c52-b8fc981d4a66"
      unitRef="shares">156746</tars:EquitySecuritiesFVNINumberOfShares>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyOA_285a9734-699c-4b17-b66f-8393b0bcff0f">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfMS0xLTEtMS02Njk1MQ_241c2a62-a81d-4625-ae5e-0b27b19e2f9d"
      unitRef="usd">108000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfMy0xLTEtMS02Njk1MQ_36a313b3-b4e2-44f7-95cd-1ae11636398c"
      unitRef="usd">-17000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmQ2ZWVjZTNjY2I4MTRhM2Y4ZjMwNWNiYjgzNTViMmVlL3RhYmxlcmFuZ2U6ZDZlZWNlM2NjYjgxNGEzZjhmMzA1Y2JiODM1NWIyZWVfNC0xLTEtMS02Njk1MQ_72f45a41-34e3-4935-902b-c0aec6fbbbb8"
      unitRef="usd">91000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i146bb14301f4414c9c5b8c6fbedb27b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfMS0xLTEtMS02Njk1MQ_c27da141-ea13-43e8-9d2c-955c8c4eb7ab"
      unitRef="usd">663000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfMy0xLTEtMS02Njk1MQ_bd0c71fb-75f5-4a56-86b3-6fcd7e1827d8"
      unitRef="usd">-245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5d7883646fff46a8b814bffcd6ed96c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjRlYjhhOGIxOGU1ZTRiMDNiOGJmODFhOTgxYzQwMjk4L3RhYmxlcmFuZ2U6NGViOGE4YjE4ZTVlNGIwM2I4YmY4MWE5ODFjNDAyOThfNC0xLTEtMS02Njk1MQ_713d18b4-5d81-4f6b-9b53-f03f051c24b2"
      unitRef="usd">418000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMzEyOQ_5ecafd93-066a-4b84-b524-b4bb6cd4d98b">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy0xLTEtMS03ODQ5NQ_6bd65590-9b5c-4548-83e8-62e99f8302c9"
      unitRef="usd">185000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4b552e3d3e6478a9f79127736c53136_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy03LTEtMS03ODQ5NQ_f78329a3-ad5b-43a8-b1ad-7288d6d4e6a4"
      unitRef="usd">185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy0xLTEtMS02Njk1MQ_fb14c47d-1c8a-470b-91bf-8f783ea3e108"
      unitRef="usd">65812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMy03LTEtMS02Njk1MQ_99bb6e18-93d6-4aa5-bca3-f67f2005cb78"
      unitRef="usd">65812000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfNi0xLTEtMS02Njk1MQ_63999868-d800-4169-ad3b-c6edd49e4f79"
      unitRef="usd">65997000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfNi03LTEtMS02Njk1MQ_71978a06-5206-43f1-85c6-9f5acf5242be"
      unitRef="usd">65997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS0xLTEtMS02Njk1MQ_f5ad4d08-06c5-468c-b108-406e848b273a"
      unitRef="usd">49037000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS0zLTEtMS02Njk1MQ_e633a758-164e-45b5-b5df-6f416d06a8bf"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS01LTEtMS02Njk1MQ_1a278e55-9c17-497b-bceb-0571b2f2738c"
      unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf2c1689602145ffa7cfe46f044e0dc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfOS03LTEtMS02Njk1MQ_aede23dd-b22a-421a-ad35-0624c20baece"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtMS0xLTEtNjY5NTE_b3803539-e3c8-47d9-b9b0-6492b71af579"
      unitRef="usd">65188000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtMy0xLTEtNjY5NTE_3c319261-2cd4-4b27-bab4-25b66f4a2745"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtNS0xLTEtNjY5NTE_b1231e53-1ad3-48ce-8722-e4d53caa9c03"
      unitRef="usd">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7494a6d8c7fb4ce19624be505d391926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTAtNy0xLTEtNjY5NTE_3608e7b7-7732-4ea9-92fc-cb3a8fc8836d"
      unitRef="usd">65148000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMS0xLTEtNjkyODQ_7ed5f3b9-8ec9-40d7-a18e-7103f54cec4a"
      unitRef="usd">12773000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMy0xLTEtNjkyODQ_df049489-bc5d-488d-a73f-e2cb6be24487"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNS0xLTEtNjkyODQ_4aae7040-bfe4-4b31-8469-0fe3961a8e95"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79a5b6a31e8645f8a1689cdfd172f97b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNy0xLTEtNjkyODQ_ba5b001e-fe11-46cf-9750-97baf727bfb2"
      unitRef="usd">12777000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMS0xLTEtNjY5NTE_9dc33b52-f1e0-4fe8-bb17-fbf2f168c9bb"
      unitRef="usd">8293000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtMy0xLTEtNjY5NTE_a291950c-0319-41fe-8775-e1cd2184f0b7"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNS0xLTEtNjY5NTE_fccc1d2e-6156-41b5-b0c6-88d21c17a901"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cd78452f56c409da10b9b7aa95e5c6c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTEtNy0xLTEtNjY5NTE_706bed7e-d833-446e-9fe2-3902d7fc9f2a"
      unitRef="usd">8297000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItMS0xLTEtNjY5NTE_ff95fb69-ba61-4828-9307-f9ecb92aab3f"
      unitRef="usd">135291000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItMy0xLTEtNjY5NTE_d810a9c0-57c0-42c0-ae27-f829b049b987"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItNS0xLTEtNjY5NTE_97d605e8-d7bb-4d74-abbe-ea709824733c"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTItNy0xLTEtNjY5NTE_acad9997-18f4-476f-b8e9-80bd83a01b8b"
      unitRef="usd">135222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtMS0xLTEtNjY5NTE_570d6cd3-b532-4e52-8139-7ab011c3fa43"
      unitRef="usd">1231000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtMy0xLTEtNjY5NTE_1c302268-9210-4e0b-9990-237ddb1f1bd8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtNS0xLTEtNjY5NTE_05838f07-cbd1-4715-8cae-6eb7cc34ddc0"
      unitRef="usd">925000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTUtNy0xLTEtNjY5NTE_4e888692-16d3-4fdc-a581-2b1051a7b494"
      unitRef="usd">306000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtMS0xLTEtNjY5NTE_6c57a98d-5807-4c76-b464-a4aeee91353e"
      unitRef="usd">1231000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtMy0xLTEtNjY5NTE_1086b238-8394-48d9-9677-f10ac62a3637"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtNS0xLTEtNjY5NTE_62f84c83-0342-48c2-bf39-7d62339c7fc4"
      unitRef="usd">925000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOjZmNzFlZWE3MzEzZjRiYjBiMTg2MmU3MjU0NTczNjY5L3RhYmxlcmFuZ2U6NmY3MWVlYTczMTNmNGJiMGIxODYyZTcyNTQ1NzM2NjlfMTYtNy0xLTEtNjY5NTE_59bf1cb8-896b-4ff3-9cdf-2e50dcd1eb40"
      unitRef="usd">306000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMy0xLTEtMS02Njk1MQ_baf2ce28-a17e-4028-8243-50bf27dd52c4"
      unitRef="usd">64685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b0256b4f7bc471698e819ba39b63c4f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMy03LTEtMS02Njk1MQ_1fd75e58-f50c-4e6a-a7be-8ff9b9aa4359"
      unitRef="usd">64685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC0xLTEtMS02OTI0OQ_7b606e82-346a-493a-a868-2152eb1d1d47"
      unitRef="usd">4978000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC03LTEtMS02OTI0OQ_18f56de4-625a-4a0d-bbfe-3d62ddeac753"
      unitRef="usd">4978000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNS0xLTEtMS02OTI0OQ_8977159c-b7aa-492b-be26-8ad51e89ec1f"
      unitRef="usd">1997000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNS03LTEtMS02OTI0OQ_956ae68e-6160-4f5a-8170-8d32f08cfa01"
      unitRef="usd">1997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC0xLTEtMS02Njk1MQ_e9a907cf-8f77-4b76-8898-48bb0c11bbd9"
      unitRef="usd">71660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNC03LTEtMS02Njk1MQ_4eddb5a0-3793-42af-a50d-9aca48d468a7"
      unitRef="usd">71660000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS0xLTEtMS02OTI1Nw_a2839c9a-d06d-4c3f-92e1-d34dafa3d890"
      unitRef="usd">69720000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS0zLTEtMS02OTI1Nw_43a00a3c-7772-401d-a694-590085e5d1df"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS01LTEtMS02OTI1Nw_44a64aa8-5b13-4310-9862-50d97feca8bd"
      unitRef="usd">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf5597704788449bbbcea9eba34b39aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOS03LTEtMS02OTI1Nw_e8f12a8d-192e-4a53-96f4-6f5957cd29ee"
      unitRef="usd">69644000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtMS0xLTEtNjkyNTc_59db50d0-56e4-4c4f-8f78-d7693ca4099e"
      unitRef="usd">58358000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtMy0xLTEtNjkyNTc_31e897ee-a5a0-4032-86bf-9b7f06a16f7a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtNS0xLTEtNjkyNTc_07979a51-9123-4841-8beb-77ed75428cad"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3631e96ef564c579622dff441e974e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTAtNy0xLTEtNjkyNTc_19255677-e322-4acb-8cc6-35cff4a2d1c4"
      unitRef="usd">58358000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtMS0xLTEtNjkyNTc_009f2ad2-7b72-4c5f-bcaa-fc46cdc3cd7a"
      unitRef="usd">11524000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtMy0xLTEtNjkyNTc_833a1911-52c5-42a6-8a05-029746b2b22d"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtNS0xLTEtNjkyNTc_f236a1a8-d496-49a0-8e9d-bc8a047c3a55"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe3af3744bea4434818663e6ea1800b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTEtNy0xLTEtNjkyNTc_ac677b4b-e6da-4bfd-a250-08f16f89dee8"
      unitRef="usd">11521000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy0xLTEtMS02Njk1MQ_8aacd49a-5f15-4703-a4a0-56b180f05892"
      unitRef="usd">5838000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy0zLTEtMS02Njk1MQ_86532237-7b98-407b-9aec-b3d7b82273ae"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy01LTEtMS02Njk1MQ_84d7ccd0-d20d-4144-8168-1a7688e725a0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id293f7748a664952b30b29710a563efc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfNy03LTEtMS02Njk1MQ_2b4fd838-da8d-4827-851f-1081a5e579fd"
      unitRef="usd">5843000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC0xLTEtMS02Njk1MQ_ba6e864c-635e-40a4-acbe-1e3220b3261e"
      unitRef="usd">145440000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC0zLTEtMS02Njk1MQ_ccf04d75-0cf0-4718-b694-a7bbb0bb2560"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC01LTEtMS02Njk1MQ_9de899ab-5af0-426d-a100-d637c5612400"
      unitRef="usd">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfOC03LTEtMS02Njk1MQ_03d85b46-13e5-4e26-99ce-ad185a7fcbb7"
      unitRef="usd">145366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtMS0xLTEtNjkyNzI_1e1d32ac-acfc-4fca-b7cb-a581f9f30d60"
      unitRef="usd">1231000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtMy0xLTEtNjkyNzI_f446c52a-c8ce-49ca-ae97-4e210c689876"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtNS0xLTEtNjkyNzI_34669c40-93b5-40f3-9c44-feed00468035"
      unitRef="usd">860000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTYtNy0xLTEtNjkyNzI_fea0266e-e846-40bc-a470-dc601491f737"
      unitRef="usd">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctMS0xLTEtNjkyNzI_06627abb-d8e1-49e9-b69b-d19640b57fcc"
      unitRef="usd">1231000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctMy0xLTEtNjkyNzI_a0da8017-2041-4a7f-97a6-209214e3a764"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctNS0xLTEtNjkyNzI_0546b9bb-fdc6-4d4e-a709-8e7c157285f7"
      unitRef="usd">860000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RhYmxlOmFiMDYxYzdkZDNmNjQ4OGFiNDU2NTgxOGNmOWI4NmUxL3RhYmxlcmFuZ2U6YWIwNjFjN2RkM2Y2NDg4YWI0NTY1ODE4Y2Y5Yjg2ZTFfMTctNy0xLTEtNjkyNzI_de60fe7f-6d74-4f04-a7bd-552a68bee8d3"
      unitRef="usd">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ2MQ_e618bfc9-6cea-4c83-9f56-ab42500c1c74"
      unitRef="security">4</tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i02393f415335453b90d7884e68e659ee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjMyOA_075ea64b-0b7b-4f54-aa3a-d9a2ddf10e3b">P4Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i533c566d81f044ba9eae18e652238819_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDUyNg_0f67f7f9-5673-4a8d-87be-384c8a68c4c3"
      unitRef="usd">5800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i533c566d81f044ba9eae18e652238819_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDU0NQ_88d57da0-d9e7-413f-8b2c-597c8eea951e"
      unitRef="usd">5700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ2OQ_550f1354-0860-454e-b333-862747d01fec"
      unitRef="security">3</tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i54617256e4f143fc8a0b0c96a6a280ce_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMjE5OTAyMzI2MjM1Mg_63742686-f6b6-4673-974e-f9a51c15ad74">P5Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i762203c8d41341b6a256214747c9a07c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDQ4NA_e67d9b32-a5f3-4b13-8806-1916653dce8e"
      unitRef="usd">4600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i762203c8d41341b6a256214747c9a07c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81Mi9mcmFnOjVlZmE1OWI5Mzg2YzQ4MWJiYzBkZTRkMWUzYjE1ZjU3L3RleHRyZWdpb246NWVmYTU5YjkzODZjNDgxYmJjMGRlNGQxZTNiMTVmNTdfMTA5OTUxMTYzNDUwNw_f14a08e5-6768-4537-88ad-8a729706b90b"
      unitRef="usd">4600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyOA_4727c24a-3589-4122-804a-28378e123d2a">BALANCE SHEET ACCOUNT DETAIL&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended March 31, 2023 and 2022 was $0.1 million and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Other Accrued Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other accrued liabilities consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyNA_f63e3c9b-f2a5-4385-bf15-3c63e4df14d9">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i61cebed72353446c84a867bf93927fcb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMS0xLTEtMS02Njk1MQ_af6e0aa6-feeb-4b11-85fa-7d0467b57fda"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1b89b78a42a4429a8d3f77392ce80a4a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMS0zLTEtMS02Njk1MQ_347d56de-674d-4d2e-b8ce-e52c0e37b836"
      unitRef="usd">714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d9112849a364d638fb3efe500b2b222_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMi0xLTEtMS02Njk1MQ_21628c24-aa22-4189-b036-c5422fb85d11"
      unitRef="usd">215000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iafd02acbbe7a4774a2097f5656e5f09d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMi0zLTEtMS02Njk1MQ_e04fd966-c685-4a29-9469-debd63427ca1"
      unitRef="usd">197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibb8f8b00797641848f2b5a4b1b905ee3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMy0xLTEtMS02Njk1MQ_75852bac-69b4-4ea9-807e-f706a65c394f"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie853a328a5ec41d3972f307e7901c482_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfMy0zLTEtMS02Njk1MQ_816a8a5b-89df-4184-b96f-7a5440721784"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8ff25d218e04f7a9b1566f714bb8346_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNC0xLTEtMS02Njk1MQ_b339ac11-716a-4bd5-a8fe-5d2c378ab859"
      unitRef="usd">569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9db3a5e7cdb34537b766bd622dc616b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNC0zLTEtMS02Njk1MQ_877d59a7-3a9a-4ce4-8f11-b8801898010b"
      unitRef="usd">425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNS0xLTEtMS02Njk1MQ_e49f3b44-36ac-47bb-b049-7b0bd137ee68"
      unitRef="usd">1842000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNS0zLTEtMS02Njk1MQ_85b82105-15a0-44e3-9847-dd4d6749ebfe"
      unitRef="usd">1503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNi0xLTEtMS02Njk1MQ_12ba27e5-4cfe-4356-b098-f186595c1aa1"
      unitRef="usd">649000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNi0zLTEtMS02Njk1MQ_d0c4c518-5866-47ec-932d-79eee0128401"
      unitRef="usd">546000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNy0xLTEtMS02Njk1MQ_2cb1c2df-7902-4178-bfe5-7e26bc51236b"
      unitRef="usd">1193000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjY5MDFmZmUyZjEyZTQyY2Y5MWRlYTIxZTAxOTY0MDgyL3RhYmxlcmFuZ2U6NjkwMWZmZTJmMTJlNDJjZjkxZGVhMjFlMDE5NjQwODJfNy0zLTEtMS02Njk1MQ_7591c593-9300-4a1c-a08e-95ff75ed63da"
      unitRef="usd">957000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfODY1_103390f3-8998-4c42-a547-38c5e7dc2192"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMjE5OTAyMzI1ODA1Mg_a0de1c74-9da2-4e21-9e58-79458f4cd7fc"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RleHRyZWdpb246MDExMTdiNWNmMGQ1NDUwMGI3M2RmOWE5YTJkYzYwYjZfMTIyNg_1b5f6ac2-af40-492a-9b7e-837140b5e647">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other accrued liabilities consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMS0xLTEtMS02Njk1MQ_5a1de8ee-2208-4374-a089-acf657727c2d"
      unitRef="usd">7566000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMS0zLTEtMS02Njk1MQ_b990fb05-2f82-4d1b-936b-76cfd7f610e6"
      unitRef="usd">5269000</us-gaap:AccountsPayableTradeCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMi0xLTEtMS02OTY5NQ_c0a80a0b-bcb2-4d4b-b2ee-93034e84323d"
      unitRef="usd">542000</tars:AccruedClinicalStudiesCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMi0zLTEtMS02OTY5NQ_28f1d87e-cf1e-410f-a5f4-59b81e6f72ca"
      unitRef="usd">3691000</tars:AccruedClinicalStudiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMy0xLTEtMS02Njk1MQ_e7006865-a42d-4755-b6d3-a30cabce120e"
      unitRef="usd">703000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfMy0zLTEtMS02Njk1MQ_507f3f41-4c9c-4921-aa9f-e2670abf577c"
      unitRef="usd">721000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNi0xLTEtMS02Njk1MQ_1f461dcc-98d2-409a-90fd-4c190b64430b"
      unitRef="usd">224000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNi0zLTEtMS02Njk1MQ_a0cfdf65-c670-470b-986c-e41dce918870"
      unitRef="usd">215000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNy0xLTEtMS02Njk1MQ_7f5d88b6-6cb4-46fc-8eeb-6d514820165d"
      unitRef="usd">14000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfNy0zLTEtMS02Njk1MQ_c48da500-7be5-4e31-93b8-90f931e39385"
      unitRef="usd">14000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfOS0xLTEtMS02Njk1MQ_7061ee9e-2475-4a79-8a69-559d5d7ec10b"
      unitRef="usd">9049000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80MC9mcmFnOjAxMTE3YjVjZjBkNTQ1MDBiNzNkZjlhOWEyZGM2MGI2L3RhYmxlOjhmODE5ZTYxMmEyMTQzM2U5OWQwM2YzNGQ4YzQ1ZmZhL3RhYmxlcmFuZ2U6OGY4MTllNjEyYTIxNDMzZTk5ZDAzZjM0ZDhjNDVmZmFfOS0zLTEtMS02Njk1MQ_39937816-3f7d-4322-9e43-c180fb43e1bc"
      unitRef="usd">9910000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTE3OA_ebf82b81-0bb1-4df3-86be-abcd68df8498">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-On Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an  initial underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of additional 289,832 shares at $13.50 per share was concurrently completed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross proceeds from this offering were $79.5&#160;million (before underwriting discounts, commissions and other estimated offering expenses), resulting in net proceeds of $74.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Outstanding and Reserves for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had 26.8 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,068,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,346,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,930,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,663,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,899,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,723,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,460,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i917bf9bfe034449b834be912de58d1fa_D20220501-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDQ1OA_ba22c99f-59e2-43ab-9f00-30b3693821d6"
      unitRef="shares">5600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7e27f78c37544ca1b323673fc30d9a3b_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDUwMw_94c510e5-de20-43ae-a72b-b919ad5b8b56"
      unitRef="usdPerShare">13.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iac59350831b24dfdacee66f79da8ab72_D20220501-20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDU5NA_5a4ba64e-39a9-4203-81c8-2832a74dc7ad"
      unitRef="shares">840000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib4149d89cf8448a9a0e2ea0b40d6ac4c_D20220601-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDc2Ng_8e5175b6-1321-49a1-b928-dc33d392dbd8"
      unitRef="shares">289832</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ide4416d2143c4221be97d977037586b4_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDc4MA_1dcd61dc-f24a-4e0c-9115-b06f587cc613"
      unitRef="usdPerShare">13.50</us-gaap:SaleOfStockPricePerShare>
    <tars:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDg2OA_e4b328a0-5e5e-4ccd-b953-59d29e3a2e76"
      unitRef="usd">79500000</tars:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i03bdedb589504c0f8d1c8bf07080aad5_D20220501-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTA5OTUxMTYzMDk4NQ_7cbb183a-5f3a-4cdb-bf06-08eb36d09d67"
      unitRef="usd">74300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE4ODA2_97dcfbe2-d4b3-428d-b769-315f54dd1172"
      unitRef="shares">26800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE4ODA2_b948f31c-7fcc-40da-95a2-a0bfe9a3c1e8"
      unitRef="shares">26800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE3MTMx_5b1054ab-f1d2-4101-bade-5b989bbf2788"
      unitRef="shares">26700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfNTQ5NzU1ODE3MTMx_df551c2b-4088-4310-b3ad-befd0ae00834"
      unitRef="shares">26700000</us-gaap:CommonStockSharesIssued>
    <tars:CommonStockNumberOfVotes
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMjkx_f373f1dc-0e59-489a-a181-d9ce0ad00422"
      unitRef="vote">1</tars:CommonStockNumberOfVotes>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RleHRyZWdpb246OTBkNjA3Y2QyYjVjNDAzNDhhMGMyOGQ5YzAyY2Y3MGZfMTE3OQ_d1c6a39b-7681-4dfa-9569-4aa0e4178708">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,068,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,346,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,930,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,663,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,899,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,723,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,460,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMS0xLTEtMS02Njk1MQ_895e2e64-a9b4-4688-a591-64e9469e3fcb"
      unitRef="shares">8068595</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMS0zLTEtMS02Njk1MQ_408f4d5d-5a5e-483a-b633-46da2645c6a3"
      unitRef="shares">8346738</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMi0xLTEtMS02Njk1MQ_399d934f-d33b-44c1-b1b9-695c8436fc06"
      unitRef="shares">2930594</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMi0zLTEtMS02Njk1MQ_4cfda4ea-0c62-459c-9084-8ac9e63a6ff7"
      unitRef="shares">2663319</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMy0xLTEtMS02Njk1MQ_da0bdc20-08a9-4fd1-a2fc-1a17bd43dbdf"
      unitRef="shares">4596414</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfMy0zLTEtMS02Njk1MQ_51d94538-2dcd-4cfe-acb1-700535698063"
      unitRef="shares">3899342</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNC0xLTEtMS02Njk1MQ_1c085c6e-6cb7-469f-a476-58b5295366cb"
      unitRef="shares">1128373</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNC0zLTEtMS02Njk1MQ_a16aeb7e-fe87-4051-8082-27ba01029d7f"
      unitRef="shares">551258</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNS0xLTEtMS02Njk1MQ_09fa9596-35de-4237-833d-30e216b2a135"
      unitRef="shares">16723976</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80My9mcmFnOjkwZDYwN2NkMmI1YzQwMzQ4YTBjMjhkOWMwMmNmNzBmL3RhYmxlOmEyZDU1YzJmNDVmNTQxMmNiY2IyYWU5Y2RjNzJmNjIwL3RhYmxlcmFuZ2U6YTJkNTVjMmY0NWY1NDEyY2JjYjJhZTljZGM3MmY2MjBfNS0zLTEtMS02Njk1MQ_588c4597-62bc-45ff-874a-e7274b6c5838"
      unitRef="shares">15460657</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjI5_c051f2a4-004e-448a-97ad-e2b1e51b5f81">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,899,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,028,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested&#x2014;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,568,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there was approximately $29.8&#160;million of unrecorded compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;647,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;As of March&#160;31, 2023, there was approximately $16.8&#160;million of unrecorded compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.5 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjMw_3f4dde1c-a2d2-4fed-b080-920f775eb529">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47bc68703c824e77bffd6af8ae80c0f5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMi01LTEtMS02Njk1MQ_40aa455c-5a4f-4236-b941-82b6a4b809b9"
      unitRef="usd">1163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6729c6febce8422b827027ebc9a6d64e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMi03LTEtMS02Njk1MQ_7c116d60-86df-47ae-a681-cc51ad82aeed"
      unitRef="usd">678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a2fca5aed6f4a76b7dd655630e82a4b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMy01LTEtMS02Njk1MQ_b29dd3f8-4329-402d-8766-5a670b38f102"
      unitRef="usd">2743000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95cb4582644f423d9136ef1e85e60b7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfMy03LTEtMS02Njk1MQ_caf0a46d-3096-49bb-926e-87291e591893"
      unitRef="usd">1996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfNC01LTEtMS02Njk1MQ_4ba7861d-fa52-448b-b0e4-4c989ea31ce4"
      unitRef="usd">3906000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjE4ZjQwZjNmNDRlZTQ0NjE4NzJjNDlkMTM1ZTYwZjY2L3RhYmxlcmFuZ2U6MThmNDBmM2Y0NGVlNDQ2MTg3MmM0OWQxMzVlNjBmNjZfNC03LTEtMS02Njk1MQ_0d57066b-1e32-4cb8-b15b-b1ecca92afc2"
      unitRef="usd">2674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNA_3e53ce49-d794-46f9-a2c2-e539c4518cce">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMi0yLTEtMS04MjUzMA_ec94107c-fbc7-4604-b637-2a0f2ea144a0"
      unitRef="number">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMi00LTEtMS04MjUzMA_522ba851-756c-45da-969a-251e2689cf35"
      unitRef="number">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMy0yLTEtMS04MjUzMA_d1608c70-46d0-49fc-b100-af3af70ed682"
      unitRef="number">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfMy00LTEtMS04MjUzMA_3fa60cc3-c7e5-443a-8928-3794c2b625d7"
      unitRef="number">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNC0yLTEtMS04MjUzMA_4c98719f-9312-4b43-8015-e72a0739b01d">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNC00LTEtMS04MjUzMA_0a42475c-a470-4ab4-b672-665811851098">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNS0yLTEtMS04MjUzMA_e9724514-afbc-4153-b722-9f2e2f3a455d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNS00LTEtMS04MjUzMA_48378622-c600-4688-a981-18b70f7558ff"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNi0yLTEtMS04MjUzMA_a2c047c0-ce3a-4641-a892-511e7cb185fd"
      unitRef="usdPerShare">15.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOmU4MDAxMjEzZDBhYjQxYTVhMDgwZWMwYTFhNmI1MWEyL3RhYmxlcmFuZ2U6ZTgwMDEyMTNkMGFiNDFhNWEwODBlYzBhMWE2YjUxYTJfNi00LTEtMS04MjUzMA_c0ae970d-26e0-4313-8d69-91f3351a1927"
      unitRef="usdPerShare">19.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNQ_dd4e2f01-4a70-4c12-84e8-f82c77ce757b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,899,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,028,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested&#x2014;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,568,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of March&#160;31, 2023.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS0xLTEtMS04MjMyMQ_f32470d5-92ba-4c6b-b4c6-62e7f92ecd09"
      unitRef="shares">3899342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS0zLTEtMS04MjMyMQ_4ea0ca74-6169-4283-a607-563b555c326b"
      unitRef="usdPerShare">16.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4b780947480b4ec7a25152b3ae0a3150_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS01LTEtMS04MjMyMQ_7a654af0-4ece-4fa3-aea2-0c360a42cc4c">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMS03LTEtMS04MjMyMQ_dcb6231b-a8c4-4f5d-873e-fcbf956b754a"
      unitRef="usd">19196000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMi0xLTEtMS04MjMyMQ_305241dc-c732-416a-b67d-b82308517c72"
      unitRef="shares">728169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMi0zLTEtMS04MjMyMQ_881aae5d-024a-46af-9274-8ab09015c2f3"
      unitRef="usdPerShare">15.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMy0xLTEtMS04MjMyMQ_8913c474-df77-42f0-8156-bd8364b13d5b"
      unitRef="shares">6443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfMy0zLTEtMS04MjMyMQ_5049415e-2def-486c-8cf1-3386e07c8788"
      unitRef="usdPerShare">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNC0xLTEtMS04MjMyMQ_ecebb086-e1da-4c9e-9a71-dd585e8afef1"
      unitRef="shares">24654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNC0zLTEtMS04MjMyMQ_f9ca758e-ec28-4e60-9450-e384086100c0"
      unitRef="usdPerShare">21.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS0xLTEtMS04MjMyMQ_82f8ee3a-12c9-4c23-91b4-769d6d2c9346"
      unitRef="shares">4596414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS0zLTEtMS04MjMyMQ_b2e682b4-69f5-4eed-8ae0-88a67520b256"
      unitRef="usdPerShare">16.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS01LTEtMS04MjMyMQ_ac8252bc-341a-42a3-971c-1542b6195379">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNS03LTEtMS04MjMyMQ_35c8b8bd-fc48-496d-ad6b-2693192c4715"
      unitRef="usd">15316000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi0xLTEtMS04MjMyMQ_7082884c-2d1f-4074-bb3b-a8ff00cf88fd"
      unitRef="shares">2028011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi0zLTEtMS04MjMyMQ_cb637966-0fee-48c0-a6ea-02f093587e68"
      unitRef="usdPerShare">14.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi01LTEtMS04MjMyMQ_3e0f4937-878b-4a3b-a96e-19a6d65863dd">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNi03LTEtMS04MjMyMQ_dfa959a9-d943-4432-9849-808a3954724a"
      unitRef="usd">12045000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy0xLTEtMS04MjMyMQ_06d5090a-b169-4c05-b11d-e53bd97550e4"
      unitRef="shares">2568403</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy0zLTEtMS04MjMyMQ_1a42233c-94ff-4a17-afe6-60d5301ae343"
      unitRef="usdPerShare">18.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy01LTEtMS04MjMyMQ_bd84ba47-a22a-46c3-be33-44ce6c677eaf">P8Y9M29D</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjFlOTdlNDU4NjM1YjQ0MTU5MmJhMzU0OThhMGY1MzFjL3RhYmxlcmFuZ2U6MWU5N2U0NTg2MzViNDQxNTkyYmEzNTQ5OGEwZjUzMWNfNy03LTEtMS04MjMyMQ_700048cb-72eb-4ae3-8d65-9017a48b94ee"
      unitRef="usd">3271000</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4Mjg2_8d8825d0-0498-490c-a212-a62681db0566"
      unitRef="usd">29800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8503e32597854aa6a46c8b8515cc5b3d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzIw_5d4f1ba7-9b31-45da-a96a-ff8f85e8502b">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfMjE5OTAyMzI2MDAwNw_e1b152f3-c5b0-48d5-ab5e-c6246f4fd024">Restricted stock unit activity during the three months ended March 31, 2023 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;647,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i514d107167894741a8b7f284d591b2b0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMS0yLTEtMS04MjQwMA_698d3245-521f-4c05-8a3f-6062be64dfb0"
      unitRef="shares">551258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i514d107167894741a8b7f284d591b2b0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMS00LTEtMS04MjQwMA_efdbdc4f-4616-4975-96e3-f3f99fc9b5d9"
      unitRef="usdPerShare">17.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMi0yLTEtMS04MjQwMA_ecc7594e-4141-4cf4-94b0-a1e07b2b9ad9"
      unitRef="shares">647768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMi00LTEtMS04MjQwMA_308398bc-4dcf-4e37-b2ff-5f9840d5a1a3"
      unitRef="usdPerShare">15.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMy0yLTEtMS04MjQwMA_5cdfc6ff-6238-4d04-88aa-54e6590c599d"
      unitRef="shares">66611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfMy00LTEtMS04MjQwMA_56acb146-d5fe-4e44-8f75-142adc412027"
      unitRef="usdPerShare">19.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNC0yLTEtMS04MjQwMA_d795517c-6883-4344-9455-50fe83394c75"
      unitRef="shares">4042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNC00LTEtMS04MjQwMA_73c92fde-c773-4266-a2e5-db10723c0609"
      unitRef="usdPerShare">19.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNS0yLTEtMS04MjQwMA_fe473699-fcc0-4f56-8fe2-8863267a6358"
      unitRef="shares">1128373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RhYmxlOjVkYmUxYTk0Yzc2MzRjYjlhMDA3YzJkNTA4MDQ4MzJiL3RhYmxlcmFuZ2U6NWRiZTFhOTRjNzYzNGNiOWEwMDdjMmQ1MDgwNDgzMmJfNS00LTEtMS04MjQwMA_2035e6f9-e239-4a68-81f4-1a656dc0993d"
      unitRef="usdPerShare">16.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i3558f809862443fe9aaf961e3fe46862_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzA1_f034d1b1-6643-42c9-a6b2-e1b3bdddff23"
      unitRef="usd">16800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i12575a1150b347c085aa996e5a3d2e78_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80Ni9mcmFnOjllYTA2MGQ5NzU1NTQ5ZTBiY2FlYTFmNzk3MWY3OGJjL3RleHRyZWdpb246OWVhMDYwZDk3NTU1NDllMGJjYWVhMWY3OTcxZjc4YmNfNTQ5NzU1ODE4MzMz_80ec5ddb-6abb-441d-9ba7-fbb4ac0d1960">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDA2_ce9b38e9-afaa-40e7-b5df-f2a3fadaddbd">NET LOSS PER SHARE&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,742,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options exercised prior to vesting&#x2014; remaining unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,724,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDAz_c722b0f5-b623-467b-a851-d854ee345fb5">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,742,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfMy01LTEtMS02Njk1MQ_fdc71e83-a940-4584-a433-63f96c290c57"
      unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfMy03LTEtMS02Njk1MQ_8514c88b-c44e-4267-b2af-c28243183e5a"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC01LTEtMS02Njk1MQ_a77ce0ed-98e4-45ae-91b2-38eea7fc43f5"
      unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC01LTEtMS02Njk1MQ_f03200f5-b735-4dc8-b206-0854392918e0"
      unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC03LTEtMS02Njk1MQ_6ee8f735-49fc-4282-9758-397f1aa86a7c"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNC03LTEtMS02Njk1MQ_890e09c7-e1e7-4ab8-a1e0-21bd517337e0"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS01LTEtMS02Njk1MQ_d87b9876-305e-445c-b58d-6bfe40d86635"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS01LTEtMS02Njk1MQ_edf5e02d-854d-4360-bf13-432f6a11b3c6"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS03LTEtMS02Njk1MQ_5a418156-65b9-4a9e-adf3-5c1419319887"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOjU2ZDdhOTIwMWYzNzQzN2VhMjdhZGZlNzdjMzg1YTc0L3RhYmxlcmFuZ2U6NTZkN2E5MjAxZjM3NDM3ZWEyN2FkZmU3N2MzODVhNzRfNS03LTEtMS02Njk1MQ_9f17b9a8-3620-453c-8bf9-8a0a6be5d2ab"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RleHRyZWdpb246ZDk0NTUwYjU3MWQyNDcwNGI4MDYwNmI1MTkzOTc5MTJfNDA0_fc033449-51e4-4758-8544-49058822dfe2">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options exercised prior to vesting&#x2014; remaining unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,724,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68cb6ee1927b4f99ada59e4d064573f2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMi01LTEtMS02Njk1MQ_990991af-75ae-4bda-9426-e3a9637bdec0"
      unitRef="shares">4596414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ded64e9a23d4e3ebbacb7b216bb928a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMi03LTEtMS02Njk1MQ_0de931eb-8196-4edb-9cc3-722b1d61d300"
      unitRef="shares">3561261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5b81ae74dba9486c9d47805cc82049c8_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy01LTEtMS03MTM5Nw_0ed69497-0304-4663-b657-eeda1bbb2c2c"
      unitRef="shares">1128373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie88f78cb86a54bd88f68fd667ba9bf91_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy03LTEtMS03MTM5Nw_4cb1bc6a-bd3b-446a-acfd-7d938d7296ec"
      unitRef="shares">351422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e1f95855536428d8e7258cfd624dd7c_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy01LTEtMS02Njk1MQ_b6ee0282-0c6d-4de8-accd-e16d6f53bfa1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if0991bb1e26c40059e9714e160dcd466_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfMy03LTEtMS02Njk1MQ_a09d635d-4740-4c3f-999e-e4f6708562e5"
      unitRef="shares">12531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfNS01LTEtMS02Njk1MQ_f8fe3128-d67b-4aae-99f8-adef0a26c372"
      unitRef="shares">5724787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF80OS9mcmFnOmQ5NDU1MGI1NzFkMjQ3MDRiODA2MDZiNTE5Mzk3OTEyL3RhYmxlOmQ5ZjUyZDhjODFlODQzZWU5OTBjNGM4Y2E2NTNmODVjL3RhYmxlcmFuZ2U6ZDlmNTJkOGM4MWU4NDNlZTk5MGM0YzhjYTY1M2Y4NWNfNS03LTEtMS02Njk1MQ_cfe89a74-6c02-4bf6-b72c-1e4c8dadbf14"
      unitRef="shares">3925214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNzk4Mw_3e82c049-7e5d-4412-be0e-de01591a9e81">COMMITMENTS&#160;&amp;amp; CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;In-License Agreements for Lotilaner&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;January 2019 Agreement for Skin and Eye Disease or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#x201c;Elanco&#x201d;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0&#160;million upfront upon contract execution in January 2019 and a total of $3.0&#160;million for two specified clinical milestone achievements in September 2020 and April 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone of $1.0&#160;million was included in research and development expense on the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2023. The milestone achievement fully offset a $0.6&#160;million remaining prepayment and $0.4&#160;million was recognized in accounts payable and other accrued liabilities on the accompanying Condensed Balance Sheets as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March&#160;31, 2023, the Company is obligated to make further cash payments to Elanco of $2.4 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $79.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;September 2020 Agreement for All Other Diseases or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a preexisting consulting agreement with a board member that was appointed in December 2021. This consulting agreement provides for annual cash compensation of approximately $0.2&#160;million and option grants to purchase 45,134 shares of the Company&#x2019;s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This consulting agreement may be terminated by either party with ten days notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2023, the Company entered into a separation and severance agreement with its former Chief Financial Officer, which provides for the following benefits effective upon and after June 15, 2023: severance payments equal to nine months of base salary and 10 months of company-paid continued benefits coverage, a lump sum bonus payment payable in 2024 equal to one-third of the former Chief Financial Officer's 2023 annual target bonus adjusted based on the 2023 Company performance score,  accelerated vesting of options in 40,744 shares of the Company&#x2019;s common stock, and an option exercise &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period extension for certain options, in exchange for a release and waiver of claims and continued compliance with his confidentiality obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnities and Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODMyNTQz_08c93b81-11af-4cec-b059-84d9071d6245"
      unitRef="usd">1000000</tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment
      contextRef="i0e64247629bd49ad88f0a146a9a98bde_D20190101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODMyODA5_15c62973-db81-4e3f-b147-061092631c24"
      unitRef="usd">3000000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment
      contextRef="i2d1eebcc98854765b87cca237a5b757f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzMjA3_94f6567f-5994-468e-b1b7-8fd766f7c6dc"
      unitRef="usd">1000000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementRightsAndObligationsRemainingPrepayment
      contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzNDEx_18064412-a30c-41ac-8b23-511e93360b9b"
      unitRef="usd">-600000</tars:CollaborativeArrangementRightsAndObligationsRemainingPrepayment>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQzNDQw_d65ea3e3-e41e-4c3c-85f8-507a7d80e2a1"
      unitRef="usd">400000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <tars:CollaborativeArrangementFutureCashPayments
      contextRef="i859b21f6d2d440d78aeb12f136556886_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQxMzgz_dcc0758c-82c6-4684-850c-ac4116ab4d3a"
      unitRef="usd">2400000</tars:CollaborativeArrangementFutureCashPayments>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="ifd840a9974534e8a86fb288669a39d26_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODM0Mzc5_e5a8dec0-3781-4331-a283-c48306f83567"
      unitRef="usd">79000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTE1Ng_a890570d-cb34-4e61-b8b0-1460838b69ae"
      unitRef="shares">222460</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i16e987985ddd4de8a1c0dcbb9c401c64_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTI3NA_941ee0bd-c22f-40c3-af61-801d4e9ad8df"
      unitRef="usd">3100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice
      contextRef="i7122162b9e8442fb9dbe528f8bf4e6db_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTI3OA_301f917a-135c-4e6c-af0e-87b0009aabbb"
      unitRef="usdPerShare">14.0003</us-gaap:SharePrice>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment
      contextRef="ib6d21b9d0b1d41519dfdd05a63606147_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMjY0_11e33250-1807-4302-8613-4bdb3c6af9b3"
      unitRef="usd">500000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i76624ba745b8460b9f60a3265e3b69fc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMTA0_82f90eda-8083-44f7-98a7-3c2ea1562408"
      unitRef="usd">4000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i662dee756fdb482ab237e7e724a9180c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfNTQ5NzU1ODQwMjE3_1cfa5dc2-f818-449e-b699-8979df0b6a2b"
      unitRef="usd">77000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:NumberOfEmploymentArrangementsWithExecutiveOfficers
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMxMDg2OA_2e4b8b1c-2ba2-403f-982a-10b55ab7ce6f"
      unitRef="contract">7</tars:NumberOfEmploymentArrangementsWithExecutiveOfficers>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="ifc838841c8c34d339322513ad5186477_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzEzNA_61e55797-2d0b-410c-abae-f5b9bb110384"
      unitRef="usd">200000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <tars:RelatedPartyTransactionOptionToPurchaseShares
      contextRef="i42809a841f17475d971438d5fe3366fb_D20211231-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE2Mw_76d3af9a-bc30-4f95-90c1-68575bb2808a"
      unitRef="shares">45134</tars:RelatedPartyTransactionOptionToPurchaseShares>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7d5bc0dd6d674c43a5676efe1c51dae5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE0OA_0b7e24da-eff5-4355-9242-6a4e64b580d1"
      unitRef="usdPerShare">2.01</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7fdb0d02a3f4465f9adaa728283ff184_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzI4MzE1NQ_dde9460b-742f-4809-a805-27a7e2749e94"
      unitRef="usdPerShare">34.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <tars:PostemploymentBenefitsDurationOfBaseSalarySeverancePayments
      contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODcxNw_71df504f-56c1-4fbd-a7ac-79453653bced">P9M</tars:PostemploymentBenefitsDurationOfBaseSalarySeverancePayments>
    <tars:PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage
      contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODcxOA_4882864b-9f53-414c-87ec-e90daedb2e9f">P10M</tars:PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="iec8d04e7eb784f03b78366354ece2a2d_D20230504-20230504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81NS9mcmFnOmU5M2QxN2I0NDU5ZDRkMjFiMGQxMzdlMWJkODk2ZWQ4L3RleHRyZWdpb246ZTkzZDE3YjQ0NTlkNGQyMWIwZDEzN2UxYmQ4OTZlZDhfMjE5OTAyMzMwODY5Mg_9fb8b6b4-34c3-4ea2-8160-2f463b53dbee"
      unitRef="shares">40744</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMTkzNg_554af217-543c-4f21-ae2f-dcab3e999913">OUT-LICENSE AGREEMENT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License of TP-03 Commercial Rights in the China Territory in March 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 26, 2021, the Company entered into The China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company assessed this arrangement in accordance with ASC 606 and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory, and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0&#160;million, (ii) a second cash payment of $10.0&#160;million, (iii) a $10.0&#160;million milestone that was determined to be within the control of the Company, and (iv) $1.2&#160;million representing the initial fair value of the equity warrant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company accounted for each performance obligation as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Out-License&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Services &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In February 2023, a specified milestone event was triggered resulting in $2.5&#160;million recognized as license fees and collaboration revenue in the Condensed Statements of Operations for the three months ended March&#160;31, 2023. This cash payment was received in the second quarter of 2023. Through March&#160;31, 2023, the Company had received payments from LianBio totaling $80.0&#160;million, comprised of initial consideration of $15.0&#160;million and $65.0&#160;million for the achievement of specified milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestone and one-time payments of up to an aggregate of $25.0&#160;million (including the $2.5&#160;million cash payment received in the second quarter of 2023), (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0&#160;million, (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales, and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss relates to the satisfaction of performance obligations including (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the completion of U.S. clinical activities and then providing LianBio with the related data to supplement its local pivotal trial package for TP-03 in the treatment of Demodex blepharitis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company made a contractual payment in the amount of $2.5&#160;million to Elanco following the receipt of $25&#160;million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4&#160;million of cost of license fees and collaboration revenue upon receipt of $10&#160;million of cash proceeds from LianBio for the achievement of a clinical development milestone.&lt;/span&gt;&lt;/div&gt;The expenses recognized under the China-Out License were not material for the three month periods ended March 31, 2023 and 2022.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTExMA_6338e673-f513-4ad0-8361-5f1ca694f1f1"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiability>
    <tars:RevenueRemainingPerformanceObligationAdditionalCashPayment
      contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA2Ng_fd18e552-95f3-4cfd-8dbe-d29f9bdc3028"
      unitRef="usd">10000000</tars:RevenueRemainingPerformanceObligationAdditionalCashPayment>
    <tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="if69314c7f4594e288ffe725501411cd7_I20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA4MQ_362af494-8277-46c5-99f2-feacf19ef9b8"
      unitRef="usd">10000000</tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i4deb7fc864cf40d58681297bddbc56fc_I20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTA5Ng_335c10f1-4f31-482e-9925-fba1531076e0"
      unitRef="usd">1200000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NTQ5_a04aa0b7-b019-461f-9697-2341c1296e77"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8637cc436fcd44d58ba1f8037dad5983_D20210326-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTkw_40269d31-bf96-44db-84dc-9d6074fd09c8"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id7350246746e45e096c4b5c05592d2bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NDc1_b1ab55b5-2052-40fb-8e55-16cca389f634"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiability>
    <tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODI5NTE0_c2ba87f2-58e3-4e79-ab76-1b833093205e"
      unitRef="usd">65000000</tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="iaf97cfe62ca84c60a72f0201b537a3e2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfOTEx_b8d9ec27-8b41-411f-878e-631b89dfce31"
      unitRef="usd">25000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccf21b9984ce48b9af4dd06ae5b531eb_D20230201-20230228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI3MTEyNQ_c6209683-b26e-4cf0-85d8-86635a3514d1"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="id7350246746e45e096c4b5c05592d2bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMTA5MQ_447139b1-2a65-4094-914d-aac1913f4e47"
      unitRef="usd">100000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices
      contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzMjA3_02a2fa2b-a376-48a7-aca1-417766dc6123"
      unitRef="shares">187500</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices
      contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzNDQx_af3ef857-c04c-42cf-982b-c0d5575890be"
      unitRef="usd">5500000</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices
      contextRef="i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfNTQ5NzU1ODMzNDky_5ee0561c-4135-4e96-b79c-0b65e2a70cf0"
      unitRef="usdPerShare">29.30</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices>
    <tars:UpfrontPayment
      contextRef="i20fc38686769463e89dccae19d75a856_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ2NA_d47c614b-1692-4c17-9f28-7092991eeba0"
      unitRef="usd">2500000</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="i93d63e21c49245618766f49acefdeffc_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ3OA_b3837877-cf3a-4cd0-8177-59169bdbd6b6"
      unitRef="usd">25000000</tars:UpfrontPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifb291c31a4554839b5b0b66a4fe2675f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTQ5MQ_eedf8a70-8d12-45d6-acdb-1e5fc9bd270d"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <tars:UpfrontPayment
      contextRef="i08f0b2c2b8d64ed1aed8211167ca0c9f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF81OC9mcmFnOjhlMTUyNzY2NTlmYjQ3NjdhNGUzNzY5ODJhYTgwYzQ5L3RleHRyZWdpb246OGUxNTI3NjY1OWZiNDc2N2E0ZTM3Njk4MmFhODBjNDlfMjE5OTAyMzI4MTUwNQ_0511d698-ed06-4fd7-ae1e-ecbc571b162f"
      unitRef="usd">10000000</tars:UpfrontPayment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMQ_0f7f78ed-636b-4779-a35a-592a82259979">CREDIT FACILITY AGREEMENT&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0&#160;million draw.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0&#160;million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0&#160;million was drawn on or before March 15, 2023 and at least an additional $5&#160;million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 15, 2023, the Company made a $5.0&#160;million draw (including SVB's commitment of $1.25&#160;million) from the $25.0&#160;million tranche that became available upon submission of the NDA. As of March&#160;31, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $130.0&#160;million with tranched availability as follows: $20.0&#160;million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022, $35.0&#160;million available upon FDA approval of TP-03, $50.0&#160;million available upon achievement of product net revenue thresholds, and $25.0&#160;million available upon lender approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.00% as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.2 million was derived by multiplying 4.75% by the $25.0&#160;million outstanding principal balance as of March&#160;31, 2023 and is accreted to interest expense through maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of March&#160;31, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 12.12% and 9.66%, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization as of March&#160;31, 2023 and December&#160;31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i9982c244cae049c2b927906df44008a4_D20220202-20220202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODExOQ_f87f03e1-2e89-438c-b0fc-915d74bc25b7"
      unitRef="usd">20000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5bbbc17db51145c1b3991110981ecf19_I20230105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODEzNA_f3d569ff-6720-4f10-a4d8-bf0775ca1a68"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements
      contextRef="ic6757e8b476a41fd8f001984f0e90cab_I20230105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE0OQ_b7cff1ff-287b-4be5-abac-aadb3de4dc2f"
      unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <tars:LineOfCreditFacilityDrawDownIncrements
      contextRef="ic6757e8b476a41fd8f001984f0e90cab_I20230105"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI4MTIyNg_510cb86e-8880-44fd-ad6b-9d0dc62768db"
      unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ib5ab2b8124224aeeaacabd23e0670fc6_D20230315-20230315"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE5Mw_44631f35-76d0-4650-86f7-f1582e9fdbaa"
      unitRef="usd">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="iead63404689e4c9fb5d3dd9c7e44eb93_D20230315-20230315"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE3OA_3278eb15-dba3-411a-9309-efc2acbeda50"
      unitRef="usd">1250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5bbbc17db51145c1b3991110981ecf19_I20230105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjE5OTAyMzI3ODE2Mw_64047ee2-031e-4dbc-b4b8-c619552a92c6"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1ODc5_d1d094d6-7ebd-48a1-8cfb-f5a1033e940e"
      unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib138596b65dc49378e26b8bcfa849a7c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTE1_437a2476-df78-4d5a-a80e-4e6582e07405"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i57aedd3d329a44348c333722afc8f2da_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTQ5_2d3b9eeb-28c8-42a5-95c6-5679cc2c8582"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i12dac813311e4f7c9349b2c69b102372_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI1OTgz_7ddb0457-6d22-445c-910e-1dab3f956299"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iea7de7306a164d21817ad5a9f76cd054_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI2MDE3_3b67b219-661b-48a9-a789-be408f705974"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements
      contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTk0_939649cf-feed-4a41-b24c-f3c8f480eb64"
      unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idde37c43b07847328ecd4970539db537_D20220202-20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMTc2_ecc4e645-2ff6-4a54-b5cf-30d3756586fc"
      unitRef="number">0.0445</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iefb591f932524f878ed995d1d169d6e6_D20220202-20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMTk4_72a2c7d3-d735-463d-84b3-e16a43153387"
      unitRef="number">0.1145</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODMwMjAy_585a2dd1-4425-4383-a404-54af880ab5cc"
      unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i9982c244cae049c2b927906df44008a4_D20220202-20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTIxOA_be8e17c8-f04c-4d58-9c46-68a2a4d13a8a"
      unitRef="number">0.0325</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i63781028d94a4277a261f195f03cebe0_D20220930-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTI2NQ_4fcf10ae-7204-4627-b7c0-76fb8ddc2ed7"
      unitRef="number">0.0800</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentInterest
      contextRef="i9af35563ebb945b9a4b563b46884004c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTU0MA_40bed852-4f64-4d5f-9de6-105bd90158ef"
      unitRef="usd">1200000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
    <tars:LineOfCreditFacilityPeriodicPaymentInterestRate
      contextRef="i5a9ac178deb9497b9d90d4a4e28e9570_I20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMTYxMA_0d093cae-1701-48e3-887d-60d99e8ee3ad"
      unitRef="number">0.0475</tars:LineOfCreditFacilityPeriodicPaymentInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODM2OTA0_a6652ad4-c43a-4ee1-b632-3432100b8fb0"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i02c235ffc9cd4f13aed7b2acbb556ebc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI5Njg0_099a9e94-90e3-4118-9041-f1ccb8714556"
      unitRef="number">0.1212</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2f5516daf64a47d4948fc6884c6bf78b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfNTQ5NzU1ODI5Njk0_51442d25-7de9-47ed-b81b-75bcc5294ec6"
      unitRef="number">0.0966</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMg_6169de50-302c-4786-9955-e0162c3bf4df">&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMS0xLTEtMS02Njk1MQ_73ea9813-ef09-40c0-b843-a263dded0963"
      unitRef="usd">602000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMS0zLTEtMS02Njk1MQ_39f0f97b-f2fb-4982-8cc3-05ae2c98deef"
      unitRef="usd">274000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMi0xLTEtMS02Njk1MQ_7028e32d-82a8-4ac9-87fb-d16aa1d06fa0"
      unitRef="usd">53000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMi0zLTEtMS02Njk1MQ_f3c0164c-07e1-492e-8e47-4fdd36d7f1ec"
      unitRef="usd">32000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMy0xLTEtMS02Njk1MQ_66467b24-4a3a-415e-b96f-caf6c9aca959"
      unitRef="usd">29000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfMy0zLTEtMS02Njk1MQ_882de72d-7c07-4398-8f79-273cf6c4e327"
      unitRef="usd">23000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfNC0xLTEtMS02Njk1MQ_efee62a7-09a9-453c-8a82-d8df9709006f"
      unitRef="usd">684000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i72a26a95ce8a47b1987095b563bb3706_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjljMWVmOTUxM2VlMDQzMmJiOWY4YmQ0YmFmMWE0MDhlL3RhYmxlcmFuZ2U6OWMxZWY5NTEzZWUwNDMyYmI5ZjhiZDRiYWYxYTQwOGVfNC0zLTEtMS02Njk1MQ_a32d6690-d80d-4410-85a9-d7dacde7f7d0"
      unitRef="usd">329000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RleHRyZWdpb246MzE3ZjQ0MzBlM2ZiNDI2ZGIxZDI5MWE3NDQ0MjU2ZWFfMjcyMA_b38a122c-2428-4d47-8d54-94fb73e7a270">The principal balance of this Credit Facility and related accretion and amortization as of March&#160;31, 2023 and December&#160;31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMS0xLTEtMS02Njk1MQ_a6652ad4-c43a-4ee1-b632-3432100b8fb0"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMS0zLTEtMS03MTAxMQ_d117ce95-50f4-4dc8-966b-8dca8227efe8"
      unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMi0xLTEtMS02Njk1MQ_e89b4af0-a0cf-4046-a1ba-b0cf772553bd"
      unitRef="usd">875000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMi0zLTEtMS03MTAxMQ_31632d73-8424-4d9d-9556-60d562549f0b"
      unitRef="usd">875000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMy0xLTEtMS02Njk1MQ_a1e95aa0-016d-44fd-8199-4fbd64454d15"
      unitRef="usd">-226000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfMy0zLTEtMS03MTAxMQ_7ee6c600-e487-40a0-afc8-e42f8df554d9"
      unitRef="usd">-174000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNC0xLTEtMS02Njk1MQ_2819b6b7-5911-4c87-a93d-e63da4c54237"
      unitRef="usd">164000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNC0zLTEtMS03MTAxMQ_ebb8321d-90e3-4879-9242-9c97b0abf8e0"
      unitRef="usd">135000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:LongTermDebt
      contextRef="i20710df36adc404dad2e0ed426a82823_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNS0xLTEtMS02Njk1MQ_c851b001-8a61-4794-8106-fe29ad77a7b3"
      unitRef="usd">24515000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ife6229fc8e68402f9b920eda1e0e260c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF82MS9mcmFnOjMxN2Y0NDMwZTNmYjQyNmRiMWQyOTFhNzQ0NDI1NmVhL3RhYmxlOjgzZWQ0YjExZDk4YjQ2M2E4NmUxNWU0ZTliNTQwZTE1L3RhYmxlcmFuZ2U6ODNlZDRiMTFkOThiNDYzYTg2ZTE1ZTRlOWI1NDBlMTVfNS0zLTEtMS03MTAxMQ_f6ae9249-d814-43a8-ace4-4bfd008101ff"
      unitRef="usd">19434000</us-gaap:LongTermDebt>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF84OTAvZnJhZzplNzQ4NDM0OWIxYmE0ZmZlYWY5MTc4NDVhYjg0ZmJkYi90ZXh0cmVnaW9uOmU3NDg0MzQ5YjFiYTRmZmVhZjkxNzg0NWFiODRmYmRiXzIxOTkwMjMyNTU2OTc_cfc81a94-68d1-40fd-8796-e0b3d9177527">SUBSEQUENT EVENTOn May 2, 2023 the Company amended the existing facilities lease, extending the term for three years through January 31, 2027.</us-gaap:SubsequentEventsTextBlock>
    <tars:LesseeOperatingLeaseRemainingLeaseTermExtension
      contextRef="i80393f9b040b4bbdbc5232b580944b52_I20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3NzllZGRlOWRjOTRjNTViYjdjZDhkMWY2ZjUyMjRkL3NlYzoyNzc5ZWRkZTlkYzk0YzU1YmI3Y2Q4ZDFmNmY1MjI0ZF84OTAvZnJhZzplNzQ4NDM0OWIxYmE0ZmZlYWY5MTc4NDVhYjg0ZmJkYi90ZXh0cmVnaW9uOmU3NDg0MzQ5YjFiYTRmZmVhZjkxNzg0NWFiODRmYmRiXzU0OTc1NTgxNDAwNA_d2babe77-b257-4c85-b519-199dde0bb085">P3Y</tars:LesseeOperatingLeaseRemainingLeaseTermExtension>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMX[S$\G7V>[KG$O)H^QPQ:C/A'Y W5]P+@\G^A\4&_BC_P!02P,$%     @
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M"F&0_2US_Z#%MKNHO1-:B[H;;A@%\$8 OJ\%\/7NP=S]#G?]JW\!4$L#!!0
M   ( /.!J5:%ZZTMZP(   X*   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULK9;1;ILP%(9?Q6+3U$I=,"2$M$N0VE35=C$I:K3M8MJ% R?!*F!FFZ3;
MT^\8* LM3<BT7"2V.?_O[YCCV-.=D \J!M#D,4TR-;-BK?,KVU9A#"E3 Y%#
MAD_60J9,8U=N;)5+8%$I2A/;I71LIXQG5C MQQ8RF(I")SR#A22J2%,F?]U
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M<RH#.:D'<E+&T2,#>9.&<@.:RU*0HU<>711+^<[E_C]W/$F0W, ]!5GT;]<
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M:NKC\ ;"$#.$.4F3.RNQ$C4]C#/G[?TD'%+- U7SH=14!QLX0T[ &>,=JK,
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MV;(IKN%Y W:A]\6ZO#'%PIBV -)NRPZ>LVU1N1:ME>UWH$S]NEB9UG1ET^S
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M1.G*;H<+ W0IBT"A%/6CZ3QXX@Y,UV_@QFS/V0BD\V^8K]8/-#*#0+_L0A!
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M*?'=Y4$/F=8Y^&.1'0"B+;/V /O]73+WV4;S 4PDT$#./_/W$1Z@!5 ^P90
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M!&#V$4 HWT9@H=23N>LTNT_Y\M@O0>KKFC3&HEX'X*-=.U;F9 N2B^?U:-I
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MA$M>A8DS/[R!<.61'CR@HW"M-.3Z>&-,V?>=70R]!OJV/4W'(9Z6FZSOAT?
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M?_GZB-MW]1^]V])/\2U<W[L-_;DV &@Z? "^1S[J/W""\-N,/_X?4$L#!!0
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MZ$>VXD7!R3$'*#PUD9H#7JJ[0WCBTY_U%3>^VH=1N,@?>/U>'[_&0R\( OP
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M256[X5PS]G1PWM9W' VI .VI3%.Y OZ^5O[9WN)V[;U]B=V>(#Z)9F_3PNG
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MRS=2+W!0Z)V,QCM(MK,[J/$-,G?N;,QL _6;8!_YWG#8VR.H>_CS8!^>>*.
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M-8@]T/5E6[]85507W%99NBZK;D;?)ZB= <WOE+*G%[=!^\4S_0%02P,$%
M  @ \X&I5NNEL$G2!   = L  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&ULG59K;]LV%/TK%V[1!Z#:>OB9)@:2-$73K4@6MQN&81]HZ=HB2I$J2<7Q
M?OTN25EQTB3M]L46*=YSS[DO\7"C]%=3(EJXJ80T1[W2VOI@,#!YB14S?56C
MI#<KI2MF::G7 U-K9(4WJL0@C>/QH&)<]N:'?N]2SP]58P67>*G!-%7%]/8$
MA=H<]9+>;N.*KTOK-@;SPYJM<8'V2WVI:37H4 I>H31<2="X.NH=)P<G0W?>
M'_B=X\;L/8-3LE3JJUN<%T>]V!%"@;EU"(S^KO$4A7! 1.-;B]GK7#K#_><=
M^GNOG;0LF<%3)?[@A2V/>M,>%+ABC;!7:O,!6STCAY<K8?PO;,+9E#SFC;&J
M:HUI77$9_ME-&X<]@VG\B$':&J2>=W#D6;YCELT/M=J =J<)S3UXJ=Z:R''I
MDK*PFMYRLK/SA57YUU*) K5Y"6??&FZWAP-+R.[](&]13@)*^@A*!I^4M*6!
M,UE@<==^0(PZ6NF.UDGZ). GION0)1&D<9H]@9=U,C./ESV"%X3!7\=+8S55
MPM\/:0P0PX<A7'<<F)KE>-2C\C>HK[$W?_$L&<=OGR X[ @.GT+_Z3P\B?(P
MQ\7GB]-?/ES\^N[L:O'BV31-)F_A[+<OYY__A/=*4%>^N9!PV2P%S^%BM4+-
MY1K.)7QB6Q?^- );(IRJJF9R"SG]"[18 (-5,*?FJH.YVIDW5 <:N#6P*%&L
MX K7W$7>=^+",HO4V)8 -# )7'++F0A6&\VM10F&"21 &$7C.([B. 93,A+E
M]APP$:D(S+C  ;-$I]8\]R;/DZP_BJ$F"MZF#Y_W%#!A%*PUDTZ$D]:YI=@3
M3!:_*4BZJCU9JTB<SDOJ?&AJMYP. QU6%-P=(>)/,W,^[@?(<^V[,']L).[%
M^0Z9FFD7&+$%O$&=<^,9<[,CQV2QGYR7IHO:'KET.HNF6;HC283NQP<VS+&6
M>:,UI47L99E"IRR!K+4RQ$>K'+$PL-*J:IGL%&V0@)Y/9OT1S2DA'+U72Z0,
M[VERYPIN<M5(:R(?*&[<?#=>BB(M&M!83N.6I';8>$,?(8/F=40? D,#UVUR
M"9*^6ATGE_C)L)_MW/==6"I?;RX1%XTUEKPX4^?L*O2'\47XOK$-$3TWIF&2
MBNC8P]$4RLMN#'FK=YACM226[>Z][BA9 >FX/^U"X&QH8[+;\ )J]-\BL8V<
MESOE0N%H7&^Y:-P2[L,9(R8A6=^; "6-6^&*0X&B<KI6]F[14V7LP0&&<<@V
M3!<A]&UQM$.C\$%9A:#P75!NFYJ$QT%:G(S;:46UG#L>UPB7@K49]0?/J);4
M%K%-Q.6NG=PQ<(K"C8#_0WZ7[IIP<#_RWT5]E]JVQX*.GR#_4\2G43R>1J/9
MB)ZRX3B:9-/_Z\_5QH]CD$:S+":'0WH:C[,H2V;MN=#GYI&R@%>-I JV[9OP
M^/J_2!V2UW$T3(:01=/9C.2FKC$L32>'&N0VTN7\1Q3N^'W0'211DE)()QF,
M1DF4CJ;M<+D=GW<*NXMO0CE(LV@V&4,RBH;C.!J/)O#05W>P=Q.J4*_]?<_-
M-AHXX5+4[797RN-PD[H]'NZC5()K3B$2N"+3N#\9]4"'.UY86%7[>]526;JE
M^<>2KL6HW0%ZOU+4A>W".>@NVO-_ 5!+ P04    " #S@:E686]1('8%  "?
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RU5]MRVS80_94=)<TX
M,S3%FTC)L3TC7YIFVL2>R$D>.GV R)6$,4FH "39_?KN I0B)[:3/O1%N.T=
MYRRAXXW2MV:!:.&NJ5MSTEM8NSSJ]TVYP$:84"VQI9.9THVPM-3SOEEJ%)53
M:NI^$D5YOQ&R[9T>N[UK?7JL5K:6+5YK,*NF$?K^#&NU.>G%O>W&1SE?6-[H
MGQXOQ1PG:#\MKS6M^CLKE6RP-5*UH'%VTAO'1V<9RSN!SQ(W9F\.G,E4J5M>
MO*M.>A$'A#66EBT(&M9XCG7-ABB,OSN;O9U+5MR?;ZW_ZG*G7*;"X+FJO\C*
M+DYZPQY4.!.KVGY4F]^PRV? ]DI5&_<+&R^;I3TH5\:JIE.F"!K9^E'<=778
M4QA&3R@DG4+BXO:.7)07PHK38ZTVH%F:K/'$I>JT*3C9\J5,K*9327KV=&)5
M>7MX1GE5<*X:NFLCN%S'?4O66:9?=I;.O*7D"4LIO%>M71BX;"NL'NKW*:I=
M:,DVM+/D68/OA0XAC0-(HB1]QEZZ2S5U]M*G4ET(C5VJU^*>D&5AK+5HY^CF
M?XZGQFJ"R5^/)>]M9X_;9NH<F:4H\:1'W#"HU]@[??4BSJ,WST2>[2+/GK/^
MGR[I64N/QSFYN3K__?!L/+F\@/.K]]>7'R;CFW=7'\#[G3J_Y9Y?P#N>(VR$
M(6:6:M[*?TA&MF 72$QC8='>RW9.\1(<6K8PL<*Z2AM0,[A:HG;&#(C6IZ5Q
MP6Q?(_RAC 'J.,Z<76A$:#RXD,$%!(URL<.&,T"3! 1KU=1HS!'<.+5]3'ZK
MYE0^4A7<-ANI<$UM:NG@\!+B(,Y3&O-B"&^QI7AK)R4J(J)DK'!'@20HLI2$
M1Z,<;I0E(?-4W5Y"&HRBG,8DR(N,8D28":EA+>H5<EGFA$=+:LX$J*6O$-<9
MC974A>A,N )R:2I:[[1@9;C@O']6"PI@4BY4C::S<KC4LF2!1E58!^##4_[*
M?-7X5+;+E?WY\GUQ;8^#6E-]Y@A:FMO#&>M*2H0P9D%SE%F81/ +Q.$PI^$[
MM;6JJ42UM/=0Q.&(1(HB+&BX)*B5+$G&&C@@B-W3?9G7D(?)P/]<R+4DC%5P
M+[&NO+M7+X9)G+PA U]G6Z>'6Z>N;(>NB'NW0,!\4'Y&PB","AY'81%[6A"
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M@'L.^X552_<$G2I+#UHW7= _"-0L0.<SI>QVP0YV_TE._P502P,$%     @
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MPX+Z,VIW@/:WBMYF-W$7]!U__B]02P,$%     @ \X&I5FK[J!H/"P  I!X
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M 4K< JQ?J"JH8@W_$9$YVS^!KX:^+J:,K>*J9'8S8CZT+LE9Z #BO@6V"%
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M%,2*ORZT/H#]*V-HI_@#^L\P^P-02P,$%     @ \X&I5JAOG2$N(0  6&H
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULM5UI<]M&FOXK*.WLC%1%
MTI*<:YS$5;)BSW@GB3V6D_VPM1^:0)/L&$0SW8!DYM?O>_4%@O0QLU6I6"*!
M/M[S>8]N??=@W3N_T;JOWF_;SG]_MNG[W9-'CWR]T5OE%W:G._AF9=U6]?"K
M6S_R.Z=50R]MVT?7EY=?/=HJTYT]_8X^>^V>?F>'OC6=?NTJ/VRWRNV?Z=8^
M?']V=18^>&/6FQX_>/3TNYU:ZSO=_[)[[>"W1W&4QFQUYXWM*J=7WY_=7#UY
M=O45OD!/_&KT@\]^KG K2VO?X2\OF^_/+G%%NM5UCT,H^.=>W^JVQ9%@';_+
MH&=Q3GPQ_SF,_H(V#YM9*J]O;?O?INDWWY]]<U8U>J6&MG]C'_ZN94-?XGBU
M;3W]OWK@9[_^\JRJ!]_;K;P,*]B:CO]5[X40V0O?7!YYX5I>N*9U\T2TRA]4
MKYY^Y^Q#Y?!I& U_H*W2V[ XTR%7[GH'WQIXKW]ZQ]RH[*JZ,^O.K$RMNKZZ
MJ6L[=+WIUM5KVYK::%^IKJE^\1H??>Y[ Q2!#\_#UQ??/>IA/3CJHUKF?L9S
M7Q^9^W'UD^WZC:^>=XUNRO<?P3[B9J[#9IY=GQSP)^46U>.K675]>?WXQ'B/
M(W$>TWB/CXPW187_N5GZWH$P_>_4AGF\+Z;'0PU[XG>JUM^?@0IY[>[UV=,_
M_\?55Y??GECM%W&U7YP:_>FKG7:*%GNGUZ X_=0"3P_QUE8-L'56]1M=W=KM
M3G7[:J-\96ELW<Q ]CK0UH:D 8R!ZLP?\)OI?;4</ SG65!6IE-=;51;F8YM
M!^H@JB'\MUX[O8;A4)^,K^![FG WN)WU0&.0,'VOVH%WDX:"1=!87:UI$GQ)
MM:VM9?155:N=Z>%)_!:>]K;K= O6P]O!U=HOJK=I8W_^CV^NK[[^UE?UQNB5
M;!$G;'1MT.K,M^J==M7Y[:L??KJ8T1YOZ='G[W4]H#6I7JU 8;2;P13W:##H
MH3023 S6X6"'N-*P;GZ*ET?+_M#.%Z2<KH$'VGW!J;@AYA&* .REUP[LAD9J
MJ1[6%W@)Z^PTS+VSKE?+5F?+]BP_BQ-"^644RB]/2M0SXC#L]S4*?-<3IZ8$
M\S.&F63FK05CTGG8[XM(O3MXGLCA09B!:TNMNPHT<*<<RFY7U9:$U/1[,+_]
MIEKK#FC1MGOP&K7>]2COR1;LG(%Q=RV:O[._W=R\/KO 09 3OW0&'Z8)\=M?
M%G<+^!;Y;SK@A-D>T0R0##^@Y>UMA>ZFNKJ<_Y/D@1:$8[NA%1$![1E:>H]H
M@E_>@40ZTP<[_?Q]O5'=FLBS-9Y\Z/G9W?/;LXL)^<&]$15Q=Q\@8&.KSH(<
M=74[-*1^80GY=L@$6-O#H[ BIW\?#))ZN:^07D0/G+(%Z<P(XM,T.(#?V*&%
MEU!*5>#3;T/'_CS210T-$?WH.$0\W:+]JGA!\(G30&GAVEB&;KIN@&'>D&Z@
MT0H<^4?4Y+U6KM+HMZH?=*VW2S 4XGFN9Q58S)5I=<8\(#T.!!ZJWE177[.+
M8G,4!",1_IEJR<;=$2Y3Q&1^,SBWF5!\_&;&*'A'/ **"=(!M^GT!B$5*,&/
MUON/&^:NM_6[C6T;,*A"H^HY<+0'\0GT_= 8M\IOJA>  9,Q[#=.ZVK+$(!)
M66Z2!A>".ET-G7":R.:S#R9TRY]4><M\]VH;?)#RDY*@6!*.B=8L2)#=F4Y<
M4#*^Z!56"#])2U3S&\ Y>G56/6P,;!3$&>;N\2W;@;'I4']:47'09X?ZF+T7
M2;=2QE6[W!3"$.AZ)HT+BUGZ"ER\8O^->E#H;6-\W5K/5K$G*@<59OT!I8F\
MFQ/OT#<9VWCBD6J]'3'J W)]H#V$-XA=(&\@J*#8SFX_0M-[]G - 8L!?K"P
M[K&M^D0C=8+_O+DZ;B[(X#'O_T%A=T3KJ@.">*^< 8$P76,0)-P39 CC 0_
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M%EJB<>_[EF+XSH:UT&2H>QQOAM>R6KFL(S>*JZ3 X]T>@61(I3QYZWLW;'.
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MXA[PTNXR#93ZX?3B"]']]=FB>A5[."Y#)P9\#E &R,_0143A5K4&EM$9A=(
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M0*-_ :-,E5+?#PWU\[/.%(O&3#+:?NG SI-7X77IZK\H@3Y' /H0 4@.16?
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M&C"=PP?@>^1C^ 4GB'],ZNG_ 5!+ P04    " #S@:E6^[,DSGH&  "P%
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MLV_<R/]/PY_1*XY])X@SDU0:*-E IR1*G33)#)V"".YL88A+B9/X1%IJ="K
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MW>!\/CI2SLE0SLG1=']](0Z-=JB<X%(^=3[I9:+<%ZT13J ]5,NCX(>5^+K
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MNH&ZOV1,OIWH#NH-T>@_4$L#!!0    ( /.!J5:?=Q9%@PD  #E8   9
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M)#HC7A.&&/$!X$N X\LE!@SPY7%%XSXE4I/K!PP*(NNQ2XH^5&IRG8 ^ ?[
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MM]6XU(/C?0S.G6<$_K')>\AW+I'G>-[^+9>'E@CG9N #?D>^VX$7= GPY3E
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M!16M(6"_YQ\*".DS@J(U!=R5?5QC#6'VDB>$;SF51:62K?7:J%4VT/(-*"T
MI86@M B*UI1W5\-Q^S]Y^>N"5GQ :0$H+02E15"T9F+LRD>NN7YT\BK8;2F4
MC"=C_Z">,F_I-^ZW+'#-<776!)(60=&:FNPJ1ZZY= 2SQAV>L"J=FR/I_)R=
MXC,$]1E!T4JM[+V]OHSP9;$K*U#,-KDL=[;JUGKG][;8[SQHOW.OY^7^[0Y3
M;B<_8*[4%2@E"X5T>B.5;+S<H2TO)%L7.XJO3$J6%:<K@M7K67=0OR\8DQ\7
MVD&]3S[['U!+ P04    " #S@:E6GT:W\Q@#  "!"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6RMEMMNVS ,AE]%\("M!;;Z(!^2+@G0IAO6BP%!
MN\/%L O59F*AMN1*<M*^_2C;,=+$"39@-XED\Z?XB13ER4:J1YT#&/)<%D)/
MG=R8ZM)U=9I#R?2%K$#@FZ54)3,X52M75PI8UHC*P@T\+W9+QH4SFS3/%FHV
MD;4IN("%(KHN2Z9>KJ&0FZGC.]L'=WR5&_O G4TJMH)[,-^KA<*9VWO)> E"
M<RF(@N74N?(OYXFU;PQ^<-CHG3&Q) ]2/MK);39U/!L0%) :ZX'AWQKF4!36
M$8;QU/ET^B6M<'>\]?ZY84>6!Z9A+HN?/#/YU!DY)(,EJPMS)S=?H..)K+]4
M%KKY)9O.UG-(6FLCRTZ,$91<M/_LN=N''8$?'A$$G2#X6P'M!+0!;2-KL&Z8
M8;.)DANBK#5ZLX-F;QHUTG!ALWAO%+[EJ#.S>R/3QUP6&2C]CGQZJKEY(1_(
M?<X4:'('&M0:,H+E0FZUKIE(@9S=@&&\T.=HJ!O#B6LP%NO13;MUK]MU@R/K
M?F7J@E#_/0F\@ [(YZ?E-Y#V\N"UW,4=Z+<AZ+<A:/S1(_XZ\%]7#]HH+*W?
M0T2MBW#8A3UNE[IB*4P=/$_-OCFSMV_\V/LXQ/>?G+VBI3TM/>6]33J1E3U(
MFJC=)"]K4RL@*\6$(6=M=L^'-J-=(6I6L*UB/1MY\2@:1Q-WO<LY8$?#.*&C
MWNX50M@CA"<1YK(LL0OHAH1MF,J&0?BV:&N!)4Y,#K9D//*IK KY D#:O5C4
M*LVQ&Y!%P<00;GB $8RI%XW#/=P!NSBFU!\/XT8];O0/&;-0B,E$1K Q:X,#
M+E8GTQ4=Q!5&XSCT]^,_M*.C\9B&P7#\<1]_?#)^;"1&\=1@U&W*:L'-<9!:
MK%$ V7F7MC9E[1F]Q6P*V_N/YBH^8/#]8$03NL=Z:!=%?A =J<RD1TU.HGZ3
MAA5=7R1R2=+=2NU+]%2NDL/XXR2@XR3> Q@PC,+8BZ-D#\'=N2#LY8S==\6Q
MD I8HM2[2-"':B^\=F)DU=P9#]+@#=0,<_Q& &4-\/U22K.=V&NH_^J8_0%0
M2P,$%     @ \X&I5C[(80(? P  B L  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&ULQ59=;YLP%/TK%JNF3FK+5T*2+D%JTFZKM$I1TVX/TQX<N FH
M@)GM).U^_:X-H2&ET2HA]05L<^_Q.<<7N,,-XP\B I#D,4TR,3(B*?-STQ1!
M!"D59RR'#)\L&$^IQ"E?FB+G0$.=E":F8UF>F=(X,_RA7IMR?\A6,HDSF'(B
M5FE*^=,8$K89&;:Q7;B-EY%4"Z8_S.D29B#O\RG'F5FAA'$*F8A91C@L1L:%
M?3ZQ+96@(W[$L!$[8Z*DS!E[4)/K<&18BA$D$$@%0?&VA@DDB4)"'G]*4*/:
M4R7NCK?H7[1X%#.G B8L^1F',AH9?8.$L*"K1-ZRS3<H!7457L 2H:]D4\3V
M!@8)5D*RM$Q&!FF<%7?Z6!JQDX XS0E.F>#L)W1>27#+!%<++9AI69=44G_(
MV89P%8UH:J"]T=FH)L[4,<XDQZ<QYDE_)EGP<#I&(T(R82E6AZ#:WU-R]:AF
M0(XO0=(X$9]P[7YV28Z//I$C$F?D+F(K0;-0#$V)5!2@&93;CHMMG5>V=<D-
MRV0DR%460EC/-U%"I</9ZA@[!P%O*#\CKGU"',MQ&_A,_C_=.4#'K6QU-9[[
MFJT1Y7 ZU[9.Z1/6O207G--L"6I\LC4W).@?F= \EC2)_T)X0BY2ML+H7]\1
MDEQ+2,7O)G^+_3O-^ZN7_USD-("1@6^W +X&P__XP?:LSTWFM 16LZI36=4Y
MA.[?,91.A*[#PK!@IPZ;I!=XGL93GZFU[PXL;VBN=R6]#'*\7J<*JE'M5E2[
M!ZG>HGC*@T@?6@AK_ CFZCB;2!Y$>NOYM 16$^U5HKUW+F6O3:M: JM9U:NL
MZK5<R@5>=Z=*;=MS]TKY99#7ZS=7<K]BVC_(]"MDP)&K.C(:XG\E%I)3]4=M
M8GD0ZZT'U!)83?:@DCUXYUH>M&E52V UJVSKN3.P6J[F$K#VT>UU]LNY(<H>
M#+R]@C9W>IH4^%*W>@(IX"D4;4&U6K63%[J)VEL?JS93]TK/,$6/BC_]99P)
MDL "(:VS'KYBO&C[BHEDN>Z<YDQB'Z:'$;;*P%4 /E\P)K<3M4'5?/O_ %!+
M P04    " #S@:E6LRS:]B$#  #G"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6RM5FUOVC 0_BNG;)I::9 WWMI!)*"=M@_54*NU'Z9],.0 BR3.
M; /EW^_LA Q00)VV+XGMW#U^GO/Y+OVMD"NU1-3PFB:9&CA+K?-;UU6S):9,
M-46.&7V9"YDR35.Y<%4ND<76*4W<P/,Z;LIXYD1]NS:145^L=<(SG$A0ZS1E
M<C?"1&P'CN_L%Q[Y8JG-@AOU<[; )]3?\XFDF5NAQ#S%3'&1@<3YP!GZM^.>
ML;<&SQRWZF ,1LE4B)69?(T'CF<(88(S;1 8O38XQB0Q0$3C5XGI5%L:Q\/Q
M'OVSU4Y:IDSA6"0O/-;+@=-S(,8Y6R?Z46R_8*FG;?!F(E'V"=O2UG-@ME9:
MI*4S,4AY5KS9:QF' P>_>\8A*!V"MSJ$I4-HA1;,K*P[IEG4EV(+TE@3FAG8
MV%AO4L,S<XI/6M)73GXZ>M)BMFJ,*! QC$5*R:&8C6\#GEFR+L9#18><FZ$"
M,0?K ]_*A:L[U(PGZII<WH,+:LDDJKZKB9W9PYV53$8%D^ ,DQ >1*:7"NZS
M&.-C?Y=45=*"O;11<!'P@<DFA/Y'"+P@K.$S?KM[<(%.6$4ZM'CAN4B;N)21
MGK =W00-0RE9MD [_C&<*BTIK7_6Q:[ ;M5CFZM^JW(VPX%#=UFAW* 3?7CG
M=[Q/=<+_$]A1&%I5&%J7T*,7>[$H!FR#DNH$2*Y6C;E$!)YII TU2*:Q+@@%
MLE_DLJE/F\AK>BTZG<VAO'HSO]>I[(Z8MROF[;]COA$)W8^$ZUT=V78=BZY_
M<T*VWJS;K>?:J;AV+G*]?\VI3A)7BF@*5SR#'3*IKNN(7D;J%)X00FJO9UT^
M_0O"D;QN):][$?*.;WB,60P[CDE\-E\*$-\[C.U)^"^:'''K5=QZ;TJ3QCY-
M%G3'=2,FCC!G7,*&ZBI"CM1+;2$5MI#"U5K%Q:HI%+4G56S<.^#JMYM>]T12
MC=4-)=Z)*O>@9Z0H%[:5*IB)=::+&ENM5MUZ:)O4R?J(NGC1=/_ %+\ 5$$7
MG#I$@G."I*RF7)=%6RTF6N2V,TV%ICYGATOZ$T%I#.C[7 B]GY@-JG^;Z#=0
M2P,$%     @ \X&I5H. ;R@J!0  41D  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&ULQ9E;;^(X%,>_BI4=K5JI);%S(>D"$M#9W7FHIFJG,P^C?3#$
M0-1<6-M ^?9K)R$)23 , NU+FP2?R^_8SOEC>IN$OK,%(1Q\1&',^MJ"\^6#
MKK/I@D28=9(EB<4GLX1&F(M;.M?9DA+LIT91J"/#</0(![$VZ*7/GNF@EZQX
M&,3DF0*VBB),MR,2)IN^!K7=@Y=@ON#R@3[H+?&<O!+^MGRFXDXOO/A!1&(6
M)#&@9-;7AO!AC!QID([X'I -JUP#B3))DG=Y\\7O:X;,B(1DRJ4++/ZMR9B$
MH?0D\O@W=ZH5,:5A]7KG_<\47L!,,"/C)/P1^'S1UUP-^&2&5R%_239_DQS(
MEOZF2<C2OV"3CS4T,%TQGD2YL<@@"N+L/_[("U$Q0/8! Y0;H)H!= X8F+F!
MF8)FF:58CYCC08\F&T#E:.%-7J2U2:T%31#+:7SE5'P:"#L^>.7)]/U^) KA
M@W$2B=7!<%K?>Y!^!+XNT]NA+'? M^#FD7 <A.Q6C'A[?00WGV[!)Z #ML"4
M,!#$X"T..+L3#\7UMT6R8CCV64_G(EL94Y_FF8VRS-"!S$SPE,1\P<#GV"=^
MB_U8;0^1PH$NRE34"NUJ-4)*CT^8=H )[P RD-F6D-K\D4P+<Z1(QRRFSDS]
MF8>F3E;\?M*<NB&E.)X3L=DXF&Q!==PSWJ:/AQM,_;M\<L5D?5UQQL4\!?$<
M_'Q)PA"(32+'_-,V<5E>5GM>\L7SP)9X2OJ:>+,P0M=$&_S^&W2,/]J*=B%G
M>R6TBA):*N^#$9D'<2RA)SC$\92 FVP=W[9A9[[LU)=\/:X'INMYIB4F<UTE
M4L8\D\@NB&PET5]BZKF8:!6'W>#H(A<Z7@U#&>A,#*? <)08GS\(G0;L"(C3
M +EW+,NL<2@CG<G1+3BZ2@ZQBV8D.#8AW28'LAS;JH$H0YT)XA8@KGI"LG?#
M*=O$;=!8MN=8L([3'%??3GN9>D6FWBE+!T]"=9I>([QX+[L&A+4TE='.K#HT
MRO9L*&G>XC5AQ]9/[F./Q79<RZAO!76P<V$J6@/^'QWK#OQ(U9H8/5P3*M0G
MV+T_P#,-Q'+].9PP3H5D;&UG>=87ZF>7\K9?8U36&/UJ2ULQ'RP)S21:^P+*
M?+J5!02=3J,CJ$.?BU;J':C4 F5O.P$H\P11E<CN&-TZT374!RSE!U3KCTJ;
M.X'):C*ACE%_7ZE#GHM4Z@^H%B"5CG<"DMV"!#NPL?"NH45@*4;@$352:WXG
M@#DMZ\_I-+1)/N[PQMO/N)0=4*T[]IK@">EV6]*U.LBIIWL-"0)+#0+5(J1L
MAB<@N<W*NAUHUXF4$<\E*K4*])0=<=>X[G>-ZX7(LQ>YVL;BRZML62L<@F^$
M1JV0%Q(G>2VN(750*7606NI4.GH;ZQ%K%VP)I@Q $,EO_0"YP,?;MG.'\8F>
MD-WB89^M5#Y(V?6K^[&536W=S3,R,S8!J8"[AOQ I?Q :OFQVZ*ME&K37=V]
M'27R#E->0XF@4HF@4XY>6D[-JD)VM!.R(Z60'<[GE,PQ)^"+V/!!S((I^([#
MU3'5BBYZ"G,I;_L%+8404@NA8WL_LW;VU)P)Z^VI;9@'/:>]FZ)2TR"UICFV
M>YL'*A 95KW5J(.<6^)2Q""UB%'N3*=1.!-UZ\I2'>!7 ?3*H75$Z#P]RV=@
MFJQBGIU?%T^+WPN&Z2FY7@[/?FQXPE1\Z6$@)#-A:G2ZHM(T.[_/;GBR3(_
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MRZCW3\E6R=SBVU":F&XK4F>QK*T-=P.;#)(#E][?J?;^<9EW*D_S%\&[0-$
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M .EU=1L4ME':B>*%Z35+KJ!SF6$*WQ9$: =87W&N=A.]0?VU$OT"4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;,6:6T_C.!3'OXJ5'8U
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M<. XCK_O'9/#AJ9H;>]XM7<\O7=$ XY@ E*<(.&C3-31_X#C%9(>UUMSD[3
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MHK3XLJ XX62C7IV_$,Y)J@[7",:(R@[B]R4A?'<B!ZB^[YC_"U!+ P04
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M:;[1MKDV\%!:2<6+)AAZ4%!6_^+'!L1>P/!0P+ )&+X(B \%1$U ]+*%Z$!
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M*Q:KID[:"H%\=%V"E":MUH=*5=-N#],>'+@)5HV=V9>DW:_?-1"6)C3:PU[
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M"\8%T/>%UKB=N!\TG3S^ U!+ P04    " #S@:E6];L0(-0"  #C!P  &0
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M[36"/",@S\:!7'"[9TN)(,\)R/.XD-=@2R,.H3RP7356*+"6<56QE0$$^9J
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M2P$"% ,4    " #S@:E6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /.!J5:FHBDC[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M /.!J5:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ \X&I5O]MPR[O!0  S!\  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M /.!J59S*A(<R 4  /<7   8              " @3,.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #S@:E6A>NM+>L"   ."@  &
M            @($Q%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ \X&I5L1_1XW7!0  #AD  !@              ("!4A<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /.!J597W0W<- <   @Y
M   8              " @5\=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #S@:E6KP"%_M,'   F(@  &               @('))
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ \X&I5E-[E1'.
M!P  Z!$  !@              ("!TBP  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( /.!J5:IE[76X",  *=Q   8              "
M@=8T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #S@:E6
M^G>YU# *  #E'0  &               @('L6   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ \X&I5IG9V!'Y P  _0@  !D
M     ("!4F,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /.!J58'BZS9=@H  *@<   9              "
M@4V!  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ \X&I
M5NMXJ$\S"   R10  !D              ("!^HL  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #S@:E65PQUQTL"   8!0  &0
M        @(%DE   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( /.!J5:H;YTA+B$  %AJ   9              " @>:6  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ \X&I5ONS),YZ!@  L!0
M !D              ("!2[@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #S@:E6\3($=H8#  "&"   &0              @('\O@
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /.!J587RR$]
M'P,  'T'   9              " @;G"  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ \X&I5N/O/K;Y!   P@P  !D
M ("!#\8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #S
M@:E6 K(Q[;@#  "N"   &0              @($_RP  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /.!J58ZG(G2O ,  !T)   9
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M970R."YX;6Q02P$"% ,4    " #S@:E6>K@:1^@"  !^!P  &0
M    @(&"Z0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M /.!J5:]:E@DGP8  $4K   9              " @:'L  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ \X&I5D@@2(5+!   /Q@  !D
M             ("!=_,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #S@:E6GOY.%A8#  "]"   &0              @('Y]P  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /.!J5:6SHS_U 0
M #,?   9              " @4;[  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ \X&I5I]&M_,8 P  @0@  !D              ("!
M40 ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #S@:E6
M/LAA A\#  "("P  &0              @(&@ P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( /.!J5:S+-KV(0,  .<(   9
M      " @?8& 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ \X&I5H. ;R@J!0  41D  !D              ("!3@H! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #S@:E6@M=0#^L"   F"@
M&0              @(&O#P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( /.!J58@*=O--@,  +L*   9              " @=$2 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ \X&I5AI*>EKR
M @  N0@  !D              ("!/A8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #S@:E6 B&K894#  ":#P  &0
M@(%G&0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( /.!
MJ5;F3F;R3 4  .LA   9              " @3,= 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ \X&I5B D9OS;!   GAL  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( /.!J5;;]0(>\ $  +,$   9
M  " @1L^ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M\X&I5@R@!\I0 P  L!4   T              ( !0D ! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #S@:E6EXJ[',     3 @  "P              @ &]
M0P$ 7W)E;',O+G)E;'-02P$"% ,4    " #S@:E6U;OOMA($  !D(   #P
M            @ &F1 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ \X&I
M5I(LH):X 0  YQP  !H              ( !Y4@! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ \X&I5HQ/ZH^Z 0  [AP  !,
M         ( !U4H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _
)#P  P$P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>280</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of Business and Presentation of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</Role>
      <ShortName>Description of Business and Presentation of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Balance Sheet Account Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetail</Role>
      <ShortName>Balance Sheet Account Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitment &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingencies</Role>
      <ShortName>Commitment &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Out-License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreement</Role>
      <ShortName>Out-License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Credit Facility Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreement</Role>
      <ShortName>Credit Facility Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Balance Sheet Account Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailTables</Role>
      <ShortName>Balance Sheet Account Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/BalanceSheetAccountDetail</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Credit Facility Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementTables</Role>
      <ShortName>Credit Facility Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails</Role>
      <ShortName>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Shares Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossPerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails</Role>
      <ShortName>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Employment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Out-License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreementDetails</Role>
      <ShortName>Out-License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/OutLicenseAgreement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Credit Facility Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementDetails</Role>
      <ShortName>Credit Facility Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreementTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails</Role>
      <ShortName>Credit Facility Agreement - Summary of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails</Role>
      <ShortName>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tars-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SubsequentEvent</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionDueFromToRelatedParty in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tars-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: tars:PostemploymentBenefitsPercentOfAnnualBonusPaidOut, us-gaap:DebtSecuritiesAvailableForSaleTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 -  tars-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="tars-20230331.htm">tars-20230331.htm</File>
    <File>exhibit311-33123.htm</File>
    <File>exhibit312-33123.htm</File>
    <File>exhibit321-33123.htm</File>
    <File>exhibit322-33123.htm</File>
    <File>tars-20230331.xsd</File>
    <File>tars-20230331_cal.xml</File>
    <File>tars-20230331_def.xml</File>
    <File>tars-20230331_lab.xml</File>
    <File>tars-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="531">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tars-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 531,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 164,
   "dts": {
    "calculationLink": {
     "local": [
      "tars-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tars-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tars-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tars-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tars-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tars-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 429,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://tarsusrx.com/20230331": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 10
   },
   "keyCustom": 39,
   "keyStandard": 241,
   "memberCustom": 18,
   "memberStandard": 30,
   "nsprefix": "tars",
   "nsuri": "http://tarsusrx.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://tarsusrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Balance Sheet Account Detail",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetail",
     "shortName": "Balance Sheet Account Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://tarsusrx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://tarsusrx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://tarsusrx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitment & Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://tarsusrx.com/role/CommitmentContingencies",
     "shortName": "Commitment & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Out-License Agreement",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://tarsusrx.com/role/OutLicenseAgreement",
     "shortName": "Out-License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Credit Facility Agreement",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreement",
     "shortName": "Credit Facility Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://tarsusrx.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Balance Sheet Account Detail (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailTables",
     "shortName": "Balance Sheet Account Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://tarsusrx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://tarsusrx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://tarsusrx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Credit Facility Agreement (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementTables",
     "shortName": "Credit Facility Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Description of Business and Presentation of Financial Statements (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
     "shortName": "Description of Business and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositsAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositsAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "tars:EquityWarrantsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:WarrantAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i6fcd2d4fefbd47d69adbec610980dd7c_D20210301-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:WarrantAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "ife6229fc8e68402f9b920eda1e0e260c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails",
     "shortName": "Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "ife6229fc8e68402f9b920eda1e0e260c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
     "shortName": "Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
     "shortName": "Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "tars:CommonStockNumberOfVotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails",
     "shortName": "Stockholders' Equity - Shares Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "ife6229fc8e68402f9b920eda1e0e260c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i514d107167894741a8b7f284d591b2b0_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i514d107167894741a8b7f284d591b2b0_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://tarsusrx.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
     "shortName": "Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i1d2cb915c5e2438e89ce7cc3a2696296_D20190101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
     "shortName": "Commitment & Contingencies - Employment Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Out-License Agreement (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://tarsusrx.com/role/OutLicenseAgreementDetails",
     "shortName": "Out-License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i5c6261f1479f48748257ee5fbf2f8f03_D20210301-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Credit Facility Agreement (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
     "shortName": "Credit Facility Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "ib5ab2b8124224aeeaacabd23e0670fc6_D20230315-20230315",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails",
     "shortName": "Credit Facility Agreement - Summary of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
     "shortName": "Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i20710df36adc404dad2e0ed426a82823_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i80393f9b040b4bbdbc5232b580944b52_I20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tars:LesseeOperatingLeaseRemainingLeaseTermExtension",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://tarsusrx.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i80393f9b040b4bbdbc5232b580944b52_I20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tars:LesseeOperatingLeaseRemainingLeaseTermExtension",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i146bb14301f4414c9c5b8c6fbedb27b7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
     "shortName": "Condensed Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i146bb14301f4414c9c5b8c6fbedb27b7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Description of Business and Presentation of Financial Statements",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements",
     "shortName": "Description of Business and Presentation of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://tarsusrx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20230331.htm",
      "contextRef": "i065f5fbe5d674c3281fb0c97e75ec118_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r269",
      "r299",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r326",
      "r440",
      "r464",
      "r474",
      "r475",
      "r493",
      "r498",
      "r503",
      "r538",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r326",
      "r440",
      "r464",
      "r474",
      "r475",
      "r493",
      "r498",
      "r503",
      "r538",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r223",
      "r441",
      "r494",
      "r502",
      "r533",
      "r534",
      "r540",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r223",
      "r441",
      "r494",
      "r502",
      "r533",
      "r534",
      "r540",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r318",
      "r326",
      "r356",
      "r357",
      "r358",
      "r416",
      "r440",
      "r464",
      "r474",
      "r475",
      "r493",
      "r498",
      "r503",
      "r532",
      "r538",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r318",
      "r326",
      "r356",
      "r357",
      "r358",
      "r416",
      "r440",
      "r464",
      "r474",
      "r475",
      "r493",
      "r498",
      "r503",
      "r532",
      "r538",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r269",
      "r299",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r526",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_AccruedClinicalStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Studies, Current",
        "label": "Accrued Clinical Studies, Current",
        "terseLabel": "Accrued clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalStudiesCurrent",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution (shares)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, value"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months",
        "label": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member]",
        "terseLabel": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ClinicalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Milestones",
        "label": "Clinical Milestones [Member]",
        "terseLabel": "Clinical milestones"
       }
      }
     },
     "localname": "ClinicalMilestonesMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CollaborativeArrangementFutureCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Future Cash Payments",
        "label": "Collaborative Arrangement, Future Cash Payments",
        "terseLabel": "Future cash payments"
       }
      }
     },
     "localname": "CollaborativeArrangementFutureCashPayments",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementMaximumMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment",
        "label": "Collaborative Arrangement, Maximum Milestone Payment",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment",
        "terseLabel": "Contractual milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsContractualMilestonePayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementRightsAndObligationsRemainingPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Remaining Prepayment",
        "label": "Collaborative Arrangement, Rights And Obligations, Remaining Prepayment",
        "terseLabel": "Remaining prepayment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRemainingPrepayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CommercialAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Sales Milestones",
        "label": "Commercial And Sales Milestones [Member]",
        "terseLabel": "Commercial and sales milestones"
       }
      }
     },
     "localname": "CommercialAndSalesMilestonesMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "terseLabel": "Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant",
        "terseLabel": "Stock options reserved for future grant (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "terseLabel": "Stock options issued and outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan",
        "terseLabel": "Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Number Of Votes",
        "label": "Common Stock, Number Of Votes",
        "terseLabel": "Common stock votes"
       }
      }
     },
     "localname": "CommonStockNumberOfVotes",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_CreditFacilityFirstAmendmentTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, First Amendment, Tranche Two",
        "label": "Credit Facility, First Amendment, Tranche Two [Member]",
        "terseLabel": "Credit Facility, First Amendment, Tranche Two"
       }
      }
     },
     "localname": "CreditFacilityFirstAmendmentTrancheTwoMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Four",
        "label": "Credit Facility, Tranche Four [Member]",
        "terseLabel": "Credit Facility, Tranche Four"
       }
      }
     },
     "localname": "CreditFacilityTrancheFourMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche One",
        "label": "Credit Facility, Tranche One [Member]",
        "terseLabel": "Credit Facility, Tranche One"
       }
      }
     },
     "localname": "CreditFacilityTrancheOneMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Three",
        "label": "Credit Facility, Tranche Three [Member]",
        "terseLabel": "Credit Facility, Tranche Three"
       }
      }
     },
     "localname": "CreditFacilityTrancheThreeMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Two",
        "label": "Credit Facility, Tranche Two [Member]",
        "terseLabel": "Credit Facility, Tranche Two"
       }
      }
     },
     "localname": "CreditFacilityTrancheTwoMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents",
        "label": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents",
        "terseLabel": "Debt securities, available for sale and cash and cash equivalents"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities",
        "label": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities",
        "terseLabel": "Number of securities with contractual maturity between one and five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Deferred offering costs included within accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ElancoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elanco",
        "label": "Elanco [Member]",
        "terseLabel": "Elanco"
       }
      }
     },
     "localname": "ElancoMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016",
        "label": "Equity Incentive Plan 2016 [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquitySecuritiesFVNINumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Number Of Shares",
        "label": "Equity Securities, FV-NI, Number Of Shares",
        "terseLabel": "Equity securities (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINumberOfShares",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_EquityWarrantsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrants, Fair Value Disclosure",
        "label": "Equity Warrants, Fair Value Disclosure",
        "terseLabel": "Equity warrants (for LianBio shares)"
       }
      }
     },
     "localname": "EquityWarrantsFairValueDisclosure",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Public Offering",
        "label": "Follow-On Public Offering [Member]",
        "terseLabel": "Follow-On Public Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LesseeOperatingLeaseRemainingLeaseTermExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Remaining Lease Term, Extension",
        "label": "Lessee, Operating Lease, Remaining Lease Term, Extension",
        "terseLabel": "Lease term extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTermExtension",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_LianBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LianBio",
        "label": "LianBio [Member]",
        "terseLabel": "LianBio"
       }
      }
     },
     "localname": "LianBioMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LicenseAndCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration",
        "label": "License And Collaboration [Member]",
        "terseLabel": "License fees and Collaboration"
       }
      }
     },
     "localname": "LicenseAndCollaborationMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LineOfCreditFacilityDrawDownIncrements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Draw Down Increments",
        "label": "Line of Credit Facility, Draw Down Increments",
        "terseLabel": "Increments to draw on credit facility at company's election"
       }
      }
     },
     "localname": "LineOfCreditFacilityDrawDownIncrements",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_LineOfCreditFacilityPeriodicPaymentInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Periodic Payment, Interest Rate",
        "label": "Line of Credit Facility, Periodic Payment, Interest Rate",
        "terseLabel": "End of term charge, interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentInterestRate",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tars_LineOfCreditSVBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit, SVB",
        "label": "Line of Credit, SVB [Member]",
        "terseLabel": "Line of Credit, SVB"
       }
      }
     },
     "localname": "LineOfCreditSVBMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_MilestoneDeterminedByTheCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Determined by the Company",
        "label": "Milestone Determined by the Company [Member]",
        "terseLabel": "Milestone Determined by the Company"
       }
      }
     },
     "localname": "MilestoneDeterminedByTheCompanyMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_NumberOfEmploymentArrangementsWithExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employment Arrangements With Executive Officers",
        "label": "Number Of Employment Arrangements With Executive Officers",
        "terseLabel": "Number of employment arrangements with executive officers"
       }
      }
     },
     "localname": "NumberOfEmploymentArrangementsWithExecutiveOfficers",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_NumberOfVestedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Vested Warrants",
        "label": "Number Of Vested Warrants",
        "terseLabel": "Number of vested warrants"
       }
      }
     },
     "localname": "NumberOfVestedWarrants",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_OperatingLeaseNoncashExpense": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Noncash Expense",
        "label": "Operating Lease, Noncash Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNoncashExpense",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_PaymentsOfDeferredStockIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Deferred Stock Issuance Costs",
        "label": "Payments of Deferred Stock Issuance Costs",
        "negatedTerseLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDeferredStockIssuanceCosts",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_PostemploymentBenefitsDurationOfBaseSalarySeverancePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Postemployment Benefits, Duration of Base Salary Severance Payments",
        "label": "Postemployment Benefits, Duration of Base Salary Severance Payments",
        "terseLabel": "Months of base salary payments"
       }
      }
     },
     "localname": "PostemploymentBenefitsDurationOfBaseSalarySeverancePayments",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Postemployment Benefits, Duration of Company-Paid Benefits Coverage",
        "label": "Postemployment Benefits, Duration of Company-Paid Benefits Coverage",
        "terseLabel": "Months of continued benefits coverage"
       }
      }
     },
     "localname": "PostemploymentBenefitsDurationOfCompanyPaidBenefitsCoverage",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_PostemploymentBenefitsPercentOfAnnualBonusPaidOut": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Postemployment Benefits, Percent of Annual Bonus Paid Out",
        "label": "Postemployment Benefits, Percent of Annual Bonus Paid Out",
        "terseLabel": "Percent of annual target bonus"
       }
      }
     },
     "localname": "PostemploymentBenefitsPercentOfAnnualBonusPaidOut",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tars_RelatedPartyTransactionOptionToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Option to Purchase Shares",
        "label": "Related Party Transaction, Option to Purchase Shares",
        "terseLabel": "Option to purchase shares for consulting agreement (shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionOptionToPurchaseShares",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_RevenueRemainingPerformanceObligationAdditionalCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Additional Cash Payment",
        "label": "Revenue, Remaining Performance Obligation, Additional Cash Payment",
        "terseLabel": "Additional cash payment"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationAdditionalCashPayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount",
        "terseLabel": "Milestone payments to be achieved"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "terseLabel": "Stock issued, gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value",
        "terseLabel": "Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Early-Exercised Option",
        "label": "Share-based Payment Arrangement, Early-Exercised Option [Member]",
        "terseLabel": "Stock options exercised prior to vesting\u2014 remaining unvested"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEarlyExercisedOptionMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested",
        "label": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]",
        "terseLabel": "Restricted stock units\u2014unvested"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase obligation for stock option exercises, prior to vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_WarrantAgreementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Agreement, Number of Tranches",
        "label": "Warrant Agreement, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "WarrantAgreementNumberOfTranches",
     "nsuri": "http://tarsusrx.com/20230331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Trade accounts payable and other"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r14"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable and other"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on available-for-sale debt securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r115",
      "r126"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of debt issuance costs.",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "terseLabel": "Accumulated amortization of debt issuance costs"
       }
      }
     },
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68",
      "r141"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "(Less): Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r146",
      "r459",
      "r469",
      "r470"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r99",
      "r404",
      "r465",
      "r466",
      "r513",
      "r514",
      "r515",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r501"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r521",
      "r522",
      "r523",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r96",
      "r97",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Recognition of stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r38",
      "r49",
      "r107",
      "r288"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of end of term charge"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r32",
      "r288",
      "r399",
      "r517"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r288",
      "r399",
      "r491",
      "r492",
      "r517"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of term loan-related costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net income (loss) per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r125",
      "r143",
      "r172",
      "r208",
      "r217",
      "r221",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r378",
      "r380",
      "r390",
      "r501",
      "r536",
      "r537",
      "r579"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r136",
      "r148",
      "r172",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r378",
      "r380",
      "r390",
      "r501",
      "r536",
      "r537",
      "r579"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r229",
      "r241"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r63",
      "r228",
      "r241",
      "r454"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r57",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Presentation of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions of property and equipment included within accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r138",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r46",
      "r51",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents \u2014 end of period",
        "periodStartLabel": "Cash and cash equivalents \u2014 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r106"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Out-License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "License agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r118",
      "r131"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r249",
      "r250",
      "r471",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment &amp; Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total shares of common stock reserved (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r521",
      "r522",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r501"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,800,512 shares issued and outstanding at March\u00a031, 2023 (unaudited); 26,727,458 shares issued and outstanding at December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r153",
      "r155",
      "r161",
      "r455",
      "r460"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r123",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r313",
      "r314",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r495",
      "r497",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r34",
      "r441"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of license fees and collaboration revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r170",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r282",
      "r289",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r114",
      "r116",
      "r124",
      "r176",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r400",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r116",
      "r124",
      "r293"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Term loan, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r19",
      "r108",
      "r295",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r176",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r400",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r78",
      "r81",
      "r82",
      "r83",
      "r107",
      "r108",
      "r111",
      "r122",
      "r176",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r400",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r539"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Accretion of end of term charge"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Contractual maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Deposits Assets",
        "terseLabel": "Cash held in depository accounts"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r49",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r330",
      "r361",
      "r362",
      "r364",
      "r369",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r162",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r190",
      "r192",
      "r194",
      "r195",
      "r196",
      "r200",
      "r385",
      "r386",
      "r456",
      "r461",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r162",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r192",
      "r194",
      "r195",
      "r196",
      "r200",
      "r385",
      "r386",
      "r456",
      "r461",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Change in fair value of equity warrants issued by licensee",
        "terseLabel": "Change in fair value of equity warrants issued by licensee"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, weighted average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options, unexercised\u2014vested and unvested"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r134",
      "r156",
      "r157",
      "r158",
      "r177",
      "r178",
      "r179",
      "r181",
      "r187",
      "r189",
      "r202",
      "r235",
      "r312",
      "r365",
      "r366",
      "r367",
      "r371",
      "r372",
      "r384",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r404",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNIAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI [Abstract]",
        "terseLabel": "Long-term investments:"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r144",
      "r389"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Estimated fair value",
        "verboseLabel": "Common stock in LianBio"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r462",
      "r530"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss on equity investments",
        "terseLabel": "Unrealized loss on equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "negatedTerseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in fair value of equity warrants"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r100",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r100",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Financial instruments measured at fair value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r387",
      "r413",
      "r414",
      "r415",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r280",
      "r319",
      "r324",
      "r387",
      "r413",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r280",
      "r319",
      "r324",
      "r387",
      "r414",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r280",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r387",
      "r415",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances",
        "terseLabel": "Remeasurement of equity warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r280",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r413",
      "r414",
      "r415",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r291",
      "r310",
      "r382",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r487",
      "r527",
      "r528",
      "r529",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r50",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized gain from transactions denominated in a foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r173",
      "r188",
      "r189",
      "r207",
      "r370",
      "r373",
      "r374",
      "r463"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r109",
      "r120",
      "r159",
      "r206",
      "r398"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r38",
      "r286",
      "r296",
      "r491",
      "r492"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense related to term loan"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r40",
      "r287",
      "r491",
      "r492"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Interest expense for term loan"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r165",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest expense paid in cash"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest, current"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r172",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r379",
      "r380",
      "r381",
      "r390",
      "r485",
      "r536",
      "r579",
      "r580"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r117",
      "r129",
      "r501",
      "r519",
      "r531",
      "r573"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r137",
      "r172",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r379",
      "r380",
      "r381",
      "r390",
      "r501",
      "r536",
      "r579",
      "r580"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, aggregate principal amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to interest.",
        "label": "Line of Credit Facility, Periodic Payment, Interest",
        "terseLabel": "End of term charge"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r116",
      "r127",
      "r279",
      "r294",
      "r489",
      "r490"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities and Long-Term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r50",
      "r119",
      "r132",
      "r135",
      "r152",
      "r154",
      "r158",
      "r172",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r193",
      "r208",
      "r216",
      "r220",
      "r222",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r386",
      "r390",
      "r486",
      "r536"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued or Effective Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r208",
      "r216",
      "r220",
      "r222",
      "r486"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations before other income (expense) and income taxes"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r149",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain on marketable securities and cash equivalents",
        "verboseLabel": "Other comprehensive gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r35",
      "r49",
      "r66"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of term loan issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r41",
      "r62",
      "r163"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r501"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r147",
      "r245",
      "r246",
      "r477"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r43",
      "r94"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of equity awards"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r44",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Draw on credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r62",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r67",
      "r140"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r69",
      "r130",
      "r458",
      "r501"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r325",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r263",
      "r264",
      "r265",
      "r520",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "terseLabel": "Cash compensation for consulting agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r325",
      "r405",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r98",
      "r133",
      "r587"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r84",
      "r128",
      "r468",
      "r470",
      "r501"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r134",
      "r177",
      "r178",
      "r179",
      "r181",
      "r187",
      "r189",
      "r235",
      "r365",
      "r366",
      "r367",
      "r371",
      "r372",
      "r384",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r204",
      "r205",
      "r215",
      "r218",
      "r219",
      "r223",
      "r224",
      "r225",
      "r315",
      "r316",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r160",
      "r172",
      "r204",
      "r205",
      "r215",
      "r218",
      "r219",
      "r223",
      "r224",
      "r225",
      "r234",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r390",
      "r457",
      "r536"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r403",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issued, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Stock issued (shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Original issue price (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Outstanding potentially dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Balances of Debt, Debt Issuance Costs, and Accumulated Accretion"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Net (loss) income per share, basis and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r86",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation assumptions of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Stock details"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service condition period for full vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (shares)",
        "periodStartLabel": "Outstanding, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per stock option (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (usd per share)",
        "periodStartLabel": "Beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock issued for license agreement, share price (usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Accelerated vesting (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Unvested (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Fair market value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise price range (dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r57",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Use of Estimates"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r77",
      "r134",
      "r156",
      "r157",
      "r158",
      "r177",
      "r178",
      "r179",
      "r181",
      "r187",
      "r189",
      "r202",
      "r235",
      "r312",
      "r365",
      "r366",
      "r367",
      "r371",
      "r372",
      "r384",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r404",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r202",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Common stock issued for license agreement (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r77",
      "r84",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Exercise of vested stock options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "verboseLabel": "Common stock issued for license agreement, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of vested stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r61",
      "r501",
      "r519",
      "r531",
      "r573"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r171",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Detail"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r255",
      "r258",
      "r259",
      "r260",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r291",
      "r310",
      "r382",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r527",
      "r528",
      "r529",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "Government-related debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r483",
      "r495",
      "r497",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r191",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r190",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r505": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "https://asc.fasb.org/subtopic&trid=2229187",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001819790-23-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001819790-23-000030-xbrl.zip
M4$L#!!0    ( /.!J5:/*?7EV @  '$Q   4    97AH:6)I=#,Q,2TS,S$R
M,RYH=&WM6VUSVK@6_GY_A9;.;9,9WLQ+2TB:&0+TEIDVR1(RW?VT(]LR:");
M7DF&L+_^GB.90 )):9LN:=/.E&#K[4AZGG.>(YNCWWIGW=&?YWTR,;$@YY<G
M'P9=4BA5*I_JW4JE-^J1]Z./'TBC7/7(2-%$<\-E0D6ETC\MD,+$F+1=J<QF
ML_*L7I9J7!D-*]A5HR*DU*P<FK!P?(1WX)/1\/@_1[^52J0G@RQFB2&!8M2P
MD&2:)V/R*63ZBI1*>:VN3.>*CR>&U*JU.ODDU16?4E=NN!'L>-'/4<5='U7L
M($>^#.?'1R&?$AZ^+?"PV?*K3:_^INE5&XUZX-?KU5I(&?-;'FU%K__RP,@*
M5'=MM)D+]K80\Z0T83A^^TTM-8<S'II)VZM6_UNP]8Z/(ID8&$Q!8_?5];'6
MDV'7ID0%'R=M.Y^":[HH#J20JOVB:O\=8DDIHC$7\_:K$8^9)J=L1H8RILFK
MHH8]*&FF>.0J:OX/:Q^ =?9JEIL+W0B>L(7YGM<$F_O7$^YS0^I>V;MM\&93
M UA8IKZWK8V-MG;[P]'@W:#;&0W.3@&7PXO+SNF(C,Z>NN'#RP_]"^+5:<EK
M[-%]TCGM$:\9YE>7I[W^D(S>]\E%OWLY'(P&4+G_1_=]Y_1_?=+ICLC9.^(=
MU!O%IS[/S@7I],[.1_W>ZN[@M.R. ;]P*G:FG>%)Y[1_43K[XT/_S\4D:]5J
M;6V.]S+JF\O^Y=49%,F)].D5Z?P#O=.D2#Z6>^4B.9_8/P%3AD=S8B;4O'S1
M;!T^_1EY9;(PY%%']VI;#4_(]QE^R^TD$SIE1+$I9S.(5F;"-?D]HPKH)^9D
MR%*I#)$)>2=53+QJZ7<B(S*B2F<:]IRJF 8L,SR@0A?)( E@TP_6-_TF\% U
MAMAC9-JN@WTI#4.(CB7!(C"H!7>L#^!)"/QOE_#.;GQ [3ECXH1J0 +L>3PG
M5XF<"1:.6=%!0SE A!)&2R2H'.B-\H309$ZRQ*B,@;&@>ZP$ J10$L.5XE20
MB 9P2Q$90Z0VTM5;J_#RA?>Z>KC^F;" :4W5')O&](J!/2MC:;@7@I%@BK"Z
M"L;&"@%7H*.@6@+-P<*0*3*;\&!"=(8?R_8SIEC>"4XLYEJ X$+M-N-F A/7
M*0NLX=AO"B;+$*8_A68A\>>KR_-S<*#^BP,;.,!(Q!- $P)VB9XB$ "J0[%:
M*>=)!%Z38EX!WP.1A= G('0%*D5 /4=/FP+ D#/()2&6I,AQI^\,#;P+;<)2
MQ!J9@ J > FPM,-I:T] ]81$0L[T@@Z*C;DVD.T80O&FLQNL+*Z@6B^,6;/V
M86 _22378#,;NT-R;:=(QM%'M[;]E<Y1F@LU]&\RBCA<[NE]BX8!H8I9W &.
MN"\8XH,P +LON)Y@"ZP6@]M'UX_7(=>!D#J#=A@0E!0.@*F2 0OAMB9[@+>0
M 8 =J/K7P80F8T8ZX%.'F8 :-K-H[C%GA<TL\,I=<LP'$@=\[)^@XUWA@\,G
MVK+U0-&M@2(8".=YER50 Q729BV[P:6_ONO26][3( )Z-4S4=NO3=^C2>TQ#
M:@FHL)'_\Y MHE@):*:W;X+JP&< OWPDIS=DIJ #\*U3KJW'AEHLL?U@FK3T
M]:OQ0C%!+9YSP;'$9#&/)5C(P>^#+5H*'MK3)IWYFH><*HX3X$X6V0B68$\@
MVD&J6 ^@K:ZQ_EUJ!@89B"?8* 7QSX-,4 Q+,"UKQ%+R0 LGH%;U('SS&5:$
MR 'M6;BU!'K:?/'W?]'%8G]K_[O&FNT]]];D <)->8B<H%HF%$,4U< G%/E(
M%*K"!6B!1ISZ7' S1PVT:5BDL,6WA:YCWZVJ*TF"C837^8323*5 '6TU6Q!(
M%5H#;+HP9@E(,0$,@A*6(C6Q"J1(CB5 89Y",/I)>!(\7Y[TIU1DUO<BB%@4
M@5KG4]A^O4%U@_S:(HJXR\T2W!("&D($T$[H^S(S]X^]39RC-[499C'1YS-<
MXB_R(\MQYM8 [+%XQ@%^?$R'.\;T3IV_0\TZ^O"<)Q?4MN0.N+_ V:/RD4&0
M*437?:<^*_+CUCBQU ;NX&,"Z%T'T/7?[M"2[*U5CH RX)+OU,O-AQR9V8,J
M/,-*LAL;]YV%$ZIO]!DZ<TLQ%MHH9U<ECT!S(O@5$_GIU)WZQ6]8J&\CU%/)
MPA%3S?*.^;1+0GU%%FX/YL,%$8M+EXL18)4 2^^+0/X"I;:66H!=%!(+(Y6^
MD47V!G06Q]P8QC;&-%^"Y,*2D(--MOD>$ 1"B,80!7\QL5DPF?V=<3#9<C=+
M GM>M?_3)-C/-VAT!&AET.X<@(QG)W@*$W &L,LUS4VB.V/T"D6*T\Y6IEC5
M;Q\/+,XPOPC,>4[J3JXV^&0:0D/-;ESR!N#G60)4!@R#F"\ZC:1!(.DL!@3"
M2MAIY*%PXSGO3Z1_GG'NVP&5$RGP?$7 %;.>&I!I'POE$"XZ><"3J113AAHA
MH>/\J9?*G3N+4R'G#$IG$^G<.;U%$ #T-\JH\AK,CH^,38CS!?,!R$R58-T$
M335K+[X<0F!)!9VW>6*G;QL=YMCTI3$R;C=AK:88H$ VY>]E6&RZXN5+0^6J
M>W'(*/@?+D;.B\NVJ&+"];):^4VS=6]IM>S=6_90K_5JN=5H/'JW7V_LPV6M
MUOUC?JVM!^56\_4/8FNMW&@</#X(#LK56OU[&-NL;=5KQ9)!+2HLO$O3>G.#
M:;70*4W>%NJ%.X_/VE7BV5J+,7Y5_0Y5\_VYW>9@K4TMO28W,=FY0 S4:VY1
MIH7U5]GR&%XM'^PJAO<@6EEA33[2N<NH#XKVE=,[KW7>7;U'7HF5%T0/G\C2
MG,PW9!P/K$,>2//0""M![$,7LC#T$=?)O?SX5!;JY8O&FT-M/Q]X\V_#.FY)
ML7L9_%55\VU"=?V,]FC;??D1YG*N(!5$(VRNU9UP%I'^-0LR/-DF9^Z4Y,>;
MUMZY>^8#ZGUM-OOWL:=B9?F&::Z^O)]*]].%MGMD/&5KK_,OR6&=5W79A/K
MD,RL-_G,+P#R3_=C!/NSB./_ U!+ P04    " #S@:E6-XTXXNH(  "#,@
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MV(G$T#1CQ9JM'RD6NFAE$Q]9K1;M?N)8;VLO!(>'(762B@%S)J<@IQ0^S8C
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M3>YYIVCUF;_>I%ZT.OP/4$L#!!0    ( /.!J5:5PXQ(,LT! ".D$@ 1
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M#R;N H7_SAGEG#,^%#]<\5]U0PQ@E;K0N\/MEGQW[WN%8Q8XIU*X,=_W!X=
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M.>>6*\6]BVX*V&2:M<FT0 #,F-<A4!TX9IXZ'0DR@0@E EB4]@VRR:101A&
MZ,)S%1EEG%H;P.H/+"(?B3=^"B*=7V)5'A^;;&W6NX5C?G"9,7!*6 6A8#QA
M"BG \5@9&[ 31'$M5"1&O1%6>3E(,,6L(IG2$;L4GH\8BF!P$!G!UM/&<*O%
M-/@07V!U+ED%6,5$XC#8% (1S'B,1KH8F(B(L8"\TU/ *C-,':6)#80(1'WR
MW2C+L8N<8XRMT,&:&:!."GP+W73'%P,S,TGP?EJ<!21X% @FSBG+K 0ECV-D
MA$0FL ^R=!:,>U_@02P[*5SBC:0:S$"F"6+81T"0QDEDG!>&H5&"[<GFDBG6
M)=/B*I!,,R.\<C(YE@+6@C ;..*>:JS)3.P63*7X1N^E9)8RY@@C,'%48B&Q
M4=JD,,]I4/*_)DSW,"7!#-<S^D^2&$\+)#!>$V5)\BH9%C56"@<L@H\I9PB7
MO.2628 DD\(MB$?,@4TXLXS1P!1)YSV%UL8*(J;"7S #W#(U$$$;;H6A."C!
M..#(Y#]P/GHL2=32OEENF10">:^LD(@3XF)!(*N8MY)Q#A^U(S- H*W-3YWC
MT&VG*Y,KT=."%A(RX$:8=,8_I<Q0$7GJ$.6,>/@S#:;A5#D0'LV]D\(P42K,
MN0=MDJ "E1JT"])!*\,\\K;4,"5FN!GVYJ5BG$0N''"*-QA9G5R5F@?NQ"Q$
M($R]4'O-J2:()WHP!YA.:6Y4<$(KCKE\(ZO M*S9(C),;?0Z8,I8Q)H)I(+A
M3H(Q9S%[&]2:%@N;2FNMXB!*@3&A@B8V1A\1I@9QA=X(M:9EM4+!607V+1(J
MLL""-5QQ,*0 $VN)-9G\"@13'5;YO"IX?(40(EA-1&O-P'AB2AM-J"!88)R2
M;>@@IX!-ILIL>M$8S_&Q"69*.:=I1(@Q+K"A%JSJY)JQA&'GIX!-IEF;/.^B
M,\:R*A81+BR+TCHF<8(**F7$I-H*ZM@45"J:60'V3C(2(O,T,JV)PH8'FE(=
M(RH44E- F3)(^V58!7&+B;0BI'.XBB/M7'3P@\->4R[QVV"5&0[2'A^KI(JT
M,A*GA:4,QY#*$8!-SWU@CC(U#?J^#-)^&5;QD7,M)4HAP(QI:ZT+)L7_4F93
M4/\4L,H,4X?SE)-#:D*"9U$CRY"+2J,@'5><ZAF@S@0'5DZ+LT!'P/=8*<(Q
M2*T'4(^QH*F +'".HM-@!4X5,GC)*,_Q<4EP7ID4BV6%9L9+):)RRAN5PF_-
MJ*;49'/)%.N2:7$56"HH#EJ$R 5SL/P(0GQ,M7B"EBQ,087<&17?B"*Q)"!B
MF64\!H.DMTH*0 /&4#\%]=IG(9!R6B"!E31@991.F5]]8AGMN)%&$<<]'QW^
M+[EEJK>0Q^A:DE9AIZG77#$O0,]@K40P7,I -9V&W:89X):I@0B!FD@E8S88
MQBA36 E! _ +5@C96=C"?HT@[?$1B&") 1EPSL >C(I8;K@+H/N%IBKE=)Y^
M DU'".6TH 4* JT-C<P1SBCW)B@6'8O8&@OKPC3H_ZER(+Q2/.?X&,8$0@R@
M2ZZM84A'ZZ*),@9K%?6$TRE@F-G0,-."&3S1-$K)E!&"I<3!%(""EA@9#M!A
ME$WPC3+,I-!(8,X,(PIY%AF.4B57(06@9X/$7DP#C=[0FFUP5,(3%4"0&$J5
MB85TB&B-J%+&E.$ $T4M3**/4CO!P62R/F@B:&$_":J=$V^$6M.R6HGH/ $M
M&*+U3'JAC;<!J(0T*$<O75'Q!",ZK'B")Z1*YK4"(SA%K-^OP @>2_6J?A>6
MQ[UP=\&YT<7S-GY6P.JBP1/3A:=^4,%N=/$^#5[/:FRE0IH!$$&6!2<-X3BA
M$1.0H;>+%+^$0#Z4L@\J%WM-(AY)V=X0R Q^5$MP>/7!I%",Q2B=4MX'QIS0
MT1%0C4PPJT7$>'+/K3Q_3;(?@LUBRA>/3=XTMAE6.]U-T[SAI%J"2>X:US\R
MS:KI%[3Y''J]^IYI8U*%BWO3<FH0V@*K@6%.*4\9C#5*18M9$"H(KL,$IZ5]
M_I)D)8<,J]=1QX7P"J>LHM;H8 ).W$$(H& \S2E&WQ0=P78Q-EH=,!+,8&N$
M1QY'H[A0PN()#H,OUX*7@>2<"2P)%X%%S&ATRB"+G!9&&**0F^ -[7(M>!D.
MD2+5&G?*IUTO;($ON" 8H+YTVB Y#>ZKDHZ%&](%FPI744X9$TZQY-JR45--
M9'13D /L2[<#[]L?I%JB_<6V3R5&#U,;'P?UP6&XX2<YZH*%!!83W+B:GZ9/
MT[)J8ZLTV-.&$<,8T2F2-$H)9')!(<.FX.S 9%-JC!N\7F-,%-.&"N8%5='2
M$ -/X1J6D"E(JO0@2JW'F+MP<<N4B).)'A'CK W2,"F920'\D0L /3PB/05A
M_!-+I#$&/UD5E45(:IE*Y3 54W@-L]AJQ$.8@ES)#R-2?R]TJ\;MY>W0'5R]
M>TJ$*BA.#27*\. 8]E1+$BF2 285.Z:F(%AM&N@U/OER*D;"/<$J(!:ET19S
M(:+$+,66L"E($O\@>GT.IA?V.DV_UCKL=HY#NF]:X)_VEH)820?_IDR-5@IA
M?3HOX@06=@H.)TXXJ<9X0A G \K&@,"D8CI)D@T:$Q^X2GZVT;87'VU[(3ZY
M--L\LKW<YZ8[2$;P>MSL=]S!%3-YM=-L=D[6VU^.++0$( -FJ;T[?CK=W)/C
M]]Z3@UL?NR=WW>$1P!Z6RE')&7,&6TJHD#0ZBCP _:&A7-+RH3)WC3Q/@?..
M:\J1HM@2YJ,W+H2TDFEOE+&2S(;,70"/X]!=!&KU4]/KAWUX?A9ESC+,M$_'
MJA1CRFB# @DFG<OWPCCF1D05YT05%)5$?1A1Q?V)*C**QD#4%'^ !6!.1AT#
MQ )+H_0I*09H5B4L&RG2DI8/5*17R?.4, !J??"6*\T1<R@"8G'*1B210L9X
M?E.13B>=I@6\/%[F+@**CCO]'\2)I2OG3]\_IDM:)Y1,>S^$!2E3^EMAHC)!
M(6"7(7_0\YBNB;8=U]JNTPJ;?9C4].3GCC-)4*]+\D;HA11U"0;+<HJJ[!0F
MR\KI(;06GIE7Z/V#S^A3P@JO[PA)HIV(P;J@0#];120B$KYJ([Q@X4;07DG@
MIRF#^T<7CHO W)#H##?!B\B,%%9Z+S@'11X4,<S.F@1_"NW0-4V@[Z)OY>V\
MU^_"7<=AAF58<V<95T0P%AE)^U%4A(B#XD$@*\VLR?#KDOA5I%AQ1 ,E7$O%
MF3'"I,U[FPH\.,<M]5,DQ8LGINMONP!76H?-SB"$ K:]B#WT*K+*,?,8I1J@
M*H7*8Z.LC$0QSS6VQ$Y!#J ?T \6UGXW=_W@"PIN :+L;6QN38D3%Q,NN<&8
M(TN9=$AQ8[06@1OJ29!J^N7KQ>CS^C)&.5=1(:T$88S&H(V)6N  'YF 'R=_
MG^NU:?@\I6^4LR($K(FT+&IMO.$Z,(\$XY)&,DTR!BWXO'F44,=EG.#*J6L>
M^>!7NYW64J=U>-0OP,MZ7#'==M[>[7T)W<T]TPT?!W<W\"971 0S!H:F-H!<
M6:#!6N.LM 0+:S51TX1>9Y0M7L=NM0J;D!*L&<V4<-HSJ1# 7440TVZJ5N3G
M9(O"MS>\S_2"_V(&16QS.L*Y6]A0:>.]/[@,>^X5<2PI>'G(/+V[5I6M]C'\
M&OPL*IR@5-K:M4H8SJR';T)%+X0$3K-1XU+AS !GO8K.0@%'G6J.<2H845X%
M2;ARP%R$79QM+W76/3C+=)N#E=.421:NSR[VB4B#V6]Q(*F^*@(XK"5F 0OD
MG6="E*IH<AGF530,]L19C;GC@3"J@M(N2.>H(4(+H@N&P7JB-4PZI+?4.8*7
MZA["E UJIA6N4'FE:=JN,Z[C>\F&7H]7&.5F+LIFT]C.T'U\Y:XZ?.H9E[AH
M.^_O?4GCK'=^=/?S,AK6KV*5!5C!F 2>LIZ!J0XH"1G,A-%&*^M#R6B3QVCW
MFI$OW8X_<OWU[F;H'N?NZHPL-?-V[DRSFC<!HG7:SW$$Z_4YFW@<@G5.*\6!
MP<'.! 5J")6&6\EEG *05G+VA'/VZZ!)Q;4E.(J47XNE?"XF6$PBIFF_7ZD)
M/M_QYAAZ4GSRT2N&C-:2<<J",DI$2X!5A#94>U*RS.2PS)-UX$5IEL6V3R&2
MO>?4AL]S*%X$K:16W'O//+ K=F H6ZO!>,9.L&+I1D@/EV[X,'G1JF^.;9^Z
MDJ(,Z7NNI,6M8XE:EY@0+(C503%&HM7>!D[2Z>3(@O##XS\E?TTI?UW133=8
MYBF'U],A!V 49+%GF&/MH_>(&T$%$IC)H2L/DQ?,?EGRSJR9%47 TPOD)[V1
M_$D09@U 1*N80%9'@0PE@@=J4V;1$B.6#/W:R!!8U(<@N8C>,D6,)50&^!]A
M1F.%)IA'9XI]IM+$N#@[Y49YWNX^/W5^];R5>Y^ABDY1I1AVRE'F*=64I&K"
MQG.L!)/#"D!X$@'!9=QA$]8./V2N2X;K?1Q<O7*9@W$Y[P;7[SQO^4\\MN#?
M5)=#&Z!0Q)))[M,>+%6>QT"I$'%X1*8@4%92ZE&XY0:M?IXQ?VRXQ7/KD/?"
M"\D<HX8+*4(,V''L3>"3*W?/G_AV<OCD621: @Q *>,;C8P)'E.LL9%$$45C
MQ(I-%^G'F]%VQDD?G/*( ?:SJ<@2HO /*''*67"!&')^4HHCEIU_F#0>N'JB
M/?SG*(6W'">H=^L\P(T;QH'NZGD_'9Y?:_O\./='IGG)"$M[>8@7>72'*0:?
M>^&@Q?EY=L]]M*NW/F'A8!Z8!U";8"XRY+D2"A,MK??6@84Q-"8P A-X4CEG
M:HR)GUCGGW/3_IC_RCQ_JMH!NX&(<6RD"4TQ<S(RKED@2L68@C\YP@QCYV7)
M,R]A@%Z8F\L!N*J5MX/_.*COA11Z:-J#DF.O9H-T,3FLM6(N,&6UB<Q[)  8
M6TYQ.$\,0,[C8 A1)>N^-O,\54"NY+Q8;/N-L'L$D*_3'5P(SO.OY_=U8!>W
M$C6&]5P)*AT8@*GT'&.PGMM4X!%1Z8WG6M'SDG-$3&S$U]OC]*>['*XIRI>)
MP/*2<D28D$P$Q@/2PC'+'>)<$T]L+-W04\U@SY2:7DL7@R#.P%(LD)$DIE47
M5F%I:)B"T^IOAV>F</E]GMIP3A"!(V921Z8D4X3+$'BTD405$7V%(J[3S+QC
M6>M>H"#M]3AZ%!U50@DI-!,T*.V=,P%K+WDJ+C?B 7;. Q.8.O+-Q0>,@='8
M_1EM3"ED-?7 7@0[I@GC BLI1&3:N!!]B-%- :--$@],++IZ?4Z+EFCL*#:,
M<Z:HMMPB*X1A,1 A>7DT: +9>0P>B5<X70D@R1)'K$JI;SPVP2N",1;2&>3T
M-##:)/' =*BTU\D-JA7P6:IA$5+:'&(U 080/C*&D#)LE&& )%_;Z,.D<MKG
M3GLW>?53<<X[2LCD;>##I6[P^7.K#%(X,<E]"'GCUB?E0[+68>DMQYAQARW5
M&C0&T@H'%R_*<6/$9YY^]^XQ]71GO==A-ZO&Y<U\& 4!,[+^_.8WR#\?Q]8-
M@!$9E&42L F.'E83A'4*=P@:.6,GGQ?N29G5O-OK+\(M_GS-@-'63\8&8%Y3
MI3P+9UAN+* *3!@AS(1@#+"#)S0@(<%>%R-@03'/SC],*HM,C+HO%F/,[[UN
M7][ZE"1E!HQ>AIA0.C! A)9[ZKUV,C 6K*933\@1\+JDXN:WC[-(2 3PB_(8
MG7:>14P!ZDM;E*+E7 0[!2<3)D=)CLE[;3%57 LKN'=,4ZG NK?*NFA2%6?Y
MED@RO5!J7#L9$@025"LEVC!&F7*44DF(B4Y%XDW)"T_EA5_#M4GA!0ST=@H#
MK7%@43I-F;;$"6TQ=".G8"?V@939ZX9?R>G;726"D3Y(BH3!@J6BR5@:SXV.
M4CB/.)M\;IATS;#:.7K>4P5C7":,-@Y+Y0%[,RVM]AIY9E*D;]!<CLIVE-ZS
M7Y+DAD/L"23Q/E#I&+5(*B8I$ ( MI:(4^U3[,Q;]&S>N\=OIIL;VPP;8-5<
M[^U+%^Y./\^B$S6 ':UQU)1PPJ("Y.^UYAY[++0704P!SSS_ ;&2&U^(&P68
MGH LE=>PDA I31%3I7E$U 4;T(@;-479^8=)X\9)6%UN$O)J0I]?$'),Z:*T
MB3255 P6T &W8$E:^&:94(HAQ*8I[_O$$/)5=DM)Y!P+;Z( B90 )YB*+E'1
M"1NELB.85]+O'C!O3,A;(:IIU!8Q9)FUZ0@FH<1RA30#,3LWROGDK=3/=(SW
MR281?P3^?I>?ON^&'AAL+O2&7_>"\<5X?'[\X4_X,Q(A*74 ;*Z]T\QQ;JUT
M7GD<1>2$,/\]B<[E,[W^H D4:>7M;"_DNWO]]XPL2'[8_^,D]_V]]QBA_SM7
MW/KAS]ZA:9\_X#K-3O?]OX!B*,8_(HPSBZ:5-P?O_Z<.).A5:N&DLM%IF?;_
MS/=,NY?UX,U&-_;RLP -0Q_%UY-1OPC]T03Y.!\')NC__I'>/O/!%2$IG?;[
MHS:\<[H+QF0F9BR5O6Z(?\W]Z]>3+^<^U!/2JG1B92D1M]WO_?G. $72Y)X3
MYA9YBJY-,]]MOW<A1=',#:GQX4_;?7?CX:M4-=U=(*SM]/N=UGL*+WE70_UB
M0*-';*<+;Y6Y% ATV OOSS_\X?/>8=,,@&.+B2D>^N-Z!XEKCD.WGS)8C3HI
M^AM>'C$4H0M4X\13?6#>OC_O>,1N"P6[O>O[V]>T6M#HQY?1 KZX]JYHNWM^
MPXB*, %SQ7/P4FG&_IJC<S?>>_0F^+!?Z76:N:\47 7<<&B\S]N[[U$%%ZU<
M=O.NF(H'$.T.MH4.'L.V[ ;;RIMLB]-T;=76ZBO+E<WZ8GUE\X>\,BFCW5Q9
MVMI8JZ^M;%86:\N5E7\O_;U8^[1265JO5M<V-]?6:Z_X"C?UQ-VOL&UZ>\ K
M_4Y[OK*\L+10(8@S_>!AE\+]EH6;W(_75M<WJI4_ 0ZT.^W:40L:<941:MA(
M:U*.!(\\VL"++$R4*!PM<EH&R8/#^,XZ?I6V23#-A_S]<L<5ON2$FN9&CC_Z
M;6"7.\>?R<9Q@U:/_/[*\<XGO;^^OT9K9\WFSJ>-YOKVQOYZ?6._5O^6-_;]
M_L[RWD%UNT%V]K<&U?V-@\^TUFR<=0:U,\=WMC<.=NK-@\;9 6J<;>%&:XTV
MR%>VL[S:JK4:N+J_AG96U>EGLC-H;#O1V-\ZV]E>&]1(8[!3KS+0#J>ULUW6
MV%]MK4,?C>VOI]7ZWEZMM77L/WUC_N]_FCND>6SW#_-:'?J%<>[L_].LGNVB
M1GV%KB_OY3 VOK._L[>SO'*Z_FF%['Q3I^OUK=/OGEG#C7&9X5%EC!N2*2=<
MIE)Q8FNDXPJ +T;9UP*475+AQX);BNGKB^DO=.OKDPAP]P(:SO1#:406B"#W
M(M&#*,\7.%4/H?R/R'Q.1G)XF@AY>]FZ.3O#B7GVQ?P6Z!].__/KUJ]'I@NO
MW1QLA,-.MS]7B9UNR_2A@]/^^YB?!I_UNT?3J7Y7<_MI2T![J+8-[2U_W-O9
M_\IKG[90M04J>+G96J^O-N$W5%O^UJSNN]$SWZ OWMZI'\+8O^+&=@-5/Z7G
M#]!._>N@T=HZ@;YX=?L;_);:WAK4L#KY7%_L5S?1Z>=Z@Q3JVTCOE5,\(X'B
M#$PRFUDM4(844L0CE3R&<Q_^^U]:,O''#S7XB.&GGI>_;BUNU%<V/C<J&RM?
MUC?JE2];&YM;B[5ZI;Y> >!=!W1=P;2ROE'!_#?_>V5]M5+_>Z5R!9-?X/'%
MI7JZC#5EU^;IY_IXI G[G</WF-\Y7\4O>3OY?=X36>CYL4Z5OA^LZG0K_;U0
M^<^Y:%:&GIE*@)'YEP!<7XK^5H:^U.LJP<,O60OZW$N/9=X,LD$PW2RTIU)%
M/!ZA5?</OJ<#SXX+GX5@;,:$BIG!.F8Z6JJ<BT)X._>A:KIN[[__A07Z@^+Y
M2IKX)^&U%Y;>@B<[W>G%*S]#'62!2SE^O"(6,*$E7GD.6S"='<R3#_3'@"6:
M9F^:$<O.\BZK0;O5Y963QMGJ'B 6!HAE'U!*JT:JN/:I ?TUZ/KVVDW$<K"^
MO$L:^^ZD6O^X7]U> <2R"XBE"BBE06&\:&=_[Z"V[WBC>0=BB8IHYX+("',R
M8UB1S%H!L,4C:63 3H4P0BQL]A%+?6.QMKE6X)()@"QZ"A!+_T(XSR%+['9:
ME>_IO_.W?O'A_6P?9[@JO]K0YC[T.Y5R<GXT.0LOTO?=@.?ZR__" 8[)#SS@
M+SMI) T\U>'(>VD7NK*: P@#]6Q#]WWE.>V&E6+_.74W[&TJU]XG.6L'WU40
MBNL0,RJXSYCB---2XLPB!H8^BYJAF*(,<$:UP&R"+ !U+V%\=O;9"+MY+ZT@
M_92AX<VQT%?R71$3E34\D]S2+!WUS(P(*53-1TRT8$P;@"6+ $(V*U_^7MRH
M+BZM;-77EA8_;\Y7UFI+"Y/#5?=CJM]63HWK%ZR0HA(N6:!B>I7>87 I_,97
M\G8E[_<J;J]PB/P^[MW,U[=@W_:FR,O.M28+BHK'S#53"QR)1WD+?GZ-J_'[
M((K!WJ_9<?L@P%QY<>SSW/Z'X1JUU@:@?#C"RIM]TP]%9J'N8*GCKSM*X0U<
M"ESMA\-NYSBU,Z4>TJ%+8KU>V]MI-7B#K+ :J0YJRQLYK&DPGHW6SG;MH+;O
MF]76/P<[\"[771(=7B6KK9W]YGZCODL;9VNH]FGM;'UYIU7[M-.$<9(:V1HT
M6ANMZK<[7!*$>62XYQD!T)0QZG1FHQ0 L%0,B#*"DDMB.33-B>F&)_@DKNFP
M4A!^(0AU<[HV"H]UA3!,,?!_:0Y?N\[A7("%0*C,I$^&@[4F.=UT%J(G02(O
M203#0>&,22R5P#_E\>EP)]^/B7\K%&RETZUT^GNA6]D_ZN8]GQ=YXP M%I@N
MOZJ0BUN[NZ:=GQ7??W]E\7_5R5M;V%C87*BLM Z;G4'H%K-U760KM<["[P]W
M1I9!?Z\"G"=Q]DLH/8M0^F7</8O>=T.O-_HG'4["4XP>=EHKM I]-^H;K5K]
MG[W:IUH3GCFKGJV=KB_[@]K9"JY^JIY4EV^BA\-6H^X&PV=@+*T5U"!;='VY
M>E;=3TCD*ZW6MTX:9XLG=^-C8237&M !1X >&">9DMYG)B BF&2&"CGW 7/&
M4.6SV3UJF\J2:0] ^V]TC)^O;![EL,9B@5X&.M]6>(\2EF:(M]33Q6K[DFZN
M"8'C(RE:@H_KW7KG9)I-S1<2I=.;HO29;C3#WQN#G6U_: D#@^#K";0QJ"[_
ML[>^O7526UX\W=E>S6&L\+XP;\M?SW9:55PE_\3:XG?G4111D R%R#,&],P4
ME30S47J'O":.NKD/:]UCX(Z;LC;__)LS(PXI(/5Z]TNW ^-P,^VRF$8^6E_\
M3M(A<AML)@U#&8L\9%HRF@FI+!(:8Q*!CY9 J0'IVKGYN<O_#5H^+R5*7SH@
M*\V=_'#H^ROEY)=R<L/Q(;$FECF1<:\B<#K2F0X$=*?6'OZ54J0=4TT$5F_'
MYS%BKK0;=M@%%9T?FF8EG 9WE-+BP\^I\G+O37LV0.0J2>8>XKN8D/W.9]1-
M"?LM=H.96FWTI,US]ET91&+ .K/"4["&F,P,TRSS+CCG%. O)X!Y--._W]0F
MSXF^/G= :K[L==IO-33F*_TN4OYJHV26LB!G8))R0,4\9@)[HKA .&BP45G2
M_XK\V!"=4)G^[3)JX7]ZE7YHAL-$[DJ[H/=\!91X\RBIUXH!\03FNJJYIL'+
M]W9\K,]Q&G[_J-?/X^"Y>?/N*,9-P W=O)]#@]V"2T,W^,KA4;=WE()L^IT*
MW%'L!6#RF_T]H8X4Q[OH^N^GBD6E6B#X<8YHM$#0_8Z6/J19S!>P>)P/^Z>C
MQ0NPOHS#$STB27*DW9"=/T:7BG-RUZ],"$[\)>\/P_?S_C#733!NK^*:IM>[
M!VI^ _/2-<5JM#EHV4YS+%/2'38_D]-5&\4F%EP43MU>RK]9 8UYLI?#+Y=J
M]2$VZ<_6KC]FGP6?$6^/5KP!)K90 %.)MX>.F=IV]60=VFOL?X4^X-GE-59=
M;C8;VVMH??N?UGI]\63G4W50K=^*2,&-LT56W=[):\L;^VDLU?W=D_7M;WO0
M%F^T&KRZ_!'&OG9ZEP/S.[%.<T-I%C@5R1U#,XNBRYA#$4?XXPT;'C0 ,=CL
M=]S!?.6_BB.8N')HNI5CTSP*Z010I;?WN*"L4CZ>2SY&VG^H_$OAN(=PK-S(
MZN $TM*Z3%'!,J:"RJP2/,.&>1\)D@;C89#^R_/]^-;AB=E@O2>F :.E9GK>
M_*?RJ=FQIEFIFNY!Z%<^?UZ:'/_!W6/_[056PY41;AF>K+FYYY=0S=1O][V<
M0EC[Z79?M;6S5]T_(# 6F*<JKRUOL?7E ]X@_^S5EK\.=O:_TIWE*JY^VHC5
MLZ_?G19 2\XS0DC,F(=EUUH,^B15.E<X:*-50J%7F7LS-,%L'_'X337S^QT[
M@/=V>USW5MS_W,QK>3F*(X]K;9]"&D/%#BIN+[B#2@MF!@!Z*.)&DT>C>WFR
MZ#?\>V7/]"HQ;P9?,<TF7$R9!)*+Y#]'>7*0]#L5&T8W0)L7/A*:(DR'1[U'
MGI(K#I9S&4O>DW0Y'?6N>+@*ME:Z]; ;7"@L+TPJ10:57N4W: ^DL=([ E.B
MM]=)QYO.CT[W]TS_YMA/S/51IB$.'QZ]P^_S%=/VE=_(\!TMR#1<M_N)7>#^
MXE9X*(UBU$Y*JM K!E$,TO3Z%8TJW@QZ"\,SL%?_/OO>ZM)1MPL#&N9V2#BE
M;_I'O:E42T]RFI]]EYBE "X"^!O+C$D X0:P149=X C'B -S<Q\:H7=K-V.4
M4:I2J74J%[D:GNW$W!1)?I(($(96WN^#^!0ZM-MI)X33'%0"H)U!92W-02I-
M?APJRZ9OAF>H;RB&RS:N>E(WCN!.AOCH(.-1<QADO9G5*[\EZ9%_$$H61C?T
M]_+B/.-A.L_XW%IB.-X+X0^]WQ<JE8FG[0L<YKJ@=2+U2/6\/5W#O[.44#1:
MEGFIP<R7'F>P>!DP<12U7A?IZL:J:^X%,Z9 HX 0FTK3=&'5-\Z!1NF:I!:2
MD'732GSGKQ68P.S."[T6J"+HI7N^_ '7MV .!O,)>$!SL%JGO9'=RFZW<]+?
M.[^\ #@D%&/S(>;M(@-+$4+RW_]2A,!K_F"$Q67\Q_EMO[SAQ^,[OS&!C]'-
M/QCK^9UY>Z@Q,;$9.8=35S'4PAT,\<+'&_2"',;]/W17";,%S/38CS>0!:+'
MGUU5H 5*'W<6XZ=S(!<(>=S.VJ_F@#_S68R?>C]>P47P.<GO$(%?D='A#X6@
M/BWWUJ2][LV%9$9>ZHH9-5-OMGASV9BMU[N+&V='M;Q(5JCN$C#';J<[N,/W
M6-Q4L(T;W335;LCJLF,IHK^:CHTO'R0WY-GZ,O2W_VV_<?9MK[;<W%__M,9K
M^ULWW9 GJ>W:<G50^[1SL%Y/;L@J@W?+:]NU_=KV"EK?KD+?!Z1VUZ:=L]$
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MZ<Q2A#,6#,TTQCP34BF$M-%"^+D/$L\+@29(1<T.GK];'H?Y>H=.UBLI*'Z
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M+93::HS::NT61)'<>N8LRRQ.+E=)8V:]<AF.@AI8?;B.9NX#GL>:3I %5;I
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MF'L6'1].ZGL*5/"=(]L,0PI=H=W-2[_4;Y,6^O)?KS,ULZ+RGZ&"UV+;EPO
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M')1 "TX"<H(C[B*9X^M<S*\N;@&ZA5+XEPITS^"5+_#VR/ V5??;$$CC9D0
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M'758$@(T4B*N%E3*8!XU.6[M2.$%4N*7Y.N9C*FF!!57!U$3U]#?=:N="AB
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MI#*FSDH@-5; T[1V1A(FV=J&PHL4_G]JM\1S:F'EF>BD@D4YACZH@W#%0;$
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M\,(B8E60>-[NA 7AM//+ RG M^K ]P@'RFX+? 7@[@9P4V0WKH9UC'J B(>
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M>]TH\YWN2<O&QWQO];J=BG]=/)IR_K4(8!7DK4>(.!IO**ES2\X_6Q\-/T[
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M<C"!P1G76A7>C*BEF\"6ZL31^"SIA/O_O\-NNK2&[-.X5%5M@O1;A>C.MRO
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MS[2KO1 _?30:YI/XLTA5J;OC _SHD&=N>";9W?ZL/*=4"@V(1PY0I0R0,A#
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MC:]J%AFD7JH'1:?V)ZGK^WHE]^TFW0.GL>9W&6U\.BM,:,/?HMAO(^%C+$O
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ML+ =<S\"YG:IRX00D HI*54F&IH^PKW1A!JBM.Y4\WO#X6WQ#2WG6$%@F+"
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ME\ >:9V0E.' N*50.8V@449HK9AGEML5FW@/?FSB[=M_57)7,(A:*AQ 5FI
M!31 (1. 3&CE-?$(RHWGG&U*A%>4W[5&\V,?-D-?38'M;JF[I>Z6UE8X/LZY
MPK>OM5<"4BECN$<2*.(XH%HS8&Q4X@,7 4/(K!'K*"!O-._U,;^S.]CN8._7
M.U<99B9B+<K>ELOH_=$TC20\*X'CLOZ31UG8=KF]/Q25;54-R3I_QJVJ:[O]
M!7\&)THIR25P,@U@15P![8@!EGOGJ/(T")75-:466TQ>S<]ZLQ5IMQ0$ZL#N
M?H/=M8*5'05W%'SGF^XHN*/@^TW!:Z-P=C["FU4ZVSY"@920&G+ </Q!24!
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M//!:0"4Q%838J-\MJ>Z_=.Y-AW0=TMWYIM< Z#J?XZT 73L>:+532@F 9*"
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M/Z*]EZ_H1_R1??QR@#_MOPY55L[.>XAWOWQ%.VGF5\#68PDT$AY0&/\F,26
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MN(2"XM9Z12<5==OU^X/58F2Y  5DRT7OQ/7Z%A[?MMMG!?Q3V%&J!@(;#O5
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M_FC#1V],2^L'&V*K63L##:7U]=IIXW0O$D<$30P!OF+$=1#(.A&1EW#OQ%/
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M/M'D-84<5!#W!B!.44NE-<)';;ERQ&B%C7!",N>8PK*$.#J".%I!W!Q ')N
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M%=U.S_IH![;MR%J]?()[<ET:2(S.>Z.U ,HKG 9;RE*FK'!*J'1;Q^R*Z[X
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MH\3*V2\)[+@G.\<,=[YG=_6(_(Y"@N >(T!U\2BF?,.2LO;BL>U>^*/'9'*
M16,Y)*VN/SG,70=]1ML2##.%C]W#UM'@!EEV.R< 9[E58.FG'O^T5>8^'45_
M<6VV#O:S@ T_ZP/;+TH_]YUCT%\H5!G,S-Y)N_1(W &?QO&(R8<@]=BW7AK#
M\JX5XX]665@UK]IH(B;.4VSA.K:;>SZ61MV%S0<[8*<UBFH?M_E(%N=6[_I;
M#N5ZQ&N/,ODHK;(<D00[Y84$7[J+8OOL?A$)7C.M.?':,QX8,XQ209@-XO]G
M[\N;VS:V?+\*2L_WC5U%*-B79,95LB7G.A-)=BPGS_G'U0 :(FP0X 5(R<RG
M?^><[@; 32)E+92,.Y/$)@F@T7WVY7?,P'-\GX2HN3Y6H8* ?PCO]QVK)K,S
MD)^U>/3AE".2S%G9_;ZW=*\6H&^=XW_@^X//GLE=UP]]W4J,2'=,K)R)&-=3
M-PJCR#0-.W P*K$.?;GK3 F\8)'I(\-U/*UB"B%LEXQRK, (&5!,:OJ.[V)/
M@6,'B9MRV_:\-*(H%Q&,OHIRC#GENX9J3FFM9^4[N<0/<B%]&NI:LK&.+S_[
M7F*S-&1Z%-N&[J2AJX=&;.I>@'TC$1Q@P,#]=@>FO:+PJLU(=3P4@I;U?YG/
M4 V$S%,(U"(R76MH/:$<(X_E1IF)Q(UB(TD\ JEQ;.9ZOL=3;L:NF3#NKI9)
MULJ\1 3DD[SNB$M!2P=34-H5%H9^1(U/V2Q!=>_ 7ZJ/Y"M15N,/5-;R$_1L
MQ._JOTA?\.0 O!C6_$!<8O;D*,C1 #/0B'QN@7FN\S1U=<=V@1PMQ](]YG#/
MB=S 2$PL C169+A 3MV(@M(D,A+#8G;J.)Z;XK@YYH-3$-AI:@9.3T&/AH+,
MD_>?L1D50[RZ[V"*%!20S@+#U2V? 6GY3@A?[[VTG7U_61.V6;6K+*T1FV'T
M1%GN8*=%,XUG% <?HW82HF[""RUALUHKR@EFX639"7H8M4:SR='X@T_2+!&M
M8-ED-M#0GAT5X%'$LK"%9H2O+*1A-;:GM-9?K>I94G915@M2>=<=A@^MF]4X
M#-M-+-\QM^ 4.Q)GFK.JRGTNS,&Z+B8%K3DR.>9O%SR&3"!/C8#07@\SGFIO
M&K ;&6\ -3O,1!"N]08HY%;F>7F)A-QXMR!B!6"!K(?&8F7LEQ<53:8K%OYS
M9SE-@)'_!PEQ4EZ)'\?C(#$<[O/(#YS4L.$_8/79K@,NC<6L1'8?NH:CJS_,
M&7SORGK2NMNOY+(/IY5$F7R%UA[+637[H%:XLN2>HB[)M&JB+C^HB#R^/#V,
MOYV S6<F*6QVJKL>6'I.&B4Z\UFL^Z'CVIYK1S%/]EX60-&R86\1&HYJB=$=
MJ&G[B70>DA(D6[UC6:*^?%T*1;F2$NBM?G Z &/+"<#( :M*#U/7!I?1B?7
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M:8/]SD-/C_PPUHW(<[G%? /\2_ FPWU[A:AM"FX4226BIC6KV]G9$8_A.)>
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M(N=YP^D#XFG^C8W&:#"*/%#,L_%$6'$S2OT/NL4O"XDFV $P8DMP[C0JEM3
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M)"-9HL6(<KR8C2G&2NJFH'H>C:DU-89'9S**:% 1#3E@A[1Q6/GI6-1Q=Q)
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M1T[TI7%8 D9U3[Q2YT54D_COX$>_RDKMM),>G\&G(QK_^GQ/?H^36<\1"TY
M8<?YE&!3.GU&8HH.$N26G>[(,."HTG* 8U$UO2-,%!FHJ<%P:7!BQ=D,8!N
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MC1CV8Z@!7A\MT?IJX Y(AKMUDVY?+?I83O>Y?X.0>7^N.W^NUL!RM@53ZJN
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M>L59+2"!GAG[=@.-M!7HACW06$W /JP2,#0$+U1E<),9+$$A7PAH#O500OJ
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MT-[<LM^>:6P\!GX7%3X-Z78.0H$LXI*3[DFTZY4[W9YW5J05 X8 33ZMN-K
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MB,7<[9V>X$_T^SA7Y3E;^"$%@=KO%NT"?<5[MZW"RW"B)F&.Y["@ZC%"GPA
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M )Y%>?-)$.2E.STF\C+&#4FJNP2)K\R-_.3*(%O.V8B8_:NX?"[DZL^(%95
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M1?GBW?A*Q(T=^]9>!RLX[KC[]] *!;]V**Q>&^<0B<WPYW?_!U!+ P04
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M_86S>EN^QC3O+HDW6J=+B!XPQ01*Z02Q.%*>4;1837Z2R<9K^PJ<4S*0M^?
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MD!DI4(QWR2N;>6E=DVL"_*2VJ7JEY[><=O]Z[RTJW!=Z/6+U!;H0R4>+ BB
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M#E# GI'WZO7Z(X8I_OJW_P=02P,$%     @ \X&I5K<@H_=G1   0_<" !4
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M8TL'^NC CWA)(LH9\PL<];_.G-DELK>#FS_[ R>]P%!D)CEH<F=!6:)Y<*:
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MJU)*,@R<)\@R)"6]<!FQ>8;RIN .3Z%]M+B:S-*)"EH;5"\P3J[4]5BI^+'
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M)Z)3?PO;AB^;E0??21<'JQ__;/(\C$;?Z9R<+>\>T]$PD0)X.RNM)&NVDB[
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MH41N0=6NQC%) TZ7X&62:.Q*ZM2:UMX= WTD9#LYG;;N(W_GW,+H[/O+;V1
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M.6&LEE(9(;+RI,CL4K1D%G#'K?-KT^3N'O&$TN,2:J6M)6Z2=4SV3G;@C-&
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MLU+$PC2M%DX\S^C!:R;!%*,-RV2#Y W36[8;^/ 6<Q/57P]0Z5#6'=2$6!'
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M23+F,@N[4-_4"&%C+BB-O3>[\S'P0UF;_Z/;[.$2XG83B %Q]'WV4>SMRM^
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MREPP_ZB_J7KC/8D8CF62P20T>K<A8I#I^0=D,F(TI:F@W"F3Q6[A4V.=6K3
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M:]&SV2PVB_PWAN\IQBEMGUV%X]H+N'&CC9WLDSZM9RLX;"'Y;XV1=I)ZMLI
M&TG7P=BYG]2SZ/&VE:[S?6]WZ<JB>@Q/[Y;S^?*W3XO/*S;/^2>E]+BWN&O[
M44RS*"*!@'HER2"2200QE@%,HRSE-!8")5;*+A=KFMI0T]@*/RU 8RU8F^O
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M."!Z@L$)0D1R(:P.WU[$^JG1UR^M^0ZA Z,W>#</3KX9I[".?6470KB!89@
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M8RJ+>2BAF<1"%&4<DD@(&"99$@>)) &R"CZPJ&MJ7;:V#=#68*.<6$L\F0.
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M[?UHP1B/8KW@S9(H@2@+$*2"*IB$F&8X(BH*G.)!.FN;VI"R-;8)$W%>\G8
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MIJKM[/ZNTK;[RSTW0LT9S/URKM\HFXC5&0EC%"8\@DH@!)%0!!(<,DB9$EE
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MU Y -V -$6@Q:FXT H/2CJ+O!$)_O+3[2\<*#>O4[R.XR$M#CI=]JI=U;I,
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M5TV:C7@'S:-DQKF4'%*5)Q!SI2 1"-NFB)&6-!%$)GV2N,.*.36C7<H+5I7
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MC7HL9E$L<BZ-Z9<BHY8A4D*F4 RU<9U5)G&*,>E'H.XP^]2,4GD%UGZ==CI
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M,\YUHR TPD*KHOG97JVJ?24XRA"] [S4S?KGX3:"H%@',OAA9!K5L >%\=B
MAQW</U7BG=D<-C]J)IK/ZFFUWI2[ -MLBYE.)(V8EI#F)+)WM,2Z^BE$/,]1
M0D648J>$JVL33<V<5K+N>.=VTH)*7/?,BDYTKR=:A,)L8!O8%RZO1 P7+'KE
M970./%J:AHMZ[:P-I\_W\]O*_N=EX6_Q<54E>2XWLS0E$4HS"15&&F*,[-6E
MI%#F:<:H9N;P[\5B?W:6J1F"ARH)O)32SZ<Z#Z*;CW0S- ._[Q4JE8!W8"]B
M.,^E$X% GLCY.4;U+#K5//84NC_<.]_:.!2%\3JJ/^^7[TJ&8*4^J]+K:'%_
MSJ2(6)HK#HEFQ@+(*(,L)@*:0QA.=<X8<<NC[#/YU Q#0YKXQ'Z8.1=EQ0BO
M*96]\[#=E\#-?@P%[,!FI1$;O&H$M\EOH)$=U,*##PZU.'W2MKTQ"Y?%[3[U
MV$G=WJ"<R?'V'^.&]LPG\:W3KIX_7^_J^7'[R-5Z1A5!6N($4LR9I2%6D.%,
MP50JE)+8V+R,>G=E#BGAU.QB2\">-'CA%]'-:+[HT@QL60?KP5QI&KCU\A"+
M$++C<E#YQF^T/ 2\9_LK#S+1#3M#GW[/G\PK^-W\L,SW>= M#L6Z<<9,B4CC
ME-I^FLAN$9I#1B6#B&J,$\DY\R.E&$[4J>T5)2M>14C1(JYH$:KVV#B&66./
M'>3%5V[Z6TFC;I60:1?]D!JV5CKPKC+HPH3<7H81=/Q]9E# SVXXP\[HM_,4
MZ\WLC6654.LGMM[\^&C>J==_S(L9$GG,&68P1E1"3),8LC2++9U1I#!6><IB
ME_WBT@13L_)M&8$5$OQFQ72L5K\(8[=)#@'.P(;4&Q=GLW=-^2YC99YM&2KS
MK[V1NCCL**;EFE*-0;CZN9<)+3QL-\6&+6V&37TJ)7&49<9UA"JB&<0R3B!/
MF(9*Y2+7>13A7,V.F]</?HH]D=/GC3F6=KB7YV?U;;Y<VBM&SA9E$M[+!!M.
MES7)M<ASCB#-;5ESK(0Y#B@,A4XM?;F*A2"SPU[V?X9%;60=\A)93G$]QPD>
MW;1"T_?X=\&CEI[3"QY=7(2)!(].Y?M3!8\NPALZ>'1YHKZ7I,:94,6FJM%X
MO93-#THVK$*UVF\?DEPRAH@DA!H'7YF](!(<LDC'4"$=\52P///KB=-7D*D=
M"5K4I8T&H%;!]^ZTY\JXWJ,.C_?@=ZHUOG4YF+VG/L8<[/48E)/T5CB#7;?V
M%&/DJ]?;P#J]AKUQO+ZII7;"]=-J71KQDNJK/)ZM?[Q923431.-$Y112C<TI
M""L-*2,1E$DN(AYKB2*G['['^:9F">O,R0.9[RJ>.@,SJ"4'5G3?I--NW+L-
MX !H#FSG0@#9(QW5"9X;LE*[QQ\Y.=5)V=,<5;?'>E#SO%DK.=^\9[9US>;'
M^_FZV.RXS+X:9U%\5U]_7_VBJDR.%&F1X 2*-+5A5X&,5\8PC&*LTS2.J1).
MJ>S>,T_-Y%2R@T;X.U"*#W;RWX%: V!4\.!%\5J-;O,S*,9#AW5]X 6_5?([
M!L/]<?8@E1D*[Y&88L)\K?WX7OI UDGBXC7@>,PL??0\H%OI-4!?#I6%^6>Y
MVSRK5LR@,"ZO39N^\&LK16'Y%5?+XL-\J>XWZK&8)9P+F2L&"<\3B)54D#.E
M($V22&,:I8KYD>H'%&YR^TI;^(/8H#USMO]=E0]LOK,E.'SH-ZL<*+7S)+,.
MNNINP8&76LO!KR7'6<8>I#+A\0[&0A-0M)%I:\*#>LIS,\ <_3:'LJ7E@WY=
M]?N8+[]]6BWFXD?U__OH((U(2@C+82P1ACB3#')I3@T\31FW9P5*O%+ZW*:=
MFD$OI;8QVD]FU,:!\S/+CGB[&=SP* YL2G< [D6^ Y6XX+?ZST$"K7Y(!3*"
MCI..:M[\@#@V7)Y/]^;J*EL461:6C;&([YHN11_59D9E))7,8\BQ5A"S&$%F
MB_ 3(C,5)5Q3['6!U#79U,S/I[.]F^[ 4EW.#/5'F"LEB.8Q3"VW(L:QK6JF
M"!(J8BYYQ!1F/K2*P1 >@5=Q'(3=C'LHW 8VZ8V8QHY;04ODWNV1^]B!7!\:
MKZN0A&/ANCS5V"1:5Y4^PX%U_9F^[?>*[V9$^\>[?1O-U[PHN<1GF?$-HX1&
M4"4\A9AD.60H3V!$,8X(Y5E.O2JBNZ>;FH4NFRG8-^"XS>C??%OD=8+L>!P/
M!MW0!^P&M?(O+5G!;XVT(4_-3K $:WW7.=G(#>]<%#]M<^?T5)_+J@O'W,^6
M;MH>A1_X8OZM/&,5GY7M?V4=SK5ZJO*;9HP+1AC2$*G<F!JE(\CS7$&MTHQ2
MH72LG$Q-"&&F9HAV(H*GG8P^-RHW+HW+9=9X@+]4?/ .5,H HPUHJ6-^OEN>
M3R^Q/#YW8.,MTUC78@,OE^>%61A\N^_0;IQCQ&NU,&@<WK0%&K,G<YC6<Z%V
M_G=]"<UD)##/-!32]E]4*8$LHA*BG/&4&Z>92N3%''9NEJGM2960^V.U)WO8
M62#=/.&;X1EX!ZF1V0EX/0G"GSZL"X)0]&%GYQB7/JQ+S1/ZL,X/]WO?&R:?
M%FETDWB2:)JQ!,$\L>U***?06  ,,Q;E)%<QDHG7%<K%F:;VWE=MBE95)8+?
M2W\93:8U%6D<0Q9C 7&>9I 2&AOG/Y:90H)B06?/:LU7H^+9GG$D1._ =MET
M39!_^3>"8O1WV^]/R?),O5U6_P@%O)O%#0+FP%;W:F>"NA]!>&-\%9U !OGR
M/*,:Y:OJ'AOFZP^$XG8L,S;VW)$5E^2,F*\.4A&#:19C8ZHC":FB#"HMA4[R
M/-.<S9;JF^5J^WH+N^/9Z9U>$5J](B="#.BDE,DMR]42UM+V(H%U70(W,Q,2
MT1=E=*S W<M=4\D.2>;8B=1@/([G9WUA"L=.**ZS-W8_[D^2\G6^6:@'?;^4
M\^>YW++%O^:;[R4UI-WOO\^?OJZJ.H*W*WM<G46,,T54#!,1Y1!+$D-.$@ZS
M-./2F#"&J5/[J1YS3\W7+,6OJB@;!<!OE:@>]"J^"]!MK :&=6"#U0M1+V*6
MGMC<P-GB.^-H="X]H6@SO?0=HB<)C/70JJ:?;[=K&S@KN3'^:;GKVGV3=CV]
M9DH; Q4I N-(*F.LT@12)#44QJ_25$8X(DY51[TEF)K)>M?J>%>?VXK^)V;_
M!7'SM :%>>B#7@EGW>2XDAY4XM^!4H&[NI5RK<,0'>AZXQ>*:<-[_G&9-/K"
M<\*4T7N@?@;PPVKYS9R^'FV3HID@.(L(QU!+16MVBR1+(1:"<4VTXEGDDSK7
M'MS+;(V0*F?E HL56_;(CCL S<W^](5B8--BQ8(E%%:P<.;BG+J!+,'!T*.^
MY.>4.GY_SWYF9(*Z=V7?V?MEL5F7%])%><#[^ITM:^/Q?K76:FYVZOME95YF
M*,*I2I Y>*&,0YP2"3G.!(Q8*G+*<\E3W2-B-*(*$XTZ[>0<F_ZLQY? T9.:
MV)K^:2C3*OU!"X!VP=V.4&W_C9DO:S=O H1J_1?OI:G6>DC^YR!AZ[\DP>C9
M;A#AAD9V'U=+FQ[.; %/17Y4,Q[-,N.IQDI*J"E&$.-<0D*XAB1)!=+FOYAX
M=1;NGFYJ)_'*FLPK6K!7JA+RIQ[^[164W?:)<-@-;-IW=Q<[21MJM5>UL)?W
M['YM\*ZB$K(?WN7)QF^,=U7QLQWRKC]U@S&Q%F^MOIOAYL^J&OW#JBB.F_BV
M&OC*_]P6F[H8Y4';/MF,RB3+DL@8&T;,N1FED* 8PX3'241B3+CR2HT))=C4
M#-113W-@W*>J64C)4%CL-#E;@M+#A(586ZZ1RBSQL\2QAI@E&C+,"52:,Z98
MG*42^27JO,3JCI/74UE2T5:M7.@76CJ/?6KDY1AZ1WMS?P><VMC;GN/@E575
M^ E,;VP3V)UFY6L8M'U]:*Q#[I,AQ!I_1PT(YMF]-^3X/<-@S-X'5OU;;$<7
M<XXH#R,S)EDD8ZF@2H6-4<L4TC2*H,"(1GD61YIZE=)?FFAJN^C#>OYMOF0&
M*7M- )[*EDNOMH4$QDD"993)-\AT"6+'B%  X(8.W[ J":#I1U5B9N2LXC4!
MXRM7H @5#+DTS;B1BRO*GH09KGV^+S_<KL%3.5SQ>KOYOEI;-W-&8N.14XYA
MG,<"8A51R''$H*2V)4N"6"H2/[JWBW--S4R\:;7=,WO[3LZ>@>@NE-W,1"#L
M!K84AXWK*D'!7M*0[&=7X0A&9G9YII&YR:ZJ?$HU=OV1OI4N7$FIY%NU-D=,
M6UQGG6'KW#PL3W]G>4^RV+@<,4:01PF#.-,$DBPS[G2<F\-AQK*<>D47O268
MG(GY;@/$]IY"V\:?NXZ?JKKI^)W9"/*FJ!P5::]'%L;L+POEV13"?ZEB0?(D
M4CG4>1I#C&R6%A<)5#E-D%:49BCJ<9\YS(J-?RLYW85SVTH&?7,&WF :^<!>
MP(-SN(V*G?U,4"JBW@@&*^WQG7_DDI^>\)R6 O4=J-^N]EJ(]=9>M]F3NCE\
MJ^)-E=4_$UFN"#?GXYQP!+&4$E*1($N7CU :99SF7J[PQ9FFMDO5ESD;*R)X
M8C]LV,+/C%T&U<U<!8%J8+-4R]A<?952WH%:SG!VYRH4@>S+Y7E&M2-7U3VV
M%]<?\*_'^87],7_</M8%L%SIB&/)(54Q@=A\&R"-N( :900KRX NJ6NUS<'(
M4WOO:^'<RV8.<>I^M6_2?N!7N98K8.'O16UO*&(Y'&^T$I6S:K0+4,Y_H <_
MV&G*S#ZAYFKBS&=E?C47YCQ0GGU_7<XWQ:]U*7S]!4US$DN,..0Q155?6H[-
M_FX.%#*1(C+_<6H[/H:P4[,->XGK8I6ME;EF'_"C'!AEK;N-T=16<.A@_C7B
M@XN9EE\/,BU;7X*J?J94^PXTBO?IY3/T%\&#^FQ"7XB1J-'&^F($XDX;:8$Z
MN=6&EF$\[K61T#S@9AMKSMZQ@.WC=F&#BEUW^;M\F2S.59KE$C*<*HBS)(8L
M2BE$-(U(C(CPO%#WG']J/D)+?""5GHNY9QJM+_[.P82A4!T^Q+ #M#*[![+O
MLF[K="2C@8U)!TU Z@E>N*"$U^QCARKZ0',F@-%KF*!L[ILW;+W^,5]^*^MF
M9PC%.$NQA$BQ%&*),201H5#GE,<R2R.NG$Y*7K-.SIP]KM:;,@% K I/2^8&
MLV,:0&CPADX(N,3N?@?8!C125X7X@[.\GT=I6++WHSFGP/E^'@9'ZO<+#_>(
M\'RH+D7M''N2WAW3H(X11D)Q2-,,0ZQR!8E6&DHJHHCS3$B/^$SG5%,S-;6P
M0*LZE_] 9H_3=#? #D&18+ -;&0:Q%X?@]4G!M&-FD<$(1AZ(YW_+Z(8Z,#N
MA$?G<;M[A/$.RTZ:'!QUW9[H842/4\EMW<(^G?S-:EDVZMBRQ2]L8W_XXX,J
M"GN,CM$OYI??BR8<GE <14A!39DQMSE#D$O$+$6Y,;0IHC+-G,UM(*&F9I@/
M2T *FQ1]4B;24@XTV@&K7A4DBQ&H-/0P2*&6V,'@O\#"#7UJ#KAF?7:34(OG
ML>^\P"*.M$.-\@+Z;6J!P>[<_D+--=Y&&1B=@RTU]-@]H\0EW6N3T)12+B7/
M8I@J:D,E D/.I89Y3J36L5"I7_?,@]&]ML,Q.,#L'. 6.NA#\!P#N'TA&7JC
M*>4:(N?KG,*A0JH'8X\;,#VGUDDX].R'_-Y4J>:SBO/TRR-;+'[>%O.EL00S
M0F*M4TD@YBB#&+$8,HH)C)$25"4(Q\B)=N#"^%-S7BL102FC6H//ZLD&-)??
MREL$MOSA]N9> K/[W0T T<!O;QL=T,AW^SM\1?$S;W&AQ%^_K9[_MWFR>H'-
M7_;O[:7Q1GESKRC3O+O7/G;S;6P=BB]]S;=**V,<Y/OYDAGAWZR*33&+2))G
M-$8P83&'F$49)%@J2"22/(E9$L6\YTWLM;FG]M:W+PU92W9[-2BMZVQK5*ST
MY;6&[_;ML2:.F_LP2 ^]];= ;HM=LTC<-Q"_Z83XEMM85[#"W\1>G?FE;F%=
M(>FX@74>X@;V].^KA7FBJ-)=/JXVZNV\$(M5L5VKK^J/S<]&N_^:D9BI.#,6
M+!81ACCC$C(F)41Q'&E$4LY3KQM8YYFG9L[:@O][G8_6@R'="70WBS4(E /;
MJW,H BLVV,L-?K.2@U+T@+VOO.$*28#N-._XQ.<^<)PE//<:H)^M^JR>U7*K
M]DWHI3$[*<6V\W8N($X9@1PC"C/+)$-X'$7:R\<ZGF!JEJ>1[V]^YN8$-S>K
M<@L: QN/1C3P6R-<0/-P2>] 5N!D^%%?]DO*';_3%S_7[]4]C(L>1TTMV_HL
M0A*+2 D8:9OAA2B"G&@$F11)KK!2D1\UP_4II_9ZMV\-'NMXL=^;[@"SV[L?
M%KR!K8$339Z5.9R-<,<GD-5PF'!4.^(.P+%E\7BRGZVI\_B+KZO7PG@C:W69
MZ:[L_A%IH722<(A8G$-,L2W'BQ5,:)PAD2LFXJPA&G$S/9X2.+U*APPC UNB
M3V:@[ZPP&^Q*G^=W];-+ODOB9J2&@'D<B]5(#C8K4,ON0O89SG[UA"Z0,?.=
M?53+UA.:8S/7=Y@>Z5=OUDK.-^^9F"^,Q_!US9;BN_KZ^ZK.VLA$Q@6C.<RY
M,6V8<P89SS!$:9IS*F..L%--D,-<D_.H2FE!(Z[Q BJ!@9'8(W_F"L#=UBHP
M; -;IB[$^J0>78'.(Z,H'(0C)0KU^O+Y)?ZX8=*9SW-EB/'2=-QT.<B^<7RD
MCTDUOY@+MOAEOE#%9K5430I<%*=1'-FS*4LHQ%(+R*),PH2KE$C&8N+&1MHY
MR^3,:"TG>-P)ZF,"+F'I8C<#(#2TQ6S V<O8RU!>0LG'1 9 :RSC>(I:*)MX
M!81N:WCIX1'MX!7Y#RW@M0_WO!6<?UO.M1EXN7DMQ&J[M$DZGU:+N3#NZOYV
M2F5$4,DB*(5MI$Q(!!E6%$;F/&W&Y2)*I->5H-.T4[..7[:/YHC\H^0FWRL
M]AJ 1H6RD.K7JL_RNV(S?S1'>=_FRFXKXW: #H_WP+;V&KX#W1=ZP13JLM!M
MTG%O"KV .+DF]'MZY(ZK-:/'PW93;,QK:D3[O%HLS%G=_G*F!!4RQ@(2EL<0
MI[& -*<8*L5YGFC,&/)+?AA$S,E9QI+,ASMVW.3G.F[N"'U:&H/?K,Z@5MK1
MR1KX"^)H<%]\V8<VT+?W6+UEQ<=KINJT("_=-[5;R#]'BU0GH(-U0W6;K6?V
M<"N3[T';H*]-D;'[X*>U>IQO'V<BEH225$.1:PEQGJ:0D41 F2I-S+]TAHE7
MSO"U&:>V85CJ7-6D!BOC+)L_-K:UO3"K]<V7\ODJWFY&.RB* ]O?UT?IU>6E
M4B,N>%4+'+ 9JC,XH;)^K\XW;JZOJ_HG&;[.#[ZX'WR_W*SGRV(N*HH@F48Z
M,RXO1+$4YM ?&5<XD@1*C@0VOXC37+^0*WPHZ=2,6TO0%W-9C]9R=*^U_PK]
M.1W7.[#3.#2]U."K,CWO]4C./ZL#>Q[N 7W8"Q/V3*]:VT[>FQ^?%C:0LY0V
MX_O)3O[5C/=V]<CFRQD1F<Z5UC!2*8785L!1Q!BD*=$BCQ(F<R]'UF'.J5G[
M#ZOE-_AA_JQL_]WEM[E-GRHKB<%OE<"><0L7V-W,>6 P!S;,-^#HGQ7ECDRH
M3"B'&<?-?G*'X"3CR>/1?J;G?FF.A\;<O575G_?+.I!<?%9"S9]M=M4,8403
M+0AD-(XASF(!66*;) E&A.!Q+@7W2^=TF=;IC1DUA[.1$:QW0OI9'">TW4Q.
M, 3'L3F-N.!5(_!/MM'>#M'/UQ'UMCT^$ 4R/DY3CFI]?$ X-C]>S_JS=]3I
MFC]BQ+_.-^:;KSG!0A(!)4$:8I7$D.:V/!8+K:((Z8PK5^J.X\&GYLR40MEX
M4HQ>\9^:+&4/NHX3]+KMQJV8#&P??.'PHNJXI'<OGHZ3P48CZ;BD1INAX^)G
M^G81+S:%=3S^L,<E5<P0X;G*.86<Y1)BG4:06<\@14D6IT@GF&L?)JSC";Q>
MT]'(L*P7QLJ\"%7+Z=LF_ A&MSW^%G &?E]+T<KDFW?7$.G1 _R\VL$:?Q\-
M/W*W[_/*G;;XOO"YGL'K+2_4_]W:#BS/YO\^S)?J?J,>BUEB&2>0H)#)U.ZY
ML8(L)AKF-"4H$S'6R&G/O3;1U/;?O9R@%!3\9D4%I:R^^0^7L'6,!0= ;.A0
M;B^P_..O5Y (%3Z]-,VXT<\KRIX$+Z]]OG\9^;X=T_Z[B_(H8VD>PRS2PF[T
MEJ=?$\A2CE(48442X5L[?F:>J9F%BMEI)^<-5N$2L&Y&(0!< ]N$7DCUJ@KO
MP"%@*?BY64:O_^Y0]5S1=]?';ZOTKB[0&XJSBNM-*11G3$8PU]2X"BSGD(A<
MP4@A8QH8I6E.FC#@5X^;B,M3]@@!?AW!2#2WE$TJS6+%EC<Q[G6A[G@#<2.(
M(Q=I-WDT0W'H.< 1N/#ZW$PO4F3=H?*E@NJN1T+FRE37J.90<V^F66[FS\I>
M;!1EPOJ/69(DJ;W,A$RG&&+)C'G1!$%"TEPHP<U7RJ_TQ5^&J7DC)0W8F12*
M$,DNW8OA>'09%N*A3S7=C7'!;Y7$8)@*F/[0#9I%TBW!!/)#G"!RR_QP&ZHW
ML7&5=WN4EEBG)-K03IV66-R7[6U+2SP32<YP2A5,8Y%"',44$O,3J!!#0B4X
M2G#B=]7:3Y )7KX>TQPW*;CFG^RT@4C)@MR77*?GXKD9S0$79#1>Y#JE_%5;
MA9]*KZ[1HHP--WK8G+V=)D&9DF] ,AQI<A\AQN9/O@&H,U3*MXS6SYY^F#-N
M.2DLP=E2GO*C[I@X,QXCQ 2&&4:Q<2,C"CG.*<QQQ!5#,LVTEQOI.O'4?,</
M]Z]_OO]P__7^W1?P^N-;\.7KPYO_\_\]?'C[[O.7?P?O_O]?[[_^AY]5=%X"
M-SLX!+ #6[Z6R-7=5\6Q/ 1EJB\Z@:R9\[2CVB]?,(XMEO?S_6S4KU^^VCR9
M[?K'GHFL(;GAF$NE,(R(90QCVOAUJ2U&0]K\P6D2(2?&L.M33<T._?K7+W\%
MC;"]/;(.:-VL31C !K8OOW[9([47\SKWC;=UN8Y&('O2,=&H%N2ZPL<VP^&)
M@>K(BBME"/\PG]P8U^J36L]7\E]J_NV[[6KQK-;LFWKWAUJ+>:$^K>="S7#&
MN<(:0:V),LZ0),;B) (*A"/*&.9,1$$KR\+)/C4[5DJN)'BU+21X4FM06#TO
MUWV^^-K?$L)[\14=,?1WJ3:M<"U.JQ"PZ<P5!G>@00'4,( &!U ",6+%6OC5
M&ZN&+:#D$XA:#KHDWG5N XC0,TK:V>RUCB]8-8J-D75>S/)8<1TA#1.IF4U+
M,:=[(@3,J8B()$2DF5\/.$\!IK8K[20LKYT]HYR^X*,XH22W5W(L11#SE$&.
MLMC\38DDL=TD"/)J@SLD^",D!X\*OF-P>4!(!]Z3G7I.["%_TP6Y?RBY)VZA
M@LB^TX\;/NX)SDG@N.\X_3:7HWWKX]8>WAYTN?.U:[EW<4O&:!Z9<Q',4QI!
MC"2"/%84QHQB33B7:89]-A=? ::VN9RXL94&)2UGJ<,A+\/;^6)K/^T0#@VS
M7FXF<<A5&-@D#K< W@:R+XJ!#*3W]*,:R+[@'!O(WN/TC$09&VQ&M^'P-\;K
MG\NRRFFUK*H[E7Q86@+XPDQD>;(U45JFUO$CN;&.1.60LPC!G/,L92G66>H5
MPO::?6JFL12[S/E4YKR_5!OPM%X)I:0O^;#7$CB&=(8"=NB@#*M*0$O)[\"!
M[* 1WJ9[M,0/&$KI@UJH8(C7W..&,_K <A*0Z#5(/Z-6W>CMW<KW__QXOT\.
MH#H3.%-0Z8Q#G*,(4LX1E!'+,I4@8\F\/+RNR:9FLDK:ES)??;[/RO#L>]H)
MKIMU"@79P,:HOMIOGT??_Q-^O!_$N7+!))"IZ9QJ5,OBHO2Q(7%Z)I#=>/XX
MMR?1F7%L-"<J@SI'PMB,B!B;H6.H29(01K-,2G:3S:@GFIJ]N"6Z=1',GC:B
M!T0O9!_N @>FKD$QE%EHIGE9DW"D[%5S</SY/GVJ5H^/JV7EJ["G^88MJN/7
M9U6HM?%5WJ_6[[>;[5HU]3+O'I\6JQ]*E8\T;3YM(OE,1R)G6@MS3L(88I1G
MD#)!(4EHCK-4"^&6]!-8KJD9FDHS4)1'*F:OH2S#5J45T*LUT*5>^PJ[[=*L
M)=A\5\!\CR/0*%H='$"C*K"Z^K2+"K?PW5;N!9=S8*-8KV1S@*OT:D)5G]M+
M6NFVJ_^[F^ B^G0)>Y'%'*NOV,B+ZMF;+#CTW=W,PDTW8O^SX!@==DP+/WPH
M,LL'LTFL]V1UQ2Q)*%,<93"),PHQ3BEDQHLWSGPN8QISX]CG/6K8K\_L]&*/
M7\I>BMGBL_0,7SH@[N;Q!P+P1<DL*RP_.V 9@,KR$CR#$5F>3/C"-):7 +A.
M8GGQ27\*RW?+C3F O)\OU/J->66_K=8_9K&D5,3<&)9<<8@S)2"+=00)B@B*
M"<T9=TI1NC#^U+SW2D10R@@:(=UI+,\AV&TR N R=&S "Q(O*LL.Q7NQ69X;
M;S1"RPYEVIR671_K<<!_9]9*--W26<)H(A&!B*,<8L(B:%[/!*9YEENF_2R+
MG>CO3D:>W&M:RN9QDCJ R>% VU?YH=_%4JP^[:,/ / X#/8%8J3CW)4O@M_I
MZYRNG>>G@P?&.P&=D_/@#'/V \.FG=D4-S$C21H1BE*H<WL@X<CFG D%,Y(K
M33+,5>R5T.PU^]2,5",\9'6^4U%%&5;M+"=N)0>OJE]YUM_XK8W;T64PQ >V
MC)[)9:7XX^>3': V<C)9-?<D,\D.8.F;1G8X2,\*CD6YUDJ>+SJIZ8MG<28D
M)51#)1)CYFAJ.Q<I!EDD!:5:,4J\6MRY33LU^U:QB9<7'75O9M&;U<L1>#<;
M%A[.@8W7%>ZNNX:6/&"%@!=$H>H"W"8=MQK "XB3&@"_I_L9I8]&$U9\K]AG
M;+[L4KZ?+XV'9SNW69;47<X2R5%.HI1 02)CEZ(DA82C" HFXE29?T:I%_VY
M\\Q3,TU?MD]/B_+=,1;*4ODL5L76.@&U1F"G4LE\LE,*O!:;^7-Y^^Z92^:^
M2&XV;!#H!S9CU\ MY1XDY<P;K4 6S7W>48V:-QS'=LU_@+X=61X?YU7NIIGB
MS6II)U-F&E7,:!)SE.$4QB)2QIBE&O(<4:@TQD10*5._7@X=<TW-?+5$+5\A
MT186O/JXVBA / ^+75"[F:1   YLA(ZQ.Y S9%N7JV $Z_!R>::1F[U<5?FT
M[\OU1_JW6GOWA_AN?>2/YNLPPRA3E+(<4D1SB!/.S9DLDS8C/L^- X1)&ONV
M6VM/,#4;T<@(&B&!E=*_X]H!B-?OJFZ%9NB3E!\JO1JOG5/]IN9K!P..WH#M
MG#KGFK"=_=Q I%'NK:L[28,BPC,B8PY3'6.(29Q!9OT(G5)+))6I)(MG3R4M
MR)<-6V_<'(F1I/=YJXYU&.X%^UE]FR^7UIOG;%'FKPY+(17HFR"PX$)D".J$
M4DO'SR 7L809QI'(6!)1<S*N4'RW=.2BGNSWH-%@R)P ^:?["K@YN1-<U!&#
MCY?8PUS)PP[N6*;#&Q9VS<;B# LD];3XPL(NA3=76.#I^[D_[]E\_4^VV!HQ
M2OOYY;M2FW^L5]LG,V\=9V$+LYMO2IG?L$JX#[NN:[%Q:A*<)N9P8Z_98VQ.
M/3)1,$GB)$,<IRSRNG^Z5:"IG8VL/J!4R-[T5GM4J1-HE+H#.[7 3B_0*'9#
MH[R;U]9MFQISQ0;>?\99+.]-)13"@7:+F\49=1L(!=ZQ?0\V;L]^@F8MU7JM
M*M+U4I 9$2CF2IOS!$MBB'620DK2&,9I*BG.!$[, &8/X2OG%H*GL_B\KNVY
MAGMK=T)6"0!WX']%?XVB* 9/; V>K<Q_!W%T9WYD_P?8=O-]M;;UUW\'RU63
M"54QSI1AVE92E&>WP3-KXF9#;\1Y8+.X![BN5:M-Y'V)6<#F@I=1"-54\,P,
MXS83O*SB21/!CH_V*;\V(\TW[YFP_1I^6%H8\5T]+%6=ATLBI7F""%1(*=NN
M/(9<\0RR&"&L<4X)(^XEU9US3<U%JZ0%C;AWH!88&(E]*F2[ >XV!(%A&_IB
MJP.Q/AGA5Z#S*1@.!N%81<!]OGR>E;Q.F'17YW8/,6+%K9,NAU6T;H_TO#ZP
MMKG:!]]NU\9CJ)B]2VM=_=A2LJKULSFJ%S.2R!3IC$ F+0^J/3;SC&50YEHC
M'G,I:>SGH'G-/SW7[8"AHG;!;,'[PHB[+!1@W]:JSCLL'3G/<*[7XC@&98<"
M?.C0:@EQ)2&H)-]U53APYTK\&P4"!D;[X!8JO.DU][A!RCZPG(0:>PW2]]RY
M>E+KS0_+*K!YO926*>C)OJ'[L%&B<A9A'L$$46*LG."0:Z8A88E4<90G @N?
MD.#U*:?F4382WY6$')M=2[NGJOUQ[XB> _BNY\V0D Y^_+P9S1Y'45> @IU,
MKTXX\D'5%8#3<ZOSDSU]+N._R:TE/K4\]U\MU8#M)%XV$I\E.)4)0QP*DG.;
MJFF,3TP$C'*D;%^NB"FOLK^NR:9F=NI(9%'V"S;2WI7_OZ,-*@GTBKOR_7DM
MS.EFNV#EG6C3=M;3N^I:!D=G*A"X0_M.M9@-KN"W4M2!^M<[8!+*+^J::EPW
MR$'I$Z_'Y9E^%N:S>E;+K7IOY+2)HC:[_%_SS?<W6W-0>53K=W^(Q;:DBR\*
M9?XKO[(_9@G%*,EB!#.48V-X= (ID2GDDJ98I3IA?FRF/628FCVJ5; L2*MO
M2QMQ][,P?9;!S? ,#.[ ]JC!U;Y'H)$?_&X4 (T&MDZOU@$T2@"C13@[=0.$
M@<Q7'PE&M6HW0'1L[&X9JI\-_(=:JC5;& ?NM7R<+^>VR&8S?U9U(6$=FE4I
M83')"60T%Q!G:089BAE4.:8D4FE*5>)C]9QFG9J=JX4N'2MV(+:?O7.#W,W"
M!0=R8)O6QO!0XJ;B>(!NS5X@!;):;G..:J>\8#BV3'X/]Z_-\R+"G'$1FX,>
M55!A%MM^%)9;GG-(DHQEFFH:I;E/1T5O";QLU @M%6N&A)KV15M^A'WD?4<*
MW8_\Q7]YW&S8H* /?47:E]PW;%U@+_@"5@OZS3]Z#6$O>,Y5%O8;Z,:<7>OL
M;8I?%+.$ O+!=OW9KM<U_TSQZW+%K0#V8'R_?-INS*\-,O/%O+S2WL=JD%!1
MRK,()HKG$,=1;'PXR6"61R@C.,*$>/4?"RS?U+R]-V7I6=F67-M\T?)BTII4
M576N^)VMRR[//9-U RVJFX5]P:4:V/ZV4WDKY4"C':BZGE7ZE?1;Q1UHJPA*
M'<&ADH,&_09:A] )OX&D>YG\W[#07DP'#CR-?TGZF]6S6CM2O)Q\?D)O<"E7
M4(J6B]KV*ID^'&FT6NFS"K2+I,]_H)^K82/K]TLS5)D*5QK 69Z@+#=G*)@0
M)LW1BF#(J<10Y"BFF4X$3C,?=^','%/;\ML70/MN?]7EVD[RHMXA/._TST'L
MMGG?"-R(EV8E9E][8>:]E7:@$F@[/#?#J%M:AXK'VU+71V\\?93;5_%!/:M%
MLHL&9W&L$86IXL*<))((DD0QF'(>951@8QOZ%0.>SC4U$U'*]I=_B[/H[TE/
MS_\,H)Y>_&TPC>B15X+>@5)4D P0VG7 )+1W?&:FE_%T+ZM\T6OM>*1'K<FO
M3T:ZY::N:IXIHG1**('&0> 0RXA!(GD.<QUC22.",[>K\3-C3\T,U-*!IYJ5
M8%TW8O8HAC@"K]L$W C)P*]\@T8M67\0/"I ^H,Q4L6'*RA^11[GU>XLZCAZ
M9+PBCO.R'A1M7/A(SU/,CG7U0;?)&#ZK,@&N3(L[X6(H]K$T+G2N$A;;#&8&
ML68(,A)C& N"1((S&N=>S<UOE&=J-J^,?)]A;?$\!]VX2(YGIO&@'_I\U4W4
M;0Y60P0J ^$7ZB1VHS3CGMK"0'=RP@LT[ WT>?PZRPV_P'+S<57R^BIYQ''S
M#WN%\M8HL/-09QJG&9(I@5DB),0*Q9 +(: 42!/.S=]U[I79/9KH4S/8O]:"
M!R!+&V?IW6S[-!=TQ&W@)LJT.[#3?VR^M%'7+"1EVCB"C\^:-NJ"G"5.&U>"
M?GO?KU_^8:]:EE8 &V>MV6GGJFC"H9(HG24Y%)',(*89ADR:?\9:15KK.-?(
M*QQZ;<*I[3-[:>&Z\D: M/'_8B>WWXYS%7"W?2(DC$,'4+Z O:S5Y<E>V@&B
MIJ[0!#*B5Z<;U?2Y*G]LL)R?ZQ%)K?/^/ZM'-E]6E=UZM7ZT660/?#'_5MK&
M?[+UW-[LO#'6;VX&K@SFXVJ[W,Q$1&.<< EEKG*((\0AB1(,:1)E/*$:DP@Y
MQUYOE69J!NJ7^<+L%*NE:N*U!=BL %> B>]SY1>VO7FE' *]8^(_L&6K5;D#
M.V5 2QNP5\?24U0*@0.-[D"ETYA+Y!&&'G.I1@I<#[]D?B'O4!!W!LEOGF2\
ML'HH/ X"\<$&';D]0SL?;_M8G0P^SXO_>K]6ZGYI-A=C^#\;EW2&>40EQQCR
M*-80)TD"28(BF.*<41EE>9IYL94,+O'4-M%=K*#I+;PV0D-MI ;S6FQ@OA&^
MW$V#+[Q'4&DJRSG]6-(^R0.T]#9;AM$<6-5!HSOXW/6=&(]XWW>=7IIRWUG>
M/P?9OB_\P6CVO2?NMX%],!NC)1XTI\'7RXK*]?MJ89XOWI7E(C/)L,!YGD+.
M$8989S$D$E-(,&**,"53P7PJ%:]-Z+5]C%:8N-A+798 %RVY__)O!,7YW^OZ
M&K]MY"K\;KM 2% '-N(?CI!\UXV:MZ%UA2*0G;PZW:AFSE7Y8ROE_%S/G-S5
MVCAARS?;]5HM1<EQ6C!A3=H_C-?^8544OR[7BBTL!<LLU3(E B&8II:>3V4$
MTE1SB+(H3B7E5!,Q6ZIO-E[[U2-7UT,&I]>%5J_+B21#WHLV H)OS);W67Z5
MS5Z1 DBU7#W.EV4HVWR V0)>JS40M=J>J;\^Z^9FJ8(OPTC)P36.C=R@)3BP
MDH-75O:?;*%>(W[ 9.$>H(7*'O:9>MQTXAZ@G.07]QFCGPW\:AY[T"W'[_4?
M\V*&B"3,N ^0$J(@9JF !"D!(YU'N4Q5FN#(YW1_=I:IG<C?K!9&YE5-G](^
MO)7L*JU_/VR^JS78?&?FS3MXZ#>KEV<ET_D5<#-;-^,ZL'T:'E)OH]4)62#K
M='Z.4<U0IYK']J;[P_T,R^O'U7HS_^_R7/F@=[WGR\2Z64XHXH(E4%-DG"EB
MG"F2)2F,J%0414)2XA4][)IL:F:F+:NM\BOO]N<-V:BP(OL9D$ZDW>Q(*/P&
M-B?'T)WA:0UG*%PP"60O.J<:U6RX*'UL/9R>Z1D&6BV_V:+ADJK4#%%NC1')
ME<9I!+6R)S&FC?&0.H:8YEF492R+E%<E];E)IF8T#LNG[X"5LY>W<191QVC.
MC3@-'<$YJ)9V@\@_C-.!0:C0S;DIQ@W7="AY$J+I^FQ?&N$RZ>T36V_:1Y_B
MYQ_MWY1?7)T*K6.908)MB20S1H'D3,(TH9PF6.;F'./''NPZ]=0,1"T?* 7L
M91D\8'>S%\. .; 5\<*Q!_NO+R3!2'^=)QZ9Z]<7D%.*7^\1^IFEA_4WMJS=
M')NQL5K,975KMI2?+!5DG4FT<X%:;4P+1V*AH'--Z*UJZW,'#C0J(P%MG:QC
M?Z9;<!&4TV@0H .]JV%D&O4U#@KC\1L>=O!^+_^[QZ?%ZH=2=3NH"]?GB_(+
M5XKR>4?>7W65*D]#'W;]AI!"E*8(09(1;?.+-:09XS!AG,A8Z8SG7N21@>6;
MFG=3I<[P2U6[=PW9==6)N*83M<HUN9,W=(\*O?1N.\ ++NC >\&5"NQ0:^F]
M%0R$>*!-(;1THVX/ T%[O%$,-4TXQB]45URAB&D9<0(90@IBBC D"%MJ'Y20
M&(LHCM6MC%]HFM5M+<8O=#OC%[J9\:L'3$-?ZE]D_$(C,7ZAT1B_T%08OY _
MX]?Q(STX9\L+_LW[>2'8XC\46[];2EMJ.TLBQ!$6N7%Y4@&QS"@TWB*%2:JD
MX$D<X<RI!+9KDJD9AEI.4 D*K*3 B K>.B?!=T+:;2%" 37T?7H?C/R(?J^
MT(_S]]*@X]'_7E'K@ GXVF?[^0._L/5_J8VM]]E7NM93S1#)=1()"A7"V)*T
MF(,AB0FD21ZI!&6((*\N>!US3>VUWXO:N\"]"UDWQR 07@.__2VH]F+>U<E_
M <H#/= (Y!)TS32J2^"@\K%+X/)(SV 36]N:P<(<2LHSS-OY8KM1<I81JA-M
M#@PTBAG$:2PAD1F&*,:$2414+KPNOB_,,S4+\5%MP&)5%'O*I3L@*U%OHV*Z
MA+-CA.9V] :V%XV$MMZXJCZ[ [64 <,FW3"$"G]<F&7<,$:WJB?AB"L?[UG:
MRVSOWK(6XJ-9^P?=NO1ZN[+EQC/,:):1+('<=AG :<H@BXV=H!DCDL>4I]HK
M>_?ZE%,S&59B>X]4R@Q^JX3TC/LZ .UF*,+"-W1TU@\Y_X)39S!"58Q>GW#<
MDD]G $YJ-MV?[&E:=JW!RTE^_O%FP8H65ZS2+$ZS6,,D2FS4DJ:V,22!,A5:
M"(QRBJB77>F>;W)&I7PEI/'YY@O/$\HU9!T-23B\AK8BK2XF%6S\!RBE';0?
MF"- H2S+E=G&-2MNJI_8%,?'>M8 R/_<%IN*.7?U6LJY-55L\8G-Y?VRW?3Q
MA+?PLZU:+N:;YBZGNI^I[VLJ[A3+<,IRG/,LE<8$87,BXD1#2I,((IZK3 N.
M/5E(AA9X:B:M)9]]5<OR\?J:7;29+%1U)>M9ES#TZKM9S2FMZ<!F]_6G^S=W
MYWE&VA?L]TNQ5N;791]=>^<)6CH%+* 8"?A011A#BSMN(<=(X)\4@XPU[\V\
M(DV$6*%42:D45"JRY22,0)X:KS8F.*,1IH0G44\FD3XA]]&X0T1]E]3B$.E-
M$N(7;;\-H8%M:$NX 4+KEU4/3_SQ(H'TRPIVD'O<%C:W=W;OEIOYYL>[/\HC
M<6DM*O,QPS%20L<"IKE(S-MMH^?8%HP0I6D<T=B1R+5KDJEY=96<X-T?8"\I
MJ$1UOTB_B.CUB_00. T=&N\!D=<]^C4,>MVC7QQTM'OT:VJU[]&O?K9GE,H>
M4FS1KY)OM^N*6].,6CH51?7S]ZMU[404,Y6S2%O^9I23W':ARB&C.(88I>:_
MB*9)&L^>U9JOG,-67@+X?.G;8@R81+)Z?#3?]O*P5Q:>FW."/0DLC+CFD ?8
MM[6J2!E>E;=JA6^'$[\%<HQ]#0;ZT*&P$N9*0E")7AN:^J1FW(S[_2(T&@0,
MBO5"+E2,S&_R<4-FO8 YB:#U&Z6?[7NS6C]98A1UMH\#3J,XR2B#5',*L;2L
M/8I8$A^DHIA()K57?+YSMJDY/3MA;VN6T8VPFZT*AMO IFD/V? M,IPP"61T
MNN<:U<8XJ7UL4MP>ZF=!/JZ6JZ>2:GSY[7XI5H^J+K?95:AJGLI$91HR%6<0
M9W$"&<LUE'F49%BAC"1>I6E79YR:):FHJ.:EJ.!5'?K^Z6]^=N0ZSFZV)"AZ
M ]N3MJS@OL:O%O>G0<IWG=$)9%FNSS>J=7%6_]C"N#_8,X.QI&?=FZ[WSQ_G
M>\K"AL1PQK)49B(C4*<XA9BJ#')-$ZBCG$<ZE2*/O!*5W*:=FKUI\:>6:8[V
MOJU4Q-@@VY*M#*9[9C:ZX9]BD3"11#"G/(%8&:^1J\PL0JR1(#$2.%(].&T#
M+L.+LMF.O!IN&T+X[_C0H;8*O7;&^OM_PH_W;4[:-E=MP-14+ZA"9:JZ33IN
MXJH7$"=YK'Y/]PW>OY;2?.V*^H\/\Z6*9RK.N=0IA41*;4ZTF$%&:01CBCG%
M2.0Q<\KOZ)QE:OM!'9NN1;QK_@*LL.!AZ5$,=QE8UR#^C7"-$\7W1ZI'*+\#
MB1MB^>=&'3F8WZ'8:32_Z\-]0UK+TN/\UWSS_<VVV!A?=-U<#?Z8I9KF*DML
MFRD40XRIAI1G,60)RW$DA$:I9TBK8[:I&8)?G\QZ+3=-ET7?0%87KJZ!K$!H
M#1[(JN0$OQM!02/I'=C)&C*.Y0!)L#A6UUPCQ[$<U#Z-8[D\U).-[5FM+95'
MZ8]7+:SK&&V,$G.0E#&D,</&9X@S2"/S3\E4;-DU<IU[<4)>G&ERYF)IX/O=
M^&AFKG\'JZ?.;#Y/4-WL11"H!K855D:X$Q)44@X0\+Z*12BVN(OSC,L =TW=
M$U:WJP_X&89BO9E]6J_D5FP>FNNVDJPT83S6<20A4E$.,8T3RS6?0"D1THJD
M"8J=XMF7)IB:&:AE+-FS:C&]^& O MEM T+ ,_"KWP,9Y]?^FOI=;[MYMO6F
MFW_MW_*+PX[R<E]3JGFGKW[N1@:MM_-"+%;%UGP9/*]/NH:8T#>SU?^S)>@@
M5R8NB(0F?#HWU<LP/G4H?9'RJ>N9?E_LIE%F?>DRTUBKG,D,:JVYO0<1D%')
MH$QR'6.5<*EHCSC\T303#;CO.MOV*C(ZAM+-+/1!9AQ+L$/CW14TO%_\"SH'
M>M>/1Q_U];Z@VO$;?>EC/8L;G]E\86M9;7H7:[/ [/:HB.=,8QS!E.<"8A29
M]YI)"@45.A%429IYT3Q>GW)JSNA9=B?/5 H'H-W>^K#P#6P(CE*R[L!.>JA7
M:UCR- SA'[B#%*KN[OJ$XU;..0-P4OOF_N0M:16>W_K#AR;T#:\OAH?X$I_7
M.>@-[\M\.<\K=O[&]L8OW8:MB]E!+\96$?'G^;?O&]N4^8$OYM_*^LVB"?=N
MV>*7^<+LLZNEJNN/9PJG">$)A5$<IQ G&D.>)1PBB:,H14BGTFDG#"G4U/;*
MEJC@L9'5[_(GZ)IUFY>76HG!KY(N="R] Y52P&@%6FJ5[4QVZ[;3K*F\?X%U
MDRNQ?6R:8DQN_0ZD^Q^PCLY[TQ" 5SN:'=EN4TF4)'&Y506=:Y0-;@ATFFUQ
MD+%[%B]N>:'^[]8,].[9_%_)A31+.4YEEF20<V5O+*4Y)FIS:LSR),U)A GS
M:VAY;I*I;79[&4$I9,T+Y<O1=PY.-[?X5I &WH>\\?&O"^P (%3UW[DIQJWQ
MZU#RI)*OZ[,]7_?S+4CVUN?G'_N/U!;F]>]L+2L/_GYI//ARMRS*HI2OW]FR
MNBHM_FFLDI+W35%^'J<9EZDE,1$9Q$IH2%.>0Y4R05C&=93A'A'DL>2?:&BZ
M$K)O&?18:^]H[Z:TE.-WFFHKW78'+3'A6<(LJ_H=J&,4+>U!51ZV,?K7R2/&
M=:R_*/-P'!(OM6RA+/]88H^[FXR\&"<[U-CS]\S-LX-_5D+-G^T>6GQ4FX8@
MBI D,]\5"1%/"<1)DD/*L8:I1C(A.A%*>%5\79YJ:@YO93;6>U$]4_,N8^IF
M_\,@-;#%KD!J27D'C)P#\'!=1R-4>M[EB<;-S[NJ\$F"WO4G>@24#TO:CV],
MS#'\#2N^UW]8J_5L?FKLU2R3B*H819!QZ^"F.(,T(1)BS*G.*&=4.&7UWB+$
MU$S*VT.BBSO &DU**IG"7A':7#=AU-C_1>T5\@A.]ETWAR#R"*OQ<G>U[YN[
MVM=E,U.#_^XO[T9="(^H\ @+,E(4>+B%\0O[WHAH9YBW[]CCA75OU/X@C'OK
M6'VK4[^R/^ZE&6FNYU7WV(_;LC"")"+6-%8PB[C9ES FD$=9"@DU,&4:Q2I.
M_"I4+\PTM<VGKKTTTH)#<4$EKV^5ZB6 NS>0H+ -O$OT1JQ'M>H5-&ZH6+TT
M\LA5JU<4/*U<O?9 S^I58V;J$BF1*T2U9M"8! YQI"+(422AR#-.B)0H8UYU
M9_NAI_;J6\D\BU'W,+F=5OLI/_ +7#H' U"CG>@:JGYT/_"XQ:(G"IU4AIY^
MXL82D1:;]"^*V61]^;#\;!T%R\GX,ROFQ:_+%2_4NCS-EFV<+;?\4IBG2GOP
MABW$=E%1T:\6"^-1V,C9S!PL18IR#!4R;S1.I-G@2<J@V>ZYC".:2>RTP8\F
M\=2L1;N=>4MGT"AM&79V:H-2;TL-L]>\:H(.#G6_ RWMP6]6?U #X'F'//Q7
MR,WD3>J+,; EG=!WHG\!U=#K%+H*:S!Y7Z:4:VCX+]:##3YQC[!JY<P^Z'>/
M3XM5=>^SOQ4J+ '#NS^,A#;WZ4$;#]C8_5G&41[++(-9:HD^HY2:HZN*81(K
M(N-8"N)&%]Q7@*EM5)4*M@^6VBD!6$N+BEY$-7J83U:*>$3O^JR30PAU8/0'
MW@UJX!\TV,O?OJ,O@-4 [%0 #^, [Q$R'7@!1@J7AE\(OS#I#2AVADC[C#M>
M>/0&K0]"H[>,TS_Z<11H_:R*S7HN-JH)Q![^H/7)*M6@Z47W5E5_FG\OMM+L
MH^_^$-^M\)_91KW36HG-+%8229PG,.%I G%F]BK.2 )I&G&1)HJF2>;3J6M<
M\;VVNQ&Z@'U4&_!*UG+_9/FNJZ: \^6M%X8O]/5PCRQ-<]%'B%[=G5QPW8&]
MLJ#ZB%WXHQ\>/E&AL&\C^:H!XJ>RMV2%!6C  !8-4,$1-F@V_C(&#,R-*/SH
MP;_Q%^9<@/$%I.A+@?GXJ-9B;MMD/JEU'2AGC+ $L11&L200VYY5+*/FGP)C
M(:E*DMR3^O+,+%,[@^V%!$]62E_.RW- .NX+M\(SM/G>(U,*.$B/E@X(@G%:
MGIMC9"[+#C5/.2R[/MPC4O-AOC3N]YNUDO/->R9*+LRW:_;[V]7OR]+DE-[Z
M##,LS3$F@S'B&.(899!3E4/%N(ZBF&<1T\[!&;<YIV8+]I*!S0I((Z\-"XM2
M"Z!K-0#;E*W*V?+'OQ= +8PU=J:]]%D/AR!,>)0'-BE68!ONJD0&C<QWP$H-
MK-A@+W=X2#W"*^&A'2FB$@9BORB*'UB=@1/'H<:+E?CI=A >\7RT;Z+8&V5K
MAQ?W2ZG^^#_JQXS&QE2Q-(>9T,:09]:-RTD&HU1*1#1.A')*"[DXP]3,=IWF
M5$L)2C&!D=,W(>P8R&X+' 2>@>VM-S(]$K\N:']#PM?QB",G>EU0Z#3!Z]('
M>[*[F3'E?%%&2_?YIA_-ZKY=/;+Y<H8H(Q'B*<R8HA CE4%*$;:TPC%64<8(
MR;VXW:Y,.+77O"WO08JU%1G\5@GMF8IQ%72WHUQ(* <V"3>BZ,_NY@A-*&ZW
M:].-R^SFJ/P)KYOK<_U,S6=5*/.0#4F]5<]JL7JRGDA-4OEIM9B+'S..E6:4
M)= X$ZF]^B"0FX,@I*G0E"=9'F$OBA"'.:=F<!J1R_AT2VCP9E7XWDRX0.YF
M:P(#.;"YN8AA+? =J$0&O]5_?E5_;,#/YB7ZKX!&R .S0';(9<9139$'!,?6
MR.?1J;&6?%R5/125_)>RM$M*OGY6:_9-_<,,O7G+-FJ79-7.G\QY0E&F!8RR
MW!RA<D$AD]JV@A-*9YA&6'BY6A/3;VJ&MI$=U,+7Q/0VYES",A4:E'Y?)C>S
M/C&I)[2%C$>JLD/J#IQ\)4NT@(4+M'HG#$$E.]%OPN1Y6OII]S^$SN6FI1V/
M]>4V,7LZ%^*[DMN%>M!7]2HN*5;Q_/$TBJ,TPI @DD"<4F[^IA D-!<",9IA
M/W;]8))-;4-O%+,7$959YIWFN]C;;WYJOWLR-09;=L<-_"46<^BM]V0=N[?A
MHG,?'H!1,C3FH3:Y8'*-NSV%AO-D8PD^0=_\I_/4O/O&2S8,448A9GF<4R83
M"9F0TAC]E$"6,F6,?JPBGJ14$>:7%?7_JKN6WKAQ)'R?7Z';9@$3T(L2N8<!
MG*RS") 9&Y-X]["'!E]R&N.TLJUV)IY?ORQ*ZE:_W*1$R9I+8'<LLNJKYD>1
M+-9GW??<:/WV:8,^+@4L^X/KA[4R=KLF3-DC;\>[(^$Y,K.>K1;>D6/3?#G&
M9E@/P+RE8MGW/'&"EC,DQVE;[DWTUB\7YN31W.9;5K_7&0;PTR*-BT3S48YX
MDL4H346(J"HXPBS$O%"%S'*GC:L7^IH;.>V9VLF  5O-[G-3ZD__6IG?[_7?
MKS=LN8*S%6>I\[,AL&4M+\".SE)=3,&XJRZLTVS>6T#E3_[\;$]3BY]?<OF$
M]/G%1_IJ1QZFI9N1="U$^02YZ^P9WLBN5U)_LGY2LG-;>1%GDG*H94%Y)%!:
M:#[BBD4(TSB/,<X)3JRDD#W8,C>^:FT&O1U38  XJ30<Q6KC@\>=]:X:E?U#
M9L=?$P5B9'X[<:$(;J/5,\4V0'>= #7N=&M(^!3,' RJ-W'-_I9,+,0Y&+)C
MT<[A3;KG<KX#_33=W[M2J@6E41ZEF40X44K3)DL0%SA&6!*B$IS)3%C7^.LV
M/#<.!-L","X Z^SS-?? >IFPAD P]MN5G?=..9FG7.V5BKG7T&09F*?,[R9>
MGOS_ 3D'_' 'RGQ:73]MOI3KY9]*WJ]TBY\V^HVV/L&XTQ&L;G[ !9U*W:V7
M0OT&*[WF$R"&YJ3CX(!C[Y%HD6(B69YQQ'!(X+(-022+$T2H$C0LHCQSR^5\
M36?F1BJM=<$W,"\P*_'@C83U^;HR205&7:6/N,IK?5T<4@C^ E^""?,%MN</
M73F^VI^K8/M%,2X$QNWMI^#XB32 _6<\'_J_<NQ\GO"_EBO3'^>_<M!.GMV_
MMDW]9N1_J95N]!'>K.77Y6I9;>K=U";3<*'B."VX?BO.>"I0BB,]:88*(\II
M++E(0D&=)LT+_<UM7FO,-<M0MF>PVTQV"6:[R<8C>"//!UW<]FUMDY#]T;@E
M*IZ8]E)ODY*AI>N'?&7[6,]+556E-M56OQXS+HM($(1QH1DDRR7B2:K?PBE5
M19XI3*-LH9F-E]:7J/8Z</G6=[L9<9?QTZ>;SY\<+T7M@P:*CJ'@"5(4-B-8
MDB*.682DH!D.,Y9FJ55A@.&03;(M:ZS[QR#$[!BT/PXC$V9MV"BYK:=]]G7W
M:[_Q:6]ZG73LZ%[7Z;_JQVT?R]6#'A%?0:#DLVZBN;%(DI3FJ4I1:*Y_AU0@
MKC31X9@5) H3H<>KRW ]W<W<ABU8B<#, .R\"L#2GG="S^!J-ZB'HS7RX#9
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M +=?P_(?N YQAA<93%.\9-S$V<P3UT@<JGT9:CI;,,0URYSWWDE=[&./,,<
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MR_F9].:#]/76#V"<6_U8@74 QOTS7B<F1('!>S#!T\YR+0O(1H*F+2LR7\B
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MQ'D&[LF23YIG[EHGV#]-59<^UO,B]F@A]0"["_O\;:G47^YI4PP]B3QIH50
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MQ!2C(>G"/$^\>-%\B.E.:L9U&;H!72-Q=0"\FE6'R\JA=^$++B\V$;AG3H0
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MF9C#Z_.F8@DA,E%' 1O!N<[6\]:@:S(TX?L8&W.:NFLHN@Z@^,0PDLB%\-)
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MF]7MKD F6MG,&2^T$#A:O+)#<,HQ*"8(;IQ)SK4>WC 8,R<<J37%ZW"W9P>
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M^7B(CO'Q<I!RYXTEW2%:-@E^*"C$9<* ]7S5EE?5!+\(F?O(C6$ZZJWFI!V
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M:70S,3$M,S,Q,C,N:'1M4$L! A0#%     @ \X&I5C>-..+J"   @S(  !0
M             ( !"@D  &5X:&EB:70S,3(M,S,Q,C,N:'1M4$L! A0#%
M  @ \X&I5C'9IP#&!0  >"8  !0              ( !)A(  &5X:&EB:70S
M,C$M,S,Q,C,N:'1M4$L! A0#%     @ \X&I5F%V?J?.!0  PR4  !0
M         ( !'A@  &5X:&EB:70S,C(M,S,Q,C,N:'1M4$L! A0#%     @
M\X&I5I7#C$@RS0$ (Z02 !$              ( !'AX  '1A<G,M,C R,S S
M,S$N:'1M4$L! A0#%     @ \X&I5OBERC\^#P  3)T  !$
M ( !?^L! '1A<G,M,C R,S S,S$N>'-D4$L! A0#%     @ \X&I5@2C;B=C
M&0  A^\  !4              ( ![/H! '1A<G,M,C R,S S,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( /.!J5:W(*/W9T0  $/W @ 5              "  8(4
M @!T87)S+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " #S@:E67,H+\7;(
M  ! ?0@ %0              @ $<60( =&%R<RTR,#(S,#,S,5]L86(N>&UL
M4$L! A0#%     @ \X&I5IO8PJ0:=P  ^G4% !4              ( !Q2$#
L '1A<G,M,C R,S S,S%?<')E+GAM;%!+!08     "@ * )("   2F0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
